{"357fe51849c655d37552b3f96c67be8394a9b6e5": [["INTRODUCTION, and UltraFast LabChip MERS-CoV Real-time PCR kits (Nanobiosys, Seoul, Korea) used one step to simultaneously detect both upE and ORF1a using two single gene-targeting reagents.", [["upE", "GENE_OR_GENE_PRODUCT", 135, 138], ["ORF1a", "GENE_OR_GENE_PRODUCT", 143, 148], ["upE", "DNA", 135, 138], ["ORF1a", "PROTEIN", 143, 148], ["targeting reagents", "TREATMENT", 171, 189]]], ["None of these kits have been approved for diagnostic use; however, they were urgently introduced into clinical laboratories on June 4, 2015 because the timely diagnosis of MERS-CoV infections was essential during the nationwide MERS-CoV outbreak in Korea [1, 2] .INTRODUCTIONThe WHO and United States Centers for Disease Control and Prevention (US CDC) provided guidelines for the molecular diagnosis of MERS-CoV [3, 4] , and since June 6, 2013 the US CDC has made novel coronavirus rRT-PCR assays [5] available free of charge under emergency use authorization [6] .", [["MERS-CoV infections", "DISEASE", 172, 191], ["MERS-CoV", "ORGANISM", 172, 180], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 404, 412], ["coronavirus", "ORGANISM", 471, 482], ["MERS-CoV", "SPECIES", 172, 180], ["MERS-CoV", "SPECIES", 228, 236], ["MERS-CoV", "SPECIES", 404, 412], ["these kits", "TEST", 8, 18], ["MERS", "PROBLEM", 172, 176], ["CoV infections", "PROBLEM", 177, 191], ["Disease Control", "TREATMENT", 313, 328], ["the US CDC", "TEST", 445, 455], ["novel coronavirus rRT", "TREATMENT", 465, 486], ["PCR assays", "TEST", 487, 497]]], ["Although at least three commercial rRT-PCR assays for MERS-CoV detection were available from Altona Diagnostics, Fast Track Diagnostics [3] , and PrimerDesign (http://www.genesig.com) before the 2015 outbreak in Korea, only RealStar MERS-CoV (Altona Diagnostics, Hamburg, Germany) had been approved for the in vitro diagnosis of MERS-CoV by Conformit\u00e9 Europ\u00e9enne (CE) and authorized for emergency use only in the United States.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["MERS-CoV", "ORGANISM", 329, 337], ["rRT", "DNA", 35, 38], ["MERS-CoV", "SPECIES", 54, 62], ["RealStar MERS-CoV", "SPECIES", 224, 241], ["MERS-CoV", "SPECIES", 329, 337], ["PCR assays", "TEST", 39, 49], ["MERS", "PROBLEM", 54, 58], ["CoV detection", "TEST", 59, 72]]], ["Therefore, all six commercial kits evaluated in this study had not been validated for diagnostic use.", [["this study", "TEST", 48, 58]]], ["This study was designed to analytically and clinically validate the six above-mentioned commercial MERS CoV RNA detection kits.METHODSDuring July 6-10, 2015, each kit was validated by using the equipment recommended by each manufacturer (Table 1) .", [["MERS CoV RNA", "RNA", 99, 111], ["MERS CoV", "SPECIES", 99, 107], ["This study", "TEST", 0, 10], ["the equipment", "TREATMENT", 190, 203]]], ["To determine analytical sensitivity, the limits of detection (LOD) with 95% probability values was determined by using upE and ORF1a RNA transcripts supplied by the Institute of Virology, University of Bonn Medical Centre [7] .", [["upE and ORF1a RNA transcripts", "RNA", 119, 148]]], ["The original concentration of both RNA transcripts was 1.0 \u00d7 10 5 copies/\u03bcL.", [["RNA transcripts", "RNA", 35, 50], ["both RNA transcripts", "TREATMENT", 30, 50], ["concentration", "OBSERVATION_MODIFIER", 13, 26], ["both", "OBSERVATION_MODIFIER", 30, 34], ["RNA transcripts", "OBSERVATION", 35, 50]]], ["These were diluted to six concentrations in 0.5-log steps from 100 to 0.3 copies/reaction, and kits were tested by using 5-8-\u03bcL samples of RNA eluates per reaction.", [["kits", "TEST", 95, 99]]], ["For the Nanobiosys kit, which used 2.4-\u03bcL samples per reaction, a 0.5-log higher concentration was added for the LOD validation.", [["the Nanobiosys kit", "TEST", 4, 22], ["a 0.5-log higher concentration", "TREATMENT", 64, 94], ["the LOD validation", "TEST", 109, 127]]], ["Each concentration was tested by using 16 replicates, with the exception of PowerChek, for which 12 replicates were used.", [["PowerChek", "TREATMENT", 76, 85]]], ["A probit regression analysis in R Studio (R Studio Inc.; https://www.rstudio.com/) was performed to determine the 95% cut-off values.", [["A probit regression analysis", "TEST", 0, 28]]], ["The PowerChek, AccuPower, LightMix, and UltraFast LabChip kits used the primers and probes from the WHO-recommended rRT-PCR assay [7, To evaluate the analytical and clinical specificity of the kits, 28 respiratory virus-positive nasopharyngeal swabs were used to determine cross-reactions with human RNA or other respiratory viruses, including human coronaviruses.", [["nasopharyngeal swabs", "ANATOMY", 229, 249], ["respiratory viruses", "DISEASE", 313, 332], ["respiratory virus", "ORGANISM", 202, 219], ["nasopharyngeal swabs", "CANCER", 229, 249], ["human", "ORGANISM", 294, 299], ["human", "ORGANISM", 344, 349], ["PowerChek, AccuPower, LightMix, and UltraFast LabChip kits", "DNA", 4, 62], ["human RNA", "RNA", 294, 303], ["human", "SPECIES", 294, 299], ["human", "SPECIES", 344, 349], ["human", "SPECIES", 294, 299], ["human coronaviruses", "SPECIES", 344, 363], ["The PowerChek", "TREATMENT", 0, 13], ["LightMix", "TREATMENT", 26, 34], ["UltraFast LabChip kits", "TREATMENT", 40, 62], ["rRT-PCR assay", "TEST", 116, 129], ["the kits", "TEST", 189, 197], ["28 respiratory virus", "PROBLEM", 199, 219], ["positive nasopharyngeal swabs", "PROBLEM", 220, 249], ["human RNA", "PROBLEM", 294, 303], ["other respiratory viruses", "PROBLEM", 307, 332], ["human coronaviruses", "PROBLEM", 344, 363], ["respiratory viruses", "OBSERVATION", 313, 332]]], ["Using the Anyplex II RV16 kit (Seegene) with duplicate specimen preparations, these specimens were confirmed as positive for only single species of the following viruses: influenza virus A (n = 2), influenza virus B (n = 2), human parainfluenza virus 1 (n = 2), human parainfluenza virus 2 (n = 2), human parainfluenza virus 3 (n = 2), respiratory syncytial virus A (n = 2), respiratory syncytial virus B (n = 2), human adenovirus (n = 2), human bocavirus (n = 2), hu- man metapneumovirus (n = 2), human rhinovirus (n = 2), human coronavirus 229E (n = 2), human coronavirus OC43 (n = 2), and human coronavirus NL63 (n = 2).METHODSTo evaluate the clinical sensitivity of the assays, 18 specimens from the lower respiratory tract, including 14 known positive specimens, were obtained from five institutions.", [["specimen", "ANATOMY", 55, 63], ["specimens", "ANATOMY", 84, 93], ["specimens", "ANATOMY", 685, 694], ["lower respiratory tract", "ANATOMY", 704, 727], ["specimens", "ANATOMY", 757, 766], ["influenza virus A", "DISEASE", 171, 188], ["influenza virus B", "DISEASE", 198, 215], ["human parainfluenza virus", "DISEASE", 225, 250], ["human parainfluenza virus", "DISEASE", 262, 287], ["parainfluenza virus", "DISEASE", 305, 324], ["respiratory syncytial virus A", "DISEASE", 336, 365], ["respiratory syncytial virus B", "DISEASE", 375, 404], ["human adenovirus", "DISEASE", 414, 430], ["human bocavirus", "DISEASE", 440, 455], ["human rhinovirus", "DISEASE", 498, 514], ["coronavirus 229E", "DISEASE", 530, 546], ["coronavirus OC43", "DISEASE", 562, 578], ["coronavirus NL63", "DISEASE", 598, 614], ["specimens", "CANCER", 84, 93], ["influenza virus A", "ORGANISM", 171, 188], ["influenza virus B", "ORGANISM", 198, 215], ["human", "ORGANISM", 225, 230], ["parainfluenza virus 1", "ORGANISM", 231, 252], ["human", "ORGANISM", 262, 267], ["parainfluenza virus 2", "ORGANISM", 268, 289], ["human", "ORGANISM", 299, 304], ["parainfluenza virus 3", "ORGANISM", 305, 326], ["respiratory syncytial virus A", "ORGANISM", 336, 365], ["respiratory syncytial virus B", "ORGANISM", 375, 404], ["human", "ORGANISM", 414, 419], ["adenovirus", "ORGANISM", 420, 430], ["human", "ORGANISM", 440, 445], ["hu- man metapneumovirus", "ORGANISM", 465, 488], ["human", "ORGANISM", 498, 503], ["rhinovirus", "ORGANISM", 504, 514], ["human", "ORGANISM", 524, 529], ["coronavirus 229E", "ORGANISM", 530, 546], ["human", "ORGANISM", 556, 561], ["coronavirus OC43", "ORGANISM", 562, 578], ["human", "ORGANISM", 592, 597], ["coronavirus NL63", "ORGANISM", 598, 614], ["lower respiratory", "ORGANISM_SUBDIVISION", 704, 721], ["tract", "ORGANISM_SUBDIVISION", 722, 727], ["Anyplex II RV16 kit", "PROTEIN", 10, 29], ["influenza virus A", "SPECIES", 171, 188], ["influenza virus B", "SPECIES", 198, 215], ["human", "SPECIES", 225, 230], ["parainfluenza virus 1", "SPECIES", 231, 252], ["human", "SPECIES", 262, 267], ["parainfluenza virus 2", "SPECIES", 268, 289], ["human", "SPECIES", 299, 304], ["parainfluenza virus 3", "SPECIES", 305, 326], ["respiratory syncytial virus A", "SPECIES", 336, 365], ["respiratory syncytial virus B", "SPECIES", 375, 404], ["human", "SPECIES", 414, 419], ["human", "SPECIES", 440, 445], ["hu- man metapneumovirus", "SPECIES", 465, 488], ["human", "SPECIES", 498, 503], ["rhinovirus", "SPECIES", 504, 514], ["human", "SPECIES", 524, 529], ["coronavirus", "SPECIES", 530, 541], ["human", "SPECIES", 556, 561], ["coronavirus", "SPECIES", 562, 573], ["human", "SPECIES", 592, 597], ["coronavirus", "SPECIES", 598, 609], ["influenza virus A", "SPECIES", 171, 188], ["human parainfluenza virus 1", "SPECIES", 225, 252], ["human parainfluenza virus 2", "SPECIES", 262, 289], ["human parainfluenza virus 3", "SPECIES", 299, 326], ["respiratory syncytial virus A", "SPECIES", 336, 365], ["respiratory syncytial virus B", "SPECIES", 375, 404], ["human adenovirus", "SPECIES", 414, 430], ["human bocavirus", "SPECIES", 440, 455], ["hu- man metapneumovirus", "SPECIES", 465, 488], ["human rhinovirus", "SPECIES", 498, 514], ["human coronavirus 229E", "SPECIES", 524, 546], ["human coronavirus OC43", "SPECIES", 556, 578], ["human coronavirus", "SPECIES", 592, 609], ["duplicate specimen preparations", "TREATMENT", 45, 76], ["these specimens", "TEST", 78, 93], ["single species", "PROBLEM", 130, 144], ["influenza virus A", "PROBLEM", 171, 188], ["influenza virus B (n", "TEST", 198, 218], ["human parainfluenza virus", "TEST", 225, 250], ["human parainfluenza virus", "PROBLEM", 262, 287], ["human parainfluenza virus", "PROBLEM", 299, 324], ["respiratory syncytial virus", "PROBLEM", 336, 363], ["respiratory syncytial virus B", "PROBLEM", 375, 404], ["human adenovirus", "PROBLEM", 414, 430], ["human bocavirus", "PROBLEM", 440, 455], ["hu", "TEST", 465, 467], ["man metapneumovirus", "PROBLEM", 469, 488], ["human rhinovirus", "PROBLEM", 498, 514], ["human coronavirus", "TEST", 524, 541], ["human coronavirus OC43", "TEST", 556, 578], ["human coronavirus NL63", "TEST", 592, 614], ["the assays", "TEST", 670, 680], ["18 specimens from the lower respiratory tract", "TEST", 682, 727], ["14 known positive specimens", "PROBLEM", 739, 766], ["respiratory syncytial", "ANATOMY", 336, 357], ["respiratory syncytial", "ANATOMY", 375, 396], ["hu", "ANATOMY", 465, 467], ["metapneumovirus", "OBSERVATION", 473, 488], ["lower", "ANATOMY_MODIFIER", 704, 709], ["respiratory tract", "ANATOMY", 710, 727]]], ["The RNA eluates of nine specimens that remained after initial clinical MERS-CoV rRT-PCR testing were used following storage of < 2 months at -70\u00b0C at each institution.", [["specimens", "ANATOMY", 24, 33], ["The RNA eluates", "TEST", 0, 15], ["nine specimens", "TEST", 19, 33], ["CoV rRT", "TREATMENT", 76, 83], ["PCR testing", "TEST", 84, 95]]], ["The other nine specimens were manually prepared in our laboratory without any pretreatment and were found to be inadequate for evaluating clinical sensitivity owing to the extremely high levels of PCR inhibition.", [["specimens", "ANATOMY", 15, 24], ["clinical sensitivity", "PROBLEM", 138, 158], ["PCR inhibition", "TREATMENT", 197, 211]]], ["Therefore, only the first nine specimens were used to evaluate clinical sensitivity, and the other nine specimens with high inhibition were used to evaluate the effects of PCR inhibition on positive results.", [["specimens", "ANATOMY", 31, 40], ["specimens", "ANATOMY", 104, 113], ["clinical sensitivity", "TEST", 63, 83], ["the other nine specimens", "TEST", 89, 113], ["high inhibition", "TREATMENT", 119, 134], ["PCR inhibition", "TEST", 172, 186]]], ["In addition to determining the numbers of positives and negatives, the cycle threshold (Ct) values of the target genes and internal control were analyzed.RESULTSThe LODs for upE varied from 21.88 to 263.03 copies/reaction, and those of ORF1a varied from 6.92 to 128.82 copies/reaction (Fig. 1) .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 236, 241], ["target genes", "DNA", 106, 118], ["ORF1a", "PROTEIN", 236, 241], ["the cycle threshold", "TEST", 67, 86], ["Ct) values", "TEST", 88, 98], ["internal control", "TREATMENT", 123, 139], ["RESULTSThe LODs", "TEST", 154, 169], ["upE", "TEST", 174, 177], ["copies/reaction", "PROBLEM", 206, 221], ["ORF1a", "TEST", 236, 241]]], ["According to the probit regression analysis, the 95% confidence intervals (CI) for upE and ORF1a were found to overlap among the tested kits, with the exception of ORF1a by the PowerChek kit (Fig. 2) .", [["upE", "GENE_OR_GENE_PRODUCT", 83, 86], ["ORF1a", "GENE_OR_GENE_PRODUCT", 91, 96], ["ORF1a", "GENE_OR_GENE_PRODUCT", 164, 169], ["ORF1a", "PROTEIN", 91, 96], ["ORF1a", "PROTEIN", 164, 169], ["PowerChek kit", "PROTEIN", 177, 190], ["CI", "TEST", 75, 77], ["upE and ORF1a", "TEST", 83, 96]]], ["The LODs for upE using both the single and multiple gene-targeting formats of the 2-step kits were 1.64 and 1.45 log copies/reaction for the PowerChek kit and 1.76 and 1.61 log copies/reaction for the DiaPlexQ kit (Fig. 2 ).", [["The LODs", "TEST", 0, 8], ["the PowerChek kit", "TEST", 137, 154], ["the DiaPlexQ kit", "TREATMENT", 197, 213]]], ["The LOD for upE was 1.34 log copies/reaction for the Any-plex kit, but no CI value could be calculated because there were no positive reactions at 1.0 log copy/reaction, while all 16 replicate specimens were positive at 1.5 log copies/reaction.", [["specimens", "ANATOMY", 193, 202], ["specimens", "CANCER", 193, 202], ["The LOD", "TEST", 0, 7], ["CI value", "TEST", 74, 82], ["positive reactions", "PROBLEM", 125, 143], ["reaction", "PROBLEM", 235, 243]]], ["In contrast, although the LODs for upE and ORF1a using the LightMix kit were 2.11 log copies/reaction and 1.78 log copies/reaction, respectively, trailing of positives was observed at much lower concentrations than these LODs (Fig. 1) .", [["upE", "GENE_OR_GENE_PRODUCT", 35, 38], ["ORF1a", "GENE_OR_GENE_PRODUCT", 43, 48], ["upE", "DNA", 35, 38], ["ORF1a", "DNA", 43, 48], ["the LODs", "TEST", 22, 30], ["upE", "TEST", 35, 38], ["the LightMix kit", "TEST", 55, 71], ["reaction", "TEST", 93, 101], ["log copies/reaction", "TEST", 111, 130]]], ["The LODs for upE of three different 1-step kits, the AccuPower, Light Mix, and Ultrafast kits, were > 2.0 log copies/reaction, which was less sensitive than those of three different 2-step kits; however, this difference was not significant (Fig. 2) .", [["The LODs", "TEST", 0, 8], ["Ultrafast kits", "TEST", 79, 93]]], ["The LODs for ORF1a varied less-i.e., from 1.78 to 2.11 log copies/reaction-with the exception of the PowerChek kit, which was considerably lower at 0.84 log copies/reaction (Fig. 2) .", [["ORF1a", "GENE_OR_GENE_PRODUCT", 13, 18], ["ORF1a", "PROTEIN", 13, 18], ["The LODs", "TEST", 0, 8], ["ORF1a", "TEST", 13, 18], ["the PowerChek kit", "TEST", 97, 114]]], ["None of the kits tested in this study showed cross-reactivity with other respiratory viruses.RESULTSBased on validation tests including 28 specificity panel and nine clinical specimens, the clinical sensitivities of detecting upE and ORF1a were 100% (95% CI, 0.60-1.00) for all study kits.", [["specimens", "ANATOMY", 175, 184], ["respiratory viruses", "DISEASE", 73, 92], ["upE", "GENE_OR_GENE_PRODUCT", 226, 229], ["ORF1a", "GENE_OR_GENE_PRODUCT", 234, 239], ["the kits", "TEST", 8, 16], ["this study", "TEST", 27, 37], ["other respiratory viruses", "PROBLEM", 67, 92], ["validation tests", "TEST", 109, 125], ["specificity panel", "TEST", 139, 156], ["ORF1a", "TEST", 234, 239], ["CI", "TEST", 255, 257], ["all study kits", "TEST", 274, 288], ["respiratory viruses", "OBSERVATION", 73, 92]]], ["Specificity was 100% (95% CI, 0.79-1.00).", [["Specificity", "TEST", 0, 11], ["CI", "TEST", 26, 28]]], ["The positive samples showed a wide range of Ct values, with values between 7.6 and 11.6 resulting from all kits ( Table 2 ).", [["samples", "ANATOMY", 13, 20], ["The positive samples", "TEST", 0, 20], ["Ct values", "TEST", 44, 53], ["values", "TEST", 60, 66], ["wide", "OBSERVATION_MODIFIER", 30, 34]]], ["The Ct values of the internal control varied most with PowerChek, from 22.7-32.1, while those of DiaPlexQ, Anyplex, AccuPower, LightMix, and UltraFast all varied by < 1.0 (Table 2 ).", [["The Ct values", "TEST", 0, 13], ["PowerChek", "TEST", 55, 64], ["DiaPlexQ", "TREATMENT", 97, 105], ["Anyplex", "TREATMENT", 107, 114], ["AccuPower", "TREATMENT", 116, 125], ["LightMix", "TREATMENT", 127, 135], ["UltraFast", "TEST", 141, 150], ["internal", "ANATOMY_MODIFIER", 21, 29]]], ["ORF1b, tested by the DiaPlexQ kit, was detected in only five positive specimens (62.5%).", [["specimens", "ANATOMY", 70, 79], ["ORF1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["DiaPlexQ", "GENE_OR_GENE_PRODUCT", 21, 29], ["ORF1b", "PROTEIN", 0, 5]]], ["The upE results of the UltraFast kit were not available for three positive specimens because one of the capillary PCR chambers holding these specimens leaked.RESULTSThe effect of PCR inhibition determined by testing the nine high inhibition specimens revealed that 3-5 of the six known positive specimens were found negative or invalid by each kit ( Table 3 ).", [["specimens", "ANATOMY", 75, 84], ["capillary", "ANATOMY", 104, 113], ["specimens", "ANATOMY", 141, 150], ["specimens", "ANATOMY", 241, 250], ["specimens", "ANATOMY", 295, 304], ["capillary", "TISSUE", 104, 113], ["specimens", "CANCER", 295, 304], ["the UltraFast kit", "TEST", 19, 36], ["three positive specimens", "PROBLEM", 60, 84], ["the capillary PCR chambers", "TEST", 100, 126], ["these specimens", "TEST", 135, 150], ["PCR inhibition", "TEST", 179, 193], ["the nine high inhibition specimens", "TEST", 216, 250], ["the six known positive specimens", "PROBLEM", 272, 304]]], ["The Ct values of the internal controls from all specimens were high or extended beyond the total amplification cycles, and, therefore, false negative results were eliminated owing to internal control failure, except for those of the PowerChek and AccuPower kits.", [["specimens", "ANATOMY", 48, 57], ["The Ct values", "TEST", 0, 13], ["all specimens", "TEST", 44, 57], ["internal control failure", "PROBLEM", 183, 207], ["the PowerChek and AccuPower kits", "TREATMENT", 229, 261], ["internal", "ANATOMY_MODIFIER", 21, 29]]], ["With the AccuPower kit, the mean internal control Ct value for the high inhibition specimens was considerably prolonged to 30.1 \u00b1 0.69 compared with 25.7 \u00b1 0.31 for the sensitivity test specimens; however, there was no established cut-off point, indicating that PCR inhibition was not acceptable in the PCR reaction.", [["specimens", "ANATOMY", 83, 92], ["specimens", "ANATOMY", 186, 195], ["the AccuPower kit", "TREATMENT", 5, 22], ["the mean internal control", "TREATMENT", 24, 49], ["Ct value", "TEST", 50, 58], ["the high inhibition specimens", "TEST", 63, 92], ["the sensitivity test specimens", "TEST", 165, 195], ["PCR inhibition", "TEST", 262, 276], ["the PCR reaction", "PROBLEM", 299, 315]]], ["On the other hand, Ct values for the sensitivity test specimens and the high inhibition specimens using the PowerChek kit were not significantly different at 25.3 \u00b1 3.2 and 27.0 \u00b1 3.1, respectively.", [["specimens", "ANATOMY", 54, 63], ["specimens", "ANATOMY", 88, 97], ["Ct values", "TEST", 19, 28], ["the sensitivity test specimens", "TEST", 33, 63], ["the high inhibition specimens", "TEST", 68, 97], ["the PowerChek kit", "TEST", 104, 121]]], ["The LightMix kit produced two uncertain results with known positive specimens and one uncertain result with a known negative specimen (Table 3) .", [["specimens", "ANATOMY", 68, 77], ["specimen", "ANATOMY", 125, 133], ["The LightMix kit", "TEST", 0, 16], ["known positive specimens", "PROBLEM", 53, 77]]], ["There were no positive results detected by any of the kits among the four negative specimens included in the sensitivity test and high inhibition panels (Tables 2 and 3) .DISCUSSIONThe LOD for the upE and ORF1a rRT-PCR kits was analyzed DiT-ORF1bDISCUSSIONAnS-ICAnS-upELiS-ICAcS-ORF1aUlS-IC*PoD-ORF1aDiT-ICDiT-upEDiT-ORF1aDiT-upEDiT-ORF1bDiT-upEAnS-ICAnS-upE LiS-IC* LiS-upE LiS-ORF1aAcS-ICUlS-upEUlS-ORF1a with the same RNA transcripts used to evaluate RealStar MERS-CoV (Altona Diagnostics), which is the only kit thus far approved for diagnosis [9] .", [["specimens", "ANATOMY", 83, 92], ["LiS-ORF1aAcS-ICUlS-upEUlS-ORF1a", "CHEMICAL", 375, 406], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 463, 471], ["upE and ORF1a rRT-PCR kits", "DNA", 197, 223], ["DiT-ORF1bDISCUSSIONAnS-ICAnS-upELiS-ICAcS-ORF1aUlS-IC*PoD-ORF1aDiT-ICDiT-upEDiT-ORF1aDiT-upEDiT-ORF1bDiT-upEAnS-ICAnS-upE LiS-IC* LiS-upE LiS-ORF1aAcS", "DNA", 237, 387], ["ICUlS", "PROTEIN", 388, 393], ["upEUlS", "DNA", 394, 400], ["ORF1a", "DNA", 401, 406], ["RNA transcripts", "RNA", 421, 436], ["RealStar MERS-CoV", "SPECIES", 454, 471], ["the kits", "TEST", 50, 58], ["the sensitivity test", "TEST", 105, 125], ["high inhibition panels", "TEST", 130, 152], ["The LOD", "TEST", 181, 188], ["the upE", "TEST", 193, 200], ["ORF1a rRT", "TEST", 205, 214], ["PCR kits", "TEST", 215, 223], ["LiS", "TEST", 359, 362], ["LiS-", "TEST", 367, 371], ["LiS-ORF1aAcS", "TEST", 375, 387], ["ICUlS", "TEST", 388, 393], ["no", "UNCERTAINTY", 11, 13]]], ["When comparing the analytical sensitivities of assay systems, it is important to use consistent evaluation conditions; moreover, the quality of the source material is critical.", [["assay systems", "TEST", 47, 60], ["consistent evaluation conditions", "TEST", 85, 117]]], ["It is often difficult to find traceable source materials for the molecular diagnosis of viral infections, as only a few international standards have been established to date [10] [11] [12] .", [["viral infections", "DISEASE", 88, 104], ["[10] [11] [12]", "SIMPLE_CHEMICAL", 174, 188], ["viral infections", "PROBLEM", 88, 104], ["viral", "OBSERVATION_MODIFIER", 88, 93], ["infections", "OBSERVATION", 94, 104]]], ["As with RealStar MERS-CoV [9] , all target gene-binding sites for upE, ORF1a, and ORF1b used in the study kits were based on the oligonucleotide sequences of WHO-recommended primers and probes [3] , and the upE and ORF1a target sites were located within the RNA transcripts used in this study.", [["upE", "GENE_OR_GENE_PRODUCT", 66, 69], ["ORF1a", "GENE_OR_GENE_PRODUCT", 71, 76], ["ORF1b", "GENE_OR_GENE_PRODUCT", 82, 87], ["upE", "GENE_OR_GENE_PRODUCT", 207, 210], ["ORF1a", "GENE_OR_GENE_PRODUCT", 215, 220], ["target gene-binding sites", "DNA", 36, 61], ["upE", "DNA", 66, 69], ["ORF1a", "DNA", 71, 76], ["ORF1b", "DNA", 82, 87], ["oligonucleotide sequences", "DNA", 129, 154], ["WHO-recommended primers", "DNA", 158, 181], ["upE and ORF1a target sites", "DNA", 207, 233], ["RNA transcripts", "RNA", 258, 273], ["RealStar MERS-CoV", "SPECIES", 8, 25], ["the study kits", "TEST", 96, 110], ["the oligonucleotide sequences", "TEST", 125, 154], ["the upE", "TEST", 203, 210], ["ORF1a target sites", "TREATMENT", 215, 233], ["this study", "TEST", 282, 292], ["RNA transcripts", "OBSERVATION", 258, 273]]], ["Whole genome sequences of MERS-CoV isolates obtained during the 2015 Korean outbreak were determined by the Korea National Institute of Health and Seoul National University (gb|KT029139.1|) and the Guangdong Provincial Center for Disease Control and Prevention (gb|KT036372.1).", [["MERS-CoV", "ORGANISM", 26, 34], ["MERS-CoV", "SPECIES", 26, 34], ["CoV isolates", "TEST", 31, 43], ["Disease Control", "TREATMENT", 230, 245]]], ["Both sequences closely clustered with a strain isolated during the spring 2015 outbreak in Riyadh, Saudi Arabia (gb|KT026454.1|) [13] .", [["a strain", "PROBLEM", 38, 46]]], ["Therefore, the primers and probes used in this study were most likely not affected by sequence variations in the MERS-CoV strains circulating in this outbreak.", [["MERS-CoV strains", "ORGANISM", 113, 129], ["MERS-CoV", "SPECIES", 113, 121], ["the primers", "TEST", 11, 22], ["this study", "TEST", 42, 52], ["CoV strains", "PROBLEM", 118, 129], ["most likely not", "UNCERTAINTY", 58, 73]]], ["The RNA transcripts used to assess the analytical sensitivity in detecting upE and ORF1a [9] were not expected to have target mismatches with the primers and probes used in this study.", [["RNA transcripts", "RNA", 4, 19], ["upE", "DNA", 75, 78], ["The RNA transcripts", "TREATMENT", 0, 19], ["the analytical sensitivity", "TEST", 35, 61], ["the primers", "TREATMENT", 142, 153], ["this study", "TEST", 173, 183], ["mismatches", "OBSERVATION", 126, 136]]], ["Therefore, the LOD of all kits was analyzed by using identical source materials, and the data were comparable among various kits as well as with data from previous evaluations of RealStar MERS-CoV [9] .", [["RealStar MERS-CoV", "SPECIES", 179, 196], ["all kits", "TEST", 22, 30], ["the data", "TEST", 85, 93], ["previous evaluations", "TEST", 155, 175]]], ["The LODs for upE of the kits assessed in this study indicated approximately 10-fold lower sensitivity than the previously reported 95% cut-off value of 5.3 copies/reaction for RealStar MERS-CoV [9] .", [["RealStar MERS-CoV", "SPECIES", 176, 193], ["The LODs", "TEST", 0, 8], ["the kits", "TEST", 20, 28], ["this study", "TEST", 41, 51]]], ["The overall sensitivities for detecting upE of the kits evaluated herein were consistently lower than that of the RealStar MERS-CoV kit (Fig. 2) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["MERS", "PROTEIN", 123, 127], ["RealStar MERS-CoV", "SPECIES", 114, 131], ["The overall sensitivities", "TEST", 0, 25], ["the kits", "TEST", 47, 55]]], ["Only the LOD for ORF1a using the PowerChek duplex kit was similar to that of the RealStar kit: 9.3 copies/reaction using the RealStar MERS-CoV kit in comparison with 6.9 copies/reaction using the PowerChek kit.", [["ORF1a", "DNA", 17, 22], ["the PowerChek duplex kit", "TEST", 29, 53], ["the RealStar kit", "TEST", 77, 93], ["CoV kit", "TEST", 139, 146], ["the PowerChek kit", "TREATMENT", 192, 209]]], ["Therefore, the lower sensitivities of the kits evaluated in comparison with that of RealStar MERS-CoV could be attributed to their performances rather than instability in source materials.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["RealStar MERS-CoV", "SPECIES", 84, 101], ["the kits", "TEST", 38, 46], ["instability in source materials", "PROBLEM", 156, 187]]], ["In comparison with RealStar MERS-CoV [9] , all of the kits analyzed herein have room for improvement in their sensitivity, with the exception of ORF1a testing with the PowerChek kit.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 145, 150], ["ORF1a", "PROTEIN", 145, 150], ["RealStar MERS-CoV", "SPECIES", 19, 36], ["ORF1a testing", "TEST", 145, 158]]], ["Unlike the other tested kits, the LightMix kit demonstrated a markedly trailing tendency to yield positive results down to much lower con-centrations than its LOD and an uncertain result to even a known-negative specimen (Fig. 1) .", [["specimen", "ANATOMY", 212, 220], ["the LightMix kit", "TEST", 30, 46], ["a markedly trailing tendency", "PROBLEM", 60, 88], ["its LOD", "TEST", 155, 162]]], ["The previous study on the clinical sensitivity of RealStar MERS-CoV produced four discrepant results among 19 specimens, of which three specimens (oral, nasal, and urine specimens) showed high Ct values using the RealStar kit, but not using the comparison assay (and vice versa for one nasal specimen) [9] .", [["specimens", "ANATOMY", 110, 119], ["specimens", "ANATOMY", 136, 145], ["oral", "ANATOMY", 147, 151], ["nasal", "ANATOMY", 153, 158], ["urine specimens", "ANATOMY", 164, 179], ["nasal specimen", "ANATOMY", 286, 300], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["oral", "ORGANISM_SUBDIVISION", 147, 151], ["nasal", "ORGANISM_SUBDIVISION", 153, 158], ["urine specimens", "ORGANISM_SUBSTANCE", 164, 179], ["RealStar MERS-CoV", "SPECIES", 50, 67], ["The previous study", "TEST", 0, 18], ["the clinical sensitivity", "TEST", 22, 46], ["three specimens (oral, nasal, and urine specimens", "TEST", 130, 179], ["high Ct values", "PROBLEM", 188, 202], ["the RealStar kit", "TEST", 209, 225], ["the comparison assay", "TEST", 241, 261], ["nasal", "ANATOMY", 153, 158]]], ["This could be a result of RealStar MERS-CoV having a higher sensitivity or lower specificity than the other assay.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["RealStar MERS-CoV", "SPECIES", 26, 43], ["a higher sensitivity", "PROBLEM", 51, 71]]], ["Using the 2-step kits tested in this study, the LODs for upE using multiple gene-targeting formats were comparable to those obtained using single gene-targeting formats (Fig. 2) .", [["the 2-step kits", "TREATMENT", 6, 21], ["this study", "TEST", 32, 42], ["the LODs", "TEST", 44, 52]]], ["Therefore, implementing a 2-step approach, including performing the first screening step with a single genetargeting format, was not beneficial in terms of sensitivity.UlS-upEIn the present study, the LOD was analyzed by using a 0.5-log dilution series because a 0.5-log dilution is considered \"within physiological variation or not significant\" in viral kinetics [14] .", [["a 2-step approach", "TREATMENT", 24, 41], ["UlS", "TEST", 168, 171], ["a 0.5-log dilution series", "TREATMENT", 227, 252], ["a 0.5-log dilution", "TREATMENT", 261, 279], ["viral kinetics", "OBSERVATION", 349, 363]]], ["However, this was limited in that the 0.5-log dilution scale was too wide to estimate the CI value for the Anyplex kit (Fig. 1) , and estimation of the LOD by probit regression analysis seemed to be less appropriate for the LightMix kit with a trailing tendency to much lower concentrations.", [["the 0.5-log dilution scale", "TREATMENT", 34, 60], ["the Anyplex kit", "TEST", 103, 118], ["probit regression analysis", "TEST", 159, 185]]], ["The LOD for ORF1b using the DiaPlexQ kit was not measured, but the low sensitivity of this kit in detecting ORF1b in clinical specimens is consistent with a previous report, in which testing for ORF1b was less sensitive than testing for ORF1a or upE [7, 8] .UlS-upENo cross-reactivity was observed with other respiratory viruses, including human coronavirus, in any assays included in this study.", [["specimens", "ANATOMY", 126, 135], ["respiratory viruses", "DISEASE", 309, 328], ["ORF1b", "GENE_OR_GENE_PRODUCT", 12, 17], ["ORF1b", "GENE_OR_GENE_PRODUCT", 108, 113], ["ORF1b", "GENE_OR_GENE_PRODUCT", 195, 200], ["ORF1a", "GENE_OR_GENE_PRODUCT", 237, 242], ["upE [7, 8] .UlS", "SIMPLE_CHEMICAL", 246, 261], ["upENo", "GENE_OR_GENE_PRODUCT", 262, 267], ["human", "ORGANISM", 340, 345], ["coronavirus", "ORGANISM", 346, 357], ["ORF1b", "PROTEIN", 12, 17], ["ORF1b", "PROTEIN", 108, 113], ["ORF1b", "PROTEIN", 195, 200], ["human", "SPECIES", 340, 345], ["coronavirus", "SPECIES", 346, 357], ["human coronavirus", "SPECIES", 340, 357], ["the DiaPlexQ kit", "TEST", 24, 40], ["this kit", "TEST", 86, 94], ["ORF1b", "TEST", 195, 200], ["testing", "TEST", 225, 232], ["ORF1a", "TEST", 237, 242], ["upE", "TEST", 246, 249], [".UlS-upENo cross-reactivity", "TEST", 257, 284], ["other respiratory viruses", "PROBLEM", 303, 328], ["human coronavirus", "PROBLEM", 340, 357], ["any assays", "TEST", 362, 372], ["this study", "TEST", 385, 395], ["consistent with", "UNCERTAINTY", 139, 154], ["respiratory viruses", "OBSERVATION", 309, 328]]], ["These findings are consistent with previous evaluations that used the primers and probes recommended by WHO [7] [8] [9] .", [["previous evaluations", "TEST", 35, 55], ["the primers", "TREATMENT", 66, 77], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Therefore, all assay systems demonstrated adequate specificity.UlS-upEThe clinical sensitivities of the kits were all 100% (Table 2) .", [["all assay systems", "TEST", 11, 28], ["UlS", "TEST", 63, 66], ["the kits", "TEST", 100, 108]]], ["Because the sensitivity test panel comprised various positive specimens with a wide range of Ct values, this high sensitivity validated their diagnostic performance for MERS-CoV infection, particularly from sputum specimens, although the number of positive specimens was small.", [["specimens", "ANATOMY", 62, 71], ["sputum specimens", "ANATOMY", 207, 223], ["specimens", "ANATOMY", 257, 266], ["infection", "DISEASE", 178, 187], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 169, 177], ["sputum specimens", "CANCER", 207, 223], ["specimens", "CANCER", 257, 266], ["MERS-CoV", "SPECIES", 169, 177], ["the sensitivity test panel", "TEST", 8, 34], ["various positive specimens", "PROBLEM", 45, 71], ["Ct values", "TEST", 93, 102], ["this high sensitivity", "PROBLEM", 104, 125], ["MERS", "PROBLEM", 169, 173], ["CoV infection", "PROBLEM", 174, 187], ["sputum specimens", "TEST", 207, 223], ["positive specimens", "TEST", 248, 266], ["infection", "OBSERVATION", 178, 187], ["positive", "OBSERVATION_MODIFIER", 248, 256], ["specimens", "OBSERVATION", 257, 266], ["small", "OBSERVATION_MODIFIER", 271, 276]]], ["One of the strengths in the present study was determining the effects of PCR inhibition on clinical sensitivity and the importance of internal controls (Table 3) .", [["the present study", "TEST", 24, 41], ["PCR inhibition", "TREATMENT", 73, 87], ["clinical sensitivity", "TEST", 91, 111]]], ["The internal controls of the PowerChek kit were not affected by the inhibition.", [["internal", "OBSERVATION_MODIFIER", 4, 12]]], ["This could be because the PowerChek kit uses a less sensitive internal control that is intrinsic to human cells, although the PCR efficiency of this kit itself was also less affected.UlS-upEwww.annlabmed.org http://dx.doi.org/10.3343/alm.2016.36.5.450UlS-upEThe positivity rates for kits when testing the high inhibition panel correlated with their analytical sensitivities, as only PowerChek detected 50% of known-positive specimens.", [["cells", "ANATOMY", 106, 111], ["specimens", "ANATOMY", 424, 433], ["human", "ORGANISM", 100, 105], ["cells", "CELL", 106, 111], ["kit", "GENE_OR_GENE_PRODUCT", 149, 152], ["human cells", "CELL_TYPE", 100, 111], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["the PowerChek kit", "PROBLEM", 22, 39], ["intrinsic to human cells", "PROBLEM", 87, 111], ["the PCR", "TEST", 122, 129], ["this kit", "TEST", 144, 152], ["UlS-upEwww.annlabmed.org", "TEST", 183, 207], ["positivity rates", "TEST", 262, 278], ["kits", "TEST", 283, 287], ["testing", "TEST", 293, 300], ["their analytical sensitivities", "TEST", 343, 373], ["PowerChek", "TEST", 383, 392], ["positive specimens", "PROBLEM", 415, 433]]], ["Based on these findings, it is clear that clinical sensitivity can be significantly affected by the presence of PCR inhibitors, and analytical sensitivity may be affected by PCR inhibition-prone specimens such as sputum specimens.", [["specimens", "ANATOMY", 195, 204], ["sputum specimens", "ANATOMY", 213, 229], ["clinical sensitivity", "PROBLEM", 42, 62], ["PCR inhibitors", "TREATMENT", 112, 126], ["analytical sensitivity", "TEST", 132, 154], ["PCR inhibition", "TEST", 174, 188], ["prone specimens", "TEST", 189, 204], ["sputum specimens", "TEST", 213, 229]]], ["Therefore, optimization of the pretreatment and RNA extraction procedures is necessary to improve the sensitivity of MERS-CoV molecular diagnostics, especially for testing sputum specimens.UlS-upEThere were some noteworthy limitations of this study, including: 1) the number of specimens used to test clinical sensitivity was relatively small; 2) the reproducibility of the assay results was not validated; and 3) the effects of inhibition were qualitatively estimated.", [["sputum specimens", "ANATOMY", 172, 188], ["specimens", "ANATOMY", 278, 287], ["MERS-CoV", "SPECIES", 117, 125], ["the pretreatment", "TREATMENT", 27, 43], ["RNA extraction procedures", "TREATMENT", 48, 73], ["CoV molecular diagnostics", "TEST", 122, 147], ["testing sputum specimens", "TEST", 164, 188], ["UlS", "TEST", 189, 192], ["this study", "TEST", 238, 248], ["test clinical sensitivity", "TEST", 296, 321], ["the assay", "TEST", 370, 379]]], ["In conclusion, the commercial kits evaluated in this study demonstrated variable analytical sensitivities; however, the overall clinical sensitivity and specificity were same and were sufficient for diagnosing MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 210, 228], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 210, 218], ["MERS-CoV", "SPECIES", 210, 218], ["the commercial kits", "TEST", 15, 34], ["this study", "TEST", 48, 58], ["variable analytical sensitivities", "PROBLEM", 72, 105], ["CoV infection", "PROBLEM", 215, 228], ["infection", "OBSERVATION", 219, 228]]], ["The performance of the individual kits could be improved in terms of their analytical sensitivity, and identification of PCR inhibition with the use of appropriate internal controls is essential.", [["the individual kits", "TEST", 19, 38], ["their analytical sensitivity", "TEST", 69, 97], ["PCR inhibition", "PROBLEM", 121, 135], ["appropriate internal controls", "TREATMENT", 152, 181]]]], "c2f26553c5492b3ea15adbe296032b7e8f3b2876": [["IntroductionLoop-mediated isothermal amplification (LAMP) was first reported in 2000 [1] and has, since then, been the focus of extensive research efforts.", [["IntroductionLoop-mediated isothermal amplification", "TREATMENT", 0, 50]]], ["The number of studies performed using LAMP is increasing every year; as of November 2012, PubMed database has listed more than 750 articles on this topic.", [["LAMP", "TEST", 38, 42]]], ["The findings of reports published up to 2008 have been summarized in our previous review article published in this journal [2] ; consequently, the aim of this article is to review research activities undertaken thereafter.IntroductionResearch and development (R&D) efforts on LAMP technology in recent years have focused on two major areas.", [["LAMP technology", "TREATMENT", 276, 291]]], ["One is its practical application in clinical settings, including its role in the improvement of existing assays.", [["existing assays", "TEST", 96, 111], ["improvement", "OBSERVATION_MODIFIER", 81, 92]]], ["Since the LAMP method was invented, LAMP reactions for detecting various pathogens were developed by many research groups and their performance observed by comparing to that of existing reagents [such as polymerase chain reaction (PCR)], as reviewed in the papers [3, 4] .", [["the LAMP method", "TEST", 6, 21], ["LAMP reactions", "TEST", 36, 50], ["various pathogens", "PROBLEM", 65, 82], ["existing reagents", "TREATMENT", 177, 194], ["polymerase chain reaction", "PROBLEM", 204, 229]]], ["These initial studies can be considered as a sort of validation study to evaluate the feasibility of LAMP technology.", [["These initial studies", "TEST", 0, 21], ["validation study", "TEST", 53, 69], ["LAMP technology", "TEST", 101, 116]]], ["After these intensive validation studies, LAMP was actually applied for clinical practice.", [["these intensive validation studies", "TEST", 6, 40], ["LAMP", "TREATMENT", 42, 46], ["clinical practice", "TREATMENT", 72, 89]]], ["The second area is basic research on further simplification of the LAMP assay.", [["the LAMP assay", "TEST", 63, 77], ["second", "OBSERVATION_MODIFIER", 4, 10], ["area", "OBSERVATION_MODIFIER", 11, 15], ["basic", "OBSERVATION_MODIFIER", 19, 24], ["research", "OBSERVATION", 25, 33]]], ["Current basic research efforts now focus on testing the distinct features of the LAMP technique owing to its simplicity and rapidity of use.", [["the LAMP technique", "TREATMENT", 77, 95]]], ["Extensive improvement of LAMP technology is necessary to integrate this method into simple genetic tests to be used as point-of-care diagnostics.", [["LAMP technology", "TREATMENT", 25, 40], ["simple genetic tests", "TEST", 84, 104], ["improvement", "OBSERVATION_MODIFIER", 10, 21]]], ["Thus, this article also reviews the basic techniques involved in improvement of LAMP technology.Practical applications of LAMP reagentsThe extensive basic research efforts on LAMP have facilitated the use of LAMP technology in actual clinical settings.", [["the basic techniques", "TEST", 32, 52], ["LAMP technology", "TREATMENT", 80, 95], ["LAMP reagents", "TREATMENT", 122, 135], ["LAMP technology", "TREATMENT", 208, 223], ["extensive", "OBSERVATION_MODIFIER", 139, 148]]], ["Before 2008, the Severe Acute Respiratory Syndrome (SARS) coronavirus detection kit was the only LAMP reagent approved for in vitro diagnostics (IVD) in Japan.", [["Acute Respiratory Syndrome", "DISEASE", 24, 50], ["SARS", "DISEASE", 52, 56], ["Severe Acute Respiratory Syndrome (SARS) coronavirus", "SPECIES", 17, 69], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 13, 50], ["SARS) coronavirus detection kit", "PROBLEM", 52, 83], ["LAMP reagent", "TREATMENT", 97, 109], ["Severe", "OBSERVATION_MODIFIER", 17, 23], ["Acute", "OBSERVATION_MODIFIER", 24, 29], ["Respiratory Syndrome", "OBSERVATION", 30, 50]]], ["Currently, the number of approved LAMP reagents in Japan has increased to eight: SARS coronavirus, as mentioned, along with Mycobacterium tuberculosis (TB), Mycoplasma pneumoniae, Legionella species, influenza type A virus, H1 pdm 2009 influenza virus, H5 influenza virus, and human papilloma virus (HPV).", [["SARS coronavirus", "DISEASE", 81, 97], ["Mycobacterium tuberculosis", "DISEASE", 124, 150], ["TB", "DISEASE", 152, 154], ["Mycoplasma pneumoniae", "DISEASE", 157, 178], ["influenza type A", "DISEASE", 200, 216], ["influenza virus", "DISEASE", 236, 251], ["influenza virus", "DISEASE", 256, 271], ["human papilloma virus (HPV)", "DISEASE", 277, 304], ["SARS coronavirus", "ORGANISM", 81, 97], ["Mycobacterium tuberculosis", "ORGANISM", 124, 150], ["Mycoplasma pneumoniae", "ORGANISM", 157, 178], ["Legionella species", "ORGANISM", 180, 198], ["influenza type A virus", "ORGANISM", 200, 222], ["H1 pdm 2009 influenza virus", "ORGANISM", 224, 251], ["H5 influenza virus", "ORGANISM", 253, 271], ["human papilloma virus", "ORGANISM", 277, 298], ["HPV", "ORGANISM", 300, 303], ["Mycobacterium tuberculosis", "SPECIES", 124, 150], ["Mycoplasma pneumoniae", "SPECIES", 157, 178], ["influenza type A virus", "SPECIES", 200, 222], ["influenza virus", "SPECIES", 236, 251], ["H5 influenza virus", "SPECIES", 253, 271], ["human", "SPECIES", 277, 282], ["papilloma virus", "SPECIES", 283, 298], ["SARS coronavirus", "SPECIES", 81, 97], ["Mycobacterium tuberculosis", "SPECIES", 124, 150], ["Mycoplasma pneumoniae", "SPECIES", 157, 178], ["influenza type A virus", "SPECIES", 200, 222], ["H1 pdm 2009 influenza virus", "SPECIES", 224, 251], ["H5 influenza virus", "SPECIES", 253, 271], ["human papilloma virus", "SPECIES", 277, 298], ["HPV", "SPECIES", 300, 303], ["LAMP reagents", "TREATMENT", 34, 47], ["SARS coronavirus", "PROBLEM", 81, 97], ["Mycobacterium tuberculosis", "PROBLEM", 124, 150], ["TB", "PROBLEM", 152, 154], ["Mycoplasma pneumoniae", "PROBLEM", 157, 178], ["Legionella species", "PROBLEM", 180, 198], ["influenza type A virus", "PROBLEM", 200, 222], ["H1 pdm", "PROBLEM", 224, 230], ["influenza virus", "PROBLEM", 236, 251], ["H5 influenza virus", "PROBLEM", 253, 271], ["human papilloma virus", "PROBLEM", 277, 298], ["Mycobacterium tuberculosis", "OBSERVATION", 124, 150], ["Mycoplasma pneumoniae", "OBSERVATION", 157, 178], ["Legionella species", "OBSERVATION", 180, 198], ["papilloma virus", "OBSERVATION", 283, 298]]], ["In addition, onestep nucleic acid amplification (OSNA), an automated molecular detection system using a RT-LAMP method for detecting cancer cells that have metastasized to the lymph nodes, has also been approved as IVD in Japan [5] .", [["cancer cells", "ANATOMY", 133, 145], ["lymph nodes", "ANATOMY", 176, 187], ["nucleic acid", "CHEMICAL", 21, 33], ["cancer", "DISEASE", 133, 139], ["cancer cells", "CELL", 133, 145], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 176, 187], ["cancer cells", "CELL_TYPE", 133, 145], ["onestep nucleic acid amplification", "TEST", 13, 47], ["OSNA", "TEST", 49, 53], ["a RT-LAMP method", "TREATMENT", 102, 118], ["cancer cells", "PROBLEM", 133, 145], ["the lymph nodes", "PROBLEM", 172, 187], ["cancer", "OBSERVATION", 133, 139], ["lymph nodes", "OBSERVATION", 176, 187]]], ["Current status of the application of LAMP technology to IVD may be summarized as follows.Practical applications of LAMP reagentsA LAMP reagent kit for detecting the M. tuberculosis complex (Loopamp MTBC detection kit, TB-LAMP; Eiken Chemical, Tokyo, Japan) was launched in April 2011.", [["IVD", "MULTI-TISSUE_STRUCTURE", 56, 59], ["M. tuberculosis", "ORGANISM", 165, 180], ["M. tuberculosis", "SPECIES", 165, 180], ["M. tuberculosis", "SPECIES", 165, 180], ["LAMP technology", "TREATMENT", 37, 52], ["the M. tuberculosis complex", "PROBLEM", 161, 188], ["tuberculosis", "OBSERVATION", 168, 180]]], ["The new reagent features two improvements.", [["new", "OBSERVATION_MODIFIER", 4, 7], ["reagent", "OBSERVATION_MODIFIER", 8, 15], ["features", "OBSERVATION_MODIFIER", 16, 24], ["two", "OBSERVATION_MODIFIER", 25, 28], ["improvements", "OBSERVATION_MODIFIER", 29, 41]]], ["First, the test process has been made faster and simpler; by using the kit named the Loopamp PURE DNA extraction kit (Eiken Chemical) for sputum processing, the NALC (N-acetyl-L-cysteine)-NaOH decontamination step is no longer necessary.", [["sputum", "ANATOMY", 138, 144], ["NALC", "CHEMICAL", 161, 165], ["N-acetyl-L-cysteine", "CHEMICAL", 167, 186], ["NaOH", "CHEMICAL", 188, 192], ["N-acetyl-L-cysteine", "CHEMICAL", 167, 186], ["NaOH", "CHEMICAL", 188, 192], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["NALC", "SIMPLE_CHEMICAL", 161, 165], ["N-acetyl-L-cysteine", "SIMPLE_CHEMICAL", 167, 186], ["the test process", "TEST", 7, 23], ["the Loopamp PURE DNA extraction", "TREATMENT", 81, 112], ["sputum processing", "TEST", 138, 155], ["the NALC (N-acetyl-L-cysteine", "TREATMENT", 157, 186], ["NaOH decontamination step", "TREATMENT", 188, 213], ["no longer", "UNCERTAINTY", 217, 226]]], ["Second, TB-LAMP is now provided as a dry reagent, allowing easier storage, that is, it can be stored at room temperature with satisfactory shelf life.", [["a dry reagent", "TREATMENT", 35, 48], ["TB", "OBSERVATION", 8, 10]]], ["Figure 1 shows the operation process of PURE and TB-LAMP.", [["TB", "DISEASE", 49, 51], ["TB", "OBSERVATION", 49, 51]]], ["Mitarai et al. [6] reported the results of a clinical trial of PURE-TB-LAMP in Japan, concluding that it is a simple, effective, and rapid test for TB testing and that the sensitivity of TB-LAMP for smearnegative and culture-positive samples is about 55 %.", [["samples", "ANATOMY", 234, 241], ["PURE", "CHEMICAL", 63, 67], ["TB", "DISEASE", 148, 150], ["TB", "DISEASE", 187, 189], ["PURE", "SIMPLE_CHEMICAL", 63, 67], ["LAMP", "TREATMENT", 71, 75], ["rapid test", "TEST", 133, 143], ["TB testing", "TEST", 148, 158], ["TB", "TEST", 187, 189], ["LAMP", "TEST", 190, 194], ["culture", "TEST", 217, 224]]], ["Evaluation studies for the use of this system as a simple TB diagnostics tool suitable for use in resource-limited facilities are currently ongoing in some developing countries.Practical applications of LAMP reagentsRecently, LAMP reagents for detecting certain parasites using the same platform as that used in PURE-TB-LAMP have been commercialized.", [["PURE", "SIMPLE_CHEMICAL", 312, 316], ["Evaluation studies", "TEST", 0, 18], ["this system", "TREATMENT", 34, 45], ["LAMP reagents", "TREATMENT", 203, 216], ["LAMP reagents", "TEST", 226, 239], ["certain parasites", "PROBLEM", 254, 271]]], ["The malaria LAMP kit (Loopamp MALARIA Pan/Pf detection kit) has been launched as a CE-approved IVD.", [["malaria", "DISEASE", 4, 11], ["CE", "CHEMICAL", 83, 85], ["IVD", "TISSUE", 95, 98], ["Pf", "PROTEIN", 42, 44], ["The malaria LAMP kit", "TEST", 0, 20], ["Loopamp MALARIA Pan/Pf detection kit", "TREATMENT", 22, 58], ["a CE", "TEST", 81, 85], ["IVD", "PROBLEM", 95, 98], ["malaria", "OBSERVATION", 4, 11]]], ["It consists of two LAMP reagents, one for the detection of Plasmodium falciparum and another that reacts with all four types of human malarial parasites.", [["Plasmodium falciparum", "DISEASE", 59, 80], ["malarial parasites", "DISEASE", 134, 152], ["Plasmodium falciparum", "ORGANISM", 59, 80], ["human", "ORGANISM", 128, 133], ["Plasmodium falciparum", "SPECIES", 59, 80], ["human", "SPECIES", 128, 133], ["Plasmodium falciparum", "SPECIES", 59, 80], ["human", "SPECIES", 128, 133], ["two LAMP reagents", "TREATMENT", 15, 32], ["Plasmodium falciparum", "PROBLEM", 59, 80], ["human malarial parasites", "PROBLEM", 128, 152], ["Plasmodium falciparum", "OBSERVATION", 59, 80], ["malarial parasites", "OBSERVATION", 134, 152]]], ["The sensitivity of these reagents is enhanced by targeting of mitochondrial DNA, as demonstrated by Polley et al. [7] .", [["mitochondrial", "ANATOMY", 62, 75], ["mitochondrial", "CELLULAR_COMPONENT", 62, 75], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["mitochondrial DNA", "DNA", 62, 79], ["these reagents", "TEST", 19, 33], ["mitochondrial DNA", "PROBLEM", 62, 79], ["mitochondrial DNA", "OBSERVATION", 62, 79]]], ["They have demonstrated that the clinical sensitivity and specificity compared with a nested PCR method are 97.0 % and 99.2 % for pan-malaria detection and 98.4 % and 98.1 % for P. falciparum-specific detection, respectively, and concluded that the diagnostic accuracy of the kit is similar to that of nested PCR with greatly reduced time to availability of results.", [["P. falciparum", "ORGANISM", 177, 190], ["P. falciparum", "SPECIES", 177, 190], ["P. falciparum", "SPECIES", 177, 190], ["the clinical sensitivity", "TEST", 28, 52], ["a nested PCR method", "TEST", 83, 102], ["pan-malaria detection", "TEST", 129, 150], ["P. falciparum", "TEST", 177, 190], ["specific detection", "TEST", 191, 209], ["the kit", "TEST", 271, 278], ["nested PCR", "TEST", 301, 311]]], ["The Loopamp Trypanosoma brucei detection kit has also been developed, acting as a highly sensitive tool for the diagnosis of human African trypanosomiasis (HAT), in which sensitivity is enhanced by targeting of the multicopy gene named RIME (repetitive insertion mobile element) [9] .", [["human African trypanosomiasis", "DISEASE", 125, 154], ["HAT", "DISEASE", 156, 159], ["Loopamp Trypanosoma brucei", "ORGANISM", 4, 30], ["human", "ORGANISM", 125, 130], ["multicopy gene", "DNA", 215, 229], ["RIME", "DNA", 236, 240], ["repetitive insertion mobile element", "DNA", 242, 277], ["Trypanosoma brucei", "SPECIES", 12, 30], ["human", "SPECIES", 125, 130], ["Trypanosoma brucei", "SPECIES", 12, 30], ["human", "SPECIES", 125, 130], ["The Loopamp Trypanosoma brucei detection kit", "TEST", 0, 44], ["human African trypanosomiasis", "PROBLEM", 125, 154], ["the multicopy gene named RIME (repetitive insertion mobile element", "TREATMENT", 211, 277], ["Trypanosoma brucei", "OBSERVATION", 12, 30]]], ["Furthermore, the application of this kit as an animal test reagent for the diagnosis of surra disease and covering sickness is anticipated, on the basis of its reactivity with Trypanosoma evansi and Trypanosoma equiperdum.", [["surra", "ANATOMY", 88, 93], ["surra disease", "DISEASE", 88, 101], ["sickness", "DISEASE", 115, 123], ["Trypanosoma evansi", "DISEASE", 176, 194], ["Trypanosoma evansi", "ORGANISM", 176, 194], ["Trypanosoma equiperdum", "ORGANISM", 199, 221], ["Trypanosoma evansi", "SPECIES", 176, 194], ["Trypanosoma equiperdum", "SPECIES", 199, 221], ["Trypanosoma evansi", "SPECIES", 176, 194], ["Trypanosoma equiperdum", "SPECIES", 199, 221], ["this kit", "TREATMENT", 32, 40], ["an animal test reagent", "TEST", 44, 66], ["surra disease", "PROBLEM", 88, 101], ["sickness", "PROBLEM", 115, 123], ["Trypanosoma evansi and Trypanosoma equiperdum", "PROBLEM", 176, 221], ["surra disease", "OBSERVATION", 88, 101], ["Trypanosoma evansi", "OBSERVATION", 176, 194], ["Trypanosoma equiperdum", "OBSERVATION", 199, 221]]], ["A LAMP assay system for detecting Clostridium difficile (illumigene C. difficile; Meridian Bioscience, Cincinnati, OH, USA) has been developed in the United States.", [["Clostridium difficile", "DISEASE", 34, 55], ["Clostridium difficile", "ORGANISM", 34, 55], ["Clostridium difficile", "SPECIES", 34, 55], ["C. difficile", "SPECIES", 68, 80], ["Clostridium difficile", "SPECIES", 34, 55], ["C. difficile", "SPECIES", 68, 80], ["A LAMP assay system", "TEST", 0, 19], ["Clostridium difficile", "PROBLEM", 34, 55], ["illumigene C. difficile", "PROBLEM", 57, 80], ["Clostridium difficile", "OBSERVATION", 34, 55]]], ["This kit includes a stool collection brush and a dilution buffer, containing formalin-inactivated Staphylococcus aureus, along with LAMP reagents for the detection phase.", [["stool", "ANATOMY", 20, 25], ["formalin", "CHEMICAL", 77, 85], ["formalin", "CHEMICAL", 77, 85], ["formalin", "SIMPLE_CHEMICAL", 77, 85], ["Staphylococcus aureus", "ORGANISM", 98, 119], ["Staphylococcus aureus", "SPECIES", 98, 119], ["Staphylococcus aureus", "SPECIES", 98, 119], ["This kit", "TEST", 0, 8], ["a stool collection brush", "TREATMENT", 18, 42], ["a dilution buffer", "TREATMENT", 47, 64], ["formalin", "TREATMENT", 77, 85], ["Staphylococcus aureus", "PROBLEM", 98, 119], ["LAMP reagents", "TREATMENT", 132, 145], ["the detection phase", "TEST", 150, 169], ["stool", "OBSERVATION", 20, 25], ["Staphylococcus aureus", "OBSERVATION", 98, 119]]], ["The assay allows LAMP amplification of the tcdA gene of C. difficile and a S. aureus gene, as an external quality control, in two reaction chambers using the incubator/turbidity meter named illumipro-10.", [["tcdA", "GENE_OR_GENE_PRODUCT", 43, 47], ["C. difficile", "ORGANISM", 56, 68], ["S. aureus", "ORGANISM", 75, 84], ["tcdA gene", "DNA", 43, 52], ["C. difficile", "SPECIES", 56, 68], ["S. aureus", "SPECIES", 75, 84], ["C. difficile", "SPECIES", 56, 68], ["S. aureus", "SPECIES", 75, 84], ["The assay", "TEST", 0, 9], ["LAMP amplification", "TEST", 17, 35], ["C. difficile", "PROBLEM", 56, 68], ["a S. aureus gene", "PROBLEM", 73, 89], ["an external quality control", "TREATMENT", 94, 121], ["the incubator/turbidity", "TREATMENT", 154, 177], ["C. difficile", "OBSERVATION", 56, 68], ["aureus", "OBSERVATION", 78, 84]]], ["Lalande et al. demonstrated that the sensitivity and specificity of the illumigene C. difficile kit for the detection of toxigenic strains were comparable to those of the culture method and other PCRbased methods [11] .", [["C. difficile kit", "ORGANISM", 83, 99], ["C. difficile", "SPECIES", 83, 95], ["C. difficile", "SPECIES", 83, 95], ["the sensitivity", "TEST", 33, 48], ["the illumigene C. difficile kit", "TEST", 68, 99], ["toxigenic strains", "PROBLEM", 121, 138], ["the culture method", "TEST", 167, 185]]], ["For example, the sensitivity and specificity of the kit compared to the culture method were 91.8 % and 99.1 %, respectively.", [["the sensitivity", "TEST", 13, 28], ["the kit", "TEST", 48, 55], ["the culture method", "TEST", 68, 86]]], ["This high level of performance, combined with the speed of the process (assay results for a batch of ten stool samples can be obtained within 1 h of testing), led them to conclude that LAMP represents a preferred option for management of the disease.Evaluation of LAMP reagents developed previouslyIn recent years, many research studies have been conducted to evaluate the practicability of the previously developed LAMP reagents.", [["stool samples", "ANATOMY", 105, 118], ["a batch of ten stool samples", "TEST", 90, 118], ["management", "TREATMENT", 224, 234], ["the disease", "PROBLEM", 238, 249], ["Evaluation", "TEST", 250, 260], ["LAMP reagents", "TEST", 264, 277], ["many research studies", "TEST", 315, 336], ["LAMP reagents", "TREATMENT", 416, 429], ["disease", "OBSERVATION", 242, 249]]], ["For example, the efficacy of LAMP primers developed by Han et al. [12] in the detection and typing of four Plasmodium species has been reported by Sirichaisinthop et al. [13] , where it was demonstrated that the Han's LAMP primers were effective, with sufficient sensitivity, for field use.", [["Plasmodium species", "DISEASE", 107, 125], ["Plasmodium", "ORGANISM", 107, 117], ["LAMP primers", "TREATMENT", 29, 41], ["the detection", "TEST", 74, 87], ["four Plasmodium species", "PROBLEM", 102, 125], ["the Han's LAMP primers", "PROBLEM", 208, 230]]], ["Use of the LAMP primer set has been recommended by the National Institute of Infectious Diseases of Japan in their manual.", [["the LAMP primer", "TREATMENT", 7, 22], ["Infectious", "OBSERVATION", 77, 87]]], ["Similarly, the previously developed LAMP assays for the detection of four serotypes of dengue virus [14] , Japanese encephalitis virus [15] , and West Nile virus [16] were recently shown to effectively and rapidly detect these viruses in both acute-phase patients and vector mosquitoes in an endemic country [17] .", [["dengue", "DISEASE", 87, 93], ["Japanese encephalitis", "DISEASE", 107, 128], ["dengue virus", "ORGANISM", 87, 99], ["Japanese encephalitis virus", "ORGANISM", 107, 134], ["West Nile virus", "ORGANISM", 146, 161], ["patients", "ORGANISM", 255, 263], ["dengue virus", "SPECIES", 87, 99], ["Japanese encephalitis virus", "SPECIES", 107, 134], ["West Nile virus", "SPECIES", 146, 161], ["patients", "SPECIES", 255, 263], ["dengue virus", "SPECIES", 87, 99], ["Japanese encephalitis virus", "SPECIES", 107, 134], ["West Nile virus", "SPECIES", 146, 161], ["LAMP assays", "TEST", 36, 47], ["dengue virus", "PROBLEM", 87, 99], ["Japanese encephalitis virus", "PROBLEM", 107, 134], ["West Nile virus", "PROBLEM", 146, 161], ["these viruses", "PROBLEM", 221, 234], ["viruses", "OBSERVATION", 227, 234], ["acute", "OBSERVATION_MODIFIER", 243, 248]]], ["Furthermore, the LAMP primer set for detecting Salmonella species developed by Hara-kudo has been evaluated by Zhang et al., who demonstrated that the LAMP assay using the primer set allowed faster and equally accurate detection of Salmonella species in fresh produce [18] .", [["LAMP primer set", "DNA", 17, 32], ["Salmonella", "SPECIES", 47, 57], ["Hara-kudo", "SPECIES", 79, 88], ["Salmonella", "SPECIES", 232, 242], ["the LAMP primer", "TEST", 13, 28], ["Salmonella species", "PROBLEM", 47, 65], ["the LAMP assay", "TEST", 147, 161], ["Salmonella species", "PROBLEM", 232, 250], ["Salmonella species", "OBSERVATION", 47, 65]]], ["The performance of the two LAMP primer sets (the RIME-LAMP and SRA-LAMP) for diagnosing HAT, designed by Njiru et al. [9, 19] , has been evaluated using clinical specimens collected from patients from endemic countries [20] .", [["specimens", "ANATOMY", 162, 171], ["patients", "ORGANISM", 187, 195], ["LAMP primer sets", "DNA", 27, 43], ["RIME", "DNA", 49, 53], ["SRA", "PROTEIN", 63, 66], ["patients", "SPECIES", 187, 195], ["clinical specimens", "TEST", 153, 171]]], ["They have reported that two LAMP primer sets can detect trypanosomes not only in blood but also in cerebrospinal fluid (CSF) collected from a late-stage HAT patient.", [["blood", "ANATOMY", 81, 86], ["cerebrospinal fluid", "ANATOMY", 99, 118], ["CSF", "ANATOMY", 120, 123], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 99, 118], ["CSF", "ORGANISM_SUBSTANCE", 120, 123], ["patient", "ORGANISM", 157, 164], ["LAMP primer sets", "DNA", 28, 44], ["patient", "SPECIES", 157, 164], ["two LAMP primer sets", "TEST", 24, 44], ["trypanosomes", "PROBLEM", 56, 68], ["cerebrospinal fluid", "TEST", 99, 118], ["cerebrospinal", "ANATOMY", 99, 112], ["fluid", "OBSERVATION", 113, 118]]], ["This finding suggests that these LAMP assays can be used as a routine test for diagnosis and staging of HAT patients.Developmental prospects of new LAMP reagentsDesign and evaluation of new LAMP primers for detecting various pathogens for research purposes has also been ongoing since before 2008.", [["HAT", "DISEASE", 104, 107], ["patients", "ORGANISM", 108, 116], ["LAMP primers", "DNA", 190, 202], ["patients", "SPECIES", 108, 116], ["these LAMP assays", "TEST", 27, 44], ["a routine test", "TEST", 60, 74], ["staging", "TEST", 93, 100], ["new LAMP reagents", "TREATMENT", 144, 161], ["evaluation", "TEST", 172, 182], ["new LAMP primers", "TEST", 186, 202], ["various pathogens", "PROBLEM", 217, 234], ["research purposes", "TEST", 239, 256]]], ["Application of LAMP to the world's three major diseases, that is, TB, malaria, and human immunodeficiency virus (HIV), has also been aggressively advanced since 2009, and more than 40 scientific articles on these diseases have been published.", [["TB", "DISEASE", 66, 68], ["malaria", "DISEASE", 70, 77], ["human immunodeficiency virus (HIV)", "DISEASE", 83, 117], ["human immunodeficiency virus", "ORGANISM", 83, 111], ["human immunodeficiency virus (HIV", "SPECIES", 83, 116], ["human immunodeficiency virus", "SPECIES", 83, 111], ["HIV", "SPECIES", 113, 116], ["LAMP", "TREATMENT", 15, 19], ["TB", "PROBLEM", 66, 68], ["malaria", "PROBLEM", 70, 77], ["human immunodeficiency virus", "PROBLEM", 83, 111], ["these diseases", "PROBLEM", 207, 221], ["diseases", "OBSERVATION", 47, 55], ["malaria", "OBSERVATION", 70, 77], ["diseases", "OBSERVATION", 213, 221]]], ["Research has not, however, focused solely on these major diseases.", [["diseases", "OBSERVATION", 57, 65]]], ["Of the 17 neglected tropical diseases (NTDs) recognized by WHO [21], 14 have been studied using LAMP, these being dengue [14, 22] , rabies [23] , buruli ulcer [24, 25] , leprosy [26] , Chagas disease [27, 28] , human African trypanosomiasis [29] , leishmaniasis [30, 31] , cysticercosis [32] , echinococcosis [33] , foodborne trematode infections [34] , lymphatic filariasis [35] , schistosomiasis [36] , soil-transmitted helminthiases [37] , and yaws [38] .", [["buruli ulcer", "ANATOMY", 146, 158], ["lymphatic", "ANATOMY", 354, 363], ["NTDs", "DISEASE", 39, 43], ["dengue", "DISEASE", 114, 120], ["rabies", "DISEASE", 132, 138], ["buruli ulcer", "DISEASE", 146, 158], ["leprosy", "DISEASE", 170, 177], ["Chagas disease", "DISEASE", 185, 199], ["African trypanosomiasis", "DISEASE", 217, 240], ["leishmaniasis", "DISEASE", 248, 261], ["cysticercosis", "DISEASE", 273, 286], ["echinococcosis", "DISEASE", 294, 308], ["foodborne trematode infections", "DISEASE", 316, 346], ["lymphatic filariasis", "DISEASE", 354, 374], ["schistosomiasis", "DISEASE", 382, 397], ["soil-transmitted helminthiases", "DISEASE", 405, 435], ["yaws", "DISEASE", 447, 451], ["rabies", "ORGANISM", 132, 138], ["buruli", "ORGANISM", 146, 152], ["ulcer", "PATHOLOGICAL_FORMATION", 153, 158], ["human", "ORGANISM", 211, 216], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["the 17 neglected tropical diseases (NTDs)", "PROBLEM", 3, 44], ["rabies", "TEST", 132, 138], ["buruli ulcer", "PROBLEM", 146, 158], ["leprosy", "TEST", 170, 177], ["Chagas disease", "PROBLEM", 185, 199], ["human African trypanosomiasis", "TEST", 211, 240], ["leishmaniasis", "PROBLEM", 248, 261], ["cysticercosis", "PROBLEM", 273, 286], ["echinococcosis", "PROBLEM", 294, 308], ["foodborne trematode infections", "PROBLEM", 316, 346], ["lymphatic filariasis", "PROBLEM", 354, 374], ["schistosomiasis", "PROBLEM", 382, 397], ["17 neglected", "OBSERVATION_MODIFIER", 7, 19], ["tropical", "OBSERVATION_MODIFIER", 20, 28], ["diseases", "OBSERVATION", 29, 37], ["buruli", "ANATOMY", 146, 152], ["ulcer", "OBSERVATION", 153, 158], ["echinococcosis", "OBSERVATION", 294, 308], ["lymphatic", "ANATOMY", 354, 363], ["filariasis", "OBSERVATION", 364, 374]]], ["The three exceptions are trachoma, onchocerciasis, and dracunculiasis.", [["trachoma", "DISEASE", 25, 33], ["onchocerciasis", "DISEASE", 35, 49], ["dracunculiasis", "DISEASE", 55, 69], ["trachoma", "PROBLEM", 25, 33], ["onchocerciasis", "PROBLEM", 35, 49], ["dracunculiasis", "PROBLEM", 55, 69], ["trachoma", "OBSERVATION", 25, 33], ["onchocerciasis", "OBSERVATION", 35, 49], ["dracunculiasis", "OBSERVATION", 55, 69]]], ["Because sophisticated facilities and well-trained laboratory technicians are unavailable in most areas in which NTDs are endemic, simple and robust diagnostic tools are in high demand [39] .", [["NTDs", "DISEASE", 112, 116]]], ["It is clear that the LAMP assay system represents a promising technology in both the diagnosis and post-elimination surveillance of NTDs.", [["NTDs", "DISEASE", 132, 136], ["the LAMP assay system", "TEST", 17, 38], ["NTDs", "PROBLEM", 132, 136], ["clear", "OBSERVATION", 6, 11]]], ["In addition, because many of these diseases are zoonotic vector-borne, LAMP has also been applied to the detection of pathogens in vectors [40] and reservoir animals [41, 42] , hinting at the potential for LAMP to be useful in both epidemiological surveillance and control of infection in endemic countries.Development of the basic technology for simplification of the LAMP assayThe most distinctive characteristics of LAMP technology are its simplicity and its rapidity, which represent principal advantages of LAMP over the PCR-based technique.", [["infection", "DISEASE", 276, 285], ["these diseases", "PROBLEM", 29, 43], ["LAMP", "TREATMENT", 71, 75], ["pathogens", "PROBLEM", 118, 127], ["LAMP", "TREATMENT", 206, 210], ["epidemiological surveillance", "TEST", 232, 260], ["infection", "PROBLEM", 276, 285], ["the LAMP assay", "TEST", 365, 379], ["the PCR", "TEST", 522, 529], ["diseases", "OBSERVATION", 35, 43], ["infection", "OBSERVATION", 276, 285], ["most distinctive", "OBSERVATION_MODIFIER", 383, 399], ["LAMP technology", "OBSERVATION", 419, 434], ["rapidity", "OBSERVATION_MODIFIER", 462, 470]]], ["This research activity is reviewed next.Simplification of LAMP reactionOne target of the basic research has been to simplify the heating method for the LAMP reaction.", [["LAMP reaction", "PROBLEM", 58, 71], ["the heating method", "TREATMENT", 125, 143], ["the LAMP reaction", "PROBLEM", 148, 165], ["LAMP reaction", "OBSERVATION", 58, 71]]], ["Because LAMP is an isothermal amplification method, LAMP can be performed using an inexpensive heater such as a block heater or water bath, thereby removing the dependence upon stable electricity and allowing for LAMP to be conducted at any time in any setting.", [["an isothermal amplification method", "TEST", 16, 50], ["an inexpensive heater", "TREATMENT", 80, 101], ["a block heater or water bath", "TREATMENT", 110, 138], ["LAMP", "TREATMENT", 213, 217]]], ["LaBarre et al. have recently designed an electricity-free incubation system utilizing a phase-change material and chemically generated heat [43] .", [["an electricity-free incubation system", "TREATMENT", 38, 75], ["a phase-change material", "TREATMENT", 86, 109]]], ["When this system was applied to the LAMP technology for detecting malaria parasites, its sensitivity proved to be comparable to that observed with the use of reference heaters (thermal cyclers).", [["malaria parasites", "DISEASE", 66, 83], ["the LAMP technology", "TEST", 32, 51], ["malaria parasites", "PROBLEM", 66, 83], ["reference heaters (thermal cyclers)", "TREATMENT", 158, 193], ["malaria", "OBSERVATION", 66, 73]]], ["Curtis et al. [44] have also developed a similar chemical heater and reported that it could be used for LAMP-based HIV assays with performance comparable to results from similar studies using PCR.", [["HIV", "ORGANISM", 115, 118], ["HIV", "SPECIES", 115, 118], ["LAMP-based HIV assays", "PROBLEM", 104, 125], ["PCR", "TEST", 192, 195]]], ["Additionally, Hatano et al. [45] successfully detected anthrax by using a disposable pocket warmer and reported that their system has the potential to act as a rapid and reliable test method against anti-bioterrorism.", [["anthrax", "DISEASE", 55, 62], ["anthrax", "ORGANISM", 55, 62], ["a disposable pocket warmer", "TREATMENT", 72, 98], ["anti-bioterrorism", "PROBLEM", 199, 216]]], ["Furthermore, Nkouawa et al. [46] conducted a LAMP assay using hot water kept in a thermos bottle and demonstrated the system to be capable of detecting Taenia tapeworms in human stool samples with performance comparable to that observed with the use of a thermal cycler.", [["stool samples", "ANATOMY", 178, 191], ["Taenia tapeworms", "DISEASE", 152, 168], ["Taenia tapeworms", "ORGANISM", 152, 168], ["human", "ORGANISM", 172, 177], ["stool samples", "ORGANISM_SUBSTANCE", 178, 191], ["human", "SPECIES", 172, 177], ["Taenia tapeworms", "SPECIES", 152, 168], ["human", "SPECIES", 172, 177], ["a LAMP assay", "TEST", 43, 55], ["hot water", "TREATMENT", 62, 71], ["a thermos bottle", "TREATMENT", 80, 96], ["Taenia tapeworms", "PROBLEM", 152, 168], ["human stool samples", "TEST", 172, 191], ["a thermal cycler", "TREATMENT", 253, 269]]], ["The notion of combining these simple heating methods with the so-called lTAS (micro-total analysis system) format, described below, represents a promising line of research toward the development of a noninstructed nucleic acid test.Simplification of LAMP reactionIt is known that dried PCR reagents have been commercialized in several ready-to-use kits.", [["nucleic acid", "CHEMICAL", 214, 226], ["the so-called lTAS", "TEST", 58, 76], ["a noninstructed nucleic acid test", "TEST", 198, 231], ["LAMP reaction", "PROBLEM", 250, 263], ["dried PCR reagents", "TREATMENT", 280, 298], ["LAMP reaction", "OBSERVATION", 250, 263]]], ["Similarly, a dried formulation of LAMP has also been developed.", [["a dried formulation of LAMP", "TREATMENT", 11, 38]]], ["The benefits of drying are summarized here:Simplification of LAMP reaction\u2022 Eliminates the need for preparation and dispensation of a master mix solution. \u2022 Increases stability during storage at ambient temperature and, consequently, eliminates the need for a freezer for storage and cold chain system for transportation \u2022 Can increase the loadable sample volume, leading to an increase in sensitivity.Simplification of LAMP reactionLAMP reagents for TB, HAT, malaria, and influenza (type A and H1 pdm 2009) are dried down in the caps of reaction tubes.", [["sample", "ANATOMY", 349, 355], ["TB", "DISEASE", 451, 453], ["malaria", "DISEASE", 460, 467], ["influenza", "DISEASE", 473, 482], ["LAMP reaction", "PROBLEM", 61, 74], ["a master mix solution", "TREATMENT", 132, 153], ["a freezer for storage and cold chain system", "TREATMENT", 258, 301], ["the loadable sample volume", "TREATMENT", 336, 362], ["an increase in sensitivity", "PROBLEM", 375, 401], ["LAMP reactionLAMP reagents", "TREATMENT", 420, 446], ["TB", "PROBLEM", 451, 453], ["HAT", "PROBLEM", 455, 458], ["malaria", "PROBLEM", 460, 467], ["influenza", "PROBLEM", 473, 482], ["reaction tubes", "TREATMENT", 538, 552], ["stability", "OBSERVATION_MODIFIER", 167, 176], ["increase", "OBSERVATION_MODIFIER", 378, 386], ["malaria", "OBSERVATION", 460, 467], ["reaction tubes", "OBSERVATION", 538, 552]]], ["The dried reagents are reconstituted by loading a purified sample solution to the reaction tubes and then transferring the sample solution to the cap, as shown in Fig. 2 .", [["The dried reagents", "TREATMENT", 0, 18], ["a purified sample solution", "TREATMENT", 48, 74], ["the reaction tubes", "TREATMENT", 78, 96], ["the sample solution", "TREATMENT", 119, 138], ["reaction tubes", "OBSERVATION", 82, 96], ["cap", "OBSERVATION_MODIFIER", 146, 149]]], ["This format has been designed to minimize the time interval among the reaction tubes associated with the reconstitution of the dried LAMP reagents.", [["the reaction tubes", "TREATMENT", 66, 84], ["the dried LAMP reagents", "TREATMENT", 123, 146], ["reaction tubes", "OBSERVATION", 70, 84]]], ["The illumigene Clostridium difficile detection kit (Meridian Bioscience) also adopts the dried reagent format.Simplification of LAMP reactionRecently, New England Biolabs developed new DNA polymerases called Bst 2.0 and WarmStart Bst 2.0.", [["DNA", "CELLULAR_COMPONENT", 185, 188], ["DNA polymerases", "PROTEIN", 185, 200], ["Bst 2.0", "DNA", 208, 215], ["Clostridium difficile", "SPECIES", 15, 36], ["Clostridium difficile", "SPECIES", 15, 36], ["The illumigene Clostridium difficile detection", "TEST", 0, 46], ["new DNA polymerases", "PROBLEM", 181, 200], ["Bst", "TEST", 208, 211], ["WarmStart Bst", "TEST", 220, 233]]], ["Tanner et al. [47] evaluated the applicability of these new enzymes to LAMP and demonstrated that Bst 2.0 can catalyze the LAMP reaction more rapidly than wild-type Bst DNA polymerase, whereas the warm start version of Bst 2.0 does not reduce the LAMP reaction rate even when preincubated in the prepared LAMP reaction reagent at room temperature for 2 h before the reaction.", [["Bst 2.0", "CHEMICAL", 98, 105], ["Bst", "CHEMICAL", 219, 222], ["Bst", "SIMPLE_CHEMICAL", 98, 101], ["Bst", "GENE_OR_GENE_PRODUCT", 165, 168], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["wild-type Bst DNA polymerase", "PROTEIN", 155, 183], ["these new enzymes", "TEST", 50, 67], ["LAMP", "TEST", 71, 75], ["the LAMP reaction", "PROBLEM", 119, 136], ["type Bst DNA polymerase", "PROBLEM", 160, 183], ["the LAMP reaction rate", "TEST", 243, 265], ["the reaction", "PROBLEM", 362, 374]]], ["These findings indicate that the development of new, improved performance DNA polymerases is one of the key factors in the improvement of LAMP technology.Sample processing technologyMost existing sample processing methods involve multiple complicated processes (liquid handling using a micropipette, for example) and sophisticated equipment such as a high-speed centrifuge.", [["sample", "ANATOMY", 196, 202], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA polymerases", "PROTEIN", 74, 89], ["new, improved performance DNA polymerases", "PROBLEM", 48, 89], ["LAMP technology", "TREATMENT", 138, 153], ["sample processing methods", "TREATMENT", 196, 221], ["multiple complicated processes", "PROBLEM", 230, 260], ["a micropipette", "TREATMENT", 284, 298], ["sophisticated equipment", "TREATMENT", 317, 340], ["a high-speed centrifuge", "TREATMENT", 349, 372], ["new", "OBSERVATION_MODIFIER", 48, 51], ["improved", "OBSERVATION_MODIFIER", 53, 61], ["multiple", "OBSERVATION_MODIFIER", 230, 238], ["complicated", "OBSERVATION_MODIFIER", 239, 250]]], ["Clearly, then, the sample processing method must be significantly simplified before it can be considered for use in resource-poor environments.", [["the sample processing method", "TREATMENT", 15, 43]]], ["Some characteristics of LAMP, such as high specificity and tolerance to inhibitors [48] , contribute toward this simplification of the sample processing steps.Sample processing technologyThe procedure for the ultra-rapid extraction (PURE) method was developed as a technique for the extraction of DNA from TB cells directly from fresh sputum [6] .", [["sample", "ANATOMY", 135, 141], ["TB cells", "ANATOMY", 306, 314], ["sputum", "ANATOMY", 335, 341], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["TB cells", "CELL", 306, 314], ["TB cells", "CELL_TYPE", 306, 314], ["LAMP", "PROBLEM", 24, 28], ["The procedure", "TREATMENT", 187, 200], ["the ultra-rapid extraction (PURE) method", "TREATMENT", 205, 245], ["a technique", "TREATMENT", 263, 274], ["the extraction", "TREATMENT", 279, 293], ["DNA", "PROBLEM", 297, 300], ["TB cells", "PROBLEM", 306, 314], ["fresh sputum", "PROBLEM", 329, 341], ["LAMP", "OBSERVATION", 24, 28]]], ["The technique involves the use of an adsorbent powder that removes inhibitors from the sample without disturbing the DNA.", [["sample", "ANATOMY", 87, 93], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["an adsorbent powder", "TREATMENT", 34, 53], ["inhibitors", "TREATMENT", 67, 77], ["the DNA", "PROBLEM", 113, 120]]], ["As already mentioned, this technique eliminates the need for sophisticated equipment, such as a centrifuge, which in turn makes it suitable for use in resource-poor facilities in developing countries.Sample processing technologyNakauchi et al. [49] evaluated a simple extraction reagent for influenza virus (Looamp Extraction Reagent for Influenza virus, manufactured by Eiken Chemical): they showed that the extraction of influenza genome RNA and simultaneous removal of inhibitors is possible by only stirring a throat or nasal swab several times in this reagent.", [["throat", "ANATOMY", 514, 520], ["nasal swab", "ANATOMY", 524, 534], ["influenza virus", "DISEASE", 291, 306], ["Influenza virus", "DISEASE", 338, 353], ["influenza virus", "ORGANISM", 291, 306], ["Influenza virus", "ORGANISM", 338, 353], ["throat", "ORGANISM_SUBDIVISION", 514, 520], ["influenza genome RNA", "RNA", 423, 443], ["influenza virus", "SPECIES", 291, 306], ["Influenza virus", "SPECIES", 338, 353], ["influenza virus", "SPECIES", 291, 306], ["Influenza virus", "SPECIES", 338, 353], ["this technique", "TREATMENT", 22, 36], ["sophisticated equipment", "TREATMENT", 61, 84], ["a centrifuge", "TREATMENT", 94, 106], ["a simple extraction reagent", "TREATMENT", 259, 286], ["influenza virus", "PROBLEM", 291, 306], ["Looamp Extraction Reagent", "TREATMENT", 308, 333], ["Influenza virus", "PROBLEM", 338, 353], ["the extraction", "TREATMENT", 405, 419], ["influenza genome RNA", "PROBLEM", 423, 443], ["simultaneous removal of inhibitors", "TREATMENT", 448, 482], ["a throat", "PROBLEM", 512, 520], ["nasal swab", "TREATMENT", 524, 534], ["this reagent", "TREATMENT", 552, 564]]], ["In contrast to pretreatment methods conducted in many laboratories, this technique requires no heating and centrifugation.", [["pretreatment methods", "TEST", 15, 35], ["this technique", "TREATMENT", 68, 82], ["heating and centrifugation", "TREATMENT", 95, 121]]], ["At present, the application of this extraction reagent is limited to the influenza virus.", [["influenza", "DISEASE", 73, 82], ["influenza virus", "ORGANISM", 73, 88], ["influenza virus", "SPECIES", 73, 88], ["this extraction reagent", "TREATMENT", 31, 54], ["the influenza virus", "PROBLEM", 69, 88], ["influenza virus", "OBSERVATION", 73, 88]]], ["However, its application for the detection of other viruses represents an interesting area for future study.Sample processing technologyThe use of Whatman filter paper (FTA) technology looks to be a promising technique for stably transporting samples.", [["samples", "ANATOMY", 243, 250], ["other viruses", "PROBLEM", 46, 59], ["future study", "TEST", 95, 107], ["Whatman filter paper", "TREATMENT", 147, 167], ["viruses", "OBSERVATION", 52, 59]]], ["A number of simple methods combining the use of these cards with the PCR technique for the detection of pathogens have been reported [50] .", [["simple methods", "TREATMENT", 12, 26], ["the PCR technique", "TEST", 65, 82], ["the detection", "TEST", 87, 100], ["pathogens", "PROBLEM", 104, 113]]], ["For example, Plasmodium and Trypanosoma in blood samples collected on a FTA card can be detected by LAMP [51, 52] .", [["blood samples", "ANATOMY", 43, 56], ["Plasmodium", "ORGANISM", 13, 23], ["Trypanosoma", "ORGANISM", 28, 39], ["blood samples", "ORGANISM_SUBSTANCE", 43, 56], ["Plasmodium", "PROBLEM", 13, 23], ["blood samples", "TEST", 43, 56], ["a FTA card", "TEST", 70, 80], ["Plasmodium", "OBSERVATION_MODIFIER", 13, 23], ["Trypanosoma", "OBSERVATION_MODIFIER", 28, 39]]], ["This format may also be useful in mass screening studies and in epidemiological studies that involve the collection of samples from rural areas to reference laboratories in developing countries.Application of lTAS technologyThe isothermal amplification reaction, including LAMP, is particularly effective in combination with the technology known as lTAS, or lab-on-a-chip utilizing microfluidic technology, as reviewed by Asiello and Baeumner [53] .Application of lTAS technologyThus, studies on the integration of LAMP and lTAS have been performed by a number of research groups.", [["lTAS", "SIMPLE_CHEMICAL", 349, 353], ["lTAS", "GENE_OR_GENE_PRODUCT", 524, 528], ["lTAS", "PROTEIN", 524, 528], ["mass screening studies", "TEST", 34, 56], ["epidemiological studies", "TEST", 64, 87], ["lTAS technology", "TREATMENT", 209, 224], ["The isothermal amplification reaction", "PROBLEM", 224, 261], ["LAMP", "TREATMENT", 273, 277], ["lTAS technology", "TREATMENT", 464, 479], ["LAMP and lTAS", "TEST", 515, 528]]], ["For instance, Liu et al. successfully detected ten particles of HIV in an oral fluid sample by designing a single-use, lowcost, disposable, integrated, single-chamber LAMP cassette utilizing an FTA membrane for nucleic acid isolation, purification, and concentration [54] .", [["oral fluid sample", "ANATOMY", 74, 91], ["membrane", "ANATOMY", 198, 206], ["nucleic acid", "CHEMICAL", 211, 223], ["HIV", "ORGANISM", 64, 67], ["oral", "ORGANISM_SUBDIVISION", 74, 78], ["LAMP cassette", "DNA", 167, 180], ["HIV", "SPECIES", 64, 67], ["HIV", "SPECIES", 64, 67], ["HIV", "PROBLEM", 64, 67], ["an oral fluid sample", "TEST", 71, 91], ["single-chamber LAMP cassette", "TREATMENT", 152, 180], ["an FTA membrane", "TREATMENT", 191, 206], ["nucleic acid isolation", "TREATMENT", 211, 233], ["ten particles", "OBSERVATION_MODIFIER", 47, 60], ["HIV", "OBSERVATION", 64, 67]]], ["Similar integrated devices have been reported from several other groups [55, 56] .Application of lTAS technologyOne advantage of applying lTAS technology to LAMP is that it allows for the simultaneous assay of multiple targets.", [["Similar integrated devices", "TREATMENT", 0, 26], ["lTAS technology", "TREATMENT", 97, 112], ["the simultaneous assay", "TEST", 184, 206], ["devices", "OBSERVATION", 19, 26]]], ["Provision of effective medical treatment to patients requires a simple and swift diagnosis to detect possible pathogens causing the same clinical symptoms.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["effective medical treatment", "TREATMENT", 13, 40], ["pathogens", "PROBLEM", 110, 119], ["the same clinical symptoms", "PROBLEM", 128, 154]]], ["Consequently, Abe et al. developed a simple amplification and detection chip and a portable device for use in point-of-care testing [57] .", [["a simple amplification and detection chip", "PROBLEM", 35, 76], ["a portable device", "TREATMENT", 81, 98]]], ["Their chip incorporates a vacuum system, which eliminates the need for a pump and tubing to inject the sample solution.", [["sample", "ANATOMY", 103, 109], ["a vacuum system", "TREATMENT", 24, 39], ["a pump and tubing", "TREATMENT", 71, 88], ["the sample solution", "TREATMENT", 99, 118], ["vacuum system", "OBSERVATION", 26, 39]]], ["They have reported that the sensitivity of their system for detecting subtype-specific influenza strains from nasal swab samples is comparable to RT-PCR tests performed according to the WHO recommended protocol.", [["nasal swab samples", "ANATOMY", 110, 128], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 110, 120], ["subtype-specific influenza strains", "PROBLEM", 70, 104], ["nasal swab samples", "TEST", 110, 128], ["RT-PCR tests", "TEST", 146, 158]]], ["This kind of multiplex detection format using lTAS technology also has the advantage to reduce its production cost by lowering reaction volume.Application of lTAS technologyAt one time, simple visual detection techniques to show whether the LAMP amplification reaction takes place were intensively developed [59, 60] .", [["multiplex detection", "TEST", 13, 32], ["lTAS technology", "TREATMENT", 46, 61], ["lowering reaction volume", "PROBLEM", 118, 142], ["lTAS technology", "TREATMENT", 158, 173], ["simple visual detection techniques", "TEST", 186, 220], ["the LAMP amplification reaction", "PROBLEM", 237, 268]]], ["In recent years, however, researchers have started to pay attention to various types of detection methods using electrochemical reactions previously featured in PCR format studies [61] .", [["detection methods", "TEST", 88, 105], ["electrochemical reactions", "PROBLEM", 112, 137], ["PCR format studies", "TEST", 161, 179]]], ["The benefits of electrochemical detection methods lie in their higher sensitivity and also, practically, in the nature of the equipment for electrochemical detection, which can be designed to be smaller than that used in the optical detection format.", [["electrochemical detection methods", "TEST", 16, 49], ["electrochemical detection", "TEST", 140, 165]]], ["Safavieh et al. [62] prepared an electrochemical detection device, utilizing the LAMP assay for detecting Escherichia coli, to demonstrate its potential for its clinical application as a simple point-of-care diagnostic device.", [["Escherichia coli", "ORGANISM", 106, 122], ["Escherichia coli", "SPECIES", 106, 122], ["Escherichia coli", "SPECIES", 106, 122], ["an electrochemical detection device", "TREATMENT", 30, 65], ["the LAMP assay", "TEST", 77, 91], ["Escherichia coli", "PROBLEM", 106, 122], ["diagnostic device", "TREATMENT", 208, 225], ["Escherichia coli", "OBSERVATION", 106, 122]]], ["In addition, Sato et al. reported a method for specifically detecting DNA sequences through the use of an electrochemically active intercalator.", [["DNA", "CELLULAR_COMPONENT", 70, 73], ["DNA sequences", "DNA", 70, 83], ["DNA sequences", "TEST", 70, 83], ["an electrochemically active intercalator", "TREATMENT", 103, 143]]], ["This technology has been clinically applied in the detection and typing of HPV, named ''Clinichip HPV'' (Sekisui Medical, Tokyo, Japan) [63] .", [["HPV", "ORGANISM", 75, 78], ["HPV", "SPECIES", 75, 78], ["the detection", "TEST", 47, 60]]], ["In the paper, it was demonstrated that the Clinichip test detected 13 individual carcinogenic HPV types with high agreement (96.8-100 %) with the direct-sequencing method.", [["HPV", "ORGANISM", 94, 97], ["the Clinichip test", "TEST", 39, 57]]], ["Moreover, because the test procedures are simplified and automated, the Clinichp test has potential to be a simple and useful diagnostic tool for risk evaluation of HPV infection.SummaryThis review has highlighted the most recent advances concerning LAMP technology from two distinct points of view: first, from observation of existing applications of LAMP in clinical practice, and second, by considering basic studies that have aimed to develop simple genetic tests using LAMP.SummaryLAMP technology has been put to practical use in Japan as approved IVDs for the detection of several different pathogens.", [["HPV infection", "DISEASE", 165, 178], ["HPV", "ORGANISM", 165, 168], ["IVDs", "CANCER", 553, 557], ["HPV", "SPECIES", 165, 168], ["the test procedures", "TEST", 18, 37], ["the Clinichp test", "TEST", 68, 85], ["risk evaluation", "TEST", 146, 161], ["HPV infection", "PROBLEM", 165, 178], ["basic studies", "TEST", 406, 419], ["simple genetic tests", "TEST", 447, 467], ["IVDs", "TREATMENT", 553, 557], ["the detection", "TEST", 562, 575], ["several different pathogens", "PROBLEM", 579, 606], ["infection", "OBSERVATION", 169, 178], ["different", "OBSERVATION_MODIFIER", 587, 596], ["pathogens", "OBSERVATION", 597, 606]]], ["In the future, it is expected that application of LAMP will be expanded to include other clinically important pathogens for which nucleic acid tests using alternative amplification methods have already been approved.", [["nucleic acid", "CHEMICAL", 130, 142], ["LAMP", "TREATMENT", 50, 54], ["other clinically important pathogens", "PROBLEM", 83, 119], ["nucleic acid tests", "TEST", 130, 148], ["alternative amplification methods", "TREATMENT", 155, 188]]], ["It is also expected that LAMP technology will be applied to detect single nucleotide polymorphisms, relating to drug resistance or side effects, to predict the most effective antimicrobial therapy.", [["LAMP technology", "TREATMENT", 25, 40], ["single nucleotide polymorphisms", "PROBLEM", 67, 98], ["drug resistance", "PROBLEM", 112, 127], ["side effects", "PROBLEM", 131, 143], ["antimicrobial therapy", "TREATMENT", 175, 196], ["antimicrobial therapy", "OBSERVATION", 175, 196]]], ["Because the number of LAMP-based genetic test reagents currently approved by the certification organization outside Japan remains very small, the practical realization of LAMP technology as a simple and swift genetic test would be in high demand in many countries, especially in most developing countries where many people are facing the threat of a wide variety of infectious diseases.", [["infectious diseases", "DISEASE", 366, 385], ["people", "ORGANISM", 316, 322], ["people", "SPECIES", 316, 322], ["LAMP", "TEST", 22, 26], ["swift genetic test", "TEST", 203, 221], ["infectious diseases", "PROBLEM", 366, 385], ["small", "OBSERVATION", 135, 140], ["infectious", "OBSERVATION", 366, 376]]]], "6b8f24b5ccf13a609a902a15c218c1abc3f0944a": [["Cultural Studies of Science Education during a time of crisisThe journal Cultural Studies of Science Education (CSSE) was created 15 years ago to serve as a venue for disseminating cutting edge scholarship on science education through sociocultural lenses.", [["Cultural Studies", "TEST", 0, 16], ["crisis", "PROBLEM", 55, 61], ["sociocultural lenses", "OBSERVATION", 235, 255]]], ["Currently co-edited by Catherine Milne and myself, CSSE has grown to be an international community over the past 15 years, with a diverse authorship, committed editorial board, motivated reviewers, and a wide global reach of readership.Cultural Studies of Science Education during a time of crisisAligned with the aim of serving as a venue for scholarly innovation and dialogue, and in response to the current global circumstances, we will devote parts of the upcoming issues of the journal to papers dealing with science education during these times of uncertainty, and we call on the CSSE community to generate scholarly dialogue and reflection focused on the overarching question: How can the Cultural Studies of Science Education community contribute to understanding, responding to, and re-envisioning this era of pandemic?Cultural Studies of Science Education during a time of crisisThere are many questions that emerge when reflecting on the role of our community at this time, including: What is the role of science education in a time of a global crisis?", [["CSSE", "CHEMICAL", 51, 55], ["Cultural Studies", "TEST", 236, 252], ["crisis", "PROBLEM", 291, 297], ["scholarly innovation", "TREATMENT", 344, 364], ["science education", "TREATMENT", 514, 531], ["pandemic", "PROBLEM", 819, 827], ["Cultural Studies", "TEST", 828, 844], ["crisis", "PROBLEM", 883, 889], ["a global crisis", "PROBLEM", 1047, 1062]]], ["These are some of the questions Cath and I have been grappling with, and we hope to engage the CSSE community in reflecting on how the cultural studies of science education can contribute to new understandings relevant to the current global circumstances.", [["Cath", "TEST", 32, 36], ["the cultural studies", "TEST", 131, 151], ["science education", "TREATMENT", 155, 172]]], ["Together with Jennifer Adams, Joseph Henderson, and David Long, we will soon be issuing the complete details of a call for papers, in which we encourage the CSSE community to submit articles addressing the COVID-19 pandemic.Cultural Studies of Science Education during a time of crisisOur social and political systems are under extreme stress, and inequalities are even more glaring, \"This crisis is exposing the extreme fissures in our society and the deep and abiding obligation we have to put things right\" (Nasir and Bang, 2020) .", [["fissures", "DISEASE", 421, 429], ["the COVID", "TEST", 202, 211], ["Cultural Studies", "TEST", 224, 240], ["crisis", "PROBLEM", 279, 285], ["extreme stress", "PROBLEM", 328, 342], ["This crisis", "PROBLEM", 385, 396], ["the extreme fissures", "PROBLEM", 409, 429]]], ["Global closures of educational institutions present formidable challenges to millions of children, teachers, and parents, and the choices that we make now will likely resonate long into the future.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97]]], ["Science education is an important part of a responding to the COVID-19 pandemic and to global climate change, and we believe that the cultural studies of science education can provide critical lenses on ways to move forward in solidarity.Cultural studies of science education and innovative scholarshipIn the first editorial in 2006, founding editors Wolff-Michael Roth and Kenneth Tobin elaborated CSSE's unique focus on \"scholarly articles that employ social and cultural perspectives as foundations for research and other scholarly activities in science education and studies of science\" (Roth and Tobin 2006, p.", [["the cultural studies", "TEST", 130, 150], ["science education", "TREATMENT", 154, 171], ["Cultural studies", "TEST", 238, 254]]], ["The quarterly issues of CSSE typically present publications immersed in cultural studies perspectives, and with a diversity of foci regarding science education.", [["cultural studies", "TEST", 72, 88], ["foci", "OBSERVATION", 127, 131]]], ["A critical point for reflection emerges in my own reading of these papers collectively, which is that of the importance of supporting teachers and students in drawing on, and extending, the plethora of resources they already bring to teaching and learning settings.", [["learning settings", "TREATMENT", 247, 264]]], ["In sum, the papers in this issue serve to make strong contributions to understanding the complexities of teaching and learning science in contextually relevant ways while presenting varied considerations for working toward equitable and transformative practices for science education.Cultural studies of science education and innovative scholarshipIn Science identity as a landscape of becoming: rethinking recognition and emotions through an intersectionality lens, Lucy Avraamidou forwards intersectionality as an important methodological perspective as she highlights the value of framing science identity as a landscape of becoming.", [["science education", "TREATMENT", 266, 283], ["Cultural studies", "TEST", 284, 300], ["science education", "TREATMENT", 304, 321]]], ["In this forum paper, Behnagn extends the perspectives on emotions by exploring different methods of measuring emotions, and raising points for consideration by science education researchers interested in this area of work.Cultural studies of science education and innovative scholarshipThe nuances of becoming and being a teacher continue as a focal point of a paper set around the contribution by Augusto Macalalag Jr., Joseph Johnson and Michelle Lai, How do we do this: Learning how to teach socio-scientific issues.", [["Cultural studies", "TEST", 222, 238]]], ["The authors explore how teachers navigated curriculum to incorporate SSI into their teaching practices, and teaseapart shifts in teachers' perceptions related to field experiences designed to support the teaching of SSI.", [["SSI", "TREATMENT", 69, 72], ["SSI", "TREATMENT", 216, 219]]], ["Darren Hoeg discusses SSIs as related to environmental ethics in his response paper, foregrounding tensions in socio-scientific issues as related to developing the oil sands in Canada and connecting these to the work of Macalalag Jr., Johnson and Lai.", [["SSIs", "PROBLEM", 22, 26]]], ["Jina Chang and Jisun Park raise questions about what, and how, teachers should learn as regards socio-scientific issues as they introduce the concept of SSI-PCK, and examine connections between this framework and the research of Macalag Jr., Johnson and Lai.Cultural studies of science education and innovative scholarshipThe complexities of learning to teach science become further evident through Kristina Andersson, Annica Gullberg, Anna Danielsson, Kathryn Scantlebury, and Anita Huss\u00e9nius's paper, Chafing borderlands: obstacles for science teaching and learning in preschool teacher education.", [["SSI-PCK", "TREATMENT", 153, 160]]], ["Focusing on early childhood teachers participating in science education courses, this work explore tensions that arise between two different cultures, preschool culture and university science culture, tensions which can create what the authors aptly refer to as \"chafing\" at their borders.", [["two different cultures", "TEST", 127, 149], ["preschool culture", "TEST", 151, 168], ["university science culture", "TEST", 173, 199]]], ["The authors unpack these perspectives on borderlands through the analysis of pre-service teachers' science education experiences, as they focus on how the different cultures, and boundary lines between the cultures, affect students' perceptions and expectations for instruction.", [["the different cultures", "TEST", 151, 173], ["boundary lines", "TREATMENT", 179, 193], ["the cultures", "TEST", 202, 214]]], ["Approaches for supporting pre-service teachers as they learn to teach science are also raised and examined in Sheron Mark, Lateefah Id-Deen and Shelley Thomas' paper, Getting to the root of the matter: pre-service teachers' experiences and positionalities with learning to teach in culturally diverse contexts in which they use critical discourse analysis to examine pre-service teachers' participation and positionalities regarding learning to teach and raise implications for teacher education programs and school-based administration, in particular, as regards beliefs which may have an influence on teaching and learning.Cultural studies of science education and innovative scholarshipAnother significant consideration for science teaching and learning addressed in several papers in this issue is the role of languages for science learning and teaching.", [["Cultural studies", "TEST", 625, 641], ["science education", "TREATMENT", 645, 662], ["science teaching", "TREATMENT", 727, 743]]], ["The integral role of language and science is also the focus of Lauren Swanson, Emily Kang, and Clara Bauler's paper, Revealing a bilingual science teacher's dynamic views and practice about science and language teaching through dialogic reflections, in which they posit that a new curriculum, coupled with on-going dialogue and coteaching with one of the authors, mediated a teacher's emerging abilities to think and act in different ways.Cultural studies of science education and innovative scholarshipAs this issue of CSSE shows, the role and nuances of languages and identities for science teaching and learning are two major considerations for the work of researchers using cultural studies lenses.", [["Cultural studies", "TEST", 439, 455], ["science education", "TREATMENT", 459, 476], ["science teaching", "TREATMENT", 585, 601], ["cultural studies lenses", "TEST", 678, 701]]], ["A further integral consideration for researchers using sociocultural lenses is that of context, as Alejandro Gallard Mart\u00ednez, Wesley Pitts, Katie Milton Brkich, and S. Lizette Ramos de Robles elaborate in How does one recognize contextual mitigating factors (CMFs) as a basis to understand and arrive at better approaches to research designs?", [["CMFs", "PROTEIN", 260, 264], ["sociocultural lenses", "TREATMENT", 55, 75]]], ["Their work highlights the value of recognizing CMFs in the design of research, and they stress that how context is positioned and how phenomena are studied in research are situated, and conclude by drawing attention to the potential impact of CMF analysis on evaluating research designs.", [["CMF analysis", "TEST", 243, 255]]], ["In their response, Martin and Kang consider how CMF analysis can help researchers be more critical about their ontological-epistemological-axiological stance and how this stance informs their understandings.", [["CMF analysis", "TEST", 48, 60]]], ["Relatedly, Wilmes and I also build upon the work of Gallard Mart\u00ednez et al., as we reflect upon different elements one might consider regarding the role of context for working toward equitable, responsive practices and draw upon our own research projects to discuss CMFs related to issues of equity in teaching science with culturally and linguistically diverse students.Cultural studies of science education and innovative scholarshipThe methodological focus continues in the final paper set of this issue, beginning with Vanessa Anthony-Stevens and Sammy Matsaw Jr.'s exploration of the integration of decolonizing methodologies in the preparation of STEM researchers, The productive uncertainty of indigenous and decolonizing methodologies in the preparation of interdisciplinary STEM researchers, in which the authors examine STEM student reactions to including Indigenous ways of knowing into research methodologies courses.", [["CMFs", "DISEASE", 266, 270], ["Cultural studies", "TEST", 371, 387], ["decolonizing methodologies", "TREATMENT", 604, 630], ["indigenous and decolonizing methodologies", "PROBLEM", 701, 742], ["STEM", "ANATOMY", 653, 657], ["productive", "OBSERVATION_MODIFIER", 675, 685], ["uncertainty", "OBSERVATION_MODIFIER", 686, 697], ["indigenous", "OBSERVATION_MODIFIER", 701, 711]]], ["In working towards the goal of giving shape to defining scholarship in the field, we invite potential authors to think broadly about the role of the science education community at a time of crisis, both within and beyond COVID-19.", [["crisis", "PROBLEM", 190, 196]]], ["We hope to receive submissions from a range of scholars, contexts, and perspectives, and possible topics could include: Issues of justice and equity in science and science education during times of crises, The social and cultural production of mis/trust in science, Political ideologies, science, and conflicts between individual and social goods, Social, conceptual, ethical, epistemological issues within the field of science education, Climate change, pandemics and reflections on the role of science education, Critical analyses of policies and institutions that mediate progress, among many others possible topics and foci.", [["pandemics", "DISEASE", 455, 464], ["crises", "PROBLEM", 198, 204], ["foci", "PROBLEM", 623, 627], ["foci", "OBSERVATION", 623, 627]]], ["I hope that CSSE readers and contributing authors are as inspired as we are about this upcoming special initiative, and that we can come together in scholarly community, to focus on finding solutions and reimagining a new future during this era of COVID-19.", [["COVID-19", "CHEMICAL", 248, 256], ["COVID", "TEST", 248, 253]]], ["\"Returning to normal\" is not possible.", [["normal", "OBSERVATION", 14, 20], ["not possible", "UNCERTAINTY", 25, 37]]], ["There is a new normal, one that is shifting and changing, shrouded in uncertainties.", [["new", "OBSERVATION_MODIFIER", 11, 14], ["normal", "OBSERVATION", 15, 21], ["one", "OBSERVATION_MODIFIER", 23, 26], ["shifting", "OBSERVATION_MODIFIER", 35, 43]]]], "PMC7121751": [["IntroductionInfluenza is a contemporary worldwide scourge.", [["Influenza", "DISEASE", 12, 21], ["Influenza", "PROBLEM", 12, 21]]], ["There were three influenza pandemics in the nineteenth century.", [["influenza pandemics", "DISEASE", 17, 36], ["three influenza pandemics", "PROBLEM", 11, 36], ["influenza pandemics", "OBSERVATION", 17, 36]]], ["The most tragic one, the Spanish flu, caused 50\u2013100 m deaths and considerable economic losses, according to the contemporary estimates.", [["flu", "DISEASE", 33, 36], ["deaths", "DISEASE", 54, 60], ["Spanish flu", "SPECIES", 25, 36], ["considerable economic losses", "PROBLEM", 65, 93], ["considerable", "OBSERVATION_MODIFIER", 65, 77], ["economic losses", "OBSERVATION", 78, 93]]], ["The WHO proposed a global program for the surveillance of influenza in 1947, based on the epidemiological and virological research (Bednarska et al. 2016a; Broberg et al. 2015).", [["influenza", "DISEASE", 58, 67], ["influenza", "PROBLEM", 58, 67]]], ["This program has currently assumed a form of the Global Influenza Surveillance and Response System, Poland has been participating in since 1957.", [["Influenza", "DISEASE", 56, 65], ["Influenza", "OBSERVATION", 56, 65]]], ["The surveillance system has included the Sentinel program as of 2004.", [["The surveillance system", "TEST", 0, 23]]], ["The surveillance is pursued in cooperation with general practitioners and laboratories of 16 Provincial Sanitary-Epidemiological Stations across the country.", [["laboratories", "TEST", 74, 86]]], ["The epidemiological part of this surveillance is based on reports of cases and suspected cases of influenza and influenza-like illnesses.", [["influenza", "DISEASE", 98, 107], ["influenza-like illnesses", "DISEASE", 112, 136], ["this surveillance", "TEST", 28, 45], ["influenza", "PROBLEM", 98, 107], ["influenza", "PROBLEM", 112, 121], ["influenza", "OBSERVATION", 98, 107]]], ["The virological monitoring is based on a laboratory confirmation of infection using molecular biology methods (Bednarska et al. 2016b).", [["infection", "DISEASE", 68, 77], ["The virological monitoring", "TEST", 0, 26], ["a laboratory confirmation", "TEST", 39, 64], ["infection", "PROBLEM", 68, 77], ["infection", "OBSERVATION", 68, 77]]], ["In addition, virological data recorded in the non-Sentinel program are collected from hospitals and private physicians.IntroductionInfluenza infection, with the occurrence of complications, mortality, and absenteeism at work, bears outstanding health and socioeconomic burdens.", [["Influenza infection", "DISEASE", 131, 150], ["virological data", "TEST", 13, 29], ["IntroductionInfluenza infection", "PROBLEM", 119, 150], ["complications", "PROBLEM", 175, 188], ["absenteeism", "PROBLEM", 205, 216], ["infection", "OBSERVATION", 141, 150], ["complications", "OBSERVATION", 175, 188]]], ["This study was designed to present and compare the virological characteristics of influenza seasons in Poland in the last decade, based on the epidemiological data from the national influenza surveillance system.Material and ResultsThis article was based on the influenza surveillance system consisting of Sentinel and non-Sentinel programs, recently adopted by Poland, in which health-care professionals are obliged to report cases of acute upper airway infections.", [["airway", "ANATOMY", 448, 454], ["influenza", "DISEASE", 82, 91], ["influenza", "DISEASE", 182, 191], ["airway infections", "DISEASE", 448, 465], ["upper airway", "ORGANISM_SUBDIVISION", 442, 454], ["This study", "TEST", 0, 10], ["influenza seasons", "PROBLEM", 82, 99], ["the influenza surveillance system", "TEST", 258, 291], ["acute upper airway infections", "PROBLEM", 436, 465], ["influenza", "OBSERVATION", 82, 91], ["acute", "OBSERVATION_MODIFIER", 436, 441], ["upper", "ANATOMY_MODIFIER", 442, 447], ["airway", "ANATOMY", 448, 454], ["infections", "OBSERVATION", 455, 465]]], ["Preliminary diagnosis was done in 16 Provincial Sanitary-Epidemiological Stations throughout the country, followed by the sampling of nasopharyngeal specimens in case of suspected influenza and influenza-like infections.", [["nasopharyngeal specimens", "ANATOMY", 134, 158], ["influenza", "DISEASE", 180, 189], ["influenza-like infections", "DISEASE", 194, 219], ["nasopharyngeal specimens", "CANCER", 134, 158], ["the sampling of nasopharyngeal specimens", "TEST", 118, 158], ["influenza", "PROBLEM", 180, 189], ["influenza", "PROBLEM", 194, 203], ["like infections", "PROBLEM", 204, 219], ["nasopharyngeal", "ANATOMY", 134, 148], ["influenza", "OBSERVATION", 180, 189], ["influenza", "OBSERVATION", 194, 203], ["infections", "OBSERVATION", 209, 219]]], ["The reports were collated and coordinated by the Department of Influenza Research of the National Influenza Center at the National Institute of Public Health-National Institute of Hygiene (NIPH-NIH) in Warsaw, where the causative contagion was then verified using molecular methods.", [["Influenza", "DISEASE", 63, 72], ["Influenza", "DISEASE", 98, 107]]], ["Yearly number of collected and tested specimens in the surveillance system ranged from 2066 to 8367 during the 10-year period reviewed in this study (Cie\u015blak et al. 2017, 2018).Material and ResultsThe study material consisted of nasopharyngeal swabs or bronchial tree lavage collected from patients presenting symptoms of upper airway infection across all age groups.", [["specimens", "ANATOMY", 38, 47], ["nasopharyngeal swabs", "ANATOMY", 229, 249], ["bronchial tree lavage", "ANATOMY", 253, 274], ["upper airway", "ANATOMY", 322, 334], ["airway infection", "DISEASE", 328, 344], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 229, 249], ["patients", "ORGANISM", 290, 298], ["upper airway", "ORGANISM_SUBDIVISION", 322, 334], ["patients", "SPECIES", 290, 298], ["tested specimens", "TEST", 31, 47], ["the surveillance system", "TEST", 51, 74], ["this study", "TEST", 138, 148], ["The study material", "TEST", 197, 215], ["nasopharyngeal swabs", "TREATMENT", 229, 249], ["bronchial tree lavage", "TREATMENT", 253, 274], ["upper airway infection", "PROBLEM", 322, 344], ["nasopharyngeal", "ANATOMY", 229, 243], ["bronchial", "ANATOMY", 253, 262], ["tree lavage", "OBSERVATION", 263, 274], ["upper", "ANATOMY_MODIFIER", 322, 327], ["airway", "ANATOMY", 328, 334], ["infection", "OBSERVATION", 335, 344]]], ["Specimens were collected through the epidemic seasons from 2008/2009 to 2017/2018.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["They were further investigated using real-time polymerase chain reaction (PCR) or conventional multiplex PCR to isolate genetic material of invading contagions and thus to identify the influenza or influenza-like type of virus.Material and ResultsIn total, during the ten epidemic seasons, physicians collected and transferred to the NIPH-NIH center 44,566 samples, which gives an average of 4456 samples per season (Table 1).", [["samples", "ANATOMY", 357, 364], ["influenza", "DISEASE", 185, 194], ["influenza-like type", "ORGANISM", 198, 217], ["real-time polymerase chain reaction", "TREATMENT", 37, 72], ["PCR", "TEST", 74, 77], ["conventional multiplex PCR", "TEST", 82, 108], ["invading contagions", "PROBLEM", 140, 159], ["the influenza", "PROBLEM", 181, 194], ["influenza", "PROBLEM", 198, 207], ["type of virus", "PROBLEM", 213, 226], ["influenza", "OBSERVATION", 185, 194]]], ["In the 2008/2009\u20132017/2018 epidemic seasons, influenza type A and B viruses and influenza-like illnesses of different severity were recorded.", [["influenza type A and B viruses", "DISEASE", 45, 75], ["influenza-like illnesses", "DISEASE", 80, 104], ["influenza type A", "ORGANISM", 45, 61], ["B viruses", "ORGANISM", 66, 75], ["influenza type A", "SPECIES", 45, 61], ["B viruses", "SPECIES", 66, 75], ["influenza type A and B viruses", "PROBLEM", 45, 75], ["influenza", "PROBLEM", 80, 89], ["different severity", "PROBLEM", 108, 126]]], ["The percentage of confirmed influenza virus infections ranged from 21.4% in 2011/2012 to 96.7% in 2017/2018.", [["influenza virus infections", "DISEASE", 28, 54], ["influenza virus", "ORGANISM", 28, 43], ["influenza virus", "SPECIES", 28, 43], ["influenza virus", "SPECIES", 28, 43], ["influenza virus infections", "PROBLEM", 28, 54], ["influenza virus", "OBSERVATION", 28, 43]]], ["There was an apparent inverse relation between the frequency of influenza and influenza-like infections; the more of the former, the fewer of the latter.", [["influenza", "DISEASE", 64, 73], ["influenza-like infections", "DISEASE", 78, 103], ["influenza", "PROBLEM", 64, 73], ["influenza", "PROBLEM", 78, 87], ["like infections", "PROBLEM", 88, 103], ["influenza", "OBSERVATION", 64, 73], ["influenza", "OBSERVATION", 78, 87], ["infections", "OBSERVATION", 93, 103]]], ["In nine out of the ten seasons, type A virus predominated, with subtype A/H1N1/pdm09 in seven and A/H3N2/ in two seasons.", [["type A virus", "ORGANISM", 32, 44], ["A/H3N2", "ORGANISM", 98, 104], ["type A virus", "SPECIES", 32, 44], ["subtype A/H1N1/pdm09", "SPECIES", 64, 84], ["A/H3N2", "SPECIES", 98, 104], ["type A virus", "PROBLEM", 32, 44], ["H1N1", "PROBLEM", 74, 78], ["pdm09", "PROBLEM", 79, 84]]], ["The influenza type B virus of the Yamagata lineage predominated in the 2017/2018 season (Table 1).Material and ResultsInfections caused by influenza-like viruses were also recorded.", [["influenza type B", "DISEASE", 4, 20], ["Infections", "DISEASE", 118, 128], ["influenza-like viruses", "DISEASE", 139, 161], ["influenza type B virus", "ORGANISM", 4, 26], ["Yamagata lineage", "CELL", 34, 50], ["influenza-like viruses", "ORGANISM", 139, 161], ["influenza-", "SPECIES", 139, 149], ["influenza type B virus", "SPECIES", 4, 26], ["The influenza type B virus", "PROBLEM", 0, 26], ["influenza", "PROBLEM", 139, 148], ["like viruses", "PROBLEM", 149, 161], ["Infections", "OBSERVATION", 118, 128], ["influenza", "OBSERVATION", 139, 148]]], ["The following viruses were identified: human respiratory syncytial virus (RSV) type A and type B, parainfluenza virus types 1\u20134, human metapneumovirus (hMV), human adenovirus (ADV), human rhinovirus (RV), human coronavirus 229/NL63 and OC43/HKU1, and enterovirus.", [["respiratory syncytial virus", "DISEASE", 45, 72], ["parainfluenza virus", "DISEASE", 98, 117], ["human metapneumovirus", "DISEASE", 129, 150], ["human", "ORGANISM", 39, 44], ["respiratory syncytial virus (RSV) type A", "ORGANISM", 45, 85], ["type B", "ORGANISM", 90, 96], ["parainfluenza virus types 1\u20134", "ORGANISM", 98, 127], ["human metapneumovirus", "ORGANISM", 129, 150], ["hMV", "ORGANISM", 152, 155], ["human adenovirus", "ORGANISM", 158, 174], ["ADV", "ORGANISM", 176, 179], ["human rhinovirus", "ORGANISM", 182, 198], ["human", "ORGANISM", 205, 210], ["coronavirus 229", "ORGANISM", 211, 226], ["NL63", "GENE_OR_GENE_PRODUCT", 227, 231], ["OC43", "GENE_OR_GENE_PRODUCT", 236, 240], ["HKU1", "GENE_OR_GENE_PRODUCT", 241, 245], ["enterovirus", "ORGANISM", 251, 262], ["human", "SPECIES", 39, 44], ["respiratory syncytial virus", "SPECIES", 45, 72], ["parainfluenza virus", "SPECIES", 98, 117], ["human", "SPECIES", 129, 134], ["metapneumovirus", "SPECIES", 135, 150], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 182, 187], ["rhinovirus", "SPECIES", 188, 198], ["human", "SPECIES", 205, 210], ["coronavirus", "SPECIES", 211, 222], ["human respiratory syncytial virus", "SPECIES", 39, 72], ["RSV", "SPECIES", 74, 77], ["human metapneumovirus", "SPECIES", 129, 150], ["hMV", "SPECIES", 152, 155], ["human", "SPECIES", 158, 163], ["ADV", "SPECIES", 176, 179], ["human rhinovirus", "SPECIES", 182, 198], ["RV", "SPECIES", 200, 202], ["human coronavirus 229/NL63", "SPECIES", 205, 231], ["human respiratory syncytial virus", "PROBLEM", 39, 72], ["type B, parainfluenza virus types", "PROBLEM", 90, 123], ["human metapneumovirus (hMV", "TEST", 129, 155], ["human adenovirus", "TREATMENT", 158, 174], ["human rhinovirus (RV", "TEST", 182, 202], ["human coronavirus", "TEST", 205, 222], ["OC43/HKU1", "TEST", 236, 245], ["enterovirus", "PROBLEM", 251, 262], ["syncytial virus", "OBSERVATION", 57, 72], ["parainfluenza virus", "OBSERVATION", 98, 117]]], ["The percentage of confirmed influenza-like infections among all influenza infections ranged from 78.6% in 2011/2012 to 3.3% in 2017/2018.", [["influenza-like infections", "DISEASE", 28, 53], ["influenza infections", "DISEASE", 64, 84], ["influenza", "PROBLEM", 28, 37], ["like infections", "PROBLEM", 38, 53], ["all influenza infections", "PROBLEM", 60, 84], ["influenza", "OBSERVATION", 28, 37]]], ["It is worthy of note that RSV infection predominated in each epidemic season, with the confirmation rate ranging from 54.6% in 2008/2009 to 91.4% in 2014/2015 among all the other influenza-like viruses.", [["RSV infection", "DISEASE", 26, 39], ["influenza-like viruses", "DISEASE", 179, 201], ["RSV", "ORGANISM", 26, 29], ["influenza-like viruses", "ORGANISM", 179, 201], ["RSV", "SPECIES", 26, 29], ["RSV infection", "PROBLEM", 26, 39], ["the confirmation rate", "TEST", 83, 104], ["RSV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39], ["influenza", "OBSERVATION", 179, 188], ["viruses", "OBSERVATION", 194, 201]]], ["Interestingly, influenza-like infections were more frequent than true influenza infections in the 2013/2014 season (Table 1).DiscussionOne of the basic goals of epidemiological and virological surveillance, which has been initiated in 1947, is to protect humanity from the threat of influenza.", [["influenza-like infections", "DISEASE", 15, 40], ["influenza infections", "DISEASE", 70, 90], ["influenza", "DISEASE", 283, 292], ["influenza-like infections", "ORGANISM", 15, 40], ["influenza", "PROBLEM", 15, 24], ["infections", "PROBLEM", 30, 40], ["true influenza infections", "PROBLEM", 65, 90], ["virological surveillance", "TEST", 181, 205], ["influenza", "PROBLEM", 283, 292], ["influenza", "OBSERVATION", 15, 24], ["influenza", "OBSERVATION", 283, 292]]], ["This goal has been reiterated in the 2019 publication of WHO entitled \u201cGlobal Influenza Strategy 2019\u20132030\u201d (WHO 2019).", [["Influenza", "DISEASE", 78, 87]]], ["The surveillance is designed to monitor the spread of influenza virus from animals to humans.", [["influenza", "DISEASE", 54, 63], ["influenza virus", "ORGANISM", 54, 69], ["humans", "ORGANISM", 86, 92], ["humans", "SPECIES", 86, 92], ["influenza virus", "SPECIES", 54, 69], ["humans", "SPECIES", 86, 92], ["The surveillance", "TEST", 0, 16], ["influenza virus", "PROBLEM", 54, 69], ["influenza", "OBSERVATION", 54, 63]]], ["Molecular biology has been used to define the type of virus that circulates in a population in a given epidemic season as a candidate for the optimum seasonal composition of influenza vaccine.", [["influenza", "DISEASE", 174, 183], ["virus", "PROBLEM", 54, 59], ["influenza vaccine", "TREATMENT", 174, 191], ["virus", "OBSERVATION", 54, 59]]], ["Further, influenza and influenza-like infection morbidity, comorbidity, and death have been recorded and expressed as the incidence of confirmed and suspected cases, the number of referrals to hospital, and variable activities of circulating influenza A and B type and influenza-like viruses.", [["influenza", "DISEASE", 9, 18], ["influenza-like infection", "DISEASE", 23, 47], ["death", "DISEASE", 76, 81], ["influenza-like viruses", "DISEASE", 269, 291], ["circulating influenza A", "ORGANISM", 230, 253], ["B type", "ORGANISM", 258, 264], ["influenza-like viruses", "ORGANISM", 269, 291], ["influenza", "PROBLEM", 9, 18], ["influenza", "PROBLEM", 23, 32], ["infection morbidity", "PROBLEM", 38, 57], ["comorbidity", "PROBLEM", 59, 70], ["death", "PROBLEM", 76, 81], ["circulating influenza A", "PROBLEM", 230, 253], ["influenza", "PROBLEM", 269, 278], ["influenza", "OBSERVATION", 9, 18]]], ["There are over 200 respiratory influenza-related viruses that circulate in the population.", [["200 respiratory influenza", "PROBLEM", 15, 40], ["related viruses", "PROBLEM", 41, 56], ["respiratory influenza", "OBSERVATION", 19, 40]]], ["Therefore, virological surveillance is essential from both confirmatory and clinical standpoints.", [["virological surveillance", "TEST", 11, 35]]], ["The latter has to do with advance preparation of proper vaccine composition for each upcoming season, taking into account the genetic and antigenic diversity of recently circulating influenza viruses as well as with the use of recently available novel antiviral medicines.DiscussionIn the past, Poland used to send reports to the WHO Collaborating Center for Reference and Research on Influenza of the National Institute for Medical Research in London and then as of the 2015/2016 season to the WHO Collaborating Center for Reference and Research on Influenza of the Francis Crick Institute in London.", [["influenza viruses", "DISEASE", 182, 199], ["influenza viruses", "ORGANISM", 182, 199], ["proper vaccine composition", "TREATMENT", 49, 75], ["recently circulating influenza viruses", "PROBLEM", 161, 199], ["novel antiviral medicines", "TREATMENT", 246, 271], ["influenza viruses", "OBSERVATION", 182, 199]]], ["On the basis of reports submitted by national influenza centers, virological situation can be traced in a given continent and also worldwide.", [["virological situation", "PROBLEM", 65, 86]]], ["In its current form, the Global Influenza Surveillance and Response System consists of 6 WHO Collaborating Centers for Reference and Research and 149 National Influenza Centers, including 1 in the Department of Influenza Research of the National Influenza Center at the NIPH-NIH.", [["Influenza", "DISEASE", 32, 41], ["Influenza", "DISEASE", 159, 168], ["Influenza", "DISEASE", 211, 220], ["Influenza", "DISEASE", 246, 255], ["Influenza", "PROBLEM", 211, 220]]], ["Their main task is to send epidemiological and virological reports and full documentation on selected isolated influenza viruses to relevant WHO reference centers.DiscussionIn the case of the 2008/2009 season, the peak of influenza in both Poland and Europe fell on the 1st week of February 2009 (MRC 2008).", [["influenza viruses", "DISEASE", 111, 128], ["influenza", "DISEASE", 222, 231], ["selected isolated influenza viruses", "PROBLEM", 93, 128], ["influenza", "PROBLEM", 222, 231], ["influenza", "OBSERVATION", 222, 231]]], ["Influenza A/H1N1/pdm09 was the predominant type A virus, which was confirmed in Europe in 53% of the submitted reports.", [["Influenza A/H1N1/pdm09", "ORGANISM", 0, 22], ["type A virus", "ORGANISM", 43, 55], ["Influenza A/H1N1/pdm09", "SPECIES", 0, 22], ["type A virus", "SPECIES", 43, 55], ["Influenza", "PROBLEM", 0, 9], ["H1N1", "PROBLEM", 12, 16], ["pdm09", "PROBLEM", 17, 22]]], ["Likewise, the confirmation rate for this virus amounted to 54.5% in Poland.", [["the confirmation rate", "TEST", 10, 31], ["this virus", "PROBLEM", 36, 46]]], ["There were no influenza-related deaths recorded in Poland in that season (Czarkowski et al. 2011).DiscussionIn the 2009/2010 season, Europe was dominated by influenza virus A, subtype A/H1N1/pdm09.", [["deaths", "DISEASE", 32, 38], ["influenza virus", "DISEASE", 157, 172], ["influenza virus A", "ORGANISM", 157, 174], ["subtype A/H1N1", "ORGANISM", 176, 190], ["influenza virus", "SPECIES", 157, 172], ["influenza virus A", "SPECIES", 157, 174], ["subtype A/H1N1/pdm09", "SPECIES", 176, 196], ["influenza", "PROBLEM", 14, 23], ["influenza virus A", "PROBLEM", 157, 174], ["H1N1", "PROBLEM", 186, 190], ["pdm09", "PROBLEM", 191, 196], ["no", "UNCERTAINTY", 11, 13], ["influenza", "OBSERVATION", 14, 23], ["influenza virus", "OBSERVATION", 157, 172]]], ["Although many infections were caused by travelers entering a country, this virus prevailed in most countries in which it has already stayed and widely circulated.", [["infections", "DISEASE", 14, 24], ["many infections", "PROBLEM", 9, 24], ["this virus", "PROBLEM", 70, 80], ["many", "OBSERVATION_MODIFIER", 9, 13], ["infections", "OBSERVATION", 14, 24]]], ["According to a WHO report, seasonal influenza viruses A/H1N1/, A/H3N2/, and type B continued to circulate, albeit at rather low levels.", [["influenza viruses", "DISEASE", 36, 53], ["influenza viruses", "ORGANISM", 36, 53], ["A/H1N1", "ORGANISM", 54, 60], ["A/H3N2", "ORGANISM", 63, 69], ["type B", "ORGANISM", 76, 82], ["A/H1N1/, A/H3N2", "SPECIES", 54, 69], ["seasonal influenza viruses", "PROBLEM", 27, 53], ["H1N1", "PROBLEM", 56, 60], ["H3N2", "PROBLEM", 65, 69], ["type B", "PROBLEM", 76, 82]]], ["In Europe, the highest incidence and number of deaths due to infection with A/H1N1/pdm09 virus was recorded in the United Kingdom.", [["deaths", "DISEASE", 47, 53], ["infection", "DISEASE", 61, 70], ["A/H1N1/pdm09 virus", "ORGANISM", 76, 94], ["A/H1N1/pdm09 virus", "SPECIES", 76, 94], ["infection", "PROBLEM", 61, 70], ["A/H1N1/pdm09 virus", "PROBLEM", 76, 94], ["infection", "OBSERVATION", 61, 70]]], ["In Poland, according to NIPH-NIH data, the number of reported cases of influenza infection was very low in the 2009/2010 season when compared with other seasons and also with data from other European countries.", [["influenza infection", "DISEASE", 71, 90], ["influenza infection", "PROBLEM", 71, 90]]], ["The peak incidence was exceptionally early in Poland as it took place in the last week of November 2010.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["Influenza A(H1N1)pdm09 was the predominant type A virus (MRC 2009).", [["Influenza A(H1N1)pdm09", "ORGANISM", 0, 22], ["type A virus", "ORGANISM", 43, 55], ["Influenza A(H1N1", "SPECIES", 0, 16], ["Influenza A(H1N1)pdm09", "SPECIES", 0, 22], ["type A virus", "SPECIES", 43, 55], ["Influenza", "PROBLEM", 0, 9], ["pdm09", "PROBLEM", 17, 22]]], ["The 2010/2011 influenza season appeared 8\u201310 weeks later than that of the previous pandemic season in Europe, but still rather early compared to historical trends.", [["influenza", "DISEASE", 14, 23]]], ["Influenza A/H1N1/pdm09 remained the predominant circulating virus, but in contrast to the previous season, there were a greater co-circulation of influenza type B and an appreciable downtrend in the percentage of influenza A/H3N2/ virus (MRC 2010).DiscussionIn the 2011/2012 season, influenza virus activity began late in Europe.", [["influenza type B", "DISEASE", 146, 162], ["influenza A/H3N2/ virus", "DISEASE", 213, 236], ["influenza virus activity", "DISEASE", 283, 307], ["Influenza A/H1N1/pdm09", "ORGANISM", 0, 22], ["influenza A/H3N2/ virus", "ORGANISM", 213, 236], ["influenza virus", "ORGANISM", 283, 298], ["influenza A/H3N2/ virus", "SPECIES", 213, 236], ["Influenza A/H1N1/pdm09", "SPECIES", 0, 22], ["influenza A/H3N2/ virus", "SPECIES", 213, 236], ["Influenza", "PROBLEM", 0, 9], ["H1N1", "PROBLEM", 12, 16], ["pdm09", "PROBLEM", 17, 22], ["the predominant circulating virus", "PROBLEM", 32, 65], ["influenza type B", "PROBLEM", 146, 162], ["influenza", "PROBLEM", 213, 222], ["H3N2", "PROBLEM", 225, 229], ["influenza virus activity", "PROBLEM", 283, 307], ["predominant", "OBSERVATION_MODIFIER", 36, 47], ["circulating virus", "OBSERVATION", 48, 65], ["greater", "OBSERVATION_MODIFIER", 120, 127], ["co-circulation", "OBSERVATION", 128, 142], ["influenza", "OBSERVATION", 146, 155], ["appreciable", "OBSERVATION_MODIFIER", 170, 181], ["influenza", "OBSERVATION", 213, 222]]], ["In Europe, influenza A virus predominated and accounted for 90.5% of all infections, whereas influenza B virus accounted for 9.5%.", [["influenza A virus", "DISEASE", 11, 28], ["infections", "DISEASE", 73, 83], ["influenza B", "DISEASE", 93, 104], ["influenza A virus", "ORGANISM", 11, 28], ["influenza B virus", "ORGANISM", 93, 110], ["influenza A virus", "SPECIES", 11, 28], ["influenza B virus", "SPECIES", 93, 110], ["influenza A virus", "SPECIES", 11, 28], ["influenza B virus", "SPECIES", 93, 110], ["influenza A virus", "PROBLEM", 11, 28], ["all infections", "PROBLEM", 69, 83], ["influenza B virus", "PROBLEM", 93, 110], ["infections", "OBSERVATION", 73, 83]]], ["A different level of influenza virus activity was recorded, depending on the region.", [["influenza virus", "ORGANISM", 21, 36], ["influenza virus activity", "PROBLEM", 21, 45], ["influenza virus activity", "OBSERVATION", 21, 45]]], ["In general, influenza A/H3N2/ predominated, but there was a discrepancy between the countries of Western Europe in which the virus was more than twofold more frequent than in Eastern Europe (MRC 2011).", [["influenza A/H3N2", "ORGANISM", 12, 28], ["A/H3N2", "SPECIES", 22, 28], ["influenza", "PROBLEM", 12, 21], ["H3N2", "PROBLEM", 24, 28], ["a discrepancy", "PROBLEM", 58, 71], ["the virus", "PROBLEM", 121, 130], ["influenza", "OBSERVATION", 12, 21]]], ["In Poland, due to a considerable percentage of unsubtyped A virus, it was hard to unambiguously confirm the predominance of A/H1N1/pdm09.", [["unsubtyped A virus", "ORGANISM", 47, 65], ["A/H1N1", "ORGANISM", 124, 130], ["pdm09", "GENE_OR_GENE_PRODUCT", 131, 136], ["A virus", "SPECIES", 58, 65], ["A/H1N1/pdm09", "SPECIES", 124, 136], ["unsubtyped A virus", "PROBLEM", 47, 65], ["H1N1", "PROBLEM", 126, 130], ["pdm09", "PROBLEM", 131, 136], ["virus", "OBSERVATION", 60, 65]]], ["Nonetheless, the activity of influenza A viruses was confirmed in 21.4%.", [["influenza A viruses", "DISEASE", 29, 48], ["influenza A viruses", "ORGANISM", 29, 48], ["influenza A viruses", "SPECIES", 29, 48], ["influenza A viruses", "PROBLEM", 29, 48]]], ["On the other side, circulation of influenza-like viruses was confirmed in 78.6% of all infections in Poland, with the predominance of RSV that accounted for 86.7% of influenza-like illness (Table 1).DiscussionIn the 2012/2013 season, peak incidence was recorded in the 3rd week of January 2013.", [["influenza-like viruses", "DISEASE", 34, 56], ["infections", "DISEASE", 87, 97], ["RSV", "DISEASE", 134, 137], ["influenza-like illness", "DISEASE", 166, 188], ["influenza-like viruses", "ORGANISM", 34, 56], ["RSV", "ORGANISM", 134, 137], ["RSV", "SPECIES", 134, 137], ["influenza-like viruses", "PROBLEM", 34, 56], ["all infections in Poland", "PROBLEM", 83, 107], ["RSV", "PROBLEM", 134, 137], ["influenza", "PROBLEM", 166, 175], ["influenza", "OBSERVATION", 34, 43], ["infections", "OBSERVATION", 87, 97], ["RSV", "OBSERVATION", 134, 137]]], ["Influenza infections were recorded throughout Europe, with the predominating type A virus which accounted for 62% of all infections and clearly predominated over type B which accounted for merely 38% (MRC 2012).", [["Influenza infections", "DISEASE", 0, 20], ["infections", "DISEASE", 121, 131], ["Influenza", "ORGANISM", 0, 9], ["type A virus", "SPECIES", 77, 89], ["Influenza infections", "PROBLEM", 0, 20], ["the predominating type A virus", "PROBLEM", 59, 89], ["all infections", "PROBLEM", 117, 131], ["infections", "OBSERVATION", 10, 20], ["virus", "OBSERVATION", 84, 89], ["infections", "OBSERVATION", 121, 131]]], ["However, there were regional differences noted in the proportion of the two types as type A constituted 59% and type B 41% of infections in Western Europe whereas these proportions were 75% and 25%, respectively, in Eastern Europe.", [["infections", "DISEASE", 126, 136], ["infections", "PROBLEM", 126, 136], ["regional", "OBSERVATION_MODIFIER", 20, 28], ["differences", "OBSERVATION_MODIFIER", 29, 40], ["infections", "OBSERVATION", 126, 136]]], ["Concerning type A, subtype A/H1N1/pdm09 was recorded in 66%, and subtype A/H3N2/ in 34%.", [["type A", "CANCER", 11, 17], ["subtype A", "CANCER", 19, 28], ["H1N1", "ORGANISM", 29, 33], ["pdm09", "ORGANISM", 34, 39], ["A/H1N1/pdm09", "SPECIES", 27, 39], ["subtype A/H3N2", "SPECIES", 65, 79], ["H1N1", "PROBLEM", 29, 33], ["pdm09", "PROBLEM", 34, 39], ["subtype A/H3N2", "TEST", 65, 79], ["H3N2", "OBSERVATION", 75, 79]]], ["In Poland, influenza A/H1N1/pdm09 also predominated being responsible for 58.5% of all infections.", [["infections", "DISEASE", 87, 97], ["influenza A/H1N1", "ORGANISM", 11, 27], ["pdm09", "ORGANISM", 28, 33], ["influenza A/H1N1/pdm09", "SPECIES", 11, 33], ["influenza", "PROBLEM", 11, 20], ["H1N1", "PROBLEM", 23, 27], ["pdm09", "PROBLEM", 28, 33], ["all infections", "PROBLEM", 83, 97], ["infections", "OBSERVATION", 87, 97]]], ["In general, influenza virus activity was higher than that recorded in the previous season (Czarkowski et al. 2014).DiscussionAccording to a WHO report, type A virus predominated over the type B virus in Europe in the 2013/2014 season: 93% and 7% of infections, respectively.", [["infections", "DISEASE", 249, 259], ["influenza virus", "ORGANISM", 12, 27], ["type A virus", "ORGANISM", 152, 164], ["type B virus", "ORGANISM", 187, 199], ["type A virus", "SPECIES", 152, 164], ["type B virus", "SPECIES", 187, 199], ["influenza virus activity", "PROBLEM", 12, 36], ["type A virus", "PROBLEM", 152, 164], ["the type B virus", "PROBLEM", 183, 199], ["infections", "PROBLEM", 249, 259], ["infections", "OBSERVATION", 249, 259]]], ["Concerning influenza type A, subtype A/H1N1/pdm09 was slightly more common than A/H3N2/: 56% and 44%, respectively.", [["influenza type A", "DISEASE", 11, 27], ["influenza type A", "CANCER", 11, 27], ["subtype A/H1N1", "ORGANISM", 29, 43], ["pdm09", "GENE_OR_GENE_PRODUCT", 44, 49], ["A/H3N2", "ORGANISM", 80, 86], ["influenza type A", "SPECIES", 11, 27], ["A/H1N1/pdm09", "SPECIES", 37, 49], ["A/H3N2", "SPECIES", 80, 86], ["influenza type A", "PROBLEM", 11, 27], ["H1N1", "PROBLEM", 39, 43], ["pdm09", "PROBLEM", 44, 49], ["A/H3N2", "TEST", 80, 86], ["influenza", "OBSERVATION", 11, 20]]], ["In the European Economic Area (EEA) countries, for a change, subtype H3N2 predominated over A/H1N1/pdm09 in a ratio of approximately 2.8 (MRC 2013).", [["subtype H3N2", "ORGANISM", 61, 73], ["A/H1N1/pdm09", "SPECIES", 92, 104], ["subtype H3N2", "PROBLEM", 61, 73], ["pdm09", "PROBLEM", 99, 104], ["a ratio", "TEST", 108, 115], ["H3N2", "OBSERVATION", 69, 73]]], ["Overall, influenza viral activity was relatively very low and remained so even in the 8th week of 2014, when the highest number of influenza cases was detected.", [["influenza", "DISEASE", 131, 140], ["influenza viral activity", "TEST", 9, 33], ["influenza cases", "PROBLEM", 131, 146], ["viral activity", "OBSERVATION", 19, 33]]], ["The predominating virus type differed among various countries.", [["predominating", "OBSERVATION_MODIFIER", 4, 17], ["virus", "OBSERVATION", 18, 23]]], ["In terms of geographical spread, regional activity was largely limited to Western and Southern Europe.", [["geographical spread", "PROBLEM", 12, 31], ["geographical", "OBSERVATION_MODIFIER", 12, 24], ["spread", "OBSERVATION_MODIFIER", 25, 31], ["regional activity", "OBSERVATION", 33, 50]]], ["In some countries, detection of type A virus appreciably exceeded that of type B virus, and the proportion of subtype A/H1N1/ to A/H3N2/ demonstrated a substantial variability.", [["type A virus", "ORGANISM", 32, 44], ["type B virus", "ORGANISM", 74, 86], ["subtype A/H1N1", "ORGANISM", 110, 124], ["A/H3N2", "ORGANISM", 129, 135], ["type A virus", "SPECIES", 32, 44], ["type B virus", "SPECIES", 74, 86], ["subtype A/H1N1/ to A/H3N2", "SPECIES", 110, 135], ["type A virus", "PROBLEM", 32, 44], ["type B virus", "PROBLEM", 74, 86], ["A/H3N2", "TEST", 129, 135], ["substantial", "OBSERVATION_MODIFIER", 152, 163], ["variability", "OBSERVATION", 164, 175]]], ["In Poland, influenza A/H3N2/ virus was the predominant type A virus as it was recorded in 30.6% of all infections (Kondratiuk et al. 2016; Bednarska et al. 2015).DiscussionThe peak incidence in the 2014/2015 season in Europe, including Poland, was recorded in the 8th week of 2015.", [["infections", "DISEASE", 103, 113], ["influenza A/H3N2/ virus", "ORGANISM", 11, 34], ["type A virus", "ORGANISM", 55, 67], ["H3N2/ virus", "SPECIES", 23, 34], ["A/H3N2/ virus", "SPECIES", 21, 34], ["type A virus", "SPECIES", 55, 67], ["influenza", "PROBLEM", 11, 20], ["H3N2", "PROBLEM", 23, 27], ["virus", "PROBLEM", 29, 34], ["type A virus", "PROBLEM", 55, 67], ["all infections", "PROBLEM", 99, 113], ["infections", "OBSERVATION", 103, 113]]], ["For the entire European area, influenza type A virus predominance was confirmed in 69%, and type B virus in 31% (MRC 2014).", [["influenza type A virus", "DISEASE", 30, 52], ["influenza type A virus", "ORGANISM", 30, 52], ["type B virus", "ORGANISM", 92, 104], ["influenza type A virus", "SPECIES", 30, 52], ["type B virus", "SPECIES", 92, 104], ["influenza type A virus predominance", "TEST", 30, 65], ["type B virus", "TEST", 92, 104]]], ["Concerning type A virus, subtype A/H3N2/ (77%) predominated over A/H1N1/pdm09 (23%) (Bednarska et al. 2016c).", [["type A virus", "ORGANISM", 11, 23], ["subtype A/H3N2", "ORGANISM", 25, 39], ["type A virus", "SPECIES", 11, 23], ["A/H1N1/pdm09", "SPECIES", 65, 77], ["type A virus", "PROBLEM", 11, 23], ["H3N2", "PROBLEM", 35, 39], ["pdm09", "PROBLEM", 72, 77], ["virus", "OBSERVATION", 18, 23]]], ["The number of confirmations of A/H3N2/ significantly exceeded that of A/H1N1/pdm09 in most countries of Southern Europe.", [["A/H3N2", "ORGANISM", 31, 37], ["A/H1N1", "ORGANISM", 70, 76], ["A/H3N2", "SPECIES", 31, 37], ["A/H1N1/pdm09", "SPECIES", 70, 82], ["A/H3N2", "TREATMENT", 31, 37], ["H1N1", "PROBLEM", 72, 76], ["pdm09", "PROBLEM", 77, 82]]], ["In Poland, due to a low number of samples tested of 2512, not all of which were sub-classified, influenza A/H1N1/pdm09 was the predominant type A virus (Bednarska et al. 2016d; Hallmann-Szeli\u0144ska et al. 2016).DiscussionIn the 2015/2016 season, peak influenza incidence was recorded in the 6th week of 2016 in Europe, while it was in the 7th week of 2016 in Poland (Szyma\u0144ski et al. 2017).", [["influenza", "DISEASE", 249, 258], ["samples", "CANCER", 34, 41], ["influenza A/H1N1/pdm09", "ORGANISM", 96, 118], ["type A virus", "ORGANISM", 139, 151], ["A/H1N1/pdm09", "SPECIES", 106, 118], ["A virus", "SPECIES", 144, 151], ["a low number of samples", "PROBLEM", 18, 41], ["influenza", "PROBLEM", 96, 105], ["H1N1", "PROBLEM", 108, 112], ["pdm09", "PROBLEM", 113, 118], ["peak influenza incidence", "PROBLEM", 244, 268]]], ["Influenza type A virus predominated, confirmed in 70% of all infections in the continent, among which subtype A/H1N1/pdm09 was most frequent (49.7%).", [["Influenza type A virus", "DISEASE", 0, 22], ["infections", "DISEASE", 61, 71], ["Influenza type A virus", "ORGANISM", 0, 22], ["pdm09", "ORGANISM", 117, 122], ["Influenza type A virus", "SPECIES", 0, 22], ["Influenza type A virus", "SPECIES", 0, 22], ["subtype A/H1N1/pdm09", "SPECIES", 102, 122], ["Influenza type A virus", "PROBLEM", 0, 22], ["all infections", "PROBLEM", 57, 71], ["pdm09", "PROBLEM", 117, 122], ["infections", "OBSERVATION", 61, 71]]], ["However, in Western and Southern European regions, influenza type B virus was sometimes more frequent (MRC 2015).DiscussionThe 2016/2017 season was characterized by an early rise in infection transmission compared to previous seasons and a lack of clear pattern of influenza spread from west to east across the European area (Francis Crick Institute 2016).", [["influenza type B", "DISEASE", 51, 67], ["infection", "DISEASE", 182, 191], ["influenza", "DISEASE", 265, 274], ["influenza type B virus", "ORGANISM", 51, 73], ["influenza type B virus", "SPECIES", 51, 73], ["influenza type B virus", "PROBLEM", 51, 73], ["infection transmission", "PROBLEM", 182, 204], ["influenza spread", "PROBLEM", 265, 281], ["early", "OBSERVATION_MODIFIER", 168, 173], ["rise", "OBSERVATION_MODIFIER", 174, 178], ["infection", "OBSERVATION", 182, 191], ["influenza", "OBSERVATION", 265, 274]]], ["Influenza A/H3N2/ was the predominant type A virus, confirmed in 89% of cases.", [["Influenza A/H3N2", "ORGANISM", 0, 16], ["type A virus", "ORGANISM", 38, 50], ["Influenza A/H3N2", "SPECIES", 0, 16], ["type A virus", "SPECIES", 38, 50], ["Influenza", "PROBLEM", 0, 9], ["H3N2", "PROBLEM", 12, 16], ["type A virus", "PROBLEM", 38, 50]]], ["In Poland, type A virus also predominated (96.7%), but subtype A/H3N2/ was confirmed in just 29.7%.", [["type A virus", "ORGANISM", 11, 23], ["H3N2", "ORGANISM", 65, 69], ["type A virus", "SPECIES", 11, 23], ["type A virus", "PROBLEM", 11, 23], ["subtype A/H3N2", "TEST", 55, 69]]], ["Due to a substantial percentage of unsubtyped material, A/H3N2/ predominance could not be conclusively confirmed (Szyma\u0144ski et al. 2018, 2019; Hallmann-Szeli\u0144ska et al. 2018).DiscussionInfluenza activity in the 2017/2018 season began in October 2017 in the European area.", [["A/H3N2", "ORGANISM", 56, 62], ["unsubtyped material", "PROBLEM", 35, 54], ["A/H3N2/ predominance", "PROBLEM", 56, 76], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["percentage", "OBSERVATION_MODIFIER", 21, 31], ["unsubtyped material", "OBSERVATION", 35, 54], ["could not be conclusively", "UNCERTAINTY", 77, 102]]], ["The season was also characterized by a relatively early rise in infection transmission that spread from west to east throughout the area (Francis Crick Institute 2017).", [["infection", "DISEASE", 64, 73], ["infection transmission", "PROBLEM", 64, 86], ["relatively", "OBSERVATION_MODIFIER", 39, 49], ["early", "OBSERVATION_MODIFIER", 50, 55], ["rise", "OBSERVATION_MODIFIER", 56, 60], ["infection", "OBSERVATION", 64, 73]]], ["Initially, influenza type B virus predominated during the season and most regions.", [["influenza type B", "DISEASE", 11, 27], ["influenza type B virus", "ORGANISM", 11, 33], ["influenza type B virus", "SPECIES", 11, 33], ["influenza type B virus", "PROBLEM", 11, 33]]], ["The period of peak activity was somehow lengthened, comparably to the 2012/2013, 2014/2015, 2015/2016, and 2016/2017 seasons.", [["peak activity", "PROBLEM", 14, 27], ["peak activity", "OBSERVATION", 14, 27], ["lengthened", "OBSERVATION_MODIFIER", 40, 50]]], ["The peak incidence of infections was reported in the 1st week of February 2018, amounting to 55%.", [["infections", "DISEASE", 22, 32], ["infections", "PROBLEM", 22, 32], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["infections", "OBSERVATION", 22, 32]]], ["In Poland, peak incidence was shifted forward to the 4th week of February 2018, but a significant rise in confirmations of influenza virus started already in the 2nd week of January 2018 and lasted till the 2nd week of March 2018.", [["influenza", "DISEASE", 123, 132], ["influenza virus", "ORGANISM", 123, 138], ["a significant rise", "PROBLEM", 84, 102], ["influenza virus", "PROBLEM", 123, 138], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["rise", "OBSERVATION_MODIFIER", 98, 102], ["influenza virus", "OBSERVATION", 123, 138]]], ["Influenza was confirmed in 96.7% of all infections, with type B/Yamagata lineage predominating in 65.5% of these infections.", [["Influenza", "DISEASE", 0, 9], ["infections", "DISEASE", 40, 50], ["infections", "DISEASE", 113, 123], ["Influenza", "PROBLEM", 0, 9], ["all infections", "PROBLEM", 36, 50], ["type B/Yamagata lineage", "PROBLEM", 57, 80], ["these infections", "PROBLEM", 107, 123], ["infections", "OBSERVATION", 40, 50], ["infections", "OBSERVATION", 113, 123]]], ["All European countries and regions with the ability to sub-classify influenza viral lines reported the predominance of Yamagata lineage in this season, whereas the frequency of type A subtypes varied (Francis Crick Institute 2018).DiscussionThe peak incidence of influenza infections in Poland has been in January\u2013March each season, since the pandemic influenza of 1968/1969 (Brydak 2008).", [["influenza", "DISEASE", 68, 77], ["influenza infections", "DISEASE", 263, 283], ["influenza", "DISEASE", 352, 361], ["Yamagata lineage", "CELL", 119, 135], ["influenza viral lines", "PROBLEM", 68, 89], ["influenza infections", "PROBLEM", 263, 283], ["the pandemic influenza", "PROBLEM", 339, 361], ["viral lines", "OBSERVATION", 78, 89], ["influenza infections", "OBSERVATION", 263, 283]]], ["In nine out of the ten epidemic seasons, type A virus was the predominant source of influenza infection, whereas RSV predominated in influenza-like infections.", [["influenza infection", "DISEASE", 84, 103], ["RSV", "DISEASE", 113, 116], ["influenza-like infections", "DISEASE", 133, 158], ["type A virus", "ORGANISM", 41, 53], ["RSV", "ORGANISM", 113, 116], ["type A virus", "SPECIES", 41, 53], ["RSV", "SPECIES", 113, 116], ["type A virus", "PROBLEM", 41, 53], ["influenza infection", "PROBLEM", 84, 103], ["RSV", "PROBLEM", 113, 116], ["influenza", "PROBLEM", 133, 142], ["infections", "PROBLEM", 148, 158], ["predominant source of", "UNCERTAINTY", 62, 83], ["influenza infection", "OBSERVATION", 84, 103], ["influenza", "OBSERVATION", 133, 142], ["infections", "OBSERVATION", 148, 158]]], ["There was an increase in confirmatory laboratory findings from season to season in relation to the number of biological samples examined, from 3.2 to 42.4% over the decade.", [["samples", "ANATOMY", 120, 127], ["an increase in confirmatory laboratory findings", "PROBLEM", 10, 57], ["biological samples", "TEST", 109, 127], ["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["Although the number of samples examined largely increased, it has remained just a fraction of a percentage point of the cases and suspected cases of infection, reported by health-care providers, which enormously increased from 568,958 in the 2008/2009 season to 5,337,997 in the 2017/2018 season.", [["infection", "DISEASE", 149, 158], ["samples", "CANCER", 23, 30], ["infection", "PROBLEM", 149, 158], ["largely", "OBSERVATION_MODIFIER", 40, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["infection", "OBSERVATION", 149, 158], ["increased", "OBSERVATION_MODIFIER", 212, 221]]], ["Influenza infection remains a health scourge and a major socioeconomic burden, with a dismally low yearly vaccination rate, which recently barely reaches about 3.5% of the general population in Poland.", [["Influenza infection", "DISEASE", 0, 19], ["Influenza infection", "PROBLEM", 0, 19], ["a major socioeconomic burden", "PROBLEM", 49, 77], ["a dismally low yearly vaccination rate", "PROBLEM", 84, 122], ["infection", "OBSERVATION", 10, 19]]]], "ccba352e63a8fa0318dfe475a23669833ca09806": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus, belonging to the family Coronaviridae (Gorbalenya et al., 2020) , and causative agent of the disease Coronavirus disease 2019 .", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["Coronavirus disease", "DISEASE", 203, 222], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["a newly discovered virus", "PROBLEM", 76, 100], ["the disease Coronavirus disease", "PROBLEM", 191, 222], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["virus", "OBSERVATION", 95, 100], ["disease Coronavirus disease", "OBSERVATION", 195, 222]]], ["As of April 14 th , around 2 million cases and 120,000 deaths of COVID-19 have been confirmed globally (Johns Hopkins University & Medicine, 2020) .", [["deaths", "DISEASE", 55, 61], ["COVID", "TEST", 65, 70]]], ["Although the origin of the virus was the city of Wuhan, China, the center of the pandemic of COVID-19 is currently in Europe, with four out of the five countries accumulating more deaths worldwide located in this continent (i.e., Italy, Spain, France and United Kingdom).IntroductionThe Angiotensin-converting enzyme 2 (ACE2) protein is the receptor for different coronaviruses, including SARS-CoV-2 (Hoffmann et al., 2020) .", [["COVID", "DISEASE", 93, 98], ["deaths", "DISEASE", 180, 186], ["Angiotensin", "CHEMICAL", 287, 298], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 287, 318], ["ACE2", "GENE_OR_GENE_PRODUCT", 320, 324], ["SARS-CoV-2", "ORGANISM", 389, 399], ["Angiotensin-converting enzyme 2 (ACE2) protein", "PROTEIN", 287, 333], ["SARS-CoV", "SPECIES", 389, 397], ["the virus", "PROBLEM", 23, 32], ["COVID", "TEST", 93, 98], ["The Angiotensin-converting enzyme 2 (ACE2) protein", "TREATMENT", 283, 333], ["different coronaviruses", "PROBLEM", 354, 377], ["origin", "ANATOMY_MODIFIER", 13, 19], ["virus", "OBSERVATION", 27, 32]]], ["However, evidence is still sparse on the effect of different exposures on the interaction ACE2 -SARS-CoV-2.IntroductionSpecifically, there is not conclusive evidence on the regulation of the ACE2 in the lungs after exposure to nicotine (Oakes et al., 2018) (Brake et al., 2020) , one of the thousands of substances present in the tobacco smoke (Rodgman and Perfetti, 2013) , and how this regulation could impact the outcomes associated with the COVID-19 infection, eventually.", [["lungs", "ANATOMY", 203, 208], ["nicotine", "CHEMICAL", 227, 235], ["infection", "DISEASE", 454, 463], ["nicotine", "CHEMICAL", 227, 235], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 96, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 191, 195], ["lungs", "ORGAN", 203, 208], ["nicotine", "SIMPLE_CHEMICAL", 227, 235], ["tobacco", "ORGANISM", 330, 337], ["ACE2", "PROTEIN", 90, 94], ["ACE2", "PROTEIN", 191, 195], ["tobacco", "SPECIES", 330, 337], ["tobacco", "SPECIES", 330, 337], ["COVID-19", "SPECIES", 445, 453], ["the interaction ACE2", "TEST", 74, 94], ["CoV", "TEST", 101, 104], ["nicotine", "TREATMENT", 227, 235], ["the COVID-19 infection", "PROBLEM", 441, 463], ["sparse", "OBSERVATION_MODIFIER", 27, 33], ["not conclusive evidence", "UNCERTAINTY", 142, 165], ["lungs", "ANATOMY", 203, 208], ["infection", "OBSERVATION", 454, 463]]], ["Preliminary epidemiological data indicate that the prevalence of current smokers in hospitalized patients in China due to COVID-19 was lower than at the national level (Farsalinos et al., 2020) and that current smokers with COVID-19 seem to be at higher risk of negative progression than non-smokers (Vardavas and Nikitara, 2020) , although other authors concluded that severity is not associated with active smoking (Lippi and Henry, 2020) .Introduction.", [["smoking", "CHEMICAL", 409, 416], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Preliminary epidemiological data", "TEST", 0, 32], ["COVID", "TEST", 122, 127], ["COVID", "TREATMENT", 224, 229]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020 . . https://doi.org/10.1101 Assuming the hypothesis that smokers, due to the high level of nicotine intake, underexpress the ACE2 protein, countries with a higher prevalence of smoking may have lower attack rates of COVID-19.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 276, 299], ["nicotine", "CHEMICAL", 363, 371], ["smoking", "CHEMICAL", 449, 456], ["nicotine", "CHEMICAL", 363, 371], ["COVID-19", "CHEMICAL", 488, 496], ["nicotine", "SIMPLE_CHEMICAL", 363, 371], ["ACE2", "GENE_OR_GENE_PRODUCT", 397, 401], ["ACE2 protein", "PROTEIN", 397, 409], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["COVID", "TEST", 488, 493], ["med", "ANATOMY", 105, 108]]], ["Hence, the objective of this preliminary study was to assess the correlation between tobacco smoking and the attack rate and severity of COVID-19 at the national level in the European Union (EU).Material and methodsThis is an ecological study.", [["smoking", "CHEMICAL", 93, 100], ["tobacco", "ORGANISM", 85, 92], ["tobacco", "SPECIES", 85, 92], ["this preliminary study", "TEST", 24, 46], ["the attack rate", "TEST", 105, 120], ["COVID", "TEST", 137, 142], ["an ecological study", "TEST", 223, 242]]], ["The unit of analysis is each of the 27 member states of the EU.", [["analysis", "TEST", 12, 20]]], ["Data on confirmed cases and deaths due to the COVID-19 for each member state of the EU were retrieved from the Johns Hopkins University Coronavirus Resource Center (Dong et al., 2020) The attack rate (cumulative cases/100,000 population) and the case fatality ratio (CFR) (deaths/cumulative cases) were computed for each member state.", [["deaths", "DISEASE", 28, 34], ["deaths", "DISEASE", 273, 279], ["COVID-19", "DNA", 46, 54]]], ["Due to the nonnormality of data, we computed Spearman's rank correlation coefficients, and their 95% confidence intervals (95% CI), of the age-standardized prevalence of tobacco smoking and the attack rate and of the age-standardized prevalence of tobacco smoking and the CFR for each of the member states.", [["smoking", "CHEMICAL", 178, 185], ["smoking", "CHEMICAL", 256, 263], ["tobacco", "ORGANISM", 170, 177], ["tobacco", "ORGANISM", 248, 255], ["tobacco", "SPECIES", 170, 177], ["tobacco", "SPECIES", 248, 255], ["tobacco smoking", "OBSERVATION", 170, 185]]], ["Univariate linear regression models were computed to obtain crude regression coefficients (b), and their 95% CI, for both associations.Material and methods.", [["Univariate linear regression models", "PROBLEM", 0, 35]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["P-values were considered significant when <0.05.", [["P-values", "TEST", 0, 8]]], ["The Spearman's rank correlation coefficient of the age-standardized prevalence of tobacco smoking and the attack rate was (Figure 1, panel B ).DiscussionOur preliminary analyses show that there is a statistically significant negative correlation between the age-standardized prevalence of tobacco smoking and the attack rate of COVID-19 at the national level in the EU, meaning that in member states with a higher age-standardized prevalence of tobacco smoking the attack rate of COVID-19 has been so far lower.", [["smoking", "CHEMICAL", 90, 97], ["smoking", "CHEMICAL", 297, 304], ["smoking", "CHEMICAL", 453, 460], ["COVID-19", "CHEMICAL", 480, 488], ["COVID-19", "CHEMICAL", 480, 488], ["tobacco", "ORGANISM", 82, 89], ["tobacco", "ORGANISM", 289, 296], ["tobacco", "ORGANISM", 445, 452], ["tobacco", "SPECIES", 82, 89], ["tobacco", "SPECIES", 289, 296], ["tobacco", "SPECIES", 445, 452], ["the attack rate", "PROBLEM", 102, 117], ["DiscussionOur preliminary analyses", "TEST", 143, 177], ["COVID", "TEST", 328, 333], ["COVID", "TEST", 480, 485], ["significant", "OBSERVATION_MODIFIER", 213, 224], ["negative", "OBSERVATION", 225, 233]]], ["These preliminary results would support the hypotheses, at the ecological level only, that nicotine could downregulate the expression of ACE2 (Oakes et al., 2018) .DiscussionImportantly, due to the ongoing nature of this recent pandemic and the shortness of available data, our results should be taken with caution.DiscussionWe want to highlight that tobacco smoke contains thousands of substances, not only nicotine, including systemic irritants and toxins, such as hydrocyanic acid, sulfur dioxide, carbon monoxide, ammonia and formaldehyde, as well as around 70 carcinogenic and mutagenic substances, such as arsenic, chromium, nitrosamines and benzopyrene .", [["nicotine", "CHEMICAL", 91, 99], ["nicotine", "CHEMICAL", 408, 416], ["hydrocyanic acid", "CHEMICAL", 467, 483], ["sulfur dioxide", "CHEMICAL", 485, 499], ["carbon monoxide", "CHEMICAL", 501, 516], ["ammonia", "CHEMICAL", 518, 525], ["formaldehyde", "CHEMICAL", 530, 542], ["arsenic", "CHEMICAL", 612, 619], ["chromium", "CHEMICAL", 621, 629], ["nitrosamines", "CHEMICAL", 631, 643], ["benzopyrene", "CHEMICAL", 648, 659], ["nicotine", "CHEMICAL", 91, 99], ["nicotine", "CHEMICAL", 408, 416], ["hydrocyanic acid", "CHEMICAL", 467, 483], ["sulfur dioxide", "CHEMICAL", 485, 499], ["carbon monoxide", "CHEMICAL", 501, 516], ["ammonia", "CHEMICAL", 518, 525], ["formaldehyde", "CHEMICAL", 530, 542], ["arsenic", "CHEMICAL", 612, 619], ["chromium", "CHEMICAL", 621, 629], ["nitrosamines", "CHEMICAL", 631, 643], ["benzopyrene", "CHEMICAL", 648, 659], ["nicotine", "SIMPLE_CHEMICAL", 91, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["tobacco", "ORGANISM", 351, 358], ["nicotine", "SIMPLE_CHEMICAL", 408, 416], ["hydrocyanic acid", "SIMPLE_CHEMICAL", 467, 483], ["sulfur dioxide", "SIMPLE_CHEMICAL", 485, 499], ["carbon monoxide", "SIMPLE_CHEMICAL", 501, 516], ["ammonia", "SIMPLE_CHEMICAL", 518, 525], ["formaldehyde", "SIMPLE_CHEMICAL", 530, 542], ["arsenic", "SIMPLE_CHEMICAL", 612, 619], ["chromium", "SIMPLE_CHEMICAL", 621, 629], ["nitrosamines", "SIMPLE_CHEMICAL", 631, 643], ["benzopyrene", "SIMPLE_CHEMICAL", 648, 659], ["ACE2", "PROTEIN", 137, 141], ["tobacco", "SPECIES", 351, 358], ["nicotine", "TREATMENT", 91, 99], ["the shortness of available data", "PROBLEM", 241, 272], ["nicotine", "TREATMENT", 408, 416], ["systemic irritants", "PROBLEM", 428, 446], ["toxins", "TREATMENT", 451, 457], ["hydrocyanic acid", "TREATMENT", 467, 483], ["sulfur dioxide", "TREATMENT", 485, 499], ["carbon monoxide", "TREATMENT", 501, 516], ["ammonia", "TREATMENT", 518, 525], ["formaldehyde", "TREATMENT", 530, 542], ["mutagenic substances", "TREATMENT", 582, 602], ["arsenic, chromium", "TREATMENT", 612, 629], ["nitrosamines", "TREATMENT", 631, 643], ["benzopyrene", "TREATMENT", 648, 659]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020 May 8, . . https://doi.org/10.1101 May 8, /2020 doi: medRxiv preprint (Rodgman and Perfetti, 2013) .", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 283, 306], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["In this sense, and as other authors state (Vardavas and Nikitara, 2020) (Gorini et al., 2020) , in the absence of more data, tobacco smoking should be considered as associated with poorer prognosis of COVID-19.(which was not certified by peer review)This study contains some limitations, which should be addressed.", [["smoking", "CHEMICAL", 133, 140], ["tobacco", "ORGANISM", 125, 132], ["tobacco", "SPECIES", 125, 132], ["This study", "TEST", 250, 260]]], ["Firstly, this is an ecological study, meaning that conclusions at the individual level should not be drawn.(which was not certified by peer review)Also, data are still preliminary due to the outbreak being still ongoing and adjustment for confounders was not possible (public health measures such as lockdowns, population density of the member states, etc.).", [["an ecological study", "TEST", 17, 36]]], ["Besides, quality and accuracy of numbers on COVID-19 cases and deaths may vary between member states due to differences in capacities in national surveillance systems and definitions of case and death.(which was not certified by peer review)In conclusion, with data available as of April 14 th 2020, and at the ecological level, in the member states of the EU with higher rates of smoking, the attack rate of COVID-19 has been lower.", [["deaths", "DISEASE", 63, 69], ["death", "DISEASE", 195, 200], ["smoking", "CHEMICAL", 381, 388], ["COVID-19", "CHEMICAL", 409, 417], ["COVID-19", "CHEMICAL", 409, 417], ["numbers", "TEST", 33, 40], ["COVID", "TEST", 44, 49], ["the attack rate", "TEST", 390, 405], ["COVID", "TEST", 409, 414], ["lower", "OBSERVATION_MODIFIER", 427, 432]]], ["In this sense, further research is needed to understand the possible effect of nicotine exposure in the expression of the ACE2 protein, and eventually in the outcomes of COVID-19.AcknowledgementWe would like to thank Prof. Josep Clotet i Erra for sharing with us his research hypothesis that nicotine could downregulate the expression of ACE2.", [["nicotine", "CHEMICAL", 79, 87], ["nicotine", "CHEMICAL", 292, 300], ["nicotine", "CHEMICAL", 79, 87], ["COVID-19", "CHEMICAL", 170, 178], ["nicotine", "CHEMICAL", 292, 300], ["nicotine", "SIMPLE_CHEMICAL", 79, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["nicotine", "SIMPLE_CHEMICAL", 292, 300], ["ACE2", "GENE_OR_GENE_PRODUCT", 338, 342], ["ACE2 protein", "PROTEIN", 122, 134], ["ACE2", "PROTEIN", 338, 342], ["nicotine exposure", "TREATMENT", 79, 96], ["the ACE2 protein", "TEST", 118, 134], ["COVID", "TEST", 170, 175], ["nicotine", "TREATMENT", 292, 300]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. .Panel A. Scatterplot between attack rate and age-standardized prevalence of tobacco smokingPanel B Scatterplot between case fatality rate and age-standardized prevalence of tobacco smoking .", [["CC", "CHEMICAL", 0, 2], ["smoking", "CHEMICAL", 358, 365], ["smoking", "CHEMICAL", 455, 462], ["tobacco", "ORGANISM", 350, 357], ["tobacco", "ORGANISM", 447, 454], ["tobacco", "SPECIES", 350, 357], ["tobacco", "SPECIES", 447, 454], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Panel A. Scatterplot between attack rate and age-standardized prevalence of tobacco smokingThe copyright holder for this preprint this version posted May 8, 2020 . . https://doi.org/10.1101", [["CC", "CHEMICAL", 0, 2], ["smoking", "CHEMICAL", 286, 293], ["https://doi.org/10.1101", "CHEMICAL", 368, 391], ["tobacco", "ORGANISM", 278, 285], ["tobacco", "SPECIES", 278, 285], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 293, 313], ["med", "ANATOMY", 105, 108]]]], "PMC7323682": [["IntroductionOn December 30th, 2019 the first few cases of a novel acute respiratory infectious disease were declared in Wuhan, China [1], which were promptly associated with a new beta-coronavirus, SARS-CoV-2, causing a disease that was later named COVID-19 [2].", [["respiratory", "ANATOMY", 72, 83], ["respiratory infectious disease", "DISEASE", 72, 102], ["SARS", "DISEASE", 198, 202], ["SARS-CoV-2", "ORGANISM", 198, 208], ["SARS-CoV", "SPECIES", 198, 206], ["a novel acute respiratory infectious disease", "PROBLEM", 58, 102], ["a new beta-coronavirus", "PROBLEM", 174, 196], ["SARS", "PROBLEM", 198, 202], ["a disease", "PROBLEM", 218, 227], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory", "ANATOMY", 72, 83], ["infectious", "OBSERVATION", 84, 94], ["disease", "OBSERVATION", 220, 227]]], ["Currently, COVID-19 has affected over 5 million people causing 340.000 deaths worldwide [4].IntroductionReverse real-time PCR (RT-PCR) techniques have emerged as the (gold) standard diagnostic test for COVID-19 [5].", [["COVID-19", "CHEMICAL", 11, 19], ["deaths", "DISEASE", 71, 77], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["diagnostic test", "TEST", 182, 197], ["COVID", "TEST", 202, 207]]], ["Nevertheless, in some situations, the sensitivity of RT-PCR tests has been worse than desired due to particular issues: variable viral loads depending on sample types and time of infection (i.e. nasopharyngeal vs. oropharyngeal, upper vs. lower respiratory tract); sample collection, conservation and transport; different gene targets [6].", [["sample", "ANATOMY", 154, 160], ["nasopharyngeal", "ANATOMY", 195, 209], ["oropharyngeal", "ANATOMY", 214, 227], ["lower respiratory tract", "ANATOMY", 239, 262], ["sample", "ANATOMY", 265, 271], ["infection", "DISEASE", 179, 188], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 195, 209], ["oropharyngeal", "ORGANISM_SUBDIVISION", 214, 227], ["lower", "ORGANISM_SUBDIVISION", 239, 244], ["respiratory tract", "ORGANISM_SUBDIVISION", 245, 262], ["RT-PCR tests", "TEST", 53, 65], ["particular issues", "PROBLEM", 101, 118], ["variable viral loads", "PROBLEM", 120, 140], ["infection", "PROBLEM", 179, 188], ["nasopharyngeal vs. oropharyngeal, upper vs", "PROBLEM", 195, 237], ["lower respiratory tract", "PROBLEM", 239, 262], ["sample collection", "TEST", 265, 282], ["viral loads", "OBSERVATION", 129, 140], ["infection", "OBSERVATION", 179, 188], ["nasopharyngeal", "ANATOMY", 195, 209], ["oropharyngeal", "ANATOMY", 214, 227], ["upper", "ANATOMY_MODIFIER", 229, 234], ["respiratory tract", "ANATOMY", 245, 262]]], ["In some of those \u201chigh-clinical-suspicion-RT-PCR-negative cases\u201d, antibodies detection could be a helpful tool in COVID-19 diagnosis [[7], [8], [9], [10], [11]].", [["[8], [9]", "SIMPLE_CHEMICAL", 139, 147], ["[10], [11]]", "SIMPLE_CHEMICAL", 149, 160], ["antibodies", "PROTEIN", 66, 76], ["RT-PCR", "TEST", 42, 48], ["antibodies detection", "TEST", 66, 86], ["COVID", "TEST", 114, 119]]], ["Serology plays a key role in contact tracing, epidemiological/seroprevalence studies, identification of convalescent plasma donors and evaluation of immune response to vaccines.IntroductionDue to the presumed asymptomatic cases and the lack of large population studies, real seroprevalence remains unknown and is urgently needed to control the pandemic and to know the reliable infection rates.", [["plasma", "ANATOMY", 117, 123], ["infection", "DISEASE", 378, 387], ["convalescent", "ORGANISM", 104, 116], ["plasma", "ORGANISM_SUBSTANCE", 117, 123], ["contact tracing", "TEST", 29, 44], ["seroprevalence studies", "TEST", 62, 84], ["convalescent plasma donors", "TEST", 104, 130], ["evaluation", "TEST", 135, 145], ["immune response", "PROBLEM", 149, 164], ["vaccines", "TREATMENT", 168, 176], ["asymptomatic cases", "PROBLEM", 209, 227], ["large population studies", "TEST", 244, 268], ["the reliable infection rates", "PROBLEM", 365, 393], ["infection", "OBSERVATION", 378, 387]]], ["Multiple SARS-CoV-2 antibody detection tests have been commercialised in a short period of time with minimal validation requirements due to urgent need.", [["Multiple SARS", "TEST", 0, 13], ["CoV-2 antibody detection tests", "TEST", 14, 44], ["minimal validation requirements", "PROBLEM", 101, 132], ["SARS", "OBSERVATION", 9, 13]]], ["Most of them detect IgM, IgA and/or IgG against the nucleocapsid protein (NP) or different domains of the spike glycoprotein (S1, S2 and RBD).", [["IgM", "GENE_OR_GENE_PRODUCT", 20, 23], ["IgA", "GENE_OR_GENE_PRODUCT", 25, 28], ["IgG against the nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 36, 72], ["spike glycoprotein", "GENE_OR_GENE_PRODUCT", 106, 124], ["S1", "GENE_OR_GENE_PRODUCT", 126, 128], ["S2", "GENE_OR_GENE_PRODUCT", 130, 132], ["RBD", "GENE_OR_GENE_PRODUCT", 137, 140], ["IgM", "PROTEIN", 20, 23], ["IgA", "PROTEIN", 25, 28], ["IgG", "PROTEIN", 36, 39], ["nucleocapsid protein", "PROTEIN", 52, 72], ["NP", "PROTEIN", 74, 76], ["spike glycoprotein", "PROTEIN", 106, 124], ["S1", "PROTEIN", 126, 128], ["S2", "PROTEIN", 130, 132], ["RBD", "PROTEIN", 137, 140], ["IgM", "TEST", 20, 23], ["IgA", "TEST", 25, 28], ["IgG", "TEST", 36, 39], ["the nucleocapsid protein", "TEST", 48, 72], ["the spike glycoprotein (S1, S2 and RBD)", "PROBLEM", 102, 141]]], ["Good performance has been shown to date with commercialised or in-house Enzyme-linked Immunosorbent Assay (ELISA) tests [7,8,10,12,13].", [["Enzyme", "TEST", 72, 78], ["Immunosorbent Assay", "TEST", 86, 105]]], ["However, there is much concern about lateral flow immunoassay (LFI) tests, which are widespread due to their easy and fast performance but with no available proven sensitivity and specificity [13].IntroductionIn this study, we aimed at comparing two commercial ELISA assays with three LFI tests to detect SARS-coV-2 antibodies.Materials and methodsA total of 152 serum samples submitted to our laboratory for SARS-CoV-2 antibodies detection between 15th March and 23rd April 2020 from 130 patients were included in the study.", [["serum samples", "ANATOMY", 363, 376], ["SARS-coV-2 antibodies", "GENE_OR_GENE_PRODUCT", 305, 326], ["serum samples", "ORGANISM_SUBSTANCE", 363, 376], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 409, 419], ["patients", "ORGANISM", 489, 497], ["SARS-coV-2 antibodies", "PROTEIN", 305, 326], ["patients", "SPECIES", 489, 497], ["SARS-CoV", "SPECIES", 409, 417], ["lateral flow immunoassay (LFI) tests", "TEST", 37, 73], ["specificity", "TEST", 180, 191], ["this study", "TEST", 212, 222], ["commercial ELISA assays", "TEST", 250, 273], ["three LFI tests", "TEST", 279, 294], ["SARS", "TEST", 305, 309], ["coV", "TEST", 310, 313], ["serum samples", "TEST", 363, 376], ["SARS", "TEST", 409, 413], ["CoV", "TEST", 414, 417], ["the study", "TEST", 515, 524]]], ["We tested Euroimmun ELISA anti SARS-CoV-2 S1 domain IgA and IgG antibodies (Euroimmun Medizinische Labordiagnostika, L\u00fcbeck, Germany) and three LFI: Test 1 (Hangzhou Alltest Biotech Co., Ltd.), Test 2 (Wuhan UNscience Biotechnology Co., Ltd.), both with separated bands for IgM and IgG antibodies, and Test 3 (Guangzhou Wondfo Biotech Co., Ltd.), which detects total antibodies in a single band.", [["IgA", "GENE_OR_GENE_PRODUCT", 52, 55], ["IgM", "GENE_OR_GENE_PRODUCT", 274, 277], ["Euroimmun ELISA anti SARS-CoV-2 S1 domain IgA", "PROTEIN", 10, 55], ["IgG antibodies", "PROTEIN", 60, 74], ["IgM", "PROTEIN", 274, 277], ["IgG antibodies", "PROTEIN", 282, 296], ["total antibodies", "PROTEIN", 361, 377], ["Euroimmun", "TEST", 10, 19], ["anti SARS", "TEST", 26, 35], ["CoV", "TEST", 36, 39], ["S1 domain IgA", "TEST", 42, 55], ["IgG antibodies", "TEST", 60, 74], ["Euroimmun", "TEST", 76, 85], ["Test", "TEST", 194, 198], ["separated bands", "TEST", 254, 269], ["IgM", "TEST", 274, 277], ["IgG antibodies", "TEST", 282, 296], ["Test", "TEST", 302, 306], ["total antibodies", "TEST", 361, 377]]], ["Sixty-two sera from Jan\u2013March 2018 and 2019, considered to be negative for SARS-CoV-2, were tested to calculate specificity.", [["sera", "ANATOMY", 10, 14], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83]]], ["All tests were performed according to manufacturer\u2019s instructions.ResultsOne hundred and nine patients were microbiologically confirmed as COVID-19 cases (109/130, 84%) since RT-PCR from nose/throat swab or other respiratory tract samples and/or IgG tested positive.", [["nose", "ANATOMY", 187, 191], ["throat swab", "ANATOMY", 192, 203], ["respiratory tract samples", "ANATOMY", 213, 238], ["patients", "ORGANISM", 94, 102], ["nose", "ORGANISM_SUBDIVISION", 187, 191], ["throat", "ORGANISM", 192, 198], ["respiratory tract samples", "CANCER", 213, 238], ["IgG", "GENE_OR_GENE_PRODUCT", 246, 249], ["IgG", "PROTEIN", 246, 249], ["patients", "SPECIES", 94, 102], ["All tests", "TEST", 0, 9], ["COVID", "TEST", 139, 144], ["RT-PCR from nose/throat swab", "TEST", 175, 203], ["other respiratory tract samples", "TEST", 207, 238], ["IgG", "TEST", 246, 249], ["nose", "ANATOMY", 187, 191], ["throat", "ANATOMY", 192, 198], ["respiratory tract", "ANATOMY", 213, 230]]], ["Asymptomatic patients were detected by contact tracing.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Twenty-one patients were not confirmed to be infected by SARS-CoV-2 (NC-COVID-19) after at least two RT-PCR and antibodies negative results.ResultsDemographic data and severity of symptoms, according to the WHO criteria, are shown in Table 1.", [["SARS", "DISEASE", 57, 61], ["patients", "ORGANISM", 11, 19], ["SARS-CoV-2", "ORGANISM", 57, 67], ["patients", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["NC", "TEST", 69, 71], ["COVID", "TEST", 72, 77], ["two RT-PCR", "TEST", 97, 107], ["antibodies", "TEST", 112, 122], ["Demographic data", "TEST", 147, 163], ["symptoms", "PROBLEM", 180, 188], ["infected", "OBSERVATION", 45, 53]]], ["Six cases (5.5%) were diagnosed by serological assays.", [["serological assays", "TEST", 35, 53]]], ["ELISA IgG ratios in different illness severity groups (>10 days after the onset of symptoms) and NC-COVID-19 are shown in Fig. 1.", [["illness", "DISEASE", 30, 37], ["IgG", "GENE_OR_GENE_PRODUCT", 6, 9], ["ELISA IgG", "PROTEIN", 0, 9], ["ELISA IgG ratios", "TEST", 0, 16], ["different illness severity groups", "PROBLEM", 20, 53], ["symptoms", "PROBLEM", 83, 91], ["NC", "TREATMENT", 97, 99], ["COVID", "TEST", 100, 105]]], ["Interestingly, the ANOVA test resulted in statistically significant differences between medians of asymptomatic/mild vs severe/critical pair of groups (5.1/6.1 vs. 9.7/8.6, respectively, p \u2264 0.05).Results", [["the ANOVA test", "TEST", 15, 29], ["asymptomatic/mild vs severe/critical pair of groups", "PROBLEM", 99, 150], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["mild", "OBSERVATION_MODIFIER", 112, 116]]]], "725440a56d2d897a28023064f972d6bbc9b437c7": [["Proteins Purified in Complex with LCMV GP or ANDV GP, Functional ClusteringAnalysis of Host Protein Partners, and Additional Viral GPs that Associate with ERGIC-53, Related to Figure 1 (A) Workflow for identification of human proteins that associate with the GPs encoded by LCMV and ANDV.", [["LCMV", "ORGANISM", 34, 38], ["human", "ORGANISM", 220, 225], ["LCMV", "ORGANISM", 274, 278], ["ANDV", "GENE_OR_GENE_PRODUCT", 283, 287], ["LCMV GP", "PROTEIN", 34, 41], ["ANDV GP", "PROTEIN", 45, 52], ["human proteins", "PROTEIN", 220, 234], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["LCMV", "SPECIES", 274, 278], ["ANDV", "SPECIES", 283, 287], ["ANDV GP", "PROBLEM", 45, 52], ["ERGIC", "TEST", 155, 160], ["human proteins", "PROBLEM", 220, 234], ["LCMV", "OBSERVATION", 34, 38]]], ["HEK 293T cells were co-transfected with a plasmid encoding each respective viral GP with a C-terminal HA epitope tag and a biotin acceptor peptide (BAP), along with a second plasmid that encodes BirA, a bacterial biotin ligase, to ensure biotinylation of the viral GPs.", [["HEK 293T cells", "ANATOMY", 0, 14], ["plasmid", "ANATOMY", 42, 49], ["BAP", "CHEMICAL", 148, 151], ["C", "CHEMICAL", 91, 92], ["biotin", "CHEMICAL", 123, 129], ["biotin", "CHEMICAL", 213, 219], ["HEK 293T cells", "CELL", 0, 14], ["biotin acceptor peptide", "SIMPLE_CHEMICAL", 123, 146], ["BAP", "SIMPLE_CHEMICAL", 148, 151], ["BirA", "GENE_OR_GENE_PRODUCT", 195, 199], ["biotin", "SIMPLE_CHEMICAL", 213, 219], ["HEK 293T cells", "CELL_LINE", 0, 14], ["plasmid", "DNA", 42, 49], ["viral GP", "PROTEIN", 75, 83], ["C-terminal HA epitope tag", "DNA", 91, 116], ["BirA", "PROTEIN", 195, 199], ["bacterial biotin ligase", "PROTEIN", 203, 226], ["a plasmid", "TREATMENT", 40, 49], ["a C-terminal HA epitope tag", "TREATMENT", 89, 116], ["a biotin acceptor peptide", "TREATMENT", 121, 146], ["a second plasmid", "TREATMENT", 165, 181], ["a bacterial biotin ligase", "TREATMENT", 201, 226], ["the viral GPs", "PROBLEM", 255, 268], ["293T cells", "OBSERVATION", 4, 14], ["biotin ligase", "OBSERVATION", 213, 226], ["viral GPs", "OBSERVATION", 259, 268]]], ["As a control, cells were co-transfected with the BirA plasmid and an empty vector.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional ClusteringTwo days later, biotinylated GPs and associated host proteins were affinity purified (AP) from whole cell lysates using magnetic streptavidin beads and separated on 4-20% polyacrylamide gels for Coomassie staining.", [["cells", "ANATOMY", 14, 19], ["plasmid", "ANATOMY", 54, 61], ["cell lysates", "ANATOMY", 258, 270], ["polyacrylamide", "CHEMICAL", 328, 342], ["Coomassie", "CHEMICAL", 352, 361], ["cells", "CELL", 14, 19], ["BirA", "GENE_OR_GENE_PRODUCT", 49, 53], ["LCMV GP", "ORGANISM", 116, 123], ["AP", "SIMPLE_CHEMICAL", 243, 245], ["cell lysates", "ORGANISM_SUBSTANCE", 258, 270], ["Coomassie", "SIMPLE_CHEMICAL", 352, 361], ["BirA plasmid", "DNA", 49, 61], ["LCMV GP", "PROTEIN", 116, 123], ["ANDV GP", "PROTEIN", 127, 134], ["biotinylated GPs", "PROTEIN", 173, 189], ["associated host proteins", "PROTEIN", 194, 218], ["AP", "PROTEIN", 243, 245], ["the BirA plasmid", "TREATMENT", 45, 61], ["ANDV GP", "PROBLEM", 127, 134], ["biotinylated GPs", "TEST", 173, 189], ["associated host proteins", "PROBLEM", 194, 218], ["whole cell lysates", "TREATMENT", 252, 270], ["magnetic streptavidin beads", "TREATMENT", 277, 304], ["4-20% polyacrylamide gels", "TREATMENT", 322, 347], ["Coomassie staining", "PROBLEM", 352, 370], ["empty vector", "OBSERVATION", 69, 81], ["Complex", "OBSERVATION_MODIFIER", 103, 110], ["LCMV", "OBSERVATION", 116, 120]]], ["To determine the identity of cellular proteins captured, each Coomassie-stained gel lane was cut into sections (see dashed lines) for in-gel, tryptic digestion and mass spectrometry analysis as described in the Extended Experimental Procedures.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(B and C) Cut maps of the affinity purified LCMV GP (B) and ANDV GP (C) samples following SDS-PAGE and Coomassie staining.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(D) NIH DAVID functional clustering identifies enriched protein functional categories from proteomic datasets representing proteins identified binding to both LCMV and ANDV GP proteins, LCMV GP alone, or ANDV GP alone.", [["cellular", "ANATOMY", 29, 37], ["sections", "ANATOMY", 102, 110], ["Coomassie", "CHEMICAL", 62, 71], ["Coomassie", "CHEMICAL", 422, 431], ["cellular", "CELL", 29, 37], ["Coomassie", "SIMPLE_CHEMICAL", 62, 71], ["lines", "CELL", 123, 128], ["LCMV", "ORGANISM", 278, 282], ["LCMV", "ORGANISM", 363, 367], ["B", "CELL", 372, 373], ["Coomassie", "SIMPLE_CHEMICAL", 422, 431], ["LCMV GP", "ORGANISM", 475, 482], ["LCMV", "ORGANISM", 675, 679], ["ANDV GP", "GENE_OR_GENE_PRODUCT", 684, 691], ["LCMV GP", "ORGANISM", 702, 709], ["cellular proteins", "PROTEIN", 29, 46], ["LCMV GP", "PROTEIN", 278, 285], ["ANDV GP", "PROTEIN", 289, 296], ["LCMV GP", "PROTEIN", 363, 370], ["B", "PROTEIN", 372, 373], ["LCMV GP", "PROTEIN", 475, 482], ["ANDV GP", "PROTEIN", 486, 493], ["LCMV and ANDV GP proteins", "PROTEIN", 675, 700], ["LCMV GP", "PROTEIN", 702, 709], ["ANDV GP", "PROTEIN", 720, 727], ["ANDV", "SPECIES", 486, 490], ["LCMV", "SPECIES", 675, 679], ["ANDV", "SPECIES", 684, 688], ["ANDV", "SPECIES", 720, 724], ["cellular proteins", "PROBLEM", 29, 46], ["each Coomassie-stained gel lane", "TREATMENT", 57, 88], ["tryptic digestion", "PROBLEM", 142, 159], ["mass spectrometry analysis", "TEST", 164, 190], ["LCMV GP", "TEST", 278, 285], ["ANDV GP", "PROBLEM", 289, 296], ["Cut maps", "TEST", 329, 337], ["the affinity", "TEST", 341, 353], ["SDS", "TEST", 409, 412], ["Coomassie staining", "TEST", 422, 440], ["enriched protein functional categories", "PROBLEM", 563, 601], ["proteomic datasets", "TEST", 607, 625], ["LCMV", "TEST", 675, 679], ["LCMV", "OBSERVATION", 278, 282], ["LCMV", "OBSERVATION", 475, 479]]], ["Official gene symbols (see Tables S1A-S1C) of these data sets were entered into NIH DAVID, searched under medium stringency choosing Homo sapiens as background.", [["Official gene symbols", "DNA", 0, 21], ["S1C", "DNA", 38, 41], ["NIH DAVID", "DNA", 80, 89], ["Homo sapiens", "SPECIES", 133, 145], ["Homo sapiens", "SPECIES", 133, 145]]], ["The percent of proteins (average of functional cluster subsets) in each data set in each of these categories is provided as well as the relative enrichment of a given cluster relative to the human proteome.", [["human", "ORGANISM", 191, 196], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196]]], ["Also note that because the size of each dataset is different a category may show a higher percentage, but a lower enrichment when compared to the same category in a different data set.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(E) HEK 293T cells were transfected with the BirA plasmid and a modified pCAGGS plasmid encoding WWAV GP with a C-terminal HA epitope tag and BAP or, as a control, an empty pCAGGS plasmid.", [["HEK 293T cells", "ANATOMY", 263, 277], ["plasmid", "ANATOMY", 309, 316], ["plasmid", "ANATOMY", 339, 346], ["BAP", "CHEMICAL", 401, 404], ["C", "CHEMICAL", 371, 372], ["LCMV GP", "ORGANISM", 218, 225], ["ANDV GP", "ORGANISM", 229, 236], ["HEK 293T cells", "CELL", 263, 277], ["BirA", "GENE_OR_GENE_PRODUCT", 304, 308], ["WWAV GP", "GENE_OR_GENE_PRODUCT", 356, 363], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 432, 438], ["LCMV GP", "PROTEIN", 218, 225], ["ANDV GP", "PROTEIN", 229, 236], ["Functional Clustering(E) HEK 293T cells", "CELL_LINE", 238, 277], ["BirA plasmid", "DNA", 304, 316], ["pCAGGS plasmid", "DNA", 332, 346], ["WWAV GP", "PROTEIN", 356, 363], ["C-terminal HA epitope tag", "DNA", 371, 396], ["BAP", "PROTEIN", 401, 404], ["pCAGGS plasmid", "DNA", 432, 446], ["ANDV", "SPECIES", 229, 233], ["a lower enrichment", "PROBLEM", 106, 124], ["LCMV GP", "TEST", 218, 225], ["the BirA plasmid", "TREATMENT", 300, 316], ["a modified pCAGGS plasmid", "TREATMENT", 321, 346], ["a C-terminal HA epitope tag", "TREATMENT", 369, 396], ["an empty pCAGGS plasmid", "TREATMENT", 423, 446], ["size", "OBSERVATION_MODIFIER", 27, 31], ["higher", "OBSERVATION_MODIFIER", 83, 89], ["percentage", "OBSERVATION_MODIFIER", 90, 100], ["lower", "OBSERVATION_MODIFIER", 108, 113], ["enrichment", "OBSERVATION", 114, 124], ["Complex", "OBSERVATION_MODIFIER", 205, 212], ["LCMV", "OBSERVATION", 218, 222]]], ["Whole cell lysates (input) were collected 2 days later and incubated with streptavidin beads to isolate each biotinylated GP species (GPC and GP2).", [["cell lysates", "ANATOMY", 6, 18], ["cell lysates", "CELL", 6, 18], ["streptavidin", "GENE_OR_GENE_PRODUCT", 74, 86], ["GPC", "SIMPLE_CHEMICAL", 134, 137], ["GP2", "GENE_OR_GENE_PRODUCT", 142, 145], ["biotinylated GP species", "PROTEIN", 109, 132], ["GP2", "PROTEIN", 142, 145], ["Whole cell lysates", "TEST", 0, 18], ["streptavidin beads", "TREATMENT", 74, 92], ["GPC", "TEST", 134, 137]]], ["Input lysates and captured bead fractions were screened for GP species (GPC and GP2) (bait) and ERGIC-53 (prey) via Western blot.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(F -I) HEK 293T cells were transfected with a plasmid encoding the indicated viral GPs with a C-terminal HA epitope tag or an empty plasmid.", [["lysates", "ANATOMY", 6, 13], ["F -I) HEK 293T cells", "ANATOMY", 205, 225], ["plasmid", "ANATOMY", 250, 257], ["plasmid", "ANATOMY", 336, 343], ["C", "CHEMICAL", 298, 299], ["lysates", "ORGANISM_SUBSTANCE", 6, 13], ["GPC", "SIMPLE_CHEMICAL", 72, 75], ["GP2", "GENE_OR_GENE_PRODUCT", 80, 83], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 96, 104], ["LCMV GP", "ORGANISM", 163, 170], ["ANDV GP", "ORGANISM", 174, 181], ["HEK 293T cells", "CELL", 211, 225], ["GP species", "PROTEIN", 60, 70], ["GP2", "PROTEIN", 80, 83], ["ERGIC", "PROTEIN", 96, 101], ["LCMV GP", "PROTEIN", 163, 170], ["ANDV GP", "PROTEIN", 174, 181], ["Functional Clustering(F -I) HEK 293T cells", "CELL_LINE", 183, 225], ["plasmid", "DNA", 250, 257], ["C-terminal HA epitope tag", "DNA", 298, 323], ["empty plasmid", "DNA", 330, 343], ["ANDV", "SPECIES", 174, 178], ["Input lysates", "TEST", 0, 13], ["bead fractions", "TEST", 27, 41], ["GP species", "TEST", 60, 70], ["GPC", "TEST", 72, 75], ["GP2", "TEST", 80, 83], ["ERGIC", "TEST", 96, 101], ["Western blot", "TEST", 116, 128], ["LCMV GP", "TEST", 163, 170], ["ANDV GP", "PROBLEM", 174, 181], ["viral GPs", "TEST", 281, 290], ["a C-terminal HA epitope tag", "PROBLEM", 296, 323], ["an empty plasmid", "TREATMENT", 327, 343], ["Complex", "OBSERVATION_MODIFIER", 150, 157], ["LCMV", "OBSERVATION", 163, 167], ["viral GPs", "OBSERVATION", 281, 290], ["empty plasmid", "OBSERVATION", 330, 343]]], ["Two days later ERGIC-53 was immunoprecipitated from whole cell lysates (input).", [["cell lysates", "ANATOMY", 58, 70], ["ERGIC-53", "CHEMICAL", 15, 23], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 15, 23], ["cell lysates", "ORGANISM_SUBSTANCE", 58, 70], ["ERGIC", "PROTEIN", 15, 20], ["ERGIC", "TEST", 15, 20], ["whole cell lysates", "TEST", 52, 70]]], ["Inputs and immunoprecipitated bead fractions were screened for ERGIC-53 (bait) and the various GP species (GPC and GP2 for arenaviruses; G2 for hantaviruses) (prey) via Western blot.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 63, 71], ["GP2", "GENE_OR_GENE_PRODUCT", 115, 118], ["hantaviruses", "ORGANISM", 144, 156], ["ERGIC", "PROTEIN", 63, 68], ["GP species", "PROTEIN", 95, 105], ["GP2", "PROTEIN", 115, 118], ["immunoprecipitated bead fractions", "TEST", 11, 44], ["ERGIC", "TEST", 63, 68], ["the various GP species", "PROBLEM", 83, 105], ["GPC", "TEST", 107, 110], ["GP2", "TEST", 115, 118], ["arenaviruses", "PROBLEM", 123, 135], ["hantaviruses", "PROBLEM", 144, 156], ["bead fractions", "OBSERVATION", 30, 44]]], ["(B) Overexpression of WT ERGIC-53 enhances infectious JUNV release (related to Figure 2B ).", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 25, 33], ["JUNV", "GENE_OR_GENE_PRODUCT", 54, 58], ["WT ERGIC-53", "PROTEIN", 22, 33], ["JUNV", "PROTEIN", 54, 58], ["WT ERGIC", "TEST", 22, 30], ["enhances infectious JUNV release", "PROBLEM", 34, 66], ["infectious", "OBSERVATION", 43, 53]]], ["HEK 293T cells were transfected with a plasmid encoding Myc-tagged, WT ERGIC-53 or, as a control, an empty plasmid; 48 hr following transfection these cells were challenged with JUNV C#1 at an MOI of 0.1.", [["HEK 293T cells", "ANATOMY", 0, 14], ["plasmid", "ANATOMY", 39, 46], ["plasmid", "ANATOMY", 107, 114], ["cells", "ANATOMY", 151, 156], ["HEK 293T cells", "CELL", 0, 14], ["Myc-tagged", "GENE_OR_GENE_PRODUCT", 56, 66], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 71, 79], ["cells", "CELL", 151, 156], ["HEK 293T cells", "CELL_LINE", 0, 14], ["plasmid", "DNA", 39, 46], ["Myc-tagged, WT ERGIC-53", "DNA", 56, 79], ["empty plasmid", "DNA", 101, 114], ["WT ERGIC", "TEST", 68, 76], ["an empty plasmid", "TREATMENT", 98, 114], ["transfection these cells", "PROBLEM", 132, 156], ["an MOI", "TEST", 190, 196], ["293T cells", "OBSERVATION", 4, 14]]], ["Supernatants and cell protein lysates were collected at 24, 48, and 72 hr pi and screened for JUNV C#1 PFU via plaque assay and Myc-ERGIC-53 or CRT (loading control) via Western blot (each lane represents an individual well).", [["Supernatants", "ANATOMY", 0, 12], ["cell", "ANATOMY", 17, 21], ["lysates", "ANATOMY", 30, 37], ["plaque", "ANATOMY", 111, 117], ["Myc-ERGIC-53", "CHEMICAL", 128, 140], ["Supernatants", "CELL", 0, 12], ["cell", "CELL", 17, 21], ["lysates", "ORGANISM_SUBSTANCE", 30, 37], ["CRT", "PROTEIN", 144, 147], ["Supernatants", "TEST", 0, 12], ["cell protein lysates", "TEST", 17, 37], ["hr pi", "TEST", 71, 76], ["JUNV", "TEST", 94, 98], ["plaque assay", "TEST", 111, 123], ["Myc-ERGIC", "TEST", 128, 137], ["CRT (loading control", "TREATMENT", 144, 164], ["plaque", "OBSERVATION", 111, 117]]], ["Data are presented as mean PFU \u00b1 SEM relative to the empty vector transfected wells and are the summation of 2 independent experiments (n = 6 per time point).Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(C and D) Restriction of ERGIC-53 to the ER impairs the release of infectious JUNV C#1 and DANV (related to Figures 2C and 2D , respectively).", [["LCMV GP", "ORGANISM", 192, 199], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 258, 266], ["ER", "GENE_OR_GENE_PRODUCT", 274, 276], ["C#1", "GENE_OR_GENE_PRODUCT", 316, 319], ["DANV", "GENE_OR_GENE_PRODUCT", 324, 328], ["LCMV GP", "PROTEIN", 192, 199], ["ANDV GP", "PROTEIN", 203, 210], ["ERGIC", "PROTEIN", 258, 263], ["ER", "PROTEIN", 274, 276], ["DANV", "DNA", 324, 328], ["LCMV GP", "TEST", 192, 199], ["ANDV GP", "PROBLEM", 203, 210], ["ERGIC", "TEST", 258, 263], ["DANV", "PROBLEM", 324, 328], ["Complex", "OBSERVATION_MODIFIER", 179, 186], ["LCMV", "OBSERVATION", 192, 196], ["infectious", "OBSERVATION", 300, 310]]], ["HEK 293T cells were transfected with a plasmid encoding Myc-tagged DN ERGIC-53 or, as a control, an empty plasmid; 24 hr later cells were challenged with JUNV C#1 (C) or DANV (D) at an MOI of 0.1 or 0.001, respectively.Proteins Purified in Complex with LCMV GP or ANDV GP, Functional ClusteringSupernatants and cell protein lysates were collected at the indicated times pi and screened for lane represents an individual well).", [["HEK 293T cells", "ANATOMY", 0, 14], ["plasmid", "ANATOMY", 39, 46], ["plasmid", "ANATOMY", 106, 113], ["cells", "ANATOMY", 127, 132], ["Supernatants", "ANATOMY", 294, 306], ["cell", "ANATOMY", 311, 315], ["lysates", "ANATOMY", 324, 331], ["HEK 293T cells", "CELL", 0, 14], ["cells", "CELL", 127, 132], ["LCMV GP", "ORGANISM", 253, 260], ["ANDV GP", "GENE_OR_GENE_PRODUCT", 264, 271], ["cell", "CELL", 311, 315], ["HEK 293T cells", "CELL_LINE", 0, 14], ["plasmid", "DNA", 39, 46], ["Myc-tagged DN ERGIC-53", "DNA", 56, 78], ["empty plasmid", "DNA", 100, 113], ["LCMV GP", "PROTEIN", 253, 260], ["ANDV GP", "PROTEIN", 264, 271], ["ANDV", "SPECIES", 264, 268], ["ERGIC", "TEST", 70, 75], ["an empty plasmid", "TREATMENT", 97, 113], ["JUNV C", "TEST", 154, 160], ["DANV (D)", "PROBLEM", 170, 178], ["an MOI", "TEST", 182, 188], ["LCMV GP", "PROBLEM", 253, 260], ["ANDV GP", "PROBLEM", 264, 271], ["Functional ClusteringSupernatants", "TREATMENT", 273, 306], ["cell protein lysates", "TREATMENT", 311, 331], ["293T cells", "OBSERVATION", 4, 14]]], ["Data are presented as mean PFU \u00b1 SEM relative to the empty vector transfected wells and are representative of 2 independent experiments (n = 12 or n = 6 per experiment for JUNV C#1 or DANV, respectively).Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(E) Release of infectious JUNV C#1 is impaired in ERGIC-53 (LMAN1 -/-) null cells (related to Figure 2E ).", [["ERGIC-53 (LMAN1 -/-) null cells", "ANATOMY", 329, 360], ["LCMV GP", "ORGANISM", 238, 245], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 329, 337], ["LCMV GP", "PROTEIN", 238, 245], ["ANDV GP", "PROTEIN", 249, 256], ["ERGIC-53 (LMAN1 -/-) null cells", "CELL_LINE", 329, 360], ["ANDV", "SPECIES", 249, 253], ["JUNV C#1", "PROBLEM", 172, 180], ["DANV", "PROBLEM", 184, 188], ["LCMV GP", "TEST", 238, 245], ["ERGIC", "TEST", 329, 334], ["null cells", "PROBLEM", 350, 360], ["LCMV", "OBSERVATION", 238, 242], ["infectious", "OBSERVATION", 294, 304], ["null cells", "OBSERVATION", 350, 360]]], ["B cells from LMAN1 +/+ (2829-D) and LMAN1 -/-(CRC-78 and CRC-79) individuals were challenged with JUNV C#1 at an MOI of 1.", [["B cells", "ANATOMY", 0, 7], ["LMAN1 +/+ (2829-D", "ANATOMY", 13, 30], ["LMAN1 -/-(CRC-78", "ANATOMY", 36, 52], ["CRC-79", "ANATOMY", 57, 63], ["B cells", "CELL", 0, 7], ["LMAN1", "GENE_OR_GENE_PRODUCT", 13, 18], ["LMAN1", "GENE_OR_GENE_PRODUCT", 36, 41], ["individuals", "ORGANISM", 65, 76], ["B cells", "CELL_TYPE", 0, 7], ["B cells", "TEST", 0, 7], ["LMAN1", "TEST", 13, 18], ["LMAN1", "TEST", 36, 41], ["CRC", "TEST", 46, 49], ["CRC", "TEST", 57, 60], ["JUNV C", "TEST", 98, 104]]], ["Supernatants and cell protein lysates were collected at 48 and 72 hr pi and screened for JUNV C#1 PFU via plaque assay and ERGIC-53 or actin (loading control) via Western blot (each lane represents an individual well).", [["Supernatants", "ANATOMY", 0, 12], ["cell", "ANATOMY", 17, 21], ["lysates", "ANATOMY", 30, 37], ["plaque", "ANATOMY", 106, 112], ["Supernatants", "CELL", 0, 12], ["cell", "CELL", 17, 21], ["lysates", "ORGANISM_SUBSTANCE", 30, 37], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 123, 131], ["actin", "GENE_OR_GENE_PRODUCT", 135, 140], ["actin", "PROTEIN", 135, 140], ["Supernatants", "TEST", 0, 12], ["cell protein lysates", "TEST", 17, 37], ["JUNV", "TEST", 89, 93], ["plaque assay", "TEST", 106, 118], ["ERGIC", "TEST", 123, 128], ["actin (loading control", "TREATMENT", 135, 157], ["plaque", "OBSERVATION", 106, 112]]], ["Data are presented as mean PFU \u00b1 SEM relative to the LMAN1 +/+ cells and are representative of 2 independent experiments (n = 3 per condition per experiment).Proteins Purified in Complex with LCMV GP or ANDV GP, Functional Clustering(A -E) p < 0.001, determined using the unpaired Student's t test.", [["LMAN1 +/+ cells", "ANATOMY", 53, 68], ["LMAN1", "GENE_OR_GENE_PRODUCT", 53, 58], ["LCMV", "ORGANISM", 192, 196], ["LMAN1", "PROTEIN", 53, 58], ["the LMAN1", "TEST", 49, 58], ["LCMV GP", "TEST", 192, 199], ["Complex", "OBSERVATION_MODIFIER", 179, 186], ["LCMV", "OBSERVATION", 192, 196]]], ["(A) Depiction of ERGIC-53 mutants used in this study.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 17, 25], ["ERGIC", "PROTEIN", 17, 22], ["ERGIC", "TEST", 17, 22], ["this study", "TEST", 42, 52]]], ["ERGIC-53 is a nonglycosylated, type I transmembrane protein that forms homohexamers and consists of an ER-lumenal domain, a transmembrane domain, and a cytoplasmic domain (for review see (Hauri et al., 2000) ).", [["transmembrane", "ANATOMY", 124, 137], ["cytoplasmic", "ANATOMY", 152, 163], ["ERGIC-53", "CHEMICAL", 0, 8], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 0, 8], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["cytoplasmic", "ORGANISM_SUBSTANCE", 152, 163], ["ERGIC-53", "PROTEIN", 0, 8], ["nonglycosylated, type I transmembrane protein", "PROTEIN", 14, 59], ["homohexamers", "PROTEIN", 71, 83], ["ER", "PROTEIN", 103, 105], ["lumenal domain", "PROTEIN", 106, 120], ["transmembrane domain", "PROTEIN", 124, 144], ["cytoplasmic domain", "PROTEIN", 152, 170], ["ERGIC", "TEST", 0, 5], ["a nonglycosylated, type I transmembrane protein", "PROBLEM", 12, 59], ["lumenal", "ANATOMY_MODIFIER", 106, 113]]], ["The ERlumenal portion of the protein contains a carbohydrate recognition domain (CRD) that selectively binds high mannose glycans in a Ca 2+ -and pH-dependent manner (Appenzeller-Herzog et al., 2004; Appenzeller et al., 1999; Itin et al., 1996) .", [["Ca", "CHEMICAL", 135, 137], ["carbohydrate", "CHEMICAL", 48, 60], ["mannose", "CHEMICAL", 114, 121], ["Ca 2+", "CHEMICAL", 135, 140], ["Ca 2+", "SIMPLE_CHEMICAL", 135, 140], ["ERlumenal portion", "PROTEIN", 4, 21], ["carbohydrate recognition domain", "PROTEIN", 48, 79], ["CRD", "PROTEIN", 81, 84], ["a Ca", "TEST", 133, 137], ["pH", "TEST", 146, 148]]], ["Lectin binding can be disrupted by deletion of the entire CRD (\u2206CRD) (residues 44 -269) or specific \u03b2-strands within the CRD (e.g. strands 1 & 2 (\u2206\u03b22) (residues 43-72), 1 through 3 (\u2206\u03b23) (residues 43 -76), or 1 through 4 (\u2206\u03b24) (residues 43-83)) (Zheng et al., 2010) , or through mutation of individual amino acids (N156A or D181A) (Itin et al., 1996; Velloso et al., 2003; Zheng et al., 2010) within the CRD that are critically required for coordinating Ca 2+ -binding.", [["amino acids", "CHEMICAL", 302, 313], ["Ca", "CHEMICAL", 454, 456], ["amino acids", "CHEMICAL", 302, 313], ["Ca 2+", "CHEMICAL", 454, 459], ["Lectin", "GENE_OR_GENE_PRODUCT", 0, 6], ["CRD", "GENE_OR_GENE_PRODUCT", 58, 61], ["\u2206\u03b22", "GENE_OR_GENE_PRODUCT", 146, 149], ["\u2206\u03b23", "GENE_OR_GENE_PRODUCT", 182, 185], ["amino acids", "AMINO_ACID", 302, 313], ["CRD", "GENE_OR_GENE_PRODUCT", 404, 407], ["Ca 2+", "SIMPLE_CHEMICAL", 454, 459], ["CRD", "PROTEIN", 58, 61], ["CRD", "PROTEIN", 64, 67], ["\u03b2-strands", "DNA", 100, 109], ["CRD", "DNA", 121, 124], ["CRD", "PROTEIN", 404, 407], ["Lectin binding", "PROBLEM", 0, 14], ["the entire CRD", "PROBLEM", 47, 61], ["the CRD", "TEST", 117, 124], ["strands", "TEST", 131, 138], ["residues", "TEST", 152, 160], ["residues", "TEST", 188, 196], ["individual amino acids", "TEST", 291, 313], ["the CRD", "PROBLEM", 400, 407]]], ["The ER-lumenal region of ERGIC-53 also encodes an alpha helical domain and two cysteine residues (C466 & C475) that are all required for the formation of ERGIC-53 homohexamers.", [["ER-lumenal", "ANATOMY", 4, 14], ["cysteine", "CHEMICAL", 79, 87], ["ERGIC-53", "CHEMICAL", 154, 162], ["ER", "GENE_OR_GENE_PRODUCT", 4, 6], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 25, 33], ["cysteine", "AMINO_ACID", 79, 87], ["ER", "PROTEIN", 4, 6], ["lumenal region", "PROTEIN", 7, 21], ["ERGIC", "PROTEIN", 25, 30], ["alpha helical domain", "PROTEIN", 50, 70], ["ERGIC", "PROTEIN", 154, 159], ["ERGIC", "TEST", 25, 30], ["an alpha helical domain", "TREATMENT", 47, 70], ["two cysteine residues", "TREATMENT", 75, 96], ["ERGIC", "TEST", 154, 159], ["lumenal", "ANATOMY_MODIFIER", 7, 14], ["region", "ANATOMY_MODIFIER", 15, 21], ["ERGIC", "ANATOMY_MODIFIER", 25, 30], ["cysteine residues", "OBSERVATION", 79, 96]]], ["Deletion of the helical domain (\u2206Helix) (residues 271 -457) (Neve et al., 2005) or mutation of the cysteine residues to alanine13(C466A/C475A) (Nufer et al., 2003) results in the loss of noncovalently-associated or disulfidelinked homohexamers, respectively.", [["cysteine", "CHEMICAL", 99, 107], ["alanine13", "CHEMICAL", 120, 129], ["cysteine", "AMINO_ACID", 99, 107], ["alanine13", "GENE_OR_GENE_PRODUCT", 120, 129], ["helical domain", "PROTEIN", 16, 30], ["\u2206Helix", "PROTEIN", 32, 38], ["disulfidelinked homohexamers", "PROTEIN", 215, 243], ["mutation of the cysteine residues", "PROBLEM", 83, 116], ["the loss of noncovalently", "PROBLEM", 175, 200]]], ["Deletion of the helical domain combined with mutation of C466 and C475 to alanine (\u2206helix monomer (\u2206HM)) (Zheng et al., 2010) completely abolishes ERGIC-53 oligomerization and yields monomeric ERGIC-53, which, like the DN mutant (KKAA) (Kappeler et al., 1997) , cannot traffic beyond the ER.", [["ER", "ANATOMY", 288, 290], ["alanine", "CHEMICAL", 74, 81], ["C475", "CHEMICAL", 66, 70], ["alanine", "CHEMICAL", 74, 81], ["C466", "AMINO_ACID", 57, 61], ["C475", "AMINO_ACID", 66, 70], ["alanine", "AMINO_ACID", 74, 81], ["\u2206helix monomer", "SIMPLE_CHEMICAL", 83, 97], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 147, 155], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 193, 201], ["ER", "GENE_OR_GENE_PRODUCT", 288, 290], ["helical domain", "PROTEIN", 16, 30], ["ERGIC", "PROTEIN", 147, 152], ["ERGIC", "PROTEIN", 193, 198], ["DN mutant", "PROTEIN", 219, 228], ["KKAA", "PROTEIN", 230, 234], ["ER", "PROTEIN", 288, 290], ["Deletion of the helical domain", "PROBLEM", 0, 30], ["mutation of C466", "PROBLEM", 45, 61], ["alanine", "TEST", 74, 81], ["ERGIC", "TEST", 147, 152], ["monomeric ERGIC", "TEST", 183, 198]]], ["Additionally, several of these constructs (\u2206CRD, \u2206\u03b21, \u2206\u03b22, \u2206\u03b23, \u2206\u03b24, and \u2206HM) abolish ERGIC-53's ability to interact with MCFD2 (Zheng et al., 2010) .", [["CRD", "GENE_OR_GENE_PRODUCT", 44, 47], ["\u2206\u03b21", "GENE_OR_GENE_PRODUCT", 49, 52], ["\u2206\u03b22", "GENE_OR_GENE_PRODUCT", 54, 57], ["\u2206\u03b23", "GENE_OR_GENE_PRODUCT", 59, 62], ["\u2206\u03b24", "GENE_OR_GENE_PRODUCT", 64, 67], ["\u2206HM", "GENE_OR_GENE_PRODUCT", 73, 76], ["ERGIC-53's", "GENE_OR_GENE_PRODUCT", 86, 96], ["CRD", "PROTEIN", 44, 47], ["\u2206\u03b21", "DNA", 49, 52], ["\u03b22", "PROTEIN", 55, 57], ["\u03b23", "DNA", 60, 62], ["\u03b24", "DNA", 65, 67], ["HM", "DNA", 74, 76], ["ERGIC", "PROTEIN", 86, 91], ["these constructs", "TEST", 25, 41], ["CRD", "TEST", 44, 47], ["\u2206\u03b21", "TEST", 49, 52], ["\u2206", "TEST", 54, 55], ["\u2206", "TEST", 59, 60], ["ERGIC", "TEST", 86, 91]]], ["SS, signal sequence; F, Flag epitope tag; TM, transmembrane. and DANV by W. I. Lipkin (Columbia University).", [["transmembrane", "ANATOMY", 46, 59], ["transmembrane", "CELLULAR_COMPONENT", 46, 59], ["signal sequence; F, Flag epitope tag", "PROTEIN", 4, 40], ["TM", "PROTEIN", 42, 44], ["signal sequence", "TEST", 4, 19], ["Flag epitope tag", "TEST", 24, 40]]], ["JUNV C#1, which is an attenuated vaccine strain, was originally derived from WT JUNV strain XJ and differs by 12 amino acids (Chosewood et al., 2009; Goni et al., 2006) .", [["amino acids", "CHEMICAL", 113, 124], ["amino acids", "CHEMICAL", 113, 124], ["WT JUNV strain XJ", "ORGANISM", 77, 94], ["amino acids", "AMINO_ACID", 113, 124], ["an attenuated vaccine strain", "PROBLEM", 19, 47]]], ["Working stocks of infectious JUNV C#1 and DANV were generated in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 65, 78], ["C#1", "GENE_OR_GENE_PRODUCT", 34, 37], ["DANV", "GENE_OR_GENE_PRODUCT", 42, 46], ["Vero E6 cells", "CELL", 65, 78], ["DANV", "DNA", 42, 46], ["Vero E6 cells", "CELL_LINE", 65, 78], ["JUNV C#1", "SPECIES", 29, 37], ["DANV", "SPECIES", 42, 46], ["Vero E6", "SPECIES", 65, 72], ["DANV", "PROBLEM", 42, 46], ["infectious", "OBSERVATION", 18, 28], ["E6 cells", "OBSERVATION", 70, 78]]], ["Infectious titers of these viruses were determined via plaque assay on Vero E6 cells.", [["plaque", "ANATOMY", 55, 61], ["Vero E6 cells", "ANATOMY", 71, 84], ["Vero E6 cells", "CELL", 71, 84], ["Vero E6 cells", "CELL_LINE", 71, 84], ["Vero E6", "SPECIES", 71, 78], ["Infectious titers of these viruses", "PROBLEM", 0, 34], ["plaque assay", "TEST", 55, 67], ["Vero E6 cells", "TREATMENT", 71, 84], ["viruses", "OBSERVATION", 27, 34], ["plaque", "OBSERVATION", 55, 61], ["E6 cells", "OBSERVATION", 76, 84]]], ["VSV\u0394G encoding a GFP reporter has been described elsewhere (Takada et al., 1997) and was provided by M. Whitt (The University of Tennessee Health Science Center, Memphis, TN).", [["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 0, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 17, 20], ["VSV\u0394G", "DNA", 0, 5], ["GFP reporter", "DNA", 17, 29]]], ["An infectious stock of VSV\u0394G pseudotyped with VSV G was generated by first transfecting HEK 293T cells with a pCAGGS plasmid encoding VSV G and then 24 hr later inoculating these cells with infectious VSV\u0394G (which had previously been pseudotyped with VSV G) at a multiplicity of infection (MOI) of 3.", [["HEK 293T cells", "ANATOMY", 88, 102], ["plasmid", "ANATOMY", 117, 124], ["cells", "ANATOMY", 179, 184], ["infection", "DISEASE", 279, 288], ["VSV\u0394G pseudotyped", "ORGANISM", 23, 40], ["VSV G", "ORGANISM", 46, 51], ["HEK 293T cells", "CELL", 88, 102], ["VSV G", "GENE_OR_GENE_PRODUCT", 134, 139], ["cells", "CELL", 179, 184], ["VSV\u0394G", "CANCER", 201, 206], ["VSV G", "ORGANISM", 251, 256], ["HEK 293T cells", "CELL_LINE", 88, 102], ["pCAGGS plasmid", "DNA", 110, 124], ["VSV G", "PROTEIN", 134, 139], ["VSV", "SPECIES", 46, 49], ["VSV", "SPECIES", 134, 137], ["VSV", "SPECIES", 251, 254], ["VSV\u0394G pseudotyped", "PROBLEM", 23, 40], ["VSV G", "PROBLEM", 46, 51], ["a pCAGGS plasmid encoding VSV G", "TREATMENT", 108, 139], ["infectious VSV\u0394G", "PROBLEM", 190, 206], ["VSV G", "PROBLEM", 251, 256], ["infection", "PROBLEM", 279, 288], ["infectious", "OBSERVATION", 3, 13], ["infectious", "OBSERVATION_MODIFIER", 190, 200], ["infection", "OBSERVATION", 279, 288]]], ["Supernatants were collected 24 hr following inoculation and infectious titer was determined by enumerating green foci via focus assay in Vero E6 cells.Plasmids and TransfectionsTo identify and/or validate the interaction of human proteins, including ERGIC-53, with various viral GPs in Figures 1, 3 , 6, S1, and S6, we subcloned each respective viral GP into our previously described pCAGGS expression vector (Cornillez-Ty et al., 2009 ).", [["Supernatants", "ANATOMY", 0, 12], ["foci", "ANATOMY", 113, 117], ["Vero E6 cells", "ANATOMY", 137, 150], ["Supernatants", "CELL", 0, 12], ["Vero E6 cells", "CELL", 137, 150], ["human", "ORGANISM", 224, 229], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 250, 258], ["3", "GENE_OR_GENE_PRODUCT", 297, 298], ["S1", "GENE_OR_GENE_PRODUCT", 304, 306], ["S6", "GENE_OR_GENE_PRODUCT", 312, 314], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 384, 390], ["Vero E6 cells", "CELL_LINE", 137, 150], ["human proteins", "PROTEIN", 224, 238], ["ERGIC", "PROTEIN", 250, 255], ["S1", "PROTEIN", 304, 306], ["S6", "PROTEIN", 312, 314], ["viral GP", "DNA", 345, 353], ["pCAGGS expression vector", "DNA", 384, 408], ["human", "SPECIES", 224, 229], ["Vero E6", "SPECIES", 137, 144], ["human", "SPECIES", 224, 229], ["inoculation", "TREATMENT", 44, 55], ["infectious titer", "TEST", 60, 76], ["enumerating green foci", "PROBLEM", 95, 117], ["Plasmids", "TREATMENT", 151, 159], ["human proteins", "TEST", 224, 238], ["ERGIC", "TEST", 250, 255], ["various viral GPs", "TEST", 265, 282], ["Figures", "TEST", 286, 293], ["infectious", "OBSERVATION_MODIFIER", 60, 70], ["green foci", "OBSERVATION", 107, 117], ["E6 cells", "OBSERVATION", 142, 150]]], ["This vector expresses each GP as a fusion protein containing 3 C-terminal elements: a hemaglutinin (HA) epitope tag (YPYDVPDYA) followed by the tobacco etch virus (TEV) cleavage site (ENLYFQG) followed by a 23 amino acid biotin acceptor peptide (BAP) (MASSLRQILDSQKMEWRSNAGGS).", [["hemaglutinin", "CHEMICAL", 86, 98], ["amino acid biotin", "CHEMICAL", 210, 227], ["amino acid", "CHEMICAL", 210, 220], ["biotin", "CHEMICAL", 221, 227], ["GP", "GENE_OR_GENE_PRODUCT", 27, 29], ["hemaglutinin", "SIMPLE_CHEMICAL", 86, 98], ["tobacco etch virus", "ORGANISM", 144, 162], ["GP", "PROTEIN", 27, 29], ["fusion protein", "PROTEIN", 35, 49], ["C-terminal elements", "PROTEIN", 63, 82], ["hemaglutinin (HA) epitope tag", "PROTEIN", 86, 115], ["YPYDVPDYA", "PROTEIN", 117, 126], ["tobacco etch virus (TEV) cleavage site", "PROTEIN", 144, 182], ["tobacco etch virus", "SPECIES", 144, 162], ["a fusion protein", "TREATMENT", 33, 49], ["a hemaglutinin (HA) epitope tag (YPYDVPDYA)", "TREATMENT", 84, 127], ["the tobacco etch virus (TEV) cleavage site (ENLYFQG)", "TREATMENT", 140, 192], ["a 23 amino acid biotin acceptor peptide", "TREATMENT", 205, 244]]], ["When co-transfected with a second plasmid that encodes the bacterial biotin ligase BirA, the BAP can be biotinylated for affinity purification with streptavidin beads.", [["BAP", "CHEMICAL", 93, 96], ["biotin", "CHEMICAL", 69, 75], ["BAP", "CHEMICAL", 93, 96], ["biotin", "SIMPLE_CHEMICAL", 69, 75], ["BirA", "GENE_OR_GENE_PRODUCT", 83, 87], ["BAP", "SIMPLE_CHEMICAL", 93, 96], ["streptavidin", "GENE_OR_GENE_PRODUCT", 148, 160], ["bacterial biotin ligase", "PROTEIN", 59, 82], ["BirA", "PROTEIN", 83, 87], ["BAP", "PROTEIN", 93, 96], ["a second plasmid", "TREATMENT", 25, 41], ["the bacterial biotin ligase BirA", "TREATMENT", 55, 87], ["the BAP", "TREATMENT", 89, 96], ["affinity purification with streptavidin beads", "TREATMENT", 121, 166], ["streptavidin beads", "OBSERVATION", 148, 166]]], ["Briefly, each GP was first amplified via PCR using forward and reverse primers containing attB1 and attB2 sequences, respectively.", [["attB1", "GENE_OR_GENE_PRODUCT", 90, 95], ["attB2", "GENE_OR_GENE_PRODUCT", 100, 105], ["GP", "DNA", 14, 16], ["forward and reverse primers", "DNA", 51, 78], ["attB1 and attB2 sequences", "DNA", 90, 115], ["PCR", "TEST", 41, 44], ["forward and reverse primers", "TREATMENT", 51, 78], ["attB2 sequences", "TEST", 100, 115]]], ["In each case, the stop codon was excluded.", [["stop codon", "DNA", 18, 28], ["the stop codon", "TREATMENT", 14, 28]]], ["PCR products were subcloned into pDONR221 via a BP recombination reaction.", [["pDONR221", "GENE_OR_GENE_PRODUCT", 33, 41], ["BP", "SIMPLE_CHEMICAL", 48, 50], ["PCR products", "DNA", 0, 12], ["pDONR221", "DNA", 33, 41], ["PCR products", "TREATMENT", 0, 12], ["a BP recombination reaction", "TREATMENT", 46, 73]]], ["GP genes were then subcloned from pDONR221 into the modified pCAGGS vector via an LR recombination reaction.", [["GP", "GENE_OR_GENE_PRODUCT", 0, 2], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 61, 67], ["GP genes", "DNA", 0, 8], ["pDONR221", "DNA", 34, 42], ["pCAGGS vector", "DNA", 61, 74], ["an LR recombination reaction", "TREATMENT", 79, 107], ["LR recombination", "OBSERVATION", 82, 98]]], ["The nucleotide sequence of each GP clone was verified by DNA sequencing.", [["nucleotide", "CHEMICAL", 4, 14], ["GP clone", "CELL", 32, 40], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["GP clone", "DNA", 32, 40], ["The nucleotide sequence", "TEST", 0, 23], ["DNA sequencing", "TEST", 57, 71]]], ["GPs were subcloned from the following viral strains (for each GP, an NCBI Gene Identifier number and a Protein Locus number are listed to provide a link to the actual nucleotide sequence cloned for that particular GP and the corresponding translated amino acid sequence, respectively): ANDV strain CHI-7913 (30313864, AAO86638), SNV NMR11 (999407 (note that there are two silent mutations in our clone: G changed to T and A changed to C at positions 60 and 843, respectively, of referenced sequence), AAC42202), LASV strain Josiah (23343509, NP_694870), LCMV strain Armstrong 53b (61655715, AAX49341), JUNV strain XJ (also referred to as Parodi) (see (Reignier et al., 2006) for description of the nucleotide sequence; the amino acid sequence of the cloned gene matches JVU70799), JUNV strain C#1 (52222815, AAU34180), MACV strain Carvallo (see (Reignier et al., 2006) for description of nucleotide sequence, the amino acid sequence of the cloned gene matchesAffinity Purification of Viral GPsTo capture biotinylated viral GPs for the identification of human protein partners via mass spectrometry ( Figures 1A, 1B , S1B, and S1C) or validation of protein partners via Western blot ( Figures 1D, 1F , 1G, and S1E), HEK 293T cells were co-transfected with our modified pCAGGS plasmid that encodes each respective viral GP with a C-terminal HA epitope tag and a BAP, and a second plasmid that encodes BirA to facilitate biotinylation of the viral GPs.", [["HEK 293T cells", "ANATOMY", 1215, 1229], ["plasmid", "ANATOMY", 1378, 1385], ["nucleotide", "CHEMICAL", 167, 177], ["amino acid", "CHEMICAL", 250, 260], ["23343509, NP_694870", "CHEMICAL", 532, 551], ["nucleotide", "CHEMICAL", 698, 708], ["amino acid", "CHEMICAL", 723, 733], ["nucleotide", "CHEMICAL", 888, 898], ["amino acid", "CHEMICAL", 913, 923], ["nucleotide", "CHEMICAL", 167, 177], ["amino acid", "CHEMICAL", 250, 260], ["nucleotide", "CHEMICAL", 698, 708], ["amino acid", "CHEMICAL", 723, 733], ["nucleotide", "CHEMICAL", 888, 898], ["amino acid", "CHEMICAL", 913, 923], ["C", "CHEMICAL", 1328, 1329], ["amino acid", "AMINO_ACID", 250, 260], ["LCMV", "ORGANISM", 554, 558], ["amino acid", "AMINO_ACID", 723, 733], ["amino acid", "AMINO_ACID", 913, 923], ["human", "ORGANISM", 1053, 1058], ["HEK 293T cells", "CELL", 1215, 1229], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 1268, 1274], ["BAP", "GENE_OR_GENE_PRODUCT", 1360, 1363], ["BirA", "GENE_OR_GENE_PRODUCT", 1399, 1403], ["Protein Locus number", "DNA", 103, 123], ["GP", "DNA", 214, 216], ["amino acid sequence", "PROTEIN", 723, 742], ["amino acid sequence", "PROTEIN", 913, 932], ["human protein partners", "PROTEIN", 1053, 1075], ["S1B", "PROTEIN", 1117, 1120], ["S1C", "PROTEIN", 1126, 1129], ["protein partners", "PROTEIN", 1148, 1164], ["HEK 293T cells", "CELL_LINE", 1215, 1229], ["pCAGGS plasmid", "DNA", 1268, 1282], ["viral GP", "PROTEIN", 1312, 1320], ["C-terminal HA epitope tag", "DNA", 1328, 1353], ["BAP", "PROTEIN", 1360, 1363], ["BirA", "PROTEIN", 1399, 1403], ["human", "SPECIES", 1053, 1058], ["CHI-7913", "SPECIES", 298, 306], ["LASV strain Josiah (23343509, NP_694870)", "SPECIES", 512, 552], ["human", "SPECIES", 1053, 1058], ["GPs", "TEST", 0, 3], ["viral strains", "PROBLEM", 38, 51], ["amino acid sequence", "TEST", 250, 269], ["SNV NMR11", "TEST", 329, 338], ["two silent mutations", "PROBLEM", 368, 388], ["LASV strain Josiah", "TEST", 512, 530], ["NP", "TEST", 542, 544], ["LCMV strain Armstrong", "TEST", 554, 575], ["JUNV strain XJ", "PROBLEM", 602, 616], ["the nucleotide sequence", "TEST", 694, 717], ["the amino acid sequence", "TEST", 719, 742], ["JUNV strain C#1", "PROBLEM", 781, 796], ["nucleotide sequence", "TEST", 888, 907], ["the amino acid sequence", "TREATMENT", 909, 932], ["Viral GPs", "TEST", 984, 993], ["biotinylated viral GPs", "TEST", 1004, 1026], ["mass spectrometry", "TEST", 1080, 1097], ["Figures", "TEST", 1100, 1107], ["1A", "TEST", 1108, 1110], ["1B", "TEST", 1112, 1114], ["S1B", "TEST", 1117, 1120], ["Western blot", "TEST", 1169, 1181], ["Figures", "TEST", 1184, 1191], ["HEK 293T cells", "PROBLEM", 1215, 1229], ["our modified pCAGGS plasmid", "TREATMENT", 1255, 1282], ["a C-terminal HA epitope tag", "TREATMENT", 1326, 1353], ["a BAP", "TREATMENT", 1358, 1363], ["a second plasmid", "TREATMENT", 1369, 1385], ["BirA", "TREATMENT", 1399, 1403], ["the viral GPs", "PROBLEM", 1435, 1448], ["viral GPs", "OBSERVATION", 1439, 1448]]], ["As a control for the mass spectrometry studies and APs done to validate an interaction between a given viral GP Western blot analysis to confirm bait/prey purification or Coomassie staining for mass spectrometry analysis (described in next section).Mass SpectrometryTo identify human protein partners of LCMV GP or ANDV GP in Figures 1A, 1B , S1B, and S1C, HEK 293T cells were co-transfected with our modified pCAGGS plasmid encoding each respective viral GP with a C-terminal HA epitope tag and a biotin acceptor peptide (BAP) and a second plasmid encoding BirA to ensure biotinylation of the viral GPs.", [["HEK 293T cells", "ANATOMY", 357, 371], ["plasmid", "ANATOMY", 541, 548], ["BAP", "CHEMICAL", 523, 526], ["Coomassie", "CHEMICAL", 171, 180], ["C", "CHEMICAL", 466, 467], ["biotin", "CHEMICAL", 498, 504], ["Coomassie", "SIMPLE_CHEMICAL", 171, 180], ["human", "ORGANISM", 278, 283], ["LCMV GP", "ORGANISM", 304, 311], ["S1B", "GENE_OR_GENE_PRODUCT", 343, 346], ["S1C", "GENE_OR_GENE_PRODUCT", 352, 355], ["HEK 293T cells", "CELL", 357, 371], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 410, 416], ["biotin acceptor peptide", "SIMPLE_CHEMICAL", 498, 521], ["BAP", "SIMPLE_CHEMICAL", 523, 526], ["BirA", "GENE_OR_GENE_PRODUCT", 558, 562], ["human protein partners", "PROTEIN", 278, 300], ["LCMV GP", "PROTEIN", 304, 311], ["ANDV GP", "PROTEIN", 315, 322], ["S1B", "PROTEIN", 343, 346], ["S1C", "PROTEIN", 352, 355], ["HEK 293T cells", "CELL_LINE", 357, 371], ["pCAGGS plasmid", "DNA", 410, 424], ["viral GP", "PROTEIN", 450, 458], ["C-terminal HA epitope tag", "DNA", 466, 491], ["BirA", "PROTEIN", 558, 562], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 278, 283], ["LCMV", "SPECIES", 304, 308], ["ANDV", "SPECIES", 315, 319], ["the mass spectrometry studies", "TEST", 17, 46], ["APs", "TEST", 51, 54], ["blot analysis", "TEST", 120, 133], ["bait/prey purification", "TREATMENT", 145, 167], ["Coomassie staining", "TEST", 171, 189], ["mass spectrometry analysis", "TEST", 194, 220], ["LCMV GP", "TEST", 304, 311], ["ANDV GP", "TEST", 315, 322], ["Figures", "TEST", 326, 333], ["S1B", "TEST", 343, 346], ["our modified pCAGGS plasmid", "TREATMENT", 397, 424], ["a C-terminal HA epitope tag", "TREATMENT", 464, 491], ["a biotin acceptor peptide", "TREATMENT", 496, 521], ["a second plasmid encoding BirA", "TREATMENT", 532, 562], ["the viral GPs", "PROBLEM", 590, 603], ["viral GPs", "OBSERVATION", 594, 603]]], ["As a control, cells were co-transfected with the BirA plasmid and an empty vector.", [["cells", "ANATOMY", 14, 19], ["plasmid", "ANATOMY", 54, 61], ["cells", "CELL", 14, 19], ["BirA", "GENE_OR_GENE_PRODUCT", 49, 53], ["BirA plasmid", "DNA", 49, 61], ["the BirA plasmid", "TREATMENT", 45, 61], ["empty vector", "OBSERVATION", 69, 81]]], ["Two days later, biotinylated GPs and associated host proteins were affinity purified (AP) from whole cell lysates as described above, in an LTQ-XL linear ion trap mass spectrometer (Thermo Scientific) over the entire run using 10 MS/MS scans following each survey scan.", [["cell lysates", "ANATOMY", 101, 113], ["cell lysates", "CELL", 101, 113], ["biotinylated GPs", "PROTEIN", 16, 32], ["associated host proteins", "PROTEIN", 37, 61], ["AP", "PROTEIN", 86, 88], ["biotinylated GPs", "TEST", 16, 32], ["associated host proteins", "PROBLEM", 37, 61], ["whole cell lysates", "PROBLEM", 95, 113], ["an LTQ", "TEST", 137, 143], ["MS scans", "TEST", 233, 241], ["each survey scan", "TEST", 252, 268]]], ["Raw data were searched against the human IPI forward and reverse concatenated databases using SEQUEST software requiring tryptic peptide matches with a 2 Da mass tolerance.", [["human", "ORGANISM", 35, 40], ["human IPI forward", "DNA", 35, 52], ["reverse concatenated databases", "DNA", 57, 87], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["tryptic peptide matches", "TREATMENT", 121, 144], ["a 2 Da mass tolerance", "TREATMENT", 150, 171]]], ["Cysteine residues were required to have a static increase in 71.0 Da for acrylamide adduction, and differential modification of 16.0 Da on methionine residues was permitted.", [["Cysteine", "CHEMICAL", 0, 8], ["acrylamide", "CHEMICAL", 73, 83], ["methionine", "CHEMICAL", 139, 149], ["Cysteine", "CHEMICAL", 0, 8], ["acrylamide", "CHEMICAL", 73, 83], ["methionine", "CHEMICAL", 139, 149], ["Cysteine", "AMINO_ACID", 0, 8], ["acrylamide", "SIMPLE_CHEMICAL", 73, 83], ["methionine", "AMINO_ACID", 139, 149], ["Cysteine residues", "PROBLEM", 0, 17], ["a static increase", "TEST", 40, 57], ["acrylamide adduction", "TREATMENT", 73, 93], ["differential modification", "TEST", 99, 124], ["methionine residues", "TREATMENT", 139, 158]]], ["Host proteins were considered legitimate GP protein partners if 2 or more unique tryptic peptides were detected from a host protein in samples transfected with a given GP plasmid but not the empty vector or, alternatively, if there was a 5-fold higher quantity of total tryptic peptides detectable from a given human protein in a GP sample compared to the empty vector sample.", [["samples", "ANATOMY", 135, 142], ["human", "ORGANISM", 311, 316], ["Host proteins", "PROTEIN", 0, 13], ["GP protein partners", "PROTEIN", 41, 60], ["GP plasmid", "DNA", 168, 178], ["empty vector", "DNA", 191, 203], ["human protein", "PROTEIN", 311, 324], ["human", "SPECIES", 311, 316], ["human", "SPECIES", 311, 316], ["Host proteins", "TEST", 0, 13], ["more unique tryptic peptides", "PROBLEM", 69, 97], ["a host protein", "TEST", 117, 131], ["GP plasmid", "TREATMENT", 168, 178], ["total tryptic peptides", "PROBLEM", 264, 286], ["human protein", "PROBLEM", 311, 324]]], ["These filters resulted in a false discovery peptide rate of less than 1%.Mass SpectrometryImmunoprecipitations above in the \"Affinity Purification of Viral GPs\" section.", [["These filters", "TREATMENT", 0, 13], ["a false discovery peptide rate", "TEST", 26, 56], ["Mass SpectrometryImmunoprecipitations", "PROBLEM", 73, 110], ["Viral GPs\" section", "TREATMENT", 150, 168], ["false discovery", "OBSERVATION", 28, 43]]], ["Following centrifugation at 10,000 rpm at 4\u00b0C to remove insoluble material, protein lysates were pre-cleared by incubating them with magnetic Protein G beads (Dynabeads Protein G beads, 10004D, Invitrogen) on a rotating platform for 15 minutes at 4\u00b0C. Each cleared lysate was then incubated (on a rotating platform) with its respective antibody for 2 hr followed by magnetic Protein G beads for 1 hr.", [["lysates", "ANATOMY", 84, 91], ["lysate", "ANATOMY", 265, 271], ["C", "SIMPLE_CHEMICAL", 44, 45], ["insoluble material", "TREATMENT", 56, 74], ["protein lysates", "TEST", 76, 91], ["magnetic Protein G beads", "TREATMENT", 133, 157], ["Protein G beads", "TREATMENT", 169, 184], ["Invitrogen", "TREATMENT", 194, 204], ["a rotating platform", "TREATMENT", 209, 228], ["a rotating platform", "TREATMENT", 295, 314], ["its respective antibody", "TREATMENT", 321, 344], ["magnetic Protein G beads", "TREATMENT", 366, 390]]], ["The beads were then washed 4 times with ice cold lysis buffer to remove nonspecific proteins and excess antibody.", [["beads", "ANATOMY", 4, 9], ["nonspecific proteins", "PROTEIN", 72, 92], ["excess antibody", "PROTEIN", 97, 112], ["The beads", "TREATMENT", 0, 9], ["ice cold lysis buffer", "TREATMENT", 40, 61], ["nonspecific proteins and excess antibody", "PROBLEM", 72, 112], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["Captured bait proteins and their associated protein partners (prey) were stripped from the beads by boiling them in Laemmli buffer (with or without 5% \u03b2-mercaptoethanol) andMass Spectrometryseparated by size and charge on gradient Novex 4-20% Tris-Glycine polyacrylamide gels forMass SpectrometryWestern blot analysis to confirm bait/prey purification.", [["\u03b2-mercaptoethanol", "CHEMICAL", 151, 168], ["Tris-Glycine", "CHEMICAL", 243, 255], ["\u03b2-mercaptoethanol", "CHEMICAL", 151, 168], ["Tris-Glycine polyacrylamide", "CHEMICAL", 243, 270], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 151, 168], ["Tris-Glycine polyacrylamide gels", "SIMPLE_CHEMICAL", 243, 275], ["bait proteins", "PROTEIN", 9, 22], ["protein partners", "PROTEIN", 44, 60], ["Laemmli buffer", "TREATMENT", 116, 130], ["5% \u03b2-mercaptoethanol)", "TREATMENT", 148, 169], ["gradient Novex", "TREATMENT", 222, 236], ["Tris-Glycine polyacrylamide gels", "TREATMENT", 243, 275], ["Mass", "PROBLEM", 279, 283], ["blot analysis", "TEST", 304, 317], ["bait/prey purification", "TREATMENT", 329, 351], ["Mass", "OBSERVATION", 173, 177], ["size", "OBSERVATION_MODIFIER", 203, 207]]], ["Immunoprecipitations from cellular protein lysates were carried out using the following antibodies: ERGIC-53 was immunoprecipated with either the mouse anti-ERGIC-53 G1/93 antibody (ALX-804-602-C100, Enzo Life Sciences Farmingdale, NY) ( Figures 1E, 1I-1K , 3F, 3H, 3J, S1G and S1H) or a rabbit anti-ERGIC-53 antibody (sc-66880, Santa Cruz, Dallas, TX) ( Figure S1F and S1I); VSV G with the mouse anti-VSV G antibody (11 667 351 001, Roche Applied Science) ( Figure 3E ); JUNV GP with the mouse anti-GP1/GPC antibody GB03-BE08 (NR-2564, BEI Resources) ( Figure 1H ); or, as a control, a species matched, non-immune Mouse IgG1 Isotype (MAB002, R&D Systems Minneapolis, MN) ( Figures 1K and S1H ).Mass SpectrometryTo purify intact JUNV C#1 particles in Figure 5D , supernatant from JUNV C#1-infected Vero E6 cells was collected 72 hr post-inoculation, cleared of cells by centrifugation at 1400 RPM, then pre-cleared with magnetic Protein G beads, incubated with the GP1-specific mouse monoclonal antibody QC03-BF11 (NR-2566, BEI Resources) for 2 hr followed by magnetic Protein G beads for 1 hr.", [["cellular", "ANATOMY", 26, 34], ["lysates", "ANATOMY", 43, 50], ["supernatant", "ANATOMY", 763, 774], ["Vero E6 cells", "ANATOMY", 798, 811], ["cells", "ANATOMY", 861, 866], ["sc-66880", "CHEMICAL", 319, 327], ["GB03-BE08", "CHEMICAL", 517, 526], ["NR-2564", "CHEMICAL", 528, 535], ["QC03-BF11", "CHEMICAL", 1004, 1013], ["NR-2566", "CHEMICAL", 1015, 1022], ["cellular", "CELL", 26, 34], ["lysates", "ORGANISM_SUBSTANCE", 43, 50], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 100, 108], ["mouse", "ORGANISM", 146, 151], ["3H, 3J", "SIMPLE_CHEMICAL", 262, 268], ["S1G", "SIMPLE_CHEMICAL", 270, 273], ["S1H", "SIMPLE_CHEMICAL", 278, 281], ["rabbit", "ORGANISM", 288, 294], ["anti-ERGIC-53", "GENE_OR_GENE_PRODUCT", 295, 308], ["sc-66880", "SIMPLE_CHEMICAL", 319, 327], ["TX", "SIMPLE_CHEMICAL", 349, 351], ["VSV", "ORGANISM", 376, 379], ["mouse", "ORGANISM", 391, 396], ["anti-VSV G antibody", "GENE_OR_GENE_PRODUCT", 397, 416], ["mouse", "ORGANISM", 489, 494], ["anti-GP1", "GENE_OR_GENE_PRODUCT", 495, 503], ["Mouse", "ORGANISM", 615, 620], ["IgG1", "GENE_OR_GENE_PRODUCT", 621, 625], ["JUNV C#1", "CELL", 780, 788], ["Vero E6 cells", "CELL", 798, 811], ["cells", "CELL", 861, 866], ["GP1", "GENE_OR_GENE_PRODUCT", 965, 968], ["mouse", "ORGANISM", 978, 983], ["NR-2566", "SIMPLE_CHEMICAL", 1015, 1022], ["ERGIC", "PROTEIN", 100, 105], ["mouse anti-ERGIC-53 G1/93 antibody", "PROTEIN", 146, 180], ["S1H", "PROTEIN", 278, 281], ["rabbit anti-ERGIC-53 antibody", "PROTEIN", 288, 317], ["S1I", "PROTEIN", 370, 373], ["mouse anti-VSV G antibody", "PROTEIN", 391, 416], ["mouse anti-GP1", "PROTEIN", 489, 503], ["GPC antibody", "PROTEIN", 504, 516], ["GB03", "PROTEIN", 517, 521], ["BE08", "PROTEIN", 522, 526], ["NR", "PROTEIN", 528, 530], ["non-immune Mouse IgG1 Isotype", "PROTEIN", 604, 633], ["JUNV C#1 particles", "CELL_LINE", 729, 747], ["JUNV C#1-infected Vero E6 cells", "CELL_LINE", 780, 811], ["GP1", "PROTEIN", 965, 968], ["QC03", "PROTEIN", 1004, 1008], ["BF11", "PROTEIN", 1009, 1013], ["NR", "PROTEIN", 1015, 1017], ["mouse", "SPECIES", 146, 151], ["rabbit", "SPECIES", 288, 294], ["mouse", "SPECIES", 391, 396], ["mouse", "SPECIES", 489, 494], ["Mouse", "SPECIES", 615, 620], ["mouse", "SPECIES", 978, 983], ["mouse", "SPECIES", 146, 151], ["rabbit", "SPECIES", 288, 294], ["VSV", "SPECIES", 376, 379], ["mouse", "SPECIES", 391, 396], ["mouse", "SPECIES", 489, 494], ["Mouse", "SPECIES", 615, 620], ["Vero E6", "SPECIES", 798, 805], ["mouse", "SPECIES", 978, 983], ["Immunoprecipitations", "TEST", 0, 20], ["cellular protein lysates", "TEST", 26, 50], ["ERGIC", "TEST", 100, 105], ["the mouse anti-ERGIC", "TEST", 142, 162], ["antibody", "TEST", 172, 180], ["ALX-804-602", "TEST", 182, 193], ["Figures", "TEST", 238, 245], ["1I", "TEST", 250, 252], ["K", "TEST", 254, 255], ["3H", "TEST", 262, 264], ["3J", "TEST", 266, 268], ["S1G", "TEST", 270, 273], ["a rabbit anti-ERGIC", "TEST", 286, 305], ["antibody", "TEST", 309, 317], ["sc", "TEST", 319, 321], ["Santa Cruz", "TEST", 329, 339], ["TX", "TEST", 349, 351], ["VSV G", "TEST", 376, 381], ["the mouse anti-VSV G antibody", "TEST", 387, 416], ["JUNV GP", "TEST", 472, 479], ["the mouse anti-GP1", "TEST", 485, 503], ["GPC antibody", "TEST", 504, 516], ["GB03", "TEST", 517, 521], ["BE08", "TEST", 522, 526], ["NR", "TEST", 528, 530], ["BEI Resources", "TEST", 537, 550], ["a species", "PROBLEM", 585, 594], ["non-immune Mouse IgG1 Isotype", "TREATMENT", 604, 633], ["Mass", "TEST", 695, 699], ["SpectrometryTo", "TEST", 700, 714], ["JUNV C", "TEST", 780, 786], ["infected Vero E6 cells", "PROBLEM", 789, 811], ["magnetic Protein G beads", "TREATMENT", 920, 944], ["the GP1", "TEST", 961, 968], ["NR", "TEST", 1015, 1017], ["magnetic Protein G beads", "TREATMENT", 1060, 1084], ["cellular protein lysates", "OBSERVATION", 26, 50], ["IgG1 Isotype", "OBSERVATION", 621, 633], ["E6 cells", "OBSERVATION", 803, 811]]], ["The beads were washed 4 times with PBS containing 0.1% BSA and 1 mM calcium chloride and then boiled in Laemmli buffer to elute/lyse the captured viral particles.Mass SpectrometryThe collected lysate was then electrophoresed on a Novex 4-20% Tris-Glycine polyacrylamide gel for Western blot analysis.", [["beads", "ANATOMY", 4, 9], ["lysate", "ANATOMY", 193, 199], ["BSA", "CHEMICAL", 55, 58], ["calcium chloride", "CHEMICAL", 68, 84], ["Tris-Glycine", "CHEMICAL", 242, 254], ["calcium chloride", "CHEMICAL", 68, 84], ["Tris-Glycine polyacrylamide", "CHEMICAL", 242, 269], ["BSA", "SIMPLE_CHEMICAL", 55, 58], ["calcium chloride", "SIMPLE_CHEMICAL", 68, 84], ["Tris-Glycine polyacrylamide", "SIMPLE_CHEMICAL", 242, 269], ["The beads", "TREATMENT", 0, 9], ["PBS", "TREATMENT", 35, 38], ["0.1% BSA", "TREATMENT", 50, 58], ["1 mM calcium chloride", "TREATMENT", 63, 84], ["Laemmli buffer", "TREATMENT", 104, 118], ["Mass Spectrometry", "PROBLEM", 162, 179], ["The collected lysate", "TREATMENT", 179, 199], ["a Novex", "TREATMENT", 228, 235], ["Tris-Glycine polyacrylamide gel", "TREATMENT", 242, 273], ["Western blot analysis", "TEST", 278, 299], ["beads", "OBSERVATION_MODIFIER", 4, 9], ["viral particles", "OBSERVATION", 146, 161], ["Spectrometry", "OBSERVATION", 167, 179]]], ["Controls for this experiment included the use of the GP1-specific antibody with supernatants from mock-infected cells as well as using the MAB002 Mouse IgG1Mass SpectrometryIsotype Control antibody for immunoprecipitation from the JUNV C#1-infected supernatants. with JUNV C#1 at an MOI of 0.1.", [["supernatants", "ANATOMY", 80, 92], ["cells", "ANATOMY", 112, 117], ["supernatants", "ANATOMY", 249, 261], ["GP1", "GENE_OR_GENE_PRODUCT", 53, 56], ["cells", "CELL", 112, 117], ["Mouse", "ORGANISM", 146, 151], ["C#1", "ORGANISM", 236, 239], ["GP1", "PROTEIN", 53, 56], ["mock-infected cells", "CELL_LINE", 98, 117], ["MAB002 Mouse IgG1Mass SpectrometryIsotype Control antibody", "PROTEIN", 139, 197], ["Mouse", "SPECIES", 146, 151], ["Mouse", "SPECIES", 146, 151], ["the GP1", "TREATMENT", 49, 56], ["infected cells", "PROBLEM", 103, 117], ["the MAB002 Mouse IgG1Mass SpectrometryIsotype Control antibody", "TREATMENT", 135, 197], ["immunoprecipitation", "TEST", 202, 221], ["the JUNV C", "TEST", 227, 237], ["infected supernatants", "PROBLEM", 240, 261], ["infected cells", "OBSERVATION", 103, 117]]], ["Supernatants were collected 96 hr post-inoculation, concentrated via ultracentrifugation as described below, and screened for PFU via plaque assay, JUNV proteins (GP1, NP, and Z) or cellular proteins (ERGIC-53 and actin (loading control)) viaSDS-PAGE and Western BlotWestern blot, and viral S segment genomic RNA via quantitative RT-PCR (as described below).SDS-PAGE and Western BlotRNA was extracted from each viral preparation using the QIAamp Viral RNA Mini Kit (52906, Qiagen) according to the manufacturer instructions.", [["Supernatants", "ANATOMY", 0, 12], ["plaque", "ANATOMY", 134, 140], ["cellular", "ANATOMY", 182, 190], ["Supernatants", "CELL", 0, 12], ["JUNV proteins", "GENE_OR_GENE_PRODUCT", 148, 161], ["GP1", "GENE_OR_GENE_PRODUCT", 163, 166], ["NP", "GENE_OR_GENE_PRODUCT", 168, 170], ["cellular", "CELL", 182, 190], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 201, 209], ["actin", "GENE_OR_GENE_PRODUCT", 214, 219], ["JUNV proteins", "PROTEIN", 148, 161], ["GP1", "PROTEIN", 163, 166], ["NP", "PROTEIN", 168, 170], ["Z", "PROTEIN", 176, 177], ["cellular proteins", "PROTEIN", 182, 199], ["ERGIC", "PROTEIN", 201, 206], ["53", "PROTEIN", 207, 209], ["actin", "PROTEIN", 214, 219], ["viaSDS", "PROTEIN", 239, 245], ["viral S segment genomic RNA", "RNA", 285, 312], ["PFU via plaque assay", "TEST", 126, 146], ["JUNV proteins", "TEST", 148, 161], ["GP1", "TEST", 163, 166], ["NP", "TEST", 168, 170], ["cellular proteins", "TEST", 182, 199], ["ERGIC", "TEST", 201, 206], ["actin (loading control", "TREATMENT", 214, 236], ["viral S segment genomic RNA", "PROBLEM", 285, 312], ["quantitative RT-PCR", "TEST", 317, 336], ["plaque", "OBSERVATION", 134, 140]]], ["Virion preparations were also screened for their ability to bind host cells in a virus-cell binding assay (described below).Virus-Cell Binding AssayTo determine whether the viral particles produced in EBV-immortalized B lymphoblastoid cell lines derived from a normal (LMAN1 +/+ ; 2829-D) or ERGIC-53 null (LMAN1 -/-; CRC-78)Virus-Cell Binding Assayindividual had differing capacities to bind host cells in Figure 4G , we chilled Vero E6 cells grown in 48-well plates to 4\u00b0C, washed them twice with PBS, and then incubated duplicate wells with each viral preparation for 1.5 hrs at 4\u00b0C. Unbound virus was then aspirated and each well was washed 3 times in PBS.", [["cells", "ANATOMY", 70, 75], ["cell", "ANATOMY", 87, 91], ["Cell", "ANATOMY", 130, 134], ["B lymphoblastoid cell lines", "ANATOMY", 218, 245], ["LMAN1 +/+ ; 2829-D", "ANATOMY", 269, 287], ["Cell", "ANATOMY", 331, 335], ["cells", "ANATOMY", 398, 403], ["cells", "ANATOMY", 438, 443], ["cells", "CELL", 70, 75], ["cell", "CELL", 87, 91], ["Cell", "CELL", 130, 134], ["EBV", "ORGANISM", 201, 204], ["B lymphoblastoid cell lines", "CELL", 218, 245], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 292, 300], ["Virus", "ORGANISM", 325, 330], ["Cell", "CELL", 331, 335], ["cells", "CELL", 398, 403], ["Figure 4G", "CELL", 407, 416], ["Vero E6 cells", "CELL", 430, 443], ["host cells", "CELL_TYPE", 65, 75], ["EBV-immortalized B lymphoblastoid cell lines", "CELL_LINE", 201, 245], ["host cells", "CELL_TYPE", 393, 403], ["Vero E6 cells", "CELL_LINE", 430, 443], ["Vero E6", "SPECIES", 430, 437], ["Virion preparations", "TREATMENT", 0, 19], ["a virus-cell binding assay", "TEST", 79, 105], ["Virus", "PROBLEM", 124, 129], ["the viral particles", "PROBLEM", 169, 188], ["EBV", "TEST", 201, 204], ["immortalized B lymphoblastoid cell lines", "TREATMENT", 205, 245], ["LMAN1", "TEST", 269, 274], ["ERGIC", "TEST", 292, 297], ["null", "TEST", 301, 305], ["LMAN1", "TEST", 307, 312], ["CRC", "TEST", 318, 321], ["Virus", "PROBLEM", 325, 330], ["Cell Binding", "PROBLEM", 331, 343], ["differing capacities", "PROBLEM", 364, 384], ["chilled Vero E6 cells", "TEST", 422, 443], ["PBS", "TREATMENT", 499, 502], ["each viral preparation", "TREATMENT", 544, 566], ["Unbound virus", "PROBLEM", 587, 600], ["Cell Binding", "OBSERVATION", 130, 142], ["lymphoblastoid cell lines", "OBSERVATION", 220, 245], ["virus", "OBSERVATION", 595, 600]]], ["Following the final wash, total RNA was extracted from each monolayer using the RNeasy Mini Kit (74106, Qiagen) according to the manufacturer instructions.", [["monolayer", "ANATOMY", 60, 69], ["monolayer", "CELL", 60, 69], ["total RNA", "TREATMENT", 26, 35], ["the RNeasy Mini Kit", "TREATMENT", 76, 95]]], ["RNA samples were then subjected to quantitative RT-PCR, as described below, to determine the copies of JUNV C#1 S segment genomic RNA.Quantitative RT-PCRTo enumerate quantities of JUNV C#1 viral S segment genomic RNA, cDNA was generated using 200 nM of primer 5'-AAGGGTTTAAAAATGGTAGCAGAC-3', which is specific for the NP region of the S segment genomic (negative-sense) RNA, with Multiscribe-RT (4311235, Life Technologies, Carlsbad, CA).", [["samples", "ANATOMY", 4, 11], ["JUNV C#1", "GENE_OR_GENE_PRODUCT", 180, 188], ["JUNV C#1 S segment genomic RNA", "RNA", 103, 133], ["viral S segment genomic RNA", "RNA", 189, 216], ["cDNA", "DNA", 218, 222], ["NP region", "DNA", 318, 327], ["S segment genomic", "DNA", 335, 352], ["RNA samples", "TEST", 0, 11], ["quantitative RT-PCR", "TEST", 35, 54], ["JUNV C#1 S segment genomic RNA", "PROBLEM", 103, 133], ["Quantitative RT", "TEST", 134, 149], ["PCRTo enumerate quantities", "TEST", 150, 176], ["JUNV", "TEST", 180, 184], ["1 viral S segment genomic RNA", "PROBLEM", 187, 216], ["cDNA", "TEST", 218, 222], ["200 nM of primer", "TREATMENT", 243, 259], ["AAGGGTTTAAAAATGGTAGCAGAC", "TEST", 263, 287], ["segment", "ANATOMY_MODIFIER", 114, 121], ["genomic RNA", "OBSERVATION", 122, 133], ["segment", "ANATOMY_MODIFIER", 197, 204], ["genomic RNA", "OBSERVATION", 205, 216]]], ["Quantitative PCR was then performed using a primer-probe set originally described in (Trombley et al., 2010) .", [["Quantitative PCR", "TEST", 0, 16], ["a primer-probe set", "TREATMENT", 42, 60]]], ["Specifically, we used forward primer ( StepOnePlus Real-Time PCR System and analyzed with the provided StepOne software.Virus-Like Particle (VLP) AssayFor the VLP assays shown in Figure 4C , HEK 293T cells were initially transfected with a plasmid expressing Myc-tagged WT or DN ERGIC-53, then 24 hr later with a cocktail of 2 plasmids encoding the JUNV Z and XJ GPC proteins, respectively, to permit the formation and release of VLPs.", [["HEK 293T cells", "ANATOMY", 191, 205], ["plasmid", "ANATOMY", 240, 247], ["plasmids", "ANATOMY", 327, 335], ["HEK 293T cells", "CELL", 191, 205], ["JUNV Z", "GENE_OR_GENE_PRODUCT", 349, 355], ["XJ GPC", "GENE_OR_GENE_PRODUCT", 360, 366], ["forward primer", "DNA", 22, 36], ["HEK 293T cells", "CELL_LINE", 191, 205], ["Myc-tagged WT", "PROTEIN", 259, 272], ["DN ERGIC", "PROTEIN", 276, 284], ["JUNV Z and XJ GPC proteins", "PROTEIN", 349, 375], ["forward primer", "TREATMENT", 22, 36], ["Virus", "PROBLEM", 120, 125], ["Assay", "TEST", 146, 151], ["the VLP assays", "TEST", 155, 169], ["HEK 293T cells", "TEST", 191, 205], ["DN ERGIC", "TEST", 276, 284], ["a cocktail of 2 plasmids", "TREATMENT", 311, 335], ["the JUNV Z", "TEST", 345, 355], ["XJ GPC proteins", "TEST", 360, 375], ["VLPs", "PROBLEM", 430, 434], ["Particle", "OBSERVATION_MODIFIER", 131, 139]]], ["Cells and supernatants were collected 72 hr later and screened for the presence of various GP species (the C-terminally FLAG-tagged precursor GPC or proteolytically processed GP2) or actin (to serve as a loading control) via Western blot.", [["Cells", "ANATOMY", 0, 5], ["supernatants", "ANATOMY", 10, 22], ["C", "CHEMICAL", 107, 108], ["Cells", "CELL", 0, 5], ["FLAG", "GENE_OR_GENE_PRODUCT", 120, 124], ["GP2", "GENE_OR_GENE_PRODUCT", 175, 178], ["actin", "GENE_OR_GENE_PRODUCT", 183, 188], ["GP species", "PROTEIN", 91, 101], ["C-terminally FLAG", "PROTEIN", 107, 124], ["tagged precursor GPC", "PROTEIN", 125, 145], ["GP2", "PROTEIN", 175, 178], ["actin", "PROTEIN", 183, 188], ["supernatants", "TEST", 10, 22], ["various GP species", "PROBLEM", 83, 101], ["the C", "TEST", 103, 108], ["terminally FLAG", "TEST", 109, 124], ["GPC", "PROBLEM", 142, 145], ["a loading control", "TREATMENT", 202, 219]]], ["Cells were collected as described above in the \"Viral Challenge Assay\" section.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["VLPs were concentrated from supernatants via ultracentrifugation through sucrose (as described below) prior to Western blot analysis.Ultracentrifugation of VLPs and Authentic JUNV C#1 ParticlesThe JUNV VLPs in Figure 4C and JUNV C#1 particles in Figure 4D were concentrated via ultracentrifugation through sucrose as previously described (Neuman et al., 2008) .", [["supernatants", "ANATOMY", 28, 40], ["sucrose", "CHEMICAL", 73, 80], ["sucrose", "CHEMICAL", 306, 313], ["sucrose", "CHEMICAL", 73, 80], ["sucrose", "CHEMICAL", 306, 313], ["VLPs", "ORGANISM", 0, 4], ["sucrose", "SIMPLE_CHEMICAL", 73, 80], ["VLPs", "ORGANISM", 156, 160], ["JUNV VLPs", "ORGANISM", 197, 206], ["sucrose", "SIMPLE_CHEMICAL", 306, 313], ["JUNV C#1 particles", "CELL_LINE", 224, 242], ["VLPs", "TREATMENT", 0, 4], ["ultracentrifugation through sucrose", "TREATMENT", 45, 80], ["blot analysis", "TEST", 119, 132], ["Ultracentrifugation of VLPs", "TREATMENT", 133, 160], ["Authentic JUNV C#1 Particles", "TREATMENT", 165, 193], ["The JUNV VLPs", "TREATMENT", 193, 206], ["JUNV C#1 particles", "TREATMENT", 224, 242], ["Figure 4D", "TREATMENT", 246, 255]]], ["Briefly, supernatants were clarified of cellular debris via 2 rounds of centrifugation at 1500 rpm and 2500 rpm, respectively.", [["supernatants", "ANATOMY", 9, 21], ["cellular", "ANATOMY", 40, 48], ["cellular", "CELL", 40, 48], ["cellular debris", "PROBLEM", 40, 55], ["centrifugation", "TREATMENT", 72, 86], ["cellular debris", "OBSERVATION", 40, 55]]], ["VLPs/particles were then precipitated by dissolving polyethylene glycol MW 8,000 (81268, Sigma-Aldrich) into clarified supernatants (10% weight/volume) at 4 o C.Ultracentrifugation of VLPs and Authentic JUNV C#1 ParticlesSupernatants were then centrifuged at 10,000 RPM for 30 minutes at 4 o C to pellet VLPs/particles.", [["supernatants", "ANATOMY", 119, 131], ["polyethylene glycol", "CHEMICAL", 52, 71], ["polyethylene glycol", "CHEMICAL", 52, 71], ["VLPs", "ORGANISM", 0, 4], ["polyethylene glycol MW", "SIMPLE_CHEMICAL", 52, 74], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 89, 102], ["VLPs", "ORGANISM", 184, 188], ["VLPs/particles", "TREATMENT", 0, 14], ["dissolving polyethylene glycol MW", "TREATMENT", 41, 74], ["VLPs", "TREATMENT", 184, 188], ["Authentic JUNV C#1 ParticlesSupernatants", "TREATMENT", 193, 233]]], ["Pellets were gently resuspended in HEPES buffered saline, pH 7.4, layered onto 20% sucrose, and centrifuged at 100,000 x g in a T-865 Rotor (Thermo Scientific) for 2.5 hr at 4 o C. Pelleted virus was gently resuspended in HEPES buffered saline, pH 7.4 for use in plaque and/or Western blot assays.Confocal MicroscopyConfocal Images for all confocal experiments were obtained using a Zeiss LSM 510 Laser Scanning Confocal Microscope.", [["Pellets", "ANATOMY", 0, 7], ["plaque", "ANATOMY", 263, 269], ["sucrose", "CHEMICAL", 83, 90], ["T-865", "CHEMICAL", 128, 133], ["HEPES", "CHEMICAL", 35, 40], ["sucrose", "CHEMICAL", 83, 90], ["HEPES", "CHEMICAL", 222, 227], ["saline", "SIMPLE_CHEMICAL", 50, 56], ["sucrose", "SIMPLE_CHEMICAL", 83, 90], ["saline", "SIMPLE_CHEMICAL", 237, 243], ["C. Pelleted virus", "SPECIES", 178, 195], ["Pellets", "TREATMENT", 0, 7], ["HEPES buffered saline", "TREATMENT", 35, 56], ["pH", "TEST", 58, 60], ["Pelleted virus", "TREATMENT", 181, 195], ["HEPES buffered saline", "TREATMENT", 222, 243], ["pH", "TEST", 245, 247], ["plaque", "PROBLEM", 263, 269], ["Western blot assays", "TEST", 277, 296], ["Confocal MicroscopyConfocal Images", "TEST", 297, 331], ["all confocal experiments", "TEST", 336, 360], ["plaque", "OBSERVATION", 263, 269]]], ["Images were captured using either a 63X or 100X objective lens with a numerical aperture of 1.4.", [["Images", "TEST", 0, 6], ["a numerical aperture", "TEST", 68, 88]]], ["Optical zoom was set to 1.5X and images were obtained at 1.0 Airy unit.", [["images", "TEST", 33, 39]]], ["The colocalization analysis shown in Figure 1L was performed with the colocalization analysis module contained in the Zeiss Aim software on images that were captured using the 63X objective lens.", [["Zeiss Aim software", "DNA", 118, 136], ["The colocalization analysis", "TEST", 0, 27], ["Figure 1L", "TREATMENT", 37, 46], ["the colocalization analysis module", "TEST", 66, 100], ["images", "TEST", 140, 146]]], ["To determine background gating thresholds for colocalization analysis, we averaged the background signal from triplicate images of either mock-infected cells stained using the GB03-BE08 mouse anti-JUNV GP1/GPC antibody directly conjugated to Alexa Fluor 488 or JUNV C#1-infected cells stained with the Alexa Fluor 647-conjugated goat anti-mouse secondary antibody (gates are shown as white lines in the histogram in Figure 1L ).Flow CytometryFlow cytometry was utilized to screen, in cells expressing either WT or DN ERGIC-53, whether JUNV C#1 GP ( Figure 4B ) or hTfR1 ( Figure S4 ) was detectable at the plasma membrane and, if so, the median fluorescence intensity (MFI) of these respective signals.", [["cells", "ANATOMY", 152, 157], ["cells", "ANATOMY", 279, 284], ["cells", "ANATOMY", 484, 489], ["plasma membrane", "ANATOMY", 606, 621], ["Alexa Fluor 647", "CHEMICAL", 302, 317], ["Alexa Fluor 488", "CHEMICAL", 242, 257], ["Alexa Fluor 647", "CHEMICAL", 302, 317], ["cells", "CELL", 152, 157], ["GB03", "GENE_OR_GENE_PRODUCT", 176, 180], ["mouse", "ORGANISM", 186, 191], ["GP1", "GENE_OR_GENE_PRODUCT", 202, 205], ["GPC", "GENE_OR_GENE_PRODUCT", 206, 209], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 242, 257], ["cells", "CELL", 279, 284], ["Alexa Fluor 647", "SIMPLE_CHEMICAL", 302, 317], ["cells", "CELL", 484, 489], ["Figure 4B", "GENE_OR_GENE_PRODUCT", 549, 558], ["hTfR1", "GENE_OR_GENE_PRODUCT", 564, 569], ["Figure S4", "GENE_OR_GENE_PRODUCT", 572, 581], ["plasma membrane", "CELLULAR_COMPONENT", 606, 621], ["mock-infected cells", "CELL_LINE", 138, 157], ["GB03", "PROTEIN", 176, 180], ["BE08 mouse anti-JUNV GP1", "PROTEIN", 181, 205], ["GPC antibody", "PROTEIN", 206, 218], ["Alexa Fluor 488", "PROTEIN", 242, 257], ["JUNV C#1-infected cells", "CELL_LINE", 261, 284], ["Alexa Fluor 647-conjugated goat anti-mouse secondary antibody", "PROTEIN", 302, 363], ["gates", "PROTEIN", 365, 370], ["JUNV C#1 GP", "PROTEIN", 535, 546], ["Figure 4B", "PROTEIN", 549, 558], ["hTfR1", "PROTEIN", 564, 569], ["mouse", "SPECIES", 186, 191], ["goat", "SPECIES", 329, 333], ["anti-mouse", "SPECIES", 334, 344], ["mouse", "SPECIES", 186, 191], ["Alexa Fluor 488", "SPECIES", 242, 257], ["Alexa Fluor 647", "SPECIES", 302, 317], ["goat", "SPECIES", 329, 333], ["colocalization analysis", "TEST", 46, 69], ["triplicate images", "TEST", 110, 127], ["infected cells", "PROBLEM", 143, 157], ["the GB03", "TEST", 172, 180], ["GP1", "TEST", 202, 205], ["GPC antibody", "TEST", 206, 218], ["Alexa Fluor", "TEST", 242, 253], ["JUNV C", "TEST", 261, 267], ["infected cells", "PROBLEM", 270, 284], ["the Alexa Fluor", "TEST", 298, 313], ["conjugated goat anti-mouse secondary antibody", "TREATMENT", 318, 363], ["white lines", "TREATMENT", 384, 395], ["the histogram", "TEST", 399, 412], ["Flow Cytometry", "TEST", 428, 442], ["Flow cytometry", "TEST", 442, 456], ["WT", "TEST", 508, 510], ["ERGIC", "TEST", 517, 522], ["JUNV", "TEST", 535, 539], ["Figure 4B", "TEST", 549, 558]]], ["In both cases, HEK 293T cells were seeded in 6-well dishes and transfected the next day with plasmids encoding either", [["HEK 293T cells", "ANATOMY", 15, 29], ["plasmids", "ANATOMY", 93, 101], ["HEK 293T cells", "CELL", 15, 29], ["HEK 293T cells", "CELL_LINE", 15, 29], ["plasmids", "DNA", 93, 101], ["HEK 293T cells", "TREATMENT", 15, 29], ["plasmids", "TREATMENT", 93, 101]]]], "74688307b68b51166c24837afd144caa61073922": [["IntroductionThe achievements in human genomics have been remarkable during the last decade.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37]]], ["We are now capable of storing thousands of genome sequences from patients along with their medical records.", [["patients", "ORGANISM", 65, 73], ["genome sequences", "DNA", 43, 59], ["patients", "SPECIES", 65, 73]]], ["Today, medical professionals utilize this large-scale data to study associations or susceptibility to certain diseases.IntroductionThe recruitment for different genomic research is also increasing as the genome sequencing cost is ever-reducing through technological breakthroughs in the last few years.", [["susceptibility to certain diseases", "PROBLEM", 84, 118], ["recruitment", "OBSERVATION_MODIFIER", 135, 146], ["increasing", "OBSERVATION_MODIFIER", 186, 196]]], ["This growth in genomic data has resulted in consumer products where companies offer healthcare solutions and ancestry search based on human genomic data (e.g., Ancestry.com, 23AndMe).", [["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["This growth in genomic data", "PROBLEM", 0, 27], ["healthcare solutions", "TREATMENT", 84, 104]]], ["Informally, the string search denotes the presence (and locations) of an arbitrary query nucleotide sequence in a larger dataset.", [["nucleotide", "CHEMICAL", 89, 99], ["an arbitrary query nucleotide sequence", "TEST", 70, 108]]], ["The search results comprise the individuals who carry the same nucleotides in the corresponding positions.", [["nucleotides", "CHEMICAL", 63, 74]]], ["This problem refers to the memory accesses in the same locations within a short period while building the suffix tree.", [["the memory accesses", "TREATMENT", 23, 42], ["suffix tree", "OBSERVATION", 106, 117]]], ["Moreover, it gets severe as suffix trees perform best when the tree (vertices and edges) completely fits in the main memory.", [["fits", "DISEASE", 100, 104], ["severe as suffix trees", "PROBLEM", 18, 40], ["severe", "OBSERVATION_MODIFIER", 18, 24]]], ["Unfortunately, this is quite impossible with off-the-shelf implementations and large scale genomic data.IntroductionIn this work, we construct generalized suffix trees (GSTs) in parallel.", [["GSTs", "DNA", 169, 173], ["large scale genomic data", "TEST", 79, 103], ["generalized", "OBSERVATION_MODIFIER", 143, 154], ["suffix trees", "OBSERVATION", 155, 167]]], ["There has been several attempts in efficient, parallel suffix tree building which considers only one sequence whereas GSTs represent multiple sequences [5] .", [["GSTs", "GENE_OR_GENE_PRODUCT", 118, 122], ["GSTs", "PROTEIN", 118, 122], ["parallel suffix tree building", "TREATMENT", 46, 75], ["several", "OBSERVATION_MODIFIER", 15, 22], ["suffix tree", "OBSERVATION", 55, 66]]], ["We employed two different memory architectures for our parallel GST construction: (a) distributed and (b) shared memory.", [["GST", "GENE_OR_GENE_PRODUCT", 64, 67], ["GST", "PROTEIN", 64, 67]]], ["In a distributed architecture, we utilized multiple machines with completely separate main memory system interconnected within a network.", [["multiple machines", "TREATMENT", 43, 60]]], ["On the contrary, these processors have several cores, which share the same main memory.", [["several", "OBSERVATION_MODIFIER", 39, 46], ["cores", "OBSERVATION_MODIFIER", 47, 52]]], ["Furthermore, we employ a data specific parallelism based on the fixed nucleotide set in this construction for the shared memory architecture.", [["nucleotide", "CHEMICAL", 70, 80]]], ["Finally, our GSTs are built on file system to remove the dependency for a sizeable memory requirement.", [["GSTs", "GENE_OR_GENE_PRODUCT", 13, 17], ["GSTs", "PROTEIN", 13, 17], ["the dependency", "PROBLEM", 53, 67], ["a sizeable memory requirement", "PROBLEM", 72, 101], ["sizeable", "OBSERVATION_MODIFIER", 74, 82], ["memory requirement", "OBSERVATION", 83, 101]]], ["We can summarize our contributions below:Introduction-The primary contribution of this paper is a parallel framework using the distributed and shared memory models to construct GST for a genomic dataset. -We also utilize the external memory (or disks) since GSTs for large-scale genomic data require notable memory size, which is usually not available in a single machine. -We test the efficiency of our GST with multiple string search queries.", [["GST", "GENE_OR_GENE_PRODUCT", 177, 180], ["GSTs", "GENE_OR_GENE_PRODUCT", 258, 262], ["GST", "GENE_OR_GENE_PRODUCT", 404, 407], ["GST", "PROTEIN", 177, 180], ["GSTs", "PROTEIN", 258, 262], ["GST", "PROTEIN", 404, 407], ["a genomic dataset", "PROBLEM", 185, 202], ["GSTs", "TEST", 258, 262], ["large-scale genomic data", "PROBLEM", 267, 291], ["notable memory size", "PROBLEM", 300, 319], ["size", "OBSERVATION_MODIFIER", 315, 319]]], ["Furthermore, we analyze the parallel speedup in terms of dataset size, number of processors, and components of the hybrid memory architecture. -Experimental results show that we can achieve around 4.7 times speedup compared to the sequential algorithm with 16 processors to construct the GST for a dataset with n = 1000 sequences and 1000 nucleotides each.IntroductionNotably, Ukkonen's algorithm [14] went out of memory for n, m = 10, 000 dataset whereas our proposed approach takes 77.3 s with 16 processors.Haplotype DataIn this paper, we utilize the bi-allelic genomic data where the ratio of different nucleotides in a specific position of a chromosome is known beforehand.", [["chromosome", "ANATOMY", 647, 657], ["nucleotides", "CHEMICAL", 339, 350], ["nucleotides", "CHEMICAL", 607, 618], ["GST", "GENE_OR_GENE_PRODUCT", 288, 291], ["chromosome", "CELLULAR_COMPONENT", 647, 657], ["GST", "PROTEIN", 288, 291], ["the sequential algorithm", "TEST", 227, 251], ["Ukkonen's algorithm", "TEST", 377, 396], ["different nucleotides", "PROBLEM", 597, 618], ["size", "OBSERVATION_MODIFIER", 65, 69], ["hybrid memory architecture", "OBSERVATION", 115, 141]]], ["It is also called haplotype data, where each allele (or position) on the chromosome is inherited from a single parent.", [["chromosome", "ANATOMY", 73, 83], ["chromosome", "CELLULAR_COMPONENT", 73, 83], ["allele", "DNA", 45, 51]]], ["In other words, in one specific location, we can only perceive two variations for such a dataset; therefore, we utilize a binary representation.", [["a binary representation", "TREATMENT", 120, 143]]], ["However, our proposed method is not limited to such binary representation and generalizable over any dataset with a fixed character set.Generalized Suffix TreeSuffix Trie and Tree: Trie (from retrieval) is a data structure where each element of the data are placed in the vertex of a tree.", [["such binary representation", "PROBLEM", 47, 73], ["the data", "TEST", 245, 253], ["Suffix TreeSuffix", "OBSERVATION", 148, 165], ["Tree", "OBSERVATION_MODIFIER", 175, 179], ["vertex", "ANATOMY_MODIFIER", 272, 278], ["tree", "ANATOMY_MODIFIER", 284, 288]]], ["Here, the edges represent the relation of one data to the other.", [["edges", "OBSERVATION_MODIFIER", 10, 15]]], ["In our problem scenario, each nucleotide of the sequences can be seen as the other data points or vertices of a Trie.", [["nucleotide", "CHEMICAL", 30, 40], ["nucleotide", "CHEMICAL", 30, 40]]], ["For example, if a single vertex has only one child on a suffix trie, they are joined and denoted as a single vertex on the Suffix Tree.", [["Suffix Tree", "OBSERVATION", 123, 134]]], ["In Fig. 1 , we show two suffix tries S1 and S2 from sequences 010101 and 101010 respectively.", [["S2", "PROTEIN", 44, 46]]], ["For any sequence S1 = 010101, we consider all possible suffixes such as {1, 01, 101, 01010, 10101, 010101} and construct a trie.", [["any sequence S1", "TEST", 4, 19]]], ["The simple approach to construct such a tree will require an iteration over all suffixes and add/merge new vertices if required.Generalized Suffix TreeThe suffix tree will also represent the end of the sequence with a special end character ($).", [["The simple approach", "TREATMENT", 0, 19], ["an iteration over all suffixes", "TREATMENT", 58, 88], ["add/merge new vertices", "TREATMENT", 93, 115], ["Generalized Suffix TreeThe suffix tree", "PROBLEM", 128, 166], ["Suffix Tree", "OBSERVATION", 140, 151], ["suffix tree", "OBSERVATION", 155, 166]]], ["For example, the suffix 01 (left Fig. 1 -S1) has an end character with label S1:4 which denotes the sequence number and the start position of the suffix.", [["S1:4", "PROTEIN", 77, 81], ["left", "ANATOMY_MODIFIER", 28, 32], ["suffix", "OBSERVATION", 146, 152]]], ["Formally, we use vertex label Sx:y s.t. x \u2208 {1, n} and y \u2208 {0, m \u2212 1} for n sequences of m length.Generalized Suffix TreeGeneralized Suffix Tree (GST): Generalized Suffix Tree is a collection of suffix trees for multiple sequences.", [["GST", "PROTEIN", 146, 149], ["vertex label", "TEST", 17, 29], ["length", "TEST", 91, 97], ["Generalized Suffix", "PROBLEM", 98, 116], ["Generalized Suffix", "PROBLEM", 152, 170], ["multiple sequences", "TEST", 212, 230], ["Suffix TreeGeneralized", "OBSERVATION", 110, 132], ["Suffix Tree", "OBSERVATION", 133, 144], ["Generalized Suffix", "OBSERVATION", 152, 170], ["suffix trees", "OBSERVATION", 195, 207]]], ["Here, we merge two suffix trees S1 and S2 from Fig. 1 and construct S12 in Fig. 2 .", [["S2", "PROTEIN", 39, 41], ["S12", "PROTEIN", 68, 71], ["suffix trees", "OBSERVATION", 19, 31], ["S2", "ANATOMY", 39, 41], ["Fig", "OBSERVATION_MODIFIER", 75, 78]]], ["Fundamentally, there are no difference in constructing GST as we need to build individual suffix tree per sequence and merge them afterwards.", [["GST", "GENE_OR_GENE_PRODUCT", 55, 58], ["GST", "PROTEIN", 55, 58], ["difference in constructing GST", "PROBLEM", 28, 58], ["no", "UNCERTAINTY", 25, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38]]], ["Thus, the runtime for one GST construction depends on these suffix tree construction and size.", [["GST", "GENE_OR_GENE_PRODUCT", 26, 29], ["GST", "PROTEIN", 26, 29], ["one GST construction", "TREATMENT", 22, 42], ["these suffix tree construction", "TREATMENT", 54, 84], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["For example, the traditional algorithm (Ukkonen) to build the suffix tree has a linear runtime O(m) for m length sequences [14] .", [["the traditional algorithm", "TEST", 13, 38], ["m length sequences", "TEST", 104, 122], ["suffix tree", "OBSERVATION", 62, 73]]], ["Therefore, n sequences with m characters will be at least O(nm) along with the additional linear tree merging cost of O(n).Utility MeasureWe considered different queries to test the utility of a GST.", [["GST", "GENE_OR_GENE_PRODUCT", 195, 198], ["GST", "PROTEIN", 195, 198], ["linear", "OBSERVATION_MODIFIER", 90, 96], ["tree", "OBSERVATION_MODIFIER", 97, 101]]], ["The input will be a genomic dataset D consisting n individuals with m nucleotides.", [["nucleotides", "CHEMICAL", 70, 81], ["a genomic dataset D consisting n individuals with m nucleotides", "TREATMENT", 18, 81]]], ["The query can be of arbitrary length (1 \u2264 |q| \u2264 m).Query 1 (Exact Match-EM).For a genomic dataset D and an arbitrary query q, an exact match will only return the recordsQuery 1 (Exact Match-EM).denotes the full query and x i [j 1 , j 2 ] is a substring of the record x i given j 2 \u2265 j 1 and j 2 \u2212 j 1 = |q| \u2212 1.Query 2 (Set Maximal Match-SMM).Similarly, for the same inputs, a set maximal match will return the record x i which have the following conditions:Query 3 (Position-variant Set Maximal Match-PVSMM).Finally, for a threshold t, the PVSMM will report all records where which follow:Architecture and Design GoalsThe outline of the parallel generalized suffix tree construction and corresponding computation is depicted in Fig. 3 .", [["genomic dataset D", "DNA", 82, 99], ["arbitrary length", "TEST", 20, 36], ["the full query", "TEST", 202, 216], ["the parallel generalized suffix tree construction", "TREATMENT", 634, 683], ["suffix tree", "OBSERVATION", 659, 670]]], ["Here, the genomic dataset D |n\u00d7m| ) is operated by the data owner and the researchers have q queries on D. The researcher does not have any substantial processing power compared to the data owner since s/he is only interested in a minuscule portion of D.Architecture and Design GoalsThe high-level design of our architecture is illustrated in Fig. 3 , where the data is evenly partitioned between different computing nodes (in one/multiple clusters).", [["nodes", "OBSERVATION", 417, 422]]], ["In the distributed memory, the machines are connected via network as they have mutli-core processors and their own physical memory (RAM).", [["distributed", "OBSERVATION_MODIFIER", 7, 18], ["memory", "OBSERVATION", 19, 25]]], ["The mutli-core processors on these machines collectively use the physical memory which is called as shared memory.", [["mutli-core processors", "DNA", 4, 25]]], ["Hence, we have |p| computing nodes which construct our desired GST jointly.", [["GST", "GENE_OR_GENE_PRODUCT", 63, 66], ["GST", "PROTEIN", 63, 66], ["computing nodes", "PROBLEM", 19, 34], ["nodes", "OBSERVATION", 29, 34]]], ["Our memory dispersion tackles one of the major disadvantages of the GST construction: the sizeable memory requirement for longer sequences.", [["GST", "GENE_OR_GENE_PRODUCT", 68, 71], ["GST", "PROTEIN", 68, 71]]], ["For example, a thousand length sequence can create a maximum of a thousand vertices, and n sequences can lead to an order of nm.", [["a thousand length sequence", "PROBLEM", 13, 39]]], ["Hence, this motivates us to construct our targeted GST in a distributed memory setting.Architecture and Design GoalsThis leads to our proposed design where we distribute the data (partition) and build the suffix tree separately in different computing nodes.", [["GST", "GENE_OR_GENE_PRODUCT", 51, 54], ["nodes", "MULTI-TISSUE_STRUCTURE", 251, 256], ["GST", "PROTEIN", 51, 54], ["suffix tree", "OBSERVATION", 205, 216], ["different", "OBSERVATION_MODIFIER", 231, 240], ["computing nodes", "OBSERVATION", 241, 256]]], ["These nodes can construct each subtree which is later shared to the other nodes.", [["nodes", "ANATOMY", 6, 11], ["nodes", "MULTI-TISSUE_STRUCTURE", 6, 11], ["nodes", "OBSERVATION", 6, 11], ["nodes", "OBSERVATION", 74, 79]]], ["These shared subtrees are then merged, and the final tree includes all suffix subtrees combining the outputs from all computing nodes (Sect.", [["nodes", "OBSERVATION", 128, 133]]], ["The multiple processors in each node will also use shared memory model while constructing and merging their individual GST in parallel (Sects.", [["node", "ANATOMY", 32, 36], ["node", "MULTI-TISSUE_STRUCTURE", 32, 36], ["GST", "GENE_OR_GENE_PRODUCT", 119, 122], ["GST", "PROTEIN", 119, 122], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["node", "OBSERVATION", 32, 36]]], ["Partition the dataset for different nodes in a distributed memory architecture where individual computing nodes receive a part of the data and only constructs a subtree of the final GST (Inter-node Parallelism) 2.", [["nodes", "MULTI-TISSUE_STRUCTURE", 106, 111], ["GST", "GENE_OR_GENE_PRODUCT", 182, 185], ["GST", "PROTEIN", 182, 185], ["Inter", "PROTEIN", 187, 192], ["different nodes", "PROBLEM", 26, 41], ["individual computing nodes", "PROBLEM", 85, 111], ["the data", "TEST", 130, 138], ["nodes", "OBSERVATION", 36, 41], ["nodes", "OBSERVATION", 106, 111], ["node Parallelism", "OBSERVATION", 193, 209]]], ["As these nodes are equipped with multiple cores, they will build the individual GSTs in parallel using shared memory architecture (Intra-node Parallelism) 3.", [["nodes", "ANATOMY", 9, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 9, 14], ["GSTs", "GENE_OR_GENE_PRODUCT", 80, 84], ["GSTs", "PROTEIN", 80, 84], ["nodes", "OBSERVATION", 9, 14], ["node Parallelism", "OBSERVATION", 137, 153]]], ["Use external memory to store and share the resulting GSTs to reduce sizeable main memory requirement.Data PartitioningWe utilize different data partitioning scheme based on the memory locality, availability and the number of computing nodes: Horizontal partitioning groups a number of sequences for the existing computing nodes.", [["GSTs", "GENE_OR_GENE_PRODUCT", 53, 57], ["GSTs", "PROTEIN", 53, 57], ["sizeable main memory requirement", "PROBLEM", 68, 100], ["different data partitioning scheme", "TREATMENT", 129, 163], ["sizeable", "OBSERVATION_MODIFIER", 68, 76], ["main memory requirement", "OBSERVATION", 77, 100], ["nodes", "OBSERVATION", 235, 240], ["nodes", "OBSERVATION", 322, 327]]], ["Each node will receive one such group and construct the corresponding GST afterwards.", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["GST", "GENE_OR_GENE_PRODUCT", 70, 73], ["GST", "PROTEIN", 70, 73], ["node", "OBSERVATION", 5, 9]]], ["For example, if we have n = 100 sequences and p = 4 nodes, then we will split the data into 4 groups where each group will contain |n i | = 25 records or genomic sequences.", [["genomic sequences", "DNA", 154, 171], ["p = 4 nodes", "PROBLEM", 46, 57], ["genomic sequences", "TEST", 154, 171], ["nodes", "OBSERVATION", 52, 57]]], ["Each node, p i will build their GST on |n i | sequences of m length in parallel without any communication.", [["node", "ANATOMY", 5, 9], ["GST", "GENE_OR_GENE_PRODUCT", 32, 35], ["GST", "PROTEIN", 32, 35], ["node", "OBSERVATION", 5, 9]]], ["Figure 1 depicts a simple case of this partition scheme for n = p = 2.Data PartitioningVertical partitioning divides the data across the columns and distributes it following the aforementioned mechanism.", [["this partition scheme", "TREATMENT", 34, 55], ["columns", "ANATOMY_MODIFIER", 137, 144]]], ["For example, if we have genomic data of length m = 100 and p = 4, we will have n \u00d7 m i partitions where each dataset will have |m i | = 25 columns.", [["length m", "TEST", 40, 48]]], ["Bi-directional data partitioning combines both the horizontal and vertical approach as it divides the data into both directions.", [["Bi-directional data partitioning", "PROBLEM", 0, 32], ["horizontal", "OBSERVATION_MODIFIER", 51, 61]]], ["Given n = 100, m = 100 and p = 4, each node will receive a n i \u00d7 m i = 50 \u00d7 50 sized data for their computations.Distributed MemoryWe use several machines (or nodes) to build the final GST in parallel (Inter -node Parallelism), each with their individual global memory and connected via network.", [["node", "ANATOMY", 39, 43], ["GST", "GENE_OR_GENE_PRODUCT", 185, 188], ["GST", "PROTEIN", 185, 188], ["Inter", "PROTEIN", 202, 207], ["node", "ANATOMY", 39, 43], ["nodes", "OBSERVATION", 159, 164], ["node Parallelism", "OBSERVATION", 209, 225]]], ["After receiving the partitioned data, these computing nodes are required to build their own GSTs.", [["nodes", "MULTI-TISSUE_STRUCTURE", 54, 59], ["GSTs", "GENE_OR_GENE_PRODUCT", 92, 96], ["GSTs", "PROTEIN", 92, 96], ["these computing nodes", "PROBLEM", 38, 59], ["nodes", "OBSERVATION", 54, 59]]], ["For example, if there are p 0 , . . . , p |p| nodes then we will have GST 0 , . . . , GST |p| trees.", [["GST", "GENE_OR_GENE_PRODUCT", 70, 73], ["GST", "GENE_OR_GENE_PRODUCT", 86, 89], ["GST 0", "PROTEIN", 70, 75], ["GST", "PROTEIN", 86, 89]]], ["Regardless of the partitioning mechanism, we use the same linear time method to construct the suffix trees using Ukkonen's algorithm [14] .", [["the same linear time method", "TREATMENT", 49, 76], ["Ukkonen's algorithm", "TREATMENT", 113, 132]]], ["After these individual nodes build their GSTs, they need to share them for the merging operation described next.Distributed MemoryIn Fig. 1 , we see a horizontally partitioned GST construction.", [["nodes", "MULTI-TISSUE_STRUCTURE", 23, 28], ["GSTs", "GENE_OR_GENE_PRODUCT", 41, 45], ["GST", "GENE_OR_GENE_PRODUCT", 176, 179], ["GSTs", "PROTEIN", 41, 45], ["GST", "PROTEIN", 176, 179], ["the merging operation", "TREATMENT", 75, 96], ["a horizontally partitioned GST construction", "TREATMENT", 149, 192], ["nodes", "OBSERVATION", 23, 28]]], ["Here, two suffix trees are merged where the grey and white colored nodes belonged to different trees.", [["nodes", "ANATOMY", 67, 72], ["colored nodes", "MULTI-TISSUE_STRUCTURE", 59, 72], ["the grey and white colored nodes", "PROBLEM", 40, 72], ["suffix trees", "OBSERVATION", 10, 22], ["grey", "OBSERVATION_MODIFIER", 44, 48], ["white", "OBSERVATION_MODIFIER", 53, 58], ["colored nodes", "OBSERVATION", 59, 72]]], ["Notably, the merge operation did not duplicate any node at a particular depth.", [["node", "ANATOMY", 51, 55], ["node", "MULTI-TISSUE_STRUCTURE", 51, 55], ["the merge operation", "TREATMENT", 9, 28], ["any node", "PROBLEM", 47, 55], ["node", "OBSERVATION", 51, 55]]], ["For example, if there was already a node with the value 0 is present, then it will not create another node and simply merge onto its branches.", [["node", "ANATOMY", 36, 40], ["node", "ANATOMY", 102, 106], ["node", "MULTI-TISSUE_STRUCTURE", 36, 40], ["node", "OBSERVATION", 36, 40], ["node", "OBSERVATION", 102, 106], ["branches", "ANATOMY_MODIFIER", 133, 141]]], ["This condition is applied to all merge operations to avoid duplicate branches.Distributed MemoryHowever, for vertical and bi-directional partitioning, the merging requires an additional step for datasets where m i < m.", [["all merge operations", "TREATMENT", 29, 49], ["branches", "ANATOMY_MODIFIER", 69, 77]]], ["We illustrate this in Fig. 4 where n = 2, p = 2, m = 6 and we are creating GST for the sequences S1,S2 = {010101, 101010}.", [["GST", "GENE_OR_GENE_PRODUCT", 75, 78], ["GST", "PROTEIN", 75, 78]]], ["Here, p1 operates on {010, 101} partitions whereas p2 generates the tree for {101, 010}.", [["p1", "DNA", 6, 8], ["p2", "DNA", 51, 53]]], ["Here, the GST from p1 needs to have different end characters compared to p2 as each end points in a suffix tree needs to represent that the suffix has ended there.", [["GST", "GENE_OR_GENE_PRODUCT", 10, 13], ["GST", "PROTEIN", 10, 13], ["p1", "DNA", 19, 21], ["p2", "DNA", 73, 75], ["the GST", "TEST", 6, 13], ["different end characters", "PROBLEM", 36, 60], ["suffix tree", "OBSERVATION", 100, 111], ["suffix", "OBSERVATION", 140, 146]]], ["However, since we are splitting the data on columns, it needs to address the missing suffices.Distributed MemoryTherefore, we perform a simple merge for all cases with m i < m as we add the Path Graphs with m \u2212 m i characters on the resulting GST.", [["GST", "GENE_OR_GENE_PRODUCT", 243, 246], ["GST", "PROTEIN", 243, 246]]], ["For example, in Fig. 4 , we add the path graph of 101 (represented as %1) in all end characters of S1 in p1 (after 010).", [["S1", "PROTEIN", 99, 101], ["the path graph", "TEST", 32, 46], ["S1", "ANATOMY_MODIFIER", 99, 101]]], ["During this merge, we also do not create any duplicate nodes.", [["any duplicate nodes", "PROBLEM", 41, 60], ["nodes", "OBSERVATION", 55, 60]]], ["The addition of these paths will require the merge operation described next.Shared MemoryIn the distributed memory environment, the individual machines get a partition of the genomic data to build the corresponding GSTs.", [["GSTs", "GENE_OR_GENE_PRODUCT", 215, 219], ["GSTs", "PROTEIN", 215, 219], ["the merge operation", "TREATMENT", 41, 60], ["distributed", "OBSERVATION_MODIFIER", 96, 107], ["memory environment", "OBSERVATION", 108, 126]]], ["However, these machines or nodes also have multiple cores available in their respective processor which share the fixed global memory.", [["nodes", "ANATOMY", 27, 32], ["nodes", "OBSERVATION", 27, 32], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["cores", "OBSERVATION_MODIFIER", 52, 57], ["fixed", "OBSERVATION_MODIFIER", 114, 119], ["global memory", "OBSERVATION", 120, 133]]], ["Therefore, we also employ these cores to build and merge the GST in parallel.Shared MemoryWe utilize the fixed alphabet size property of genomic data in our shared memory model (Intra-node Parallelism).", [["Intra-node", "ANATOMY", 178, 188], ["GST", "GENE_OR_GENE_PRODUCT", 61, 64], ["GST", "PROTEIN", 61, 64], ["MemoryWe", "DNA", 84, 92], ["the fixed alphabet size", "TREATMENT", 101, 124], ["size", "OBSERVATION_MODIFIER", 120, 124], ["node Parallelism", "OBSERVATION", 184, 200]]], ["Since there can be only two possible children of the root (0/1), we can initiate two processes where one process will handle the 0 leading suffixes whereas the other process will operate on 1's.", [["root", "ANATOMY", 53, 57], ["children", "ORGANISM", 37, 45], ["root", "TISSUE", 53, 57], ["children", "SPECIES", 37, 45], ["root", "ANATOMY", 53, 57]]], ["For example, in Fig. 1 two processes p1 and p2 will generate the suffix tree of {01, 0101, 010101} and {1, 101, 10101} respectively.", [["p1", "DNA", 37, 39], ["p2", "DNA", 44, 46], ["Fig", "OBSERVATION_MODIFIER", 16, 19]]], ["The output will be two suffix trees, one from each process which can be joined with the root for the final tree.Shared MemoryIt is noteworthy that the GSTs on the partitions can also be build with this shared environment.", [["root", "ANATOMY", 88, 92], ["root", "ORGAN", 88, 92], ["GSTs", "GENE_OR_GENE_PRODUCT", 151, 155], ["GSTs", "PROTEIN", 151, 155], ["The output", "TEST", 0, 10], ["two suffix trees", "PROBLEM", 19, 35], ["output", "OBSERVATION_MODIFIER", 4, 10], ["suffix trees", "OBSERVATION", 23, 35], ["root", "OBSERVATION_MODIFIER", 88, 92]]], ["Here, we will partition the data into the cores and they will build, merge the GST in parallel.", [["GST", "GENE_OR_GENE_PRODUCT", 79, 82], ["GST", "PROTEIN", 79, 82]]], ["However, the number of cores and memory is limited in a non-distributed setting which will restrict larger GSTs.Merging GSTsAs mentioned earlier, the merge operation takes two different GSTs and adds all their vertices.", [["GSTs", "GENE_OR_GENE_PRODUCT", 107, 111], ["GSTsAs", "GENE_OR_GENE_PRODUCT", 120, 126], ["GSTs", "GENE_OR_GENE_PRODUCT", 186, 190], ["GSTs", "PROTEIN", 107, 111], ["GSTsAs", "PROTEIN", 120, 126], ["GSTs", "PROTEIN", 186, 190], ["the merge operation", "TREATMENT", 146, 165], ["cores", "OBSERVATION_MODIFIER", 23, 28]]], ["Hence, all |p| GSTs are merged into the final GST where GST = GST 0 + . . . + GST |p| .", [["| GSTs", "GENE_OR_GENE_PRODUCT", 13, 19], ["GST", "GENE_OR_GENE_PRODUCT", 46, 49], ["GST", "GENE_OR_GENE_PRODUCT", 56, 59], ["GSTs", "PROTEIN", 15, 19], ["GST", "PROTEIN", 46, 49], ["GST", "PROTEIN", 56, 59], ["GST 0", "PROTEIN", 62, 67], ["GST", "PROTEIN", 78, 81], ["GST", "TEST", 56, 59], ["GST", "TEST", 62, 65]]], ["Here, we employed the shared memory parallelism as the children of the root (0/1) are totally separate and do not have any common edges.", [["root", "ANATOMY", 71, 75], ["children", "ORGANISM", 55, 63], ["root", "TISSUE", 71, 75], ["children", "SPECIES", 55, 63], ["root", "ANATOMY", 71, 75]]], ["In other words, we can treat the root's 0 branch separately from child 1.", [["root", "ANATOMY", 33, 37], ["root", "ANATOMY", 33, 37]]], ["This allows us to perform the merge operation in parallel and utilize the Intranode parallelism in each computing nodes.Merging GSTsNotably, merging one branch of a tree is a serial operation as multiple threads cannot add/update branches simultaneously.", [["the merge operation", "TREATMENT", 26, 45], ["the Intranode parallelism", "TREATMENT", 70, 95], ["a serial operation", "TREATMENT", 173, 191], ["nodes", "OBSERVATION", 114, 119], ["branch", "OBSERVATION_MODIFIER", 153, 159], ["tree", "OBSERVATION_MODIFIER", 165, 169]]], ["This creates a bottleneck as we need to perform merge operation in all GST i 's and add the path graphs mentioned in Sect.", [["GST", "GENE_OR_GENE_PRODUCT", 71, 74], ["GST", "PROTEIN", 71, 74], ["merge operation", "TREATMENT", 48, 63], ["the path graphs", "TEST", 88, 103]]], ["However, we can use multiple cores for different branches as mentioned in Sect.", [["multiple cores for different branches", "TREATMENT", 20, 57], ["branches", "OBSERVATION_MODIFIER", 49, 57]]], ["For example, we can create two processes for handling the 0 and 1 branch from the root.", [["root", "ANATOMY", 82, 86], ["root", "TISSUE", 82, 86], ["branch", "ANATOMY_MODIFIER", 66, 72], ["root", "ANATOMY", 82, 86]]], ["Notably, this parallel operation can be followed for any dataset with fixed character set.Merging GSTsThe full merge operation is depicted in Fig. 5 where we perform the bidirectional partition and merge accordingly.", [["GSTs", "GENE_OR_GENE_PRODUCT", 98, 102], ["GSTs", "PROTEIN", 98, 102], ["this parallel operation", "TREATMENT", 9, 32], ["Merging GSTs", "PROBLEM", 90, 102], ["The full merge operation", "TREATMENT", 102, 126]]], ["Inherently, the bidirectional strategy employs both vertical and horizontal merging strategies as the end columns do not include the m \u2212 m i characters.Communication and MappingWe use a sequential distribution of work where incremental computing nodes receive contiguous segments of the data.", [["vertical and horizontal merging strategies", "TREATMENT", 52, 94], ["incremental computing nodes", "TREATMENT", 224, 251], ["contiguous segments of the data", "TEST", 260, 291], ["vertical", "OBSERVATION_MODIFIER", 52, 60], ["nodes", "OBSERVATION", 246, 251]]], ["For example, with horizontal and vertical partitioning, each node p i will receive n/p \u00d7 m and n \u00d7 m/p records, respectively.", [["node", "ANATOMY", 61, 65], ["horizontal and vertical partitioning", "PROBLEM", 18, 54], ["horizontal", "OBSERVATION_MODIFIER", 18, 28], ["vertical partitioning", "OBSERVATION", 33, 54], ["node", "OBSERVATION", 61, 65]]], ["As p i constructs its GST i , it stores it in the file system for further processing.", [["GST", "GENE_OR_GENE_PRODUCT", 22, 25], ["p i constructs", "DNA", 3, 17], ["GST", "PROTEIN", 22, 25]]], ["Upon completion, all GSTs are sent via network to the nearest processor based on latency.", [["GSTs", "GENE_OR_GENE_PRODUCT", 21, 25], ["GSTs", "PROTEIN", 21, 25], ["all GSTs", "TEST", 17, 25], ["latency", "TEST", 81, 88]]], ["For example, in Fig. 5 , P3 and P4 will send their GST to P1 and P2 respectively and P1, P2 will merge these trees in parallel.", [["Fig. 5", "ORGANISM", 16, 22], ["P3", "GENE_OR_GENE_PRODUCT", 25, 27], ["P4", "GENE_OR_GENE_PRODUCT", 32, 34], ["GST", "GENE_OR_GENE_PRODUCT", 51, 54], ["P3", "DNA", 25, 27], ["P4", "DNA", 32, 34], ["GST", "PROTEIN", 51, 54], ["P1", "DNA", 58, 60], ["P2", "DNA", 65, 67], ["P1", "DNA", 85, 87], ["P2", "DNA", 89, 91], ["P4", "TEST", 32, 34]]], ["We utilize external memory as the suffix tree are arbitrarily large for a genomic dataset and can overflow the main memory of a single computing node.Evaluation Datasets and ImplementationWe evaluate our framework on uniformly distributed synthetic datasets as it allows us to perturb the dimensions and check the performance of the underlying methods.", [["node", "ANATOMY", 145, 149], ["node", "MULTI-TISSUE_STRUCTURE", 145, 149], ["external memory", "TREATMENT", 11, 26], ["a genomic dataset", "PROBLEM", 72, 89], ["Evaluation Datasets", "TEST", 150, 169], ["main", "OBSERVATION_MODIFIER", 111, 115], ["node", "OBSERVATION", 145, 149]]], ["Notably, the sequential algorithm could not finish for larger dataset (D 10,000 ) due to its memory requirement.", [["the sequential algorithm", "TEST", 9, 33], ["its memory requirement", "PROBLEM", 89, 111]]], ["We did not consider n, m in millions due to our computational restrictions as we were only able to access a small computing cluster [1] .", [["small", "OBSERVATION_MODIFIER", 108, 113]]], ["3.2.3 whereas the hybrid method will utilize both.", [["the hybrid method", "TREATMENT", 14, 31]]], ["The shared memory architecture distributes the work into different co-located processors (cores) on one single node.", [["node", "ANATOMY", 111, 115], ["single node", "MULTI-TISSUE_STRUCTURE", 104, 115], ["memory architecture", "OBSERVATION", 11, 30], ["node", "OBSERVATION", 111, 115]]], ["Notably, in this model, we do not require any communication between two processes whereas the distributed model will incur communicating the GST s.", [["GST", "GENE_OR_GENE_PRODUCT", 141, 144], ["GST", "PROTEIN", 141, 144]]], ["However, the number of processors and memory available in shared model is fixed and limited as we can add new machines in the distributed model.", [["new machines", "TREATMENT", 106, 118]]], ["Furthermore, the proposed hybrid approach uses both distributed and shared memory model with two cores on each processor of distributed machines for the 0 and 1 branches of GSTs.Performance AnalysisIn Table 1 , The GST building time for smaller datasets (n, m \u2264 200) are almost same for all settings.", [["GSTs", "GENE_OR_GENE_PRODUCT", 173, 177], ["GST", "GENE_OR_GENE_PRODUCT", 215, 218], ["GSTs", "PROTEIN", 173, 177], ["GST", "PROTEIN", 215, 218], ["the proposed hybrid approach", "TREATMENT", 13, 41], ["smaller datasets", "PROBLEM", 237, 253], ["hybrid approach", "OBSERVATION", 26, 41], ["branches", "ANATOMY_MODIFIER", 161, 169]]], ["However, as the dataset size increases, the difference in execution time starts to diverge.", [["size", "OBSERVATION_MODIFIER", 24, 28], ["increases", "OBSERVATION_MODIFIER", 29, 38], ["difference", "OBSERVATION_MODIFIER", 44, 54]]], ["The same operation takes 3.08 min on the hybrid approach with p = 16.", [["The same operation", "TREATMENT", 0, 18], ["the hybrid approach", "TREATMENT", 37, 56], ["operation", "OBSERVATION", 9, 18]]], ["Similarly, the distributed model takes 6.09 min which shows the impact of intra-node parallelism.Performance AnalysisHowever, one interesting outcome is the shared model's performance.", [["intra-node parallelism", "PROBLEM", 74, 96], ["intra-node parallelism", "OBSERVATION", 74, 96]]], ["This depicts the necessity of the distributed or hybrid model as shared memory model are more suitable for datasets which only fits the main memory.", [["hybrid model", "OBSERVATION", 49, 61]]], ["Table 1 also shows the impact of vertical partitioning where we need to add the path graphs.", [["the path graphs", "TEST", 76, 91]]], ["This addition is the only difference from the horizontal approach as all the nodes working on data m i < m, needs to merge m \u2212 m i characters to the underlying GSTs.", [["GSTs", "GENE_OR_GENE_PRODUCT", 160, 164], ["GSTs", "PROTEIN", 160, 164], ["nodes", "OBSERVATION", 77, 82]]], ["For example, with vertical method it takes 25.24 min to process D 1000 whereas it took only 16.23 on horizontal approach.", [["vertical method", "TREATMENT", 18, 33]]], ["The performance gain with shared model compared to hybrid is also lost due to the thread synchronization as the threads operate on m i < m requires more time for sequential path graph addition.Performance AnalysisIn Table 2 , we show our best results where the data is partitioned into both directions.", [["the thread synchronization", "TREATMENT", 78, 104], ["the data", "TEST", 257, 265]]], ["Here, the tree building cost is reduced compared to the prior two approaches as it resulted in smaller sub-trees.", [["tree", "OBSERVATION_MODIFIER", 10, 14], ["reduced", "OBSERVATION_MODIFIER", 32, 39], ["smaller", "OBSERVATION_MODIFIER", 95, 102], ["sub", "OBSERVATION_MODIFIER", 103, 106]]], ["Table 3 demonstrates the granular execution time for tree building, path graph addition and the merge operation.", [["the merge operation", "TREATMENT", 92, 111], ["granular", "OBSERVATION_MODIFIER", 25, 33]]], ["For example, the tree building time decreases with the increment of processors p.", [["tree", "OBSERVATION_MODIFIER", 17, 21]]], ["Furthermore, the bi-directional tree build cost decrements with the increment in processors as it divides the data by half.Performance AnalysisIn Table 4 we summarize the speedup (= T par /T seq ) results for D 1000 .", [["the increment in processors", "TREATMENT", 64, 91]]], ["On the contrary, both distributed and our hybrid model constructed the targeted GST as it did not depend on the limited, fixed main memory of one machine.Utility MeasureWe show the execution time of the targeted queries in Table 5 .", [["GST", "GENE_OR_GENE_PRODUCT", 80, 83], ["GST", "PROTEIN", 80, 83]]], ["It denotes the efficiency of GSTs performing arbitrary string search as the time only increases with the query length |q|.", [["GSTs", "GENE_OR_GENE_PRODUCT", 29, 33], ["GSTs", "PROTEIN", 29, 33], ["the efficiency of GSTs", "PROBLEM", 11, 33], ["efficiency", "OBSERVATION_MODIFIER", 15, 25]]], ["Notably, the execution time varies slightly for different datasets as we only show the time for D 1000 and D 500 for space limitations.Related WorksThere has been multiple attempts in our targeted problem as shown in Table 6 .", [["space limitations", "PROBLEM", 117, 134], ["multiple", "OBSERVATION_MODIFIER", 163, 171]]], ["Since GST of a large genomic dataset does not fit a sizeable memory, there have been several works to construct the tree in a file system [5] .", [["GST", "GENE_OR_GENE_PRODUCT", 6, 9], ["GST", "PROTEIN", 6, 9], ["a large genomic dataset", "PROBLEM", 13, 36], ["large", "OBSERVATION_MODIFIER", 15, 20]]], ["These disk-based suffix trees usually store the individual subtree (s) on file similar to our approach [12] .", [["These disk-based suffix trees", "PROBLEM", 0, 29], ["disk", "OBSERVATION_MODIFIER", 6, 10], ["suffix trees", "OBSERVATION", 17, 29]]], ["For example, Tian et al. [13] showed a different suffix tree merging method ST-Merge using the Top-Down Disk (TDD) Algorithm.", [["a different suffix tree", "PROBLEM", 37, 60], ["the Top-Down Disk (TDD) Algorithm", "TREATMENT", 91, 124]]], ["Wavefront [6] and its successor ER A (Elastic Range) [8] both targeted diskbased and parallel approach to construct suffix trees.", [["ER", "PROTEIN", 32, 34], ["its successor ER A (Elastic Range)", "TREATMENT", 18, 52], ["suffix trees", "OBSERVATION", 116, 128]]], ["However, these works only considered a suffix tree and distributed memory model, whereas, in this work, we propose a hybrid method and GST.", [["GST", "GENE_OR_GENE_PRODUCT", 135, 138], ["GST", "PROTEIN", 135, 138], ["a hybrid method", "TREATMENT", 115, 130]]], ["Comin and Farreras [4] proposed Parallel Continuous Flow (PCF) which efficiently distributes the lexical sorting process into multiple processors.", [["Comin", "SIMPLE_CHEMICAL", 0, 5], ["Parallel Continuous Flow (PCF)", "TREATMENT", 32, 62]]], ["Analogous to this work, Shun and Blelloch [11] also proposed a parallel construction scheme utilizing cilk (shared memory) in 2014.", [["a parallel construction scheme", "TREATMENT", 61, 91]]], ["However, both works target suffix trees whereas GSTs contain a large number of sequences which is more complicated and at the same time more useful.Related WorksFinally, in a very recent work in 2019, DGST [15] offered a 3\u00d7 speed up with data-parallel platform Spark and performed better than the state-of-theart ER A [8] .", [["GSTs", "GENE_OR_GENE_PRODUCT", 48, 52], ["GSTs", "PROTEIN", 48, 52], ["ER", "PROTEIN", 313, 315], ["large", "OBSERVATION_MODIFIER", 63, 68], ["more complicated", "OBSERVATION_MODIFIER", 98, 114]]], ["However, we do not use such H/W and could not benchmark as their implementations is unavailable.ConclusionIn this paper, we constructed GSTs for genomic data in parallel using external memory.", [["GSTs", "GENE_OR_GENE_PRODUCT", 136, 140], ["GSTs", "PROTEIN", 136, 140], ["such H/W", "TREATMENT", 23, 31], ["genomic data", "TEST", 145, 157]]], ["Moreover, our methods can be utilized for constructing suffix arrays and benchmarked accordingly.", [["constructing suffix arrays", "TREATMENT", 42, 68]]], ["Nevertheless, the proposed parallel constructions can be generalized for other tree-based data structures (e.g., prefix) which can be useful for different genomic data computations.", [["different genomic data computations", "PROBLEM", 145, 180]]]], "1f574c060aa3a0ec1146563444311283340f7e1a": [["IntroductionCOVID-19 has affected the lives of billions of people in 2019-2020.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["The COVID-19 disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has caused a global health emergency.", [["COVID-19 disease", "DISEASE", 4, 20], ["acute respiratory syndrome coronavirus", "DISEASE", 41, 79], ["SARS-CoV-2", "ORGANISM", 83, 93], ["COVID-19", "SPECIES", 4, 12], ["severe acute respiratory syndrome coronavirus", "SPECIES", 34, 79], ["SARS-CoV-2", "SPECIES", 83, 93], ["The COVID-19 disease", "PROBLEM", 0, 20], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 34, 79], ["SARS-CoV", "TEST", 83, 91], ["a global health emergency", "PROBLEM", 110, 135], ["19 disease", "OBSERVATION", 10, 20], ["caused by", "UNCERTAINTY", 24, 33], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome coronavirus", "OBSERVATION", 47, 79], ["global", "OBSERVATION_MODIFIER", 112, 118], ["health emergency", "OBSERVATION", 119, 135]]], ["The number of confirmed reported cases by SARS-CoV-2 has been rising.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["rising", "OBSERVATION_MODIFIER", 62, 68]]], ["On May 31, 2020, worldwide there were 5, 939, 234 laboratory-confirmed cases with 367, 255 deaths [2].IntroductionMany countries issued a pandemic lockdown to slow down the spreading of COVID-19.", [["deaths", "DISEASE", 91, 97], ["COVID-19", "DNA", 186, 194], ["a pandemic lockdown", "TREATMENT", 136, 155], ["COVID", "TEST", 186, 191]]], ["However, those pandemic lockdowns have a massive impact on the economy.", [["massive", "OBSERVATION_MODIFIER", 41, 48], ["impact", "OBSERVATION_MODIFIER", 49, 55]]], ["All the States of the USA started reopening gradually from early May.IntroductionUnderstanding the impact of mitigation strategies on the spreading dynamic of COVID-19 during the reopening phase of the USA is essential.", [["COVID-19", "CHEMICAL", 159, 167], ["the USA", "TREATMENT", 18, 25], ["mitigation strategies", "TREATMENT", 109, 130], ["COVID", "TEST", 159, 164]]], ["In this work, we assess the impact of contact tracing under four reopening scenarios: 25% 15 reopening, 50% reopening, 75% reopening, and 100% reopening.Introduction2 .", [["contact tracing", "TEST", 38, 53]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint Individual-based contact-network models are a powerful tool to model COVID- 19 spreading due to its person-to-person spreading nature.", [["CC", "CHEMICAL", 0, 2], ["person", "SPECIES", 440, 446], ["model COVID", "TEST", 403, 414], ["med", "ANATOMY", 102, 105]]], ["In this work, we develop an individual-based network model for a college town, Manhattan, KS, where households represent nodes of the network.", [["nodes", "OBSERVATION", 121, 126]]], ["There are 20, 439 occupied households in Manhattan, KS, according to census 2018 [3] .", [["KS", "ANATOMY", 52, 54]]], ["It also allows us to include in the model a mitigation strategy at the individual level, such as contact tracing.(which was not certified by peer review)To design an epidemic model for COVID-19 is challenging, as many epidemic features of the disease are yet to be investigated, such as, for example, the transmission rate, the pre-symptomatic transmission rate, and the percentage of the 30 asymptomatic population.", [["COVID-19", "SPECIES", 185, 193], ["COVID", "TEST", 185, 190], ["the disease", "PROBLEM", 239, 250], ["the transmission rate", "TEST", 301, 322], ["the pre-symptomatic transmission rate", "TEST", 324, 361], ["disease", "OBSERVATION", 243, 250]]], ["Therefore, we use a simple epidemic model with four compartments -susceptible-exposed-infected-confirmed (SEIC)-capable of imitating the COVID-19 transmission and flexible enough to cope with new 35 information.", [["COVID-19", "SPECIES", 137, 145], ["the COVID", "TEST", 133, 142], ["infected", "OBSERVATION", 86, 94]]], ["This model has only two unknown parameters: the reproductive ratio R 0 , and the confirmed case rate or reporting rate \u03b4 2 .", [["the reproductive ratio", "TEST", 44, 66], ["case rate", "TEST", 91, 100]]], ["We use confirmed COVID-19 cases from March 25, 2020 to May 4, 2020 in Manhattan, KS as data, and estimate the unknown parameters from data.", [["KS", "ANATOMY", 81, 83], ["COVID", "TEST", 17, 22]]], ["We consider that a confirmed COVID-19 patient cannot spread the disease anymore except in his/her 40 own household.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["the disease", "PROBLEM", 60, 71], ["disease", "OBSERVATION", 64, 71]]], ["In the spreading of COVID-19, there are pre-symptomatic and asymptomatic cases that do not show any sign of illness [4] .", [["illness", "DISEASE", 108, 115], ["COVID", "TEST", 20, 25], ["pre-symptomatic and asymptomatic cases", "PROBLEM", 40, 78], ["illness", "PROBLEM", 108, 115]]], ["Besides, there is a strong possibility that infected cases not detected exist.", [["infected cases", "PROBLEM", 44, 58], ["strong possibility", "UNCERTAINTY", 20, 38], ["infected", "OBSERVATION", 44, 52]]], ["45 Since a vaccine is not available for COVID-19, contact tracing is a key mitigation strategy to control the spreading of COVID-19.", [["COVID-19", "DNA", 123, 131], ["a vaccine", "TREATMENT", 9, 18], ["COVID", "TEST", 40, 45], ["contact tracing", "TEST", 50, 65], ["COVID", "TEST", 123, 128]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint strategy that aims at identifying people who may have come into contact with a patient.", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 415, 421], ["patient", "ORGANISM", 460, 467], ["people", "SPECIES", 415, 421], ["patient", "SPECIES", 460, 467], ["med", "ANATOMY", 102, 105]]], ["This mitigation strategy prevents further spreading by isolation of exposed people.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["This mitigation strategy", "TREATMENT", 0, 24]]], ["The public health personnel have used contact tracing as a 50 tool to control disease-spreading for a long time [5] .", [["contact tracing", "TEST", 38, 53]]], ["We implement the contact tracing strategy according to CDC guidance [6] through a two-layer network model with a modified SEIC epidemic model.", [["a two-layer network model", "TREATMENT", 80, 105], ["a modified SEIC epidemic model", "TREATMENT", 111, 141]]], ["Contact tracing is effective at the early stage of an epidemic when there is a limited number of cases.", [["Contact tracing", "TEST", 0, 15]]], ["We choose a college town, Manhattan (KS), for our study.", [["our study", "TEST", 46, 55]]], ["Feasibility of contact tracing to control COVID-19 spreading was analyzed using a branching process stochastic simulation for three reproductive ratios R 0 = 1.5, 2.5, and 3.5 [7] .", [["COVID-19", "CHEMICAL", 42, 50], ["COVID-19", "DNA", 42, 50], ["contact tracing", "TEST", 15, 30], ["COVID", "TEST", 42, 47]]], ["The authors find that sufficient contact tracing with quarantine can control a new outbreak of COVID-19.", [["COVID-19", "CHEMICAL", 95, 103], ["COVID-19", "DNA", 95, 103], ["quarantine", "TREATMENT", 54, 64], ["COVID", "TEST", 95, 100]]], ["However, this article neither explored the effectiveness of contact tracing for a specific location, nor investigated the cost of contact tracing.(which was not certified by peer review)In this research, we develop an individual-based network framework to assess the 65 impact of contact-tracing in the reopening process in a college town of Kansas.(which was not certified by peer review)To analyze the cost of contact-tracing represented by the number of quarantined susceptible people, we develop a contact network and estimate the reproductive ratio R 0 and confirmed rate (infected to laboratory-confirmed transition) from observed confirmed case data in Manhattan KS.", [["KS", "ANATOMY", 670, 672], ["people", "ORGANISM", 481, 487], ["people", "SPECIES", 481, 487], ["contact tracing", "TEST", 60, 75]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)4The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint \u2022 A rigorous estimation of the reproductive ratio R 0 and confirmed case rate (infected to laboratory-confirmed transition) from observed confirmed case data.80\u2022 A thorough investigation of costs and benefits of contact-tracing in the reopening process in a college town of Kansas.80The individual-based network model is developed to represent the heterogeneity in people mixing.", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 707, 713], ["people", "SPECIES", 707, 713], ["medRxiv", "TREATMENT", 325, 332], ["the reproductive ratio", "TEST", 369, 391], ["case rate", "TEST", 410, 419], ["med", "ANATOMY", 102, 105], ["heterogeneity", "OBSERVATION", 690, 703]]], ["It can be used to estimate, and model contact-tracing for COVID-19 85 in any location.", [["COVID", "TEST", 58, 63]]], ["It can also be used for any other disease that has a similar spreading mechanism like COVID-19.80This paper is organized as follows: section 2 proposes an individual-based contact network framework with two networks: the full network and the limited network, to represents the contact situation namely before the reopening pro-Individual-based contact network modelThis section proposes a method to develop an individual-based contact network model capable of representing heterogeneous social mixing.", [["COVID-19.80", "CHEMICAL", 86, 97], ["contact network", "MULTI-TISSUE_STRUCTURE", 427, 442], ["any other disease", "PROBLEM", 24, 41], ["COVID", "TEST", 86, 91], ["the reopening pro-Individual", "TREATMENT", 309, 337], ["heterogeneous", "OBSERVATION_MODIFIER", 473, 486], ["social mixing", "OBSERVATION", 487, 500]]], ["In this network, occupied households are in the individual node level, a connection be-100 tween two households represents the contact probability between members of these households.", [["node", "ANATOMY", 59, 63], ["node", "MULTI-TISSUE_STRUCTURE", 59, 63], ["node", "OBSERVATION", 59, 63]]], ["The network has N nodes and n people.", [["N nodes", "ANATOMY", 16, 23], ["N nodes", "MULTI-TISSUE_STRUCTURE", 16, 23], ["people", "SPECIES", 30, 36], ["nodes", "OBSERVATION", 18, 23]]], ["Each age-range has n i people, where i \u2208 {1, 2, 3, 4, 5}.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29]]], ["We distribute the n people randomly into the N occupied households according to five social char-105 acteristics: age, average household sizes, family households, couple, living-alone 5 .", [["people", "SPECIES", 20, 26]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Individual-based contact network modelThe copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint [3] .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["We maintain the average household sizes, number of family households, number of couples, and number of living-alone households.", [["sizes", "OBSERVATION_MODIFIER", 34, 39]]], ["Besides, a person under 18 years old is always assigned in a house with at least one adult person.Individual-based contact network modelAfter assigning the people, an age-specific network is developed for each age 110 range and a random mixing network for all ages.", [["people", "ORGANISM", 156, 162], ["person", "SPECIES", 11, 17], ["person", "SPECIES", 91, 97], ["people", "SPECIES", 156, 162]]], ["The steps to develop age-specific networks are:115Step 1: For each person j (here, j \u2208 1, 2, ..., n), contacts c j is assigned from a Gaussian distribution N (\u00b5, \u03c3 2 ).", [["person", "SPECIES", 67, 73], ["a Gaussian distribution N", "TEST", 132, 157]]], ["The mean \u00b5 of the Gaussian distributions are taken from the daily average number of contacts per person in each age-range [9, 10, 11] .", [["person", "SPECIES", 97, 103], ["Gaussian distributions", "OBSERVATION", 18, 40]]], ["The average daily contacts per person are given in Table 1 In the random-mixing-network, the number of contacts is assigned randomly from the N (2, 1) distribution for a person j.", [["person", "SPECIES", 31, 37], ["person", "SPECIES", 170, 176]]], ["The Gaussian or normal distribution is the distribution of real numbers; therefore, the 130 number from the N (\u00b5, \u03c3 2 ) distribution is rounded to the closest integer.115Step 2: For each person j, contacts for its belonging household k is assigned by (c j \u2212 h k \u2212 1).", [["person", "SPECIES", 187, 193], ["normal", "OBSERVATION", 16, 22], ["distribution", "OBSERVATION_MODIFIER", 23, 35], ["distribution", "OBSERVATION_MODIFIER", 43, 55], ["rounded", "OBSERVATION_MODIFIER", 136, 143]]], ["Here, c j is the number of contacts for a person j, h k is the household size or number of people of the household k, person j lives in the household k, j = 1, 2, 3......n, and k = 1, 2, 3......N .", [["c j", "GENE_OR_GENE_PRODUCT", 6, 9], ["people", "ORGANISM", 91, 97], ["person", "SPECIES", 42, 48], ["people", "SPECIES", 91, 97], ["person", "SPECIES", 118, 124]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint(which was not certified by peer review)Step 3: From the mixing patterns of different age-ranges, people have a strong tendency to meet people with their same age range (more than 80%) [9, 10, 11] .", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 437, 443], ["people", "ORGANISM", 475, 481], ["people", "SPECIES", 437, 443], ["people", "SPECIES", 475, 481], ["med", "ANATOMY", 102, 105]]], ["Therefore, We keep the maximum number of contacts among the same age ranges and a small percentage for the other age ranges.", [["maximum", "OBSERVATION_MODIFIER", 23, 30], ["small", "OBSERVATION_MODIFIER", 82, 87]]], ["The percentage of contacts in the same age-specific-network for each age-range 140 is given in Table 1 .", [["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Degree d ki of a node k in the age-specific network i is s% of (c j \u2212 h k \u2212 1), here, s% of average daily contacts of a person happens with the people of his same age-range.(which was not certified by peer review)Step 4: After assigning degree, d ki for N nodes or households, The configuration network model [8] creates half-edges for each node, then chooses two 145 nodes randomly and connect their half-edges to form a full edge [8] .(which was not certified by peer review)The population and network characteristics for the five age-specific networks for Manhattan, KS are given in Table 1 .", [["node", "ANATOMY", 17, 21], ["node", "ANATOMY", 341, 345], ["KS", "ANATOMY", 570, 572], ["people", "ORGANISM", 144, 150], ["person", "SPECIES", 120, 126], ["people", "SPECIES", 144, 150], ["a node k", "TEST", 15, 23], ["node", "OBSERVATION", 17, 21], ["nodes", "OBSERVATION", 256, 261], ["node", "OBSERVATION", 341, 345], ["nodes", "OBSERVATION", 368, 373]]], ["According to census 2018, Manhattan, KS has n = 55, 489 people and N = 20, 439 occupied households [3] .(which was not certified by peer review)The full network is a combination of five age-specific networks and a random-150 mixing network.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["Adjacency matrix for the full network A f is a summation of six adjacency matrices:(which was not certified by peer review)Here, A i is the adjacency matrix for the age-specific network i, and A r is the adjacency matrix for the random mixing network.", [["matrix", "CELLULAR_COMPONENT", 150, 156], ["matrix", "CELLULAR_COMPONENT", 214, 220], ["matrix", "OBSERVATION_MODIFIER", 10, 16]]], ["However, the full network is a weighted and undi- CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint which is closed since early March 2020.", [["medRxiv preprint", "TREATMENT", 649, 665], ["med", "ANATOMY", 152, 155], ["med", "ANATOMY", 428, 431]]], ["To represent this unusual situation, the full network is modified to a limited network version.", [["this unusual situation", "PROBLEM", 13, 35]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020.Epidemic modelIn this section, we design an epidemic model to simulate the COVID-19Epidemic modelspreading; later, we estimate the unknown parameters (reproductive ratio R 0 180 and confirmed rate \u03b4 2 ) of the epidemic model.", [["CC", "CHEMICAL", 0, 2], ["reproductive ratio", "TEST", 422, 440], ["rate", "TEST", 463, 467], ["med", "ANATOMY", 102, 105]]], ["This model assumes that there is no particular mitigation strategies have applied except general lockdown.Susceptible-exposed-infected-confirmed (SEIC) epidemic modelThis research propose a susceptible-exposed-infected-confirmed (SEIC) epidemic model to simulate the spreading of COVID-19 (Fig. 2) .", [["Susceptible-exposed-infected", "DISEASE", 106, 134], ["particular mitigation strategies", "TREATMENT", 36, 68], ["COVID", "TEST", 280, 285], ["no", "UNCERTAINTY", 33, 35], ["infected", "OBSERVATION", 126, 134], ["infected", "OBSERVATION", 210, 218], ["spreading", "OBSERVATION_MODIFIER", 267, 276]]], ["This model has four compartments: susceptible S, exposed E, infected I, confirmed C. A susceptible node does not introduce to the virus yet, an exposed node introduces 190 to the virus, but the viremia level is not strong enough to infect others, an infected node has strong viremia to infect others, and a confirmed node is a laboratory-confirmed COVID-19 case.", [["node", "ANATOMY", 99, 103], ["node", "ANATOMY", 152, 156], ["node", "ANATOMY", 259, 263], ["node", "ANATOMY", 317, 321], ["viremia", "DISEASE", 194, 201], ["viremia", "DISEASE", 275, 282], ["node", "MULTI-TISSUE_STRUCTURE", 99, 103], ["node", "MULTI-TISSUE_STRUCTURE", 152, 156], ["node", "MULTI-TISSUE_STRUCTURE", 259, 263], ["node", "MULTI-TISSUE_STRUCTURE", 317, 321], ["susceptible S", "PROBLEM", 34, 47], ["A susceptible node", "PROBLEM", 85, 103], ["the virus", "PROBLEM", 126, 135], ["an exposed node", "PROBLEM", 141, 156], ["the virus", "PROBLEM", 175, 184], ["the viremia level", "TEST", 190, 207], ["an infected node", "PROBLEM", 247, 263], ["strong viremia", "PROBLEM", 268, 282], ["COVID", "TEST", 348, 353], ["susceptible", "OBSERVATION_MODIFIER", 87, 98], ["node", "OBSERVATION", 99, 103], ["node", "OBSERVATION", 152, 156], ["viremia", "OBSERVATION", 194, 201], ["not strong", "UNCERTAINTY", 211, 221], ["infected", "OBSERVATION_MODIFIER", 250, 258], ["node", "OBSERVATION", 259, 263], ["strong", "OBSERVATION_MODIFIER", 268, 274], ["viremia", "OBSERVATION", 275, 282], ["node", "OBSERVATION", 317, 321]]], ["The SEIC model has three transitions, which are divided into two categories: edge-based (S \u2192 E), and nodal (E \u2192 I; 15] .195An edge-based transition of a node depends on the state of its contacting nodes or neighbors in the contact network with its own state.", [["node", "ANATOMY", 153, 157], ["edge", "TEST", 77, 81], ["nodal (E \u2192 I", "TEST", 101, 113], ["An edge", "TEST", 123, 130], ["a node", "PROBLEM", 151, 157], ["three transitions", "OBSERVATION", 19, 36], ["nodal", "ANATOMY", 101, 106], ["edge", "OBSERVATION_MODIFIER", 126, 130], ["node", "OBSERVATION", 153, 157], ["nodes", "OBSERVATION", 197, 202]]], ["A nodal transition of a node only depends on the own state.", [["node", "ANATOMY", 24, 28], ["node", "MULTI-TISSUE_STRUCTURE", 24, 28], ["A nodal transition of a node", "PROBLEM", 0, 28], ["nodal transition", "OBSERVATION", 2, 18], ["node", "OBSERVATION", 24, 28]]], ["Each edge-based transition has an influencer compartment.", [["edge", "OBSERVATION_MODIFIER", 5, 9], ["transition", "OBSERVATION_MODIFIER", 16, 26]]], ["A transition from susceptible to exposed (S \u2192 E) of a susceptible node depends on the infected neighbors of that node.", [["node", "ANATOMY", 66, 70], ["node", "ANATOMY", 113, 117], ["node", "MULTI-TISSUE_STRUCTURE", 66, 70], ["node", "MULTI-TISSUE_STRUCTURE", 113, 117], ["A transition", "PROBLEM", 0, 12], ["a susceptible node", "PROBLEM", 52, 70], ["susceptible", "OBSERVATION_MODIFIER", 54, 65], ["node", "OBSERVATION", 66, 70], ["infected", "OBSERVATION_MODIFIER", 86, 94], ["node", "OBSERVATION", 113, 117]]], ["Therefore 200 it is an edge-based transition, and the infected compartment is the influencer compartment of this transition.", [["edge", "OBSERVATION_MODIFIER", 23, 27], ["transition", "OBSERVATION_MODIFIER", 34, 44], ["infected", "OBSERVATION", 54, 62]]], ["In this work, we are using the term 'neighbors of a node k' for the nodes, which have the shortest path length 1 from the node k.", [["node", "ANATOMY", 52, 56], ["nodes", "ANATOMY", 68, 73], ["node", "ANATOMY", 122, 126], ["node k'", "MULTI-TISSUE_STRUCTURE", 52, 59], ["nodes", "MULTI-TISSUE_STRUCTURE", 68, 73], ["the nodes", "PROBLEM", 64, 73], ["node", "OBSERVATION", 52, 56], ["nodes", "OBSERVATION", 68, 73], ["node", "ANATOMY", 122, 126]]], ["The transition rate of the susceptible to exposed (S \u2192 E) transition of a node k is \u03b2 1 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint is the number of infected neighbors of the node k.", [["node", "ANATOMY", 74, 78], ["node", "ANATOMY", 407, 411], ["medRxiv", "TREATMENT", 347, 354], ["node", "OBSERVATION", 74, 78], ["med", "ANATOMY", 126, 129], ["infected", "OBSERVATION", 381, 389], ["node", "ANATOMY", 407, 411]]], ["The transition rate for the transition exposed to infected (E \u2192 I) is \u03b4 1 .", [["\u03b4 1", "GENE_OR_GENE_PRODUCT", 70, 73], ["The transition rate", "TREATMENT", 0, 19], ["the transition", "PROBLEM", 24, 38]]], ["The confirmed rate of an infected person is \u03b4 2 .", [["person", "SPECIES", 34, 40], ["infected", "OBSERVATION", 25, 33]]], ["We assume that a laboratory-confirmed case will be isolated and cannot spread the disease outside of his household anymore.", [["the disease", "PROBLEM", 78, 89]]], ["An infected nodeStochastic simulationTo do the simulation, we use GEMFsim; it is a stochastic simulator for the 220 generalized epidemic modeling framework (GEMF), which was developed by the Network Science and Engineering (NetSE) group at Kansas State University In GEMF, the joint state of all nodes follows a Markov process that arises from 11 .", [["nodes", "MULTI-TISSUE_STRUCTURE", 296, 301], ["An infected nodeStochastic simulation", "PROBLEM", 0, 37], ["GEMFsim", "TREATMENT", 66, 73], ["all nodes", "PROBLEM", 292, 301], ["infected", "OBSERVATION_MODIFIER", 3, 11], ["nodeStochastic simulation", "OBSERVATION", 12, 37], ["joint", "ANATOMY", 277, 282], ["nodes", "OBSERVATION", 296, 301]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint Table 2 : Description of the susceptible-exposed-infected-confirmed (SEIC) epidemic model.Statestype transition transition rateStatesestimated node-level transition.", [["CC", "CHEMICAL", 0, 2], ["Statestype transition transition", "PROBLEM", 430, 462], ["med", "ANATOMY", 102, 105], ["infected", "OBSERVATION", 389, 397], ["node", "OBSERVATION", 483, 487]]], ["A node can change its state by moving from one compartment to another compartment through a transition.", [["node", "ANATOMY", 2, 6], ["node", "MULTI-TISSUE_STRUCTURE", 2, 6], ["A node", "PROBLEM", 0, 6], ["node", "OBSERVATION", 2, 6]]], ["One assumption of the GEMF system is, all the events or transitions are independent Poisson processes with the constant rate; this assumption leads the system to a continuous-time 230 Markov process.", [["the GEMF system", "TREATMENT", 18, 33]]], ["Initially, the simulation starts by setting two infected nodes randomly.Parameter estimation for the SEIC epidemic modelThe SEIC model has two unknown parameters: reproductive ratio R 0 , and 235 confirmed or reporting rate \u03b4 2 .", [["nodes", "ANATOMY", 57, 62], ["two infected nodes", "PROBLEM", 44, 62], ["Parameter estimation", "TEST", 72, 92], ["The SEIC model", "TEST", 120, 134], ["reproductive ratio", "TEST", 163, 181], ["rate", "TEST", 219, 223], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["nodes", "OBSERVATION", 57, 62]]], ["To estimate the R 0 and \u03b4 2 , we have used con- for reporting rate \u03b4 2 is 1 6.54 day \u22121 (95% confidence interval: 1 7.89 \u2212 1 6.05 day \u22121 ).12.", [["rate", "TEST", 62, 66]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint(which was not certified by peer review)These estimated values are specific for Manhattan, KS.", [["KS", "ANATOMY", 430, 432], ["CC", "CHEMICAL", 0, 2], ["These estimated values", "TEST", 379, 401], ["med", "ANATOMY", 102, 105]]], ["We have considered that some people will develop severe symptoms, and they will be reported as a con-245 firmed case of COVID-19 sooner.", [["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["severe symptoms", "PROBLEM", 49, 64], ["COVID", "TEST", 120, 125], ["severe", "OBSERVATION_MODIFIER", 49, 55]]], ["However, some people will produce deficient symptoms, and may they will not be tested.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["deficient symptoms", "PROBLEM", 34, 52]]], ["We use approximate Bayesian computation based on sequential Monte Carlo sampling (ABS-SMC) approach to estimate the parameters [18, 19] .250A sensitivity analysis for R 0 and \u03b4 2 on the mean-squared error between confirmed cases data and simulated results is presented in Fig. 6 .", [["approximate Bayesian computation", "TREATMENT", 7, 39], ["sequential Monte Carlo sampling (ABS-SMC) approach", "TREATMENT", 49, 99], ["A sensitivity analysis", "TEST", 140, 162], ["cases data", "TEST", 223, 233]]], ["From the sensitivity analysis, the mean-squared error is low when the reporting time is high.250It indicates undetected COVID-19 patients in the system.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["the sensitivity analysis", "TEST", 5, 29], ["low", "OBSERVATION_MODIFIER", 57, 60], ["system", "ANATOMY", 145, 151]]], ["It means that an infected node needs to be infected for a longer time for the better fitting with 255 the data.", [["node", "ANATOMY", 26, 30], ["node", "MULTI-TISSUE_STRUCTURE", 26, 30], ["an infected node", "PROBLEM", 14, 30], ["the data", "TEST", 102, 110], ["infected", "OBSERVATION_MODIFIER", 17, 25], ["node", "OBSERVATION", 26, 30]]], ["It also indicates that the testing of COVID-19 is not sufficient.Simulation in the reopening process without contact tracingIn this subsection, we simulate the confirmed cases (or cumulative new cases per day) for two months: June and July using the SEIC epidemic model with the estimated parameters.", [["COVID-19", "CHEMICAL", 38, 46], ["the testing of COVID", "TEST", 23, 43]]], ["To simulate, we assume that there is no change 260 except reopening from pandemic lockdown.", [["no", "UNCERTAINTY", 37, 39]]], ["We use the limited network to simulate from March 25, 2020 to May 4, 2020; then, we change the network concerning the reopening situation.265For example, for a 25% reopening situation, we add 25% missing links randomly (which are present in the full network but not in the limited network).", [["the reopening situation", "PROBLEM", 114, 137], ["a 25% reopening situation", "PROBLEM", 158, 183], ["reopening", "OBSERVATION", 118, 127]]], ["We preserve the states of each node at May 4, 2020 in the network then use it as the initial condition for the simulation for the reopening situation (from May 4, 2020 to July 1, 2020).", [["node", "OBSERVATION", 31, 35]]], ["Fig. 4 is showing the mean (dashed lines) and median 270 (solid lines) of the confirmed cases of the 1000 stochastic realizations of the four reopening situations.", [["the mean (dashed lines", "TREATMENT", 18, 40], ["median 270 (solid lines", "TREATMENT", 46, 69], ["reopening", "OBSERVATION", 142, 151]]], ["The zoom-in window in Fig. 4 shows the time period when data was used to estimate the parameters of the epidemic model.13.", [["The zoom", "TREATMENT", 0, 8]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint", "TREATMENT", 323, 339], ["med", "ANATOMY", 102, 105]]], ["The light-colored boxes represent more mse than dark-colored boxes.", [["light-colored boxes", "DNA", 4, 23], ["dark-colored boxes", "PROBLEM", 48, 66], ["more mse", "OBSERVATION_MODIFIER", 34, 42]]], ["The color boxes with number \"1\" means that mse\u2264 3, number \"2\" means that 3 <mse \u2264 10, number \"3\" means that 10 <mse \u2264 50, number \"4\" means that 50 <mse \u2264 100,number \"5\" means that 100 <mse \u2264 500,number \"6\" means that 500 <mse \u2264 1000,number \"7\" means that 1000 <mse.", [["mse \u2264", "TEST", 76, 81]]], ["More than 80% times epidemic dies out in the combinations of the black squares, and confirmed cases are less than 10.", [["the black squares", "TEST", 61, 78]]], ["The minimum error combination is showing by the red circle.", [["red circle", "OBSERVATION", 48, 58]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint15.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint15", "TREATMENT", 323, 341], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprintContact tracingContact tracing is a crucial mitigation strategy to control the spreading of 275 COVID-19.", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["Contact tracing", "TEST", 339, 354], ["Contact tracing", "TEST", 354, 369], ["a crucial mitigation strategy", "TREATMENT", 373, 402], ["med", "ANATOMY", 102, 105]]], ["In this section, we will implement contact tracing and observe the efficiency of the contact tracing in the different reopening scenarios.", [["contact tracing", "TEST", 35, 50], ["the contact tracing", "TEST", 81, 100]]], ["To implement contact tracing, we modify the basic SEIC epidemic model and propose a two-layer network model.", [["contact tracing", "TEST", 13, 28], ["a two-layer network model", "TREATMENT", 82, 107]]], ["In the implementation of the contact tracing, we follow the CDC's guidance for contact tracing [6] .Two-layer individual-based network modelThis work implements contact tracing in a two-layer network model: the contact network is in the first layer, and the tracing network is in the second layer (Fig. 5 ).", [["contact network", "MULTI-TISSUE_STRUCTURE", 211, 226], ["the contact tracing", "TEST", 25, 44], ["contact tracing", "TEST", 79, 94], ["network model", "OBSERVATION", 127, 140]]], ["In the t%-tracing-layer, t% of links of 285 each node in the contact-layer are preserved randomly to form tracing-layer (A 50% tracing-layer is presented in Fig. 5 ).", [["node", "ANATOMY", 49, 53], ["node", "MULTI-TISSUE_STRUCTURE", 49, 53], ["node", "OBSERVATION", 49, 53], ["layer", "ANATOMY_MODIFIER", 69, 74], ["layer", "OBSERVATION_MODIFIER", 114, 119]]], ["The contacts/neighbors of a confirmed (C) node in the tracing-layer will be tested and quarantined.Epidemic model for contact tracingFor the contact tracing mitigation strategy, we consider two approaches for 290 isolation: I) only infected neighbors of a confirmed case in the tracing layer will be isolated, II) all the neighbors of a confirmed case in the tracing layer will be isolated.", [["node", "ANATOMY", 42, 46], ["the tracing", "TEST", 50, 61], ["contact tracing", "TEST", 118, 133], ["node", "OBSERVATION", 42, 46]]], ["For the case I, we propose the SEICQ1 epidemic model, and for case II, we propose the SEICQ2 epidemic model.Epidemic model for contact tracingThe SEICQ1 model has six compartments: susceptible (S), exposed (E), in-295 fected (I), confirmed (C), quarantined-infected (Q I ), and removed (R).", [["contact tracing", "TEST", 127, 142], ["infected", "OBSERVATION", 257, 265]]], ["The SEICQ2 model has eight compartments: susceptible (S), exposed (E), infected (I), confirmed (C), quarantined-susceptible (Q S ), quarantined-exposed (Q E ), quarantined-infected (Q I ), and removed (R).", [["quarantined", "TEST", 100, 111], ["eight", "OBSERVATION_MODIFIER", 21, 26], ["compartments", "OBSERVATION_MODIFIER", 27, 39], ["susceptible", "OBSERVATION_MODIFIER", 41, 52], ["infected", "OBSERVATION", 71, 79], ["susceptible", "OBSERVATION_MODIFIER", 112, 123], ["infected", "OBSERVATION", 172, 180]]], ["The transitions S \u2192 E, E \u2192 I, and I \u2192 C are the same as the base SEIC model.300In the SEICQ1 model, neighbors of a confirmed node in the tracing-layer will be monitored, and infected neighbors will go to the quarantined-infected 16 .", [["node", "ANATOMY", 125, 129], ["S \u2192 E", "SIMPLE_CHEMICAL", 16, 21], ["E \u2192 I", "SIMPLE_CHEMICAL", 23, 28], ["I \u2192 C", "SIMPLE_CHEMICAL", 34, 39], ["node", "MULTI-TISSUE_STRUCTURE", 125, 129], ["The transitions S", "TEST", 0, 17], ["the tracing", "TEST", 133, 144], ["node", "OBSERVATION", 125, 129], ["infected", "OBSERVATION", 220, 228]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint17.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint17", "TREATMENT", 323, 341], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint18.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint18", "TREATMENT", 323, 341], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint (Q I ) state immediately with rate \u03b2 2 , therefore infected to quarantined-infected (I \u2192 Q I ) transition is an edge-based transition and confirmed compartment is the influencer of this transition.", [["CC", "CHEMICAL", 0, 2], ["rate", "TEST", 370, 374], ["med", "ANATOMY", 102, 105], ["infected", "OBSERVATION", 391, 399], ["infected", "OBSERVATION", 415, 423], ["edge", "OBSERVATION_MODIFIER", 452, 456]]], ["A COVID-19 positive neighbor 305 of a confirmed node will go to the confirmed state immediately with \u03b4 3 rate, Q I \u2192 C is a nodal transition.", [["node", "ANATOMY", 48, 52], ["node", "MULTI-TISSUE_STRUCTURE", 48, 52], ["COVID-19 positive neighbor 305", "DNA", 2, 32], ["A COVID", "TEST", 0, 7], ["a nodal transition", "PROBLEM", 122, 140], ["node", "OBSERVATION", 48, 52], ["nodal transition", "OBSERVATION", 124, 140]]], ["A confirmed node will be removed from the system with \u03b4 4 rate (here, \u03b4 4 = 1 14 days \u22121 ), and its neighbors are not going to be monitored anymore after 14 days.", [["node", "ANATOMY", 12, 16], ["node", "MULTI-TISSUE_STRUCTURE", 12, 16], ["node", "OBSERVATION", 12, 16]]], ["A confirmed or removed node can not spread the disease anymore.", [["node", "ANATOMY", 23, 27], ["node", "MULTI-TISSUE_STRUCTURE", 23, 27], ["removed node", "PROBLEM", 15, 27], ["the disease", "PROBLEM", 43, 54], ["node", "OBSERVATION", 23, 27], ["disease", "OBSERVATION", 47, 54]]], ["The purpose of the transition C \u2192 R is to monitor 310 the neighbors of a confirmed node for 14 days.", [["node", "ANATOMY", 83, 87], ["node", "MULTI-TISSUE_STRUCTURE", 83, 87], ["node", "OBSERVATION", 83, 87]]], ["The node transition diagram of the SEICQ1 model is given in Fig. 6a .", [["node", "ANATOMY", 4, 8], ["node", "MULTI-TISSUE_STRUCTURE", 4, 8], ["SEICQ1", "DNA", 35, 41], ["The node transition diagram", "TREATMENT", 0, 27], ["the SEICQ1 model", "TREATMENT", 31, 47], ["node", "OBSERVATION", 4, 8]]], ["A description of the 6 transitions of the SEICQ1 model is given in the Table 3 .(which was not certified by peer review)In the SEICQ2 model, neighbors (susceptible, exposed, and infected) of a 315 confirmed node in the tracing-layer will be monitored and quarantined.", [["node", "ANATOMY", 207, 211], ["node", "MULTI-TISSUE_STRUCTURE", 207, 211], ["the SEICQ1 model", "TREATMENT", 38, 54], ["the tracing", "TEST", 215, 226], ["node", "OBSERVATION", 207, 211]]], ["The SE-ICQ2 model has four new transitions than the SEICQ1 model: susceptible to quarantined-susceptible (S \u2192 Q S ), exposed to quarantined-exposed (E \u2192 Q E ), quarantined-exposed to quarantined-infected (Q E \u2192 Q I ), and quarantinedsusceptible to susceptible (Q S \u2192 S).", [["SE", "DISEASE", 4, 6], ["new", "OBSERVATION_MODIFIER", 27, 30], ["transitions", "OBSERVATION", 31, 42], ["infected", "OBSERVATION", 195, 203]]], ["The SEICQ2 model is presented in Fig 320 6b .", [["SEICQ2", "DNA", 4, 10]]], ["A description of the 10 transitions of the SEICQ2 model is given in Table 4 .Impact of contact tracingContact tracing can minimize the effect of the reopening process and control the spreading of COVID-19.", [["COVID-19", "CHEMICAL", 196, 204], ["SEICQ2", "DNA", 43, 49], ["COVID-19", "DNA", 196, 204], ["the SEICQ2 model", "TREATMENT", 39, 55], ["the reopening process", "TREATMENT", 145, 166], ["COVID", "TEST", 196, 201], ["reopening", "OBSERVATION", 149, 158]]], ["We apply contact tracing after May 4, 2020 in 325 Manhattan, KS.", [["KS", "ANATOMY", 61, 63]]], ["The dashed lines in Fig. 7 represents the mean, and solid lines represent the median of the 1000 stochastic realization for the SEICQ1 and SEICQ2 model.330The difference between SEICQ1 and SEICQ2 is that SEICQ1 quarantines only the infected neighbors of a confirmed case in the tracing layer however SEICQ219.", [["SEICQ219", "CHEMICAL", 300, 308], ["lines", "CELL", 11, 16], ["solid lines", "CELL", 52, 63], ["dashed lines", "CELL_LINE", 4, 16], ["solid lines", "CELL_LINE", 52, 63], ["SEICQ1", "DNA", 178, 184], ["SEICQ2", "DNA", 189, 195], ["SEICQ1", "DNA", 204, 210], ["The dashed lines", "TREATMENT", 0, 16], ["the SEICQ1 and SEICQ2 model", "TREATMENT", 124, 151], ["dashed lines", "OBSERVATION", 4, 16], ["mean", "OBSERVATION_MODIFIER", 42, 46], ["solid lines", "OBSERVATION", 52, 63], ["infected", "OBSERVATION", 232, 240]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint estimated(which was not certified by peer review)20 .", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint(which was not certified by peer review)21 .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint22.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint22", "TREATMENT", 323, 341], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint quarantines susceptible, exposed, and infected neighbors of a confirmed case in the tracing layer.", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["med", "ANATOMY", 102, 105]]], ["For any reopening situations, tracing more than 60% of the contacts in the SEICQ2 can reduce the median of the 1000 stochastic realizations of the confirmed cases more than 96.5% on July 1, 2020 and in the SEICQ1 can reduce the median of the 1000 stochastic realizations of the confirmed cases more than 92%.", [["SEICQ2", "DNA", 75, 81], ["any reopening situations", "PROBLEM", 4, 28], ["tracing", "TEST", 30, 37]]], ["The SEICQ2 model can reduce the 340 confirmed cases on July 1, 2020 for more than 75% in the 25% reopening, more than 82% in the 50% reopening, more than 92% in the 75%, and more than 96%(which was not certified by peer review)in the 100% reopening with compare to no-contact-tracing (SEIC model).(which was not certified by peer review)The SEICQ2 model can reduce the reported cases further compared to SEICQ1(which was not certified by peer review)for the same amount of contact tracing (Fig. 7) .", [["no-contact", "TEST", 265, 275]]], ["However, the SEICQ2 model 345 has a drawback; it isolates susceptible persons.", [["persons", "ORGANISM", 70, 77], ["persons", "SPECIES", 70, 77]]], ["The number of total quarantined susceptible households in the simulation time period for different amounts of traced contacts for the SEICQ2 model is presented in Fig. 8 .", [["the SEICQ2 model", "TREATMENT", 130, 146]]], ["The quarantined susceptible households increase with the increase of tracing; however, after tracing 20% of contacts, the quarantined susceptible households start to decrease 350 with the increase of tracing (Fig. 8 ).", [["tracing", "TEST", 93, 100], ["susceptible", "OBSERVATION_MODIFIER", 16, 27], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["If we consider quarantined susceptible households are the cost of SEICQ2 model, then it is cost-effective to trace contacts of the confirmed cases more than 20%.", [["SEICQ2 model", "TREATMENT", 66, 78]]], ["The possible reason for decreasing the number of quarantined households with the increasing of contact-tracing after 20% is the smaller number of the infected cases or the smaller epidemic 355 size.", [["infected", "DISEASE", 150, 158], ["possible reason for", "UNCERTAINTY", 4, 23], ["decreasing", "OBSERVATION_MODIFIER", 24, 34], ["smaller", "OBSERVATION_MODIFIER", 128, 135], ["infected", "OBSERVATION", 150, 158], ["smaller", "OBSERVATION_MODIFIER", 172, 179], ["epidemic", "OBSERVATION_MODIFIER", 180, 188], ["355", "OBSERVATION_MODIFIER", 189, 192], ["size", "OBSERVATION_MODIFIER", 193, 197]]], ["Although each confirmed case will give a long list of possible contacts, this effect will be balanced out by a decreasing number of the confirmed cases.ConclusionThis research studies contact tracing as a key mitigation strategy to control the COVID-19 transmission in the reopening process of a college town in the 360 rural region of the USA.", [["This research studies", "TEST", 162, 183], ["the COVID", "TEST", 240, 249]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint24.", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint24", "TREATMENT", 323, 341], ["med", "ANATOMY", 102, 105]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. network nodes.", [["network nodes", "ANATOMY", 272, 285], ["CC", "CHEMICAL", 0, 2], ["network nodes", "MULTI-TISSUE_STRUCTURE", 272, 285], ["med", "ANATOMY", 102, 105], ["nodes", "OBSERVATION", 280, 285]]], ["The pandemic lockdown reduces the contacts mostly among the people who are students.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["pandemic", "OBSERVATION_MODIFIER", 4, 12], ["lockdown", "OBSERVATION", 13, 21]]], ["Pandemic lockdown also affects people in 25-34, 35-59 age-ranges.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37]]], ["We propose a 'full network' to represent the usual situation; then, we modify the age-specific networks of the full network to represent pandemic lockdown.", [["pandemic lockdown", "TREATMENT", 137, 154], ["pandemic", "OBSERVATION", 137, 145]]], ["The full network is connected and provides an approximation of the contact network at the household level, which is useful for doing the simulation anonymously.(which was not certified by peer review)We propose a susceptible-exposed-infected-confirmed (SEIC) epidemic model in 385 the limited network to simulate COVID-19 transmission from March 25, 2020 to May 4, 2020.", [["contact network", "MULTI-TISSUE_STRUCTURE", 67, 82], ["COVID", "TEST", 313, 318]]], ["We estimate the unknown parameters of the SEIC model for the Manhattan, KS, using approximate Bayesian computation based on sequential Monte Carlo sampling.", [["approximate Bayesian computation", "TREATMENT", 82, 114], ["sequential Monte Carlo sampling", "TREATMENT", 124, 155]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint more investigation.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Asymptomatic carriers of the SARS-CoV-2 are present in the spreading of COVID-19 [20] .", [["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["SARS-CoV-2", "DNA", 29, 39], ["the SARS", "PROBLEM", 25, 33], ["COVID", "TEST", 72, 77]]], ["However, more research is needed to get information about how much an asymptomatic case can transmit the SARS-CoV-2 395 virus.", [["SARS", "DISEASE", 105, 109], ["SARS-CoV-2 395 virus", "ORGANISM", 105, 125], ["SARS-CoV-2 395 virus", "SPECIES", 105, 125], ["the SARS", "TEST", 101, 109], ["CoV", "TEST", 110, 113], ["virus", "PROBLEM", 120, 125]]], ["Asymptomatic cases are included in our model indirectly.", [["Asymptomatic cases", "PROBLEM", 0, 18]]], ["Concerning the unclear role of immunity, we assume that the immunity of a recovered COVID-19 patient is not going to fade in the short period analyzed in our simulations.(which was not certified by peer review)In addition, it is important to keep the model simple, since the data available to estimate parameters is limited.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["the data", "TEST", 271, 279]]], ["Therefore, we propose a simple but dynamic 400 and flexible epidemic model to simulate COVID-19 spreading, which has only two unknown parameters.", [["flexible epidemic model", "TREATMENT", 51, 74], ["COVID", "TEST", 87, 92]]], ["The model can easily cope with additional information that may be available in the future.(which was not certified by peer review)The estimated reproductive ratio is much smaller in Manhattan, KS (estimated R 0 = 0.71) because of the 'Stay at home' order.", [["The estimated reproductive ratio", "TEST", 130, 162], ["KS", "TEST", 193, 195], ["reproductive ratio", "OBSERVATION", 144, 162], ["much", "OBSERVATION_MODIFIER", 166, 170], ["smaller", "OBSERVATION_MODIFIER", 171, 178]]], ["A practical con-410 tact tracing approach can help to control the epidemic in those college towns.(which was not certified by peer review)We implement contact tracing by using a two-layer network model.", [["A practical con-410 tact tracing approach", "TREATMENT", 0, 41], ["a two-layer network model", "TREATMENT", 176, 201]]], ["We assess the impact of contact tracing in the four reopening situations: 25 % reopening, 50 % reopening, 75 % reopening, and 100 % reopening.", [["contact tracing", "TEST", 24, 39]]], ["Reopening without vaccination can produce more infected cases.", [["vaccination", "TREATMENT", 18, 29]]], ["It is essential to access the effi-415 cacy of the contact tracing in the reopening path.", [["the contact tracing", "TEST", 47, 66], ["reopening", "OBSERVATION", 74, 83]]], ["Our investigation indicates that more than 50% contact tracing can control the spreading of COVID-19 even in the 100% reopening situation.", [["COVID-19", "CHEMICAL", 92, 100], ["Our investigation", "TEST", 0, 17], ["contact tracing", "TEST", 47, 62], ["COVID", "TEST", 92, 97]]], ["The number of quarantined susceptible people increases with the increase of traced contacts, however after 20%, the number of quarantined susceptible people decreases with the increases of the 420 traced contacts.", [["people", "ORGANISM", 38, 44], ["people", "ORGANISM", 150, 156], ["people", "SPECIES", 38, 44], ["people", "SPECIES", 150, 156], ["susceptible", "OBSERVATION_MODIFIER", 26, 37]]], ["We consider that quarantined susceptible people represent the cost of contact tracing with a quarantined strategy.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["contact tracing", "TEST", 70, 85], ["a quarantined strategy", "TREATMENT", 91, 113]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)26The copyright holder for this preprint this version posted June 26, 2020. . https://doi.org/10.1101/2020.06.24.20139204 doi: medRxiv preprint Our investigation indicates that a sufficient amount of contact tracing can reduce the impact of COVID-19 spreading in the reopening process of a location 425 where the epidemic is in an initial stage.", [["CC", "CHEMICAL", 0, 2], ["COVID-19", "CHEMICAL", 440, 448], ["COVID-19", "CHEMICAL", 440, 448], ["medRxiv", "TREATMENT", 326, 333], ["Our investigation", "TEST", 343, 360], ["contact tracing", "TEST", 399, 414], ["COVID", "TEST", 440, 445], ["med", "ANATOMY", 102, 105]]], ["At first, the quarantined susceptible people increase with the percentage of traced contacts, however after a certain amount of traced contacts, the quarantined susceptible people start to decrease with the increase in the percentage of traced contacts.", [["people", "ORGANISM", 38, 44], ["people", "ORGANISM", 173, 179], ["people", "SPECIES", 38, 44], ["people", "SPECIES", 173, 179], ["increase", "OBSERVATION_MODIFIER", 207, 215]]]], "PMC3544629": [["BackgroundLower respiratory tract infections (LRTIs) in children and infants are common and can require hospitalization; thus, they are a major public health concern.", [["respiratory tract", "ANATOMY", 16, 33], ["BackgroundLower respiratory tract infections", "DISEASE", 0, 44], ["LRTIs", "DISEASE", 46, 51], ["BackgroundLower respiratory tract", "ORGANISM_SUBDIVISION", 0, 33], ["children", "ORGANISM", 56, 64], ["infants", "ORGANISM", 69, 76], ["children", "SPECIES", 56, 64], ["infants", "SPECIES", 69, 76], ["BackgroundLower respiratory tract infections", "PROBLEM", 0, 44], ["respiratory tract", "ANATOMY", 16, 33], ["infections", "OBSERVATION", 34, 44], ["LRTIs", "OBSERVATION", 46, 51]]], ["A number of viruses including respiratory syncytial virus (RSV), influenza viruses, parainfluenza viruses, rhinovirus, and adenovirus are responsible for LRTIs.", [["respiratory syncytial virus (RSV)", "DISEASE", 30, 63], ["influenza viruses", "DISEASE", 65, 82], ["parainfluenza viruses", "DISEASE", 84, 105], ["rhinovirus", "DISEASE", 107, 117], ["LRTIs", "DISEASE", 154, 159], ["respiratory syncytial virus", "ORGANISM", 30, 57], ["RSV", "ORGANISM", 59, 62], ["influenza viruses", "ORGANISM", 65, 82], ["parainfluenza viruses", "ORGANISM", 84, 105], ["rhinovirus", "ORGANISM", 107, 117], ["adenovirus", "ORGANISM", 123, 133], ["LRTIs", "PATHOLOGICAL_FORMATION", 154, 159], ["respiratory syncytial virus", "SPECIES", 30, 57], ["influenza viruses", "SPECIES", 65, 82], ["parainfluenza viruses, rhinovirus", "SPECIES", 84, 117], ["respiratory syncytial virus", "SPECIES", 30, 57], ["RSV", "SPECIES", 59, 62], ["parainfluenza viruses", "SPECIES", 84, 105], ["adenovirus", "SPECIES", 123, 133], ["viruses", "PROBLEM", 12, 19], ["respiratory syncytial virus", "PROBLEM", 30, 57], ["RSV", "PROBLEM", 59, 62], ["influenza viruses", "PROBLEM", 65, 82], ["parainfluenza viruses", "PROBLEM", 84, 105], ["rhinovirus", "PROBLEM", 107, 117], ["adenovirus", "PROBLEM", 123, 133], ["LRTIs", "PROBLEM", 154, 159], ["viruses", "OBSERVATION", 12, 19], ["respiratory syncytial virus", "OBSERVATION", 30, 57], ["influenza viruses", "OBSERVATION", 65, 82], ["parainfluenza viruses", "OBSERVATION", 84, 105]]], ["In children and infants, RSV is the most common cause; during the first year of life 50%\u201370% of children will have an RSV infection, and by the third year of age almost all children will have been infected.1BackgroundNeonatal and pediatric LRTIs and RSV are often mild, but can be associated with significant health resource utilization and result in an important burden on the patients, families, infrastructure, and budget of public healthcare systems [1].", [["RSV", "DISEASE", 25, 28], ["RSV infection", "DISEASE", 118, 131], ["RSV", "DISEASE", 250, 253], ["children", "ORGANISM", 3, 11], ["infants", "ORGANISM", 16, 23], ["RSV", "ORGANISM", 25, 28], ["children", "ORGANISM", 96, 104], ["RSV", "ORGANISM", 118, 121], ["children", "ORGANISM", 173, 181], ["RSV", "ORGANISM", 250, 253], ["patients", "ORGANISM", 378, 386], ["children", "SPECIES", 3, 11], ["infants", "SPECIES", 16, 23], ["children", "SPECIES", 96, 104], ["children", "SPECIES", 173, 181], ["patients", "SPECIES", 378, 386], ["RSV", "SPECIES", 25, 28], ["RSV", "SPECIES", 118, 121], ["RSV", "SPECIES", 250, 253], ["an RSV infection", "PROBLEM", 115, 131], ["RSV", "PROBLEM", 250, 253], ["RSV", "OBSERVATION", 25, 28], ["most common", "OBSERVATION_MODIFIER", 36, 47], ["RSV", "ANATOMY", 118, 121], ["infection", "OBSERVATION", 122, 131], ["infected", "OBSERVATION", 197, 205], ["LRTIs", "OBSERVATION", 240, 245]]], ["Economic analyses indicate that substantial costs are associated with outpatient physician office and emergency department visits, but that a majority of the financial burden is accounted for by costs in inpatient hospital settings [2,3].", [["Economic analyses", "TEST", 0, 17], ["substantial", "OBSERVATION_MODIFIER", 32, 43], ["costs", "OBSERVATION", 44, 49]]], ["LRTI and RSV/LRTI hospitalization rates for all children <2 years of age vary between 0.5% and 2% [4].", [["LRTI", "DISEASE", 0, 4], ["LRTI", "DISEASE", 13, 17], ["RSV", "ORGANISM", 9, 12], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["RSV", "SPECIES", 9, 12], ["LRTI", "PROBLEM", 0, 4], ["RSV", "PROBLEM", 9, 12]]], ["In comparison, LRTI, and particularly RSV specific LRTI, hospitalization rates and lengths of stay in infants and high-risk infants are substantially increased and associated with additional costs [3,4].", [["LRTI", "DISEASE", 15, 19], ["LRTI", "DISEASE", 51, 55], ["RSV", "ORGANISM", 38, 41], ["infants", "ORGANISM", 102, 109], ["infants", "ORGANISM", 124, 131], ["infants", "SPECIES", 102, 109], ["infants", "SPECIES", 124, 131], ["RSV", "SPECIES", 38, 41], ["substantially", "OBSERVATION_MODIFIER", 136, 149], ["increased", "OBSERVATION_MODIFIER", 150, 159]]], ["High-risk infants include early and late-preterm infants and those with bronchopulmonary dysplasia and congenital heart disease [3,5].BackgroundIn Canada, the annual cost of RSV-associated illness is over $18 million, and inpatient services associated with RSV/LRTI hospitalizations account for 62% of these annual expenditures [2].", [["bronchopulmonary dysplasia", "ANATOMY", 72, 98], ["heart", "ANATOMY", 114, 119], ["bronchopulmonary dysplasia", "DISEASE", 72, 98], ["congenital heart disease", "DISEASE", 103, 127], ["RSV", "DISEASE", 174, 177], ["illness", "DISEASE", 189, 196], ["RSV", "DISEASE", 257, 260], ["LRTI", "DISEASE", 261, 265], ["infants", "ORGANISM", 10, 17], ["infants", "ORGANISM", 49, 56], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 72, 98], ["heart", "ORGAN", 114, 119], ["RSV", "ORGANISM", 174, 177], ["RSV", "ORGANISM", 257, 260], ["infants", "SPECIES", 10, 17], ["infants", "SPECIES", 49, 56], ["RSV", "SPECIES", 174, 177], ["RSV", "SPECIES", 257, 260], ["early and late-preterm infants", "PROBLEM", 26, 56], ["bronchopulmonary dysplasia", "PROBLEM", 72, 98], ["congenital heart disease", "PROBLEM", 103, 127], ["RSV", "PROBLEM", 174, 177], ["RSV/LRTI hospitalizations", "PROBLEM", 257, 282], ["bronchopulmonary", "ANATOMY", 72, 88], ["dysplasia", "OBSERVATION", 89, 98], ["congenital", "OBSERVATION_MODIFIER", 103, 113], ["heart", "ANATOMY", 114, 119], ["disease", "OBSERVATION", 120, 127]]], ["Over the past two decades, the impact of LRTI hospitalizations on Canadian health resource utilization has increased as the incidences of admissions have risen from approximately 6,200 to 12,000 hospitalizations per year in children <2 years of age [2,6,7].", [["LRTI", "DISEASE", 41, 45], ["children", "ORGANISM", 224, 232], ["children", "SPECIES", 224, 232], ["LRTI hospitalizations", "TREATMENT", 41, 62]]], ["In addition, there is a pronounced seasonal variation in the incidence of LRTIs.", [["LRTIs", "DISEASE", 74, 79], ["LRTIs", "PATHOLOGICAL_FORMATION", 74, 79], ["a pronounced seasonal variation", "PROBLEM", 22, 53], ["LRTIs", "PROBLEM", 74, 79], ["pronounced", "OBSERVATION_MODIFIER", 24, 34], ["seasonal variation", "OBSERVATION", 35, 53], ["LRTIs", "OBSERVATION", 74, 79]]], ["This is likely due to the RSV season which is defined by the timing of the onset and offset of increased RSV circulation in a community.", [["RSV", "ORGANISM", 26, 29], ["RSV", "ORGANISM", 105, 108], ["RSV", "SPECIES", 26, 29], ["RSV", "SPECIES", 105, 108], ["the RSV season", "PROBLEM", 22, 36], ["increased RSV circulation", "PROBLEM", 95, 120], ["likely due to", "UNCERTAINTY", 8, 21], ["RSV", "OBSERVATION", 26, 29], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["RSV circulation", "OBSERVATION", 105, 120]]], ["In northern hemisphere countries, the RSV season usually runs from December through April and is associated with significantly increased pediatric admissions for LRTIs [8].BackgroundThe burden of disease associated with LRTIs may be reduced by effective public health prevention strategies that decrease hospitalizations and reduce lengths of stay [4].", [["LRTIs", "DISEASE", 162, 167], ["LRTIs", "DISEASE", 220, 225], ["RSV", "ORGANISM", 38, 41], ["RSV", "SPECIES", 38, 41], ["LRTIs", "PROBLEM", 162, 167], ["disease", "PROBLEM", 196, 203], ["LRTIs", "PROBLEM", 220, 225], ["hemisphere", "OBSERVATION_MODIFIER", 12, 22], ["burden", "OBSERVATION_MODIFIER", 186, 192], ["disease", "OBSERVATION", 196, 203], ["LRTIs", "OBSERVATION", 220, 225], ["reduced", "OBSERVATION_MODIFIER", 233, 240]]], ["Indeed, epidemics such as the most recent H1N1 outbreak led to rapid and important health prevention and public health initiatives to try to reduce the risk of transmission and health morbidity [9,10].", [["epidemics", "PROBLEM", 8, 17], ["public health initiatives", "TREATMENT", 105, 130]]], ["Although the effectiveness of such public health awareness campaigns are difficult to ascertain, any strategies that can decrease the incidence of severe viral respiratory infections are expected to have a considerable and important impact on acute care settings.BackgroundTo date there is limited information describing the burden of pediatric LRTIs and the impact of public health prevention strategies directed against the infections causing LRTIs on hospital settings.", [["respiratory", "ANATOMY", 160, 171], ["viral respiratory infections", "DISEASE", 154, 182], ["LRTIs", "DISEASE", 345, 350], ["infections", "DISEASE", 426, 436], ["LRTIs", "DISEASE", 445, 450], ["severe viral respiratory infections", "PROBLEM", 147, 182], ["acute care settings", "TREATMENT", 243, 262], ["pediatric LRTIs", "TREATMENT", 335, 350], ["public health prevention strategies", "TREATMENT", 369, 404], ["the infections", "PROBLEM", 422, 436], ["LRTIs", "PROBLEM", 445, 450], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["viral", "OBSERVATION_MODIFIER", 154, 159], ["respiratory infections", "OBSERVATION", 160, 182], ["LRTIs", "OBSERVATION", 345, 350], ["infections", "OBSERVATION", 426, 436], ["LRTIs", "OBSERVATION", 445, 450]]], ["In large countries such as Canada, reducing the present and projected burden of LRTIs and RSV on the public healthcare system involves detailed evaluations of the impact of these diseases on acute care in defined regions.", [["LRTIs", "DISEASE", 80, 85], ["RSV", "DISEASE", 90, 93], ["RSV", "ORGANISM", 90, 93], ["RSV", "SPECIES", 90, 93], ["LRTIs", "PROBLEM", 80, 85], ["detailed evaluations", "TEST", 135, 155], ["these diseases", "PROBLEM", 173, 187], ["acute care", "TREATMENT", 191, 201], ["large", "OBSERVATION_MODIFIER", 3, 8], ["LRTIs", "OBSERVATION", 80, 85], ["RSV", "OBSERVATION", 90, 93], ["diseases", "OBSERVATION", 179, 187], ["acute", "OBSERVATION_MODIFIER", 191, 196]]], ["In Canada, it is likely that identification of the burden of a disease in a specific province will enable the development of effective public health initiatives to reduce the incidence of the disease in this province.", [["a disease", "PROBLEM", 61, 70], ["the disease", "PROBLEM", 188, 199], ["is likely", "UNCERTAINTY", 14, 23], ["disease", "OBSERVATION", 63, 70], ["disease", "OBSERVATION", 192, 199]]], ["Accordingly, the goal of these analyses was to determine the burden of pediatric LRTIs on hospital settings in British Columbia and to identify the benefits of prevention strategies as they relate to healthcare resource demand.Statistical analysis ::: MethodsAll statistical analyses were performed with the use of MedCalc software, version 12.1.1 [17].", [["LRTIs", "DISEASE", 81, 86], ["these analyses", "TEST", 25, 39], ["prevention strategies", "TREATMENT", 160, 181], ["Methods", "TREATMENT", 252, 259], ["All statistical analyses", "TEST", 259, 283], ["LRTIs", "OBSERVATION", 81, 86]]], ["A MS Access 2007 database containing all inpatient records was used to store, manipulate, filter, and summarize the data.", [["filter", "TREATMENT", 90, 96], ["the data", "TEST", 112, 120]]], ["MS Excel 2007 was used for basic computations and to prepare charts.Statistical analysis ::: MethodsHospitalizations accounted for the total bed-days; the average number of beds was defined as total bed-days divided by the number of days in the period under analysis; average LOS was estimated as total bed-days divided by the number of hospitalizations; and the peak in bed occupancy was defined as the maximum number of beds occupied simultaneously.Statistical analysis ::: MethodsRates were calculated using the best population estimates available and the number of hospitalizations for corresponding groups defined by the patients\u2019 primary diagnosis, age, and region of residence.", [["patients", "ORGANISM", 626, 634], ["patients", "SPECIES", 626, 634], ["MethodsHospitalizations", "TREATMENT", 93, 116], ["the peak in bed occupancy", "PROBLEM", 359, 384], ["MethodsRates", "TEST", 476, 488]]], ["The confidence intervals for these rates were calculated using the normal approximation method.", [["these rates", "TEST", 29, 40]]], ["Chi-square tests were used for rate comparisons, with Yates\u2019 correction for continuity.All children (<19 years of age) ::: ResultsIn British Columbia during 2008\u20132010, diseases of the respiratory system (ICD-10 Chapter X) accounted for 14326/186609 (7.7%) primary hospital diagnoses among all children <19 years of age.", [["children", "ORGANISM", 91, 99], ["children", "ORGANISM", 293, 301], ["children", "SPECIES", 91, 99], ["children", "SPECIES", 293, 301], ["Chi-square tests", "TEST", 0, 16], ["rate comparisons", "TEST", 31, 47], ["diseases of the respiratory system", "PROBLEM", 168, 202], ["respiratory system", "ANATOMY", 184, 202]]], ["Hospitalizations for LRTI as the primary diagnosis occurred in 4588/14326 (32.0%) of all respiratory admissions in children <19 years of age.", [["LRTI", "DISEASE", 21, 25], ["children", "ORGANISM", 115, 123], ["children", "SPECIES", 115, 123], ["LRTI", "PROBLEM", 21, 25], ["respiratory", "ANATOMY", 89, 100]]], ["The average LOS in hospital for LRTI as the primary diagnosis was 3.10 days (95% confidence interval [CI] 3.03\u20133.21; 82% within 5 days); this is equivalent to a yearly average of 19.6 acute beds required to treat pediatric LRTIs (Table 3).All children (<19 years of age) ::: ResultsMost of the LRTI admissions were for an unspecified viral cause (2932/4588; 63.9%).", [["LRTI", "DISEASE", 32, 36], ["LRTIs", "DISEASE", 223, 228], ["LRTI", "DISEASE", 294, 298], ["children", "ORGANISM", 243, 251], ["children", "SPECIES", 243, 251], ["LRTI", "PROBLEM", 32, 36], ["CI", "TEST", 102, 104], ["acute beds", "PROBLEM", 184, 194], ["pediatric LRTIs", "TREATMENT", 213, 228], ["an unspecified viral cause", "PROBLEM", 319, 345], ["average", "OBSERVATION_MODIFIER", 4, 11], ["LOS", "OBSERVATION_MODIFIER", 12, 15], ["LRTIs", "OBSERVATION", 223, 228]]], ["Pneumonia, organism unspecified (ICD-10 code J18.9) was the most frequently listed LRTI as the primary diagnosis (1215/4588; 26.5%) with acute bronchiolitis due to RSV (ICD-10 code J21.0; 1198/4588; 26.1 %); acute bronchiolitis, unspecified (ICD-10 code J21.9; 854/4588; 18.6%); bronchopneumonia, unspecified organism (ICD-10 code J18.0; 354/4588; 7.7%); and viral pneumonia unspecified (ICD-10 code J12.9; 138/4588; 3%) also among the top 5 diagnoses.All children (<19 years of age) ::: ResultsRSV-specific infections accounted for 1353 (29.5%) cases of LRTI as the primary diagnosis among all children <19 years of age.", [["Pneumonia", "DISEASE", 0, 9], ["LRTI", "DISEASE", 83, 87], ["bronchiolitis", "DISEASE", 143, 156], ["RSV", "DISEASE", 164, 167], ["bronchiolitis", "DISEASE", 214, 227], ["bronchopneumonia", "DISEASE", 279, 295], ["viral pneumonia", "DISEASE", 359, 374], ["infections", "DISEASE", 508, 518], ["LRTI", "DISEASE", 555, 559], ["RSV", "ORGANISM", 164, 167], ["children", "ORGANISM", 456, 464], ["children", "ORGANISM", 595, 603], ["children", "SPECIES", 456, 464], ["children", "SPECIES", 595, 603], ["RSV", "SPECIES", 164, 167], ["Pneumonia", "PROBLEM", 0, 9], ["organism", "PROBLEM", 11, 19], ["acute bronchiolitis", "PROBLEM", 137, 156], ["RSV", "PROBLEM", 164, 167], ["ICD", "TEST", 169, 172], ["acute bronchiolitis", "PROBLEM", 208, 227], ["ICD", "TEST", 242, 245], ["bronchopneumonia", "PROBLEM", 279, 295], ["unspecified organism", "PROBLEM", 297, 317], ["ICD", "TEST", 319, 322], ["viral pneumonia", "PROBLEM", 359, 374], ["ICD", "TEST", 388, 391], ["ResultsRSV", "TEST", 488, 498], ["specific infections", "PROBLEM", 499, 518], ["LRTI", "PROBLEM", 555, 559], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["bronchiolitis", "OBSERVATION", 143, 156], ["acute", "OBSERVATION_MODIFIER", 208, 213], ["bronchiolitis", "OBSERVATION", 214, 227], ["bronchopneumonia", "OBSERVATION", 279, 295], ["viral", "OBSERVATION_MODIFIER", 359, 364], ["pneumonia", "OBSERVATION", 365, 374], ["infections", "OBSERVATION", 508, 518]]], ["Most RSV-associated hospitalizations were for acute bronchiolitis due to RSV accounting for 1198 (86%) RSV-associated hospitalizations, followed by RSV pneumonia (ICD-10 code J12.1; 115 cases; 8.5%), and acute bronchitis due to RSV (ICD-10 code J20.5; 40 cases; 3%).Infants (<1 year of age) ::: ResultsDuring 2008\u20132010, diseases of the respiratory system accounted for 2853/102972 (2.8%) primary diagnoses among infants <1 year of age (including deliveries/births).", [["RSV", "DISEASE", 5, 8], ["bronchiolitis", "DISEASE", 52, 65], ["RSV", "DISEASE", 73, 76], ["RSV", "DISEASE", 103, 106], ["RSV pneumonia", "DISEASE", 148, 161], ["bronchitis", "DISEASE", 210, 220], ["RSV", "DISEASE", 228, 231], ["RSV", "ORGANISM", 5, 8], ["RSV", "ORGANISM", 73, 76], ["RSV", "ORGANISM", 103, 106], ["RSV", "ORGANISM", 148, 151], ["RSV", "ORGANISM", 228, 231], ["Infants", "ORGANISM", 266, 273], ["infants", "ORGANISM", 412, 419], ["Infants", "SPECIES", 266, 273], ["infants", "SPECIES", 412, 419], ["RSV", "SPECIES", 5, 8], ["RSV", "SPECIES", 73, 76], ["RSV", "SPECIES", 103, 106], ["RSV", "SPECIES", 148, 151], ["RSV", "SPECIES", 228, 231], ["Most RSV", "PROBLEM", 0, 8], ["acute bronchiolitis", "PROBLEM", 46, 65], ["RSV", "PROBLEM", 73, 76], ["RSV", "PROBLEM", 103, 106], ["RSV pneumonia", "PROBLEM", 148, 161], ["ICD", "TREATMENT", 163, 166], ["acute bronchitis", "PROBLEM", 204, 220], ["RSV (ICD", "TREATMENT", 228, 236], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["bronchiolitis", "OBSERVATION", 52, 65], ["RSV", "ANATOMY", 148, 151], ["pneumonia", "OBSERVATION", 152, 161], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["bronchitis", "OBSERVATION", 210, 220], ["respiratory system", "ANATOMY", 336, 354]]], ["Hospitalizations for LRTI as the primary diagnosis occurred in 2165 (75.9%) infants <1 year of age.", [["LRTI", "DISEASE", 21, 25], ["infants", "ORGANISM", 76, 83], ["infants", "SPECIES", 76, 83], ["LRTI", "PROBLEM", 21, 25]]], ["The average LOS for LRTI as the primary diagnosis was 3.23 days (95% CI 3.10\u20133.37; 79.5% within 5 days); this translates to a yearly average of 9.6 beds per day needed to treat LRTIs in infants <1 year of age (Table 3).Infants (<1 year of age) ::: ResultsRSV-specific infections accounted for 1042 (48.1%) cases of LRTI as the primary diagnosis among infants <1 year of age.", [["LRTI", "DISEASE", 20, 24], ["LRTIs", "DISEASE", 177, 182], ["infections", "DISEASE", 268, 278], ["LRTI", "DISEASE", 315, 319], ["Infants", "ORGANISM", 219, 226], ["infants", "ORGANISM", 351, 358], ["infants", "SPECIES", 186, 193], ["Infants", "SPECIES", 219, 226], ["infants", "SPECIES", 351, 358], ["LRTI", "PROBLEM", 20, 24], ["CI", "TEST", 69, 71], ["LRTIs", "PROBLEM", 177, 182], ["specific infections", "PROBLEM", 259, 278], ["LRTI", "TREATMENT", 315, 319], ["average", "OBSERVATION_MODIFIER", 4, 11], ["LOS", "OBSERVATION_MODIFIER", 12, 15], ["LRTIs", "OBSERVATION", 177, 182], ["infections", "OBSERVATION", 268, 278]]], ["Most RSV-associated hospitalizations were for acute bronchiolitis due to RSV accounting for 961 (92.2%) RSV-associated hospitalizations, followed by RSV pneumonia (52 cases; 5%), and acute bronchitis due to RSV (29 cases; 2.8%).Infants (<1 year of age) ::: ResultsAcute bronchiolitis due to RSV was the most frequently listed LRTI as the primary diagnosis (961/2165; 44.4%) followed by acute bronchiolitis, unspecified (575/2165; 26.6 %); pneumonia, unspecified organism (194/2165; 9%); bronchopneumonia, unspecified organism (102/2165; 4.7%); and acute bronchiolitis due to other specified organisms (ICD-10 code J21.8; 51/2165; 2.4%).Infants (<1 year of age) ::: ResultsInfants <1 year of age accounted for 47 and 77% of LRTI and RSV-specific LRTI hospitalizations, respectively, among all children (Figure 1).", [["bronchiolitis", "DISEASE", 52, 65], ["RSV", "DISEASE", 73, 76], ["RSV pneumonia", "DISEASE", 149, 162], ["bronchitis", "DISEASE", 189, 199], ["RSV", "DISEASE", 207, 210], ["bronchiolitis", "DISEASE", 270, 283], ["RSV", "DISEASE", 291, 294], ["LRTI", "DISEASE", 326, 330], ["bronchiolitis", "DISEASE", 392, 405], ["pneumonia", "DISEASE", 439, 448], ["bronchopneumonia", "DISEASE", 487, 503], ["bronchiolitis", "DISEASE", 554, 567], ["LRTI", "DISEASE", 723, 727], ["LRTI", "DISEASE", 745, 749], ["RSV", "ORGANISM", 5, 8], ["RSV", "ORGANISM", 73, 76], ["RSV", "ORGANISM", 104, 107], ["RSV", "ORGANISM", 149, 152], ["RSV", "ORGANISM", 207, 210], ["Infants", "ORGANISM", 228, 235], ["RSV", "ORGANISM", 291, 294], ["Infants", "ORGANISM", 636, 643], ["RSV", "ORGANISM", 732, 735], ["children", "ORGANISM", 792, 800], ["Infants", "SPECIES", 228, 235], ["Infants", "SPECIES", 636, 643], ["children", "SPECIES", 792, 800], ["RSV", "SPECIES", 5, 8], ["RSV", "SPECIES", 73, 76], ["RSV", "SPECIES", 104, 107], ["RSV", "SPECIES", 149, 152], ["RSV", "SPECIES", 207, 210], ["RSV", "SPECIES", 291, 294], ["RSV", "SPECIES", 732, 735], ["Most RSV", "PROBLEM", 0, 8], ["acute bronchiolitis", "PROBLEM", 46, 65], ["RSV", "PROBLEM", 73, 76], ["RSV", "PROBLEM", 104, 107], ["RSV pneumonia", "PROBLEM", 149, 162], ["acute bronchitis", "PROBLEM", 183, 199], ["RSV", "PROBLEM", 207, 210], ["ResultsAcute bronchiolitis", "PROBLEM", 257, 283], ["RSV", "PROBLEM", 291, 294], ["acute bronchiolitis", "PROBLEM", 386, 405], ["pneumonia", "PROBLEM", 439, 448], ["unspecified organism", "PROBLEM", 450, 470], ["bronchopneumonia", "PROBLEM", 487, 503], ["unspecified organism", "PROBLEM", 505, 525], ["acute bronchiolitis", "PROBLEM", 548, 567], ["other specified organisms", "PROBLEM", 575, 600], ["ICD", "TEST", 602, 605], ["LRTI", "PROBLEM", 723, 727], ["RSV", "PROBLEM", 732, 735], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["bronchiolitis", "OBSERVATION", 52, 65], ["RSV", "ANATOMY", 149, 152], ["pneumonia", "OBSERVATION", 153, 162], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["bronchitis", "OBSERVATION", 189, 199], ["bronchiolitis", "OBSERVATION", 270, 283], ["RSV", "OBSERVATION", 291, 294], ["acute", "OBSERVATION_MODIFIER", 386, 391], ["bronchiolitis", "OBSERVATION", 392, 405], ["pneumonia", "OBSERVATION", 439, 448], ["bronchopneumonia", "OBSERVATION", 487, 503], ["acute", "OBSERVATION_MODIFIER", 548, 553], ["bronchiolitis", "OBSERVATION", 554, 567]]], ["Hospitalization rates for LRTI as the primary diagnosis among infants <1 year of age were significantly increased compared to children 1\u2013<19 years of age (2410/100,000 population <1 year of age vs. 235/100,000 children 1\u2013<19 years of age; P <0.0001).", [["LRTI", "DISEASE", 26, 30], ["infants", "ORGANISM", 62, 69], ["children", "ORGANISM", 126, 134], ["infants", "SPECIES", 62, 69], ["children", "SPECIES", 126, 134], ["children", "SPECIES", 210, 218], ["LRTI", "PROBLEM", 26, 30]]], ["Bed-days rates for LRTI as the primary diagnosis were significantly increased among infants <1 year of age compared to children 1\u2013<19 years of age (15,663/100,000 population <1year of age vs. 1473/100,000 children 1\u2013<19 years of age; P <0.0001).", [["LRTI", "DISEASE", 19, 23], ["children", "ORGANISM", 119, 127], ["infants", "SPECIES", 84, 91], ["children", "SPECIES", 119, 127], ["children", "SPECIES", 205, 213], ["LRTI", "PROBLEM", 19, 23]]], ["Considering the bed days spent by those patients, this is an equivalent bed rate of 21.45 beds/100,000 infants <1 year of age per day and 2.02 beds/100,000 children 1\u2013<19 years of age per day (P <0.0001).Infants at risk ::: ResultsAt-risk infants accounted for 1.8% (40/2165) of LRTI hospitalizations in all infants <1 year of age.", [["LRTI", "DISEASE", 279, 283], ["patients", "ORGANISM", 40, 48], ["Infants", "ORGANISM", 204, 211], ["infants", "ORGANISM", 239, 246], ["patients", "SPECIES", 40, 48], ["infants", "SPECIES", 103, 110], ["children", "SPECIES", 156, 164], ["Infants", "SPECIES", 204, 211], ["infants", "SPECIES", 239, 246], ["infants", "SPECIES", 308, 315], ["LRTI hospitalizations", "PROBLEM", 279, 300]]], ["The average LOS among at-risk infants was significantly longer compared to other pediatric patients (9.1 days, vs. 3.10 days, respectively P <0.0001) (Table 4).Seasonal and regional variations ::: ResultsMost LRTI hospitalizations among all children <19 years of age (LRTI, 73.1%; RSV, 88.1%) and infants <1 year of age (LRTI, 79.1%; RSV, 88.4%) occurred between November and April (Figure 2).", [["LRTI", "DISEASE", 209, 213], ["LRTI", "DISEASE", 268, 272], ["LRTI", "DISEASE", 321, 325], ["infants", "ORGANISM", 30, 37], ["patients", "ORGANISM", 91, 99], ["children", "ORGANISM", 241, 249], ["infants", "SPECIES", 30, 37], ["patients", "SPECIES", 91, 99], ["children", "SPECIES", 241, 249], ["infants", "SPECIES", 297, 304], ["RSV", "SPECIES", 281, 284], ["RSV", "SPECIES", 334, 337], ["LRTI", "TEST", 268, 272], ["RSV", "TEST", 281, 284], ["LRTI", "TEST", 321, 325], ["RSV", "TEST", 334, 337], ["average", "OBSERVATION_MODIFIER", 4, 11], ["LOS", "OBSERVATION_MODIFIER", 12, 15], ["regional variations", "OBSERVATION", 173, 192]]], ["Bed occupancy was highest in January and February of 2009 and March of 2010 with peaks of 53 beds among all children <19 years of age and 40 beds among infants <1 year of age in January and February 2009, respectively, and 64 beds among all children <19 years of age and 41 beds among infants <1 year of age in March 2010.", [["children", "ORGANISM", 108, 116], ["infants", "ORGANISM", 152, 159], ["children", "ORGANISM", 241, 249], ["infants", "ORGANISM", 285, 292], ["children", "SPECIES", 108, 116], ["infants", "SPECIES", 152, 159], ["children", "SPECIES", 241, 249], ["infants", "SPECIES", 285, 292]]], ["Regionally, LRTI hospitalization rates among all children <19 years of age and infants <1 year of age in the Interior, Northern BC, and Vancouver Island were higher than the average provincial rate and significantly lower in British Columbia\u2019s lower mainland (Table 5).Projected LRTI hospitalizations for 2020 and 2030 ::: ResultsPopulation projections estimated a 6.6% growth in the pediatric population by 2020 and 17.2% growth by 2030 (Table 6).", [["LRTI", "DISEASE", 12, 16], ["LRTI", "DISEASE", 279, 283], ["children", "ORGANISM", 49, 57], ["children", "SPECIES", 49, 57], ["infants", "SPECIES", 79, 86], ["Northern BC", "TEST", 119, 130], ["ResultsPopulation projections", "TEST", 323, 352], ["Interior", "ANATOMY_MODIFIER", 109, 117], ["significantly", "OBSERVATION_MODIFIER", 202, 215], ["lower", "OBSERVATION_MODIFIER", 216, 221], ["6.6%", "OBSERVATION_MODIFIER", 365, 369], ["growth", "OBSERVATION_MODIFIER", 370, 376]]], ["Assuming the same incidence of LRTI hospitalizations required by pediatric patients, these projections predicted a growth in LRTI bed-days of 5.5% among all children <19 years of age and 16.3% among infants <1 year of age by 2020 and 16.2% among all children <19 years of age and 14.9% among infants <1 year of age by 2030.", [["LRTI", "DISEASE", 31, 35], ["LRTI", "DISEASE", 125, 129], ["patients", "ORGANISM", 75, 83], ["children", "ORGANISM", 157, 165], ["infants", "ORGANISM", 199, 206], ["children", "ORGANISM", 250, 258], ["infants", "ORGANISM", 292, 299], ["patients", "SPECIES", 75, 83], ["children", "SPECIES", 157, 165], ["infants", "SPECIES", 199, 206], ["children", "SPECIES", 250, 258], ["infants", "SPECIES", 292, 299], ["LRTI hospitalizations", "PROBLEM", 31, 52], ["LRTI", "OBSERVATION", 31, 35]]], ["In 2020, the average number of acute care beds required to treat pediatric LRTIs will be 20.7 among all children 0\u2013<19 years of age including 11.2 among the subpopulation of infants <1 year of age.", [["LRTIs", "DISEASE", 75, 80], ["children", "ORGANISM", 104, 112], ["infants", "ORGANISM", 174, 181], ["children", "SPECIES", 104, 112], ["infants", "SPECIES", 174, 181], ["acute care beds", "TREATMENT", 31, 46], ["pediatric LRTIs", "TREATMENT", 65, 80]]], ["This will increase to a maximum bed occupancy of 68 among all children including 48 in infants <1 year of age during the peak months for LRTI hospitalizations.", [["LRTI", "DISEASE", 137, 141], ["children", "ORGANISM", 62, 70], ["infants", "ORGANISM", 87, 94], ["children", "SPECIES", 62, 70], ["infants", "SPECIES", 87, 94], ["a maximum bed occupancy", "TREATMENT", 22, 45], ["LRTI hospitalizations", "PROBLEM", 137, 158]]], ["In 2030, 22.8 acute care beds will be needed among all children <19 years of age including 11.0 among infants <1 year of age.", [["children", "ORGANISM", 55, 63], ["infants", "ORGANISM", 102, 109], ["children", "SPECIES", 55, 63], ["infants", "SPECIES", 102, 109]]], ["This will increase to a maximum bed occupancy of 74 beds among all children including 47 among infants <1 year of age in the winter months (Table 7).Impact of public health prevention strategies on future LRTI hospitalizations ::: ResultsA targeted literature review quantitating the effect of non-pharmacological interventions on LRTI hospitalizations revealed a study that indicated a 12.5% reduction in hospitalizations may be achieved using hand-washing as a public health prevention strategy [18].", [["LRTI", "DISEASE", 205, 209], ["LRTI", "DISEASE", 331, 335], ["children", "ORGANISM", 67, 75], ["infants", "ORGANISM", 95, 102], ["children", "SPECIES", 67, 75], ["infants", "SPECIES", 95, 102], ["a maximum bed occupancy", "TREATMENT", 22, 45], ["public health prevention", "TREATMENT", 159, 183], ["non-pharmacological interventions", "TREATMENT", 294, 327], ["a study", "TEST", 362, 369], ["hand-washing", "TREATMENT", 445, 457], ["a public health prevention strategy", "TREATMENT", 461, 496]]], ["This reduction was applied to the projected increase in LRTI hospitalizations for 2020 and 2030 and indicated that a prevention strategy that could replicate these findings in reducing the prevalence of LRTI admissions, in a sense, counteracts the effects of population growth.", [["LRTI", "DISEASE", 56, 60], ["LRTI", "DISEASE", 203, 207], ["This reduction", "TREATMENT", 0, 14], ["population growth", "PROBLEM", 259, 276], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["In 2020, a 12.5% decrease in hospitalizations in an anticipated <19 year old British Columbia pediatric population of 1,025,000 could potentially result in 307 less hospitalizations, 963 less bed-days, and 2.6 less beds required annually to treat LRTIs.", [["LRTIs", "DISEASE", 247, 252], ["LRTIs", "PROBLEM", 247, 252], ["LRTIs", "OBSERVATION", 247, 252]]], ["A 12.5% decrease in hospitalizations in an anticipated <1 year old British Columbia pediatric population of 52,032 could result in 160 less hospitalizations, 519 less bed-days, and 1.5 less beds.", [["decrease", "OBSERVATION_MODIFIER", 8, 16]]], ["Similarly in 2030, in a projected <19 year old population of 1,128,585, there could be 338 less hospitalizations, 1060 less bed-days, and 2.9 less beds required annually to treat LRTIs.", [["LRTIs", "DISEASE", 179, 184], ["LRTIs", "PROBLEM", 179, 184], ["LRTIs", "OBSERVATION", 179, 184]]], ["In a projected <1 year old population of 51,410, there could be 158 less hospitalizations, 513 less bed-days, and 1.4 less beds (Table 7).DiscussionLRTIs and particularly RSV associated LRTIs account for a substantial number of pediatric hospitalizations and utilize an important number of beds.", [["LRTIs", "DISEASE", 186, 191], ["RSV", "ORGANISM", 171, 174], ["RSV", "SPECIES", 171, 174], ["LRTIs", "OBSERVATION", 186, 191]]], ["In British Columbia during 2008\u201310, LRTI as the primary diagnosis accounted for a significant proportion of diseases of the respiratory system in all children <19 years of age and the majority of hospitalizations for diseases of the respiratory system in infants <1 year of age.", [["respiratory system", "ANATOMY", 233, 251], ["LRTI", "DISEASE", 36, 40], ["diseases of the respiratory system", "DISEASE", 108, 142], ["diseases of the respiratory system", "DISEASE", 217, 251], ["children", "ORGANISM", 150, 158], ["infants", "ORGANISM", 255, 262], ["children", "SPECIES", 150, 158], ["infants", "SPECIES", 255, 262], ["diseases of the respiratory system", "PROBLEM", 108, 142], ["diseases of the respiratory system", "PROBLEM", 217, 251], ["diseases", "OBSERVATION", 108, 116], ["respiratory system", "ANATOMY", 124, 142], ["respiratory system", "ANATOMY", 233, 251]]], ["Infants <1 year of age accounted for 47 and 77% hospitalizations due to pediatric LRTIs and LRTIs specifically due to RSV, respectively.", [["LRTIs", "DISEASE", 82, 87], ["LRTIs", "DISEASE", 92, 97], ["RSV", "DISEASE", 118, 121], ["RSV", "ORGANISM", 118, 121], ["Infants", "SPECIES", 0, 7], ["RSV", "SPECIES", 118, 121], ["pediatric LRTIs", "PROBLEM", 72, 87], ["LRTIs", "PROBLEM", 92, 97], ["RSV", "PROBLEM", 118, 121], ["LRTIs", "OBSERVATION", 82, 87], ["LRTIs", "OBSERVATION", 92, 97]]], ["Acute bronchiolitis due to RSV was the most frequently listed LRTI as the primary diagnosis in infants <1 year of age.", [["bronchiolitis", "DISEASE", 6, 19], ["RSV", "DISEASE", 27, 30], ["LRTI", "DISEASE", 62, 66], ["RSV", "ORGANISM", 27, 30], ["infants", "ORGANISM", 95, 102], ["infants", "SPECIES", 95, 102], ["RSV", "SPECIES", 27, 30], ["Acute bronchiolitis", "PROBLEM", 0, 19], ["RSV", "PROBLEM", 27, 30], ["bronchiolitis", "OBSERVATION", 6, 19], ["RSV", "OBSERVATION", 27, 30]]], ["There was considerable seasonal variation in the incidence of hospitalizations.", [["considerable seasonal variation", "PROBLEM", 10, 41], ["considerable", "OBSERVATION_MODIFIER", 10, 22], ["seasonal variation", "OBSERVATION", 23, 41]]], ["Most pediatric hospitalizations attributable to LRTIs in British Columbia hospitals occurred between November and April.DiscussionThese data demonstrate that LRTI and RSV specific LRTI are a significant disease burden in the pediatric population in British Columbia, especially in infants <1 year of age and those at high-risk.", [["LRTIs", "DISEASE", 48, 53], ["LRTI", "DISEASE", 158, 162], ["LRTI", "DISEASE", 180, 184], ["RSV", "ORGANISM", 167, 170], ["infants", "ORGANISM", 281, 288], ["infants", "SPECIES", 281, 288], ["RSV", "SPECIES", 167, 170], ["These data", "TEST", 130, 140], ["LRTI", "PROBLEM", 158, 162], ["RSV specific LRTI", "PROBLEM", 167, 184], ["a significant disease burden", "PROBLEM", 189, 217], ["LRTIs", "OBSERVATION", 48, 53], ["LRTI", "OBSERVATION", 158, 162], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["disease", "OBSERVATION", 203, 210]]], ["Although high-risk infants do not account for the majority of the number of pediatric LRTI hospitalizations, their hospital LOS was three times as long as other pediatric patients.", [["LRTI", "DISEASE", 86, 90], ["infants", "ORGANISM", 19, 26], ["patients", "ORGANISM", 171, 179], ["infants", "SPECIES", 19, 26], ["patients", "SPECIES", 171, 179]]], ["This suggests at-risk infants place a greater demand per patient on the acute care setting.", [["infants", "ORGANISM", 22, 29], ["patient", "ORGANISM", 57, 64], ["infants", "SPECIES", 22, 29], ["patient", "SPECIES", 57, 64]]], ["Previous studies show the lengths of RSV-associated stay in Canada range from 4.6 to 6.7 days for pediatric patients, and from 8.6 to 11.8 days for pediatric patients with diagnoses such as congenital heart disease, chronic lung disease, immunodeficiency, or multiple congenital anomalies, [19] and up to 14.71 days for preterm infants with probable RSV compared to 5.04 days for term infants [20].", [["heart", "ANATOMY", 201, 206], ["lung", "ANATOMY", 224, 228], ["RSV", "DISEASE", 37, 40], ["congenital heart disease", "DISEASE", 190, 214], ["chronic lung disease", "DISEASE", 216, 236], ["immunodeficiency", "DISEASE", 238, 254], ["congenital anomalies", "DISEASE", 268, 288], ["RSV", "DISEASE", 350, 353], ["RSV", "ORGANISM", 37, 40], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 158, 166], ["heart", "ORGAN", 201, 206], ["lung", "ORGAN", 224, 228], ["infants", "ORGANISM", 328, 335], ["RSV", "ORGANISM", 350, 353], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 158, 166], ["infants", "SPECIES", 328, 335], ["infants", "SPECIES", 385, 392], ["RSV", "SPECIES", 37, 40], ["RSV", "SPECIES", 350, 353], ["Previous studies", "TEST", 0, 16], ["RSV", "PROBLEM", 37, 40], ["congenital heart disease", "PROBLEM", 190, 214], ["chronic lung disease", "PROBLEM", 216, 236], ["immunodeficiency", "PROBLEM", 238, 254], ["multiple congenital anomalies", "PROBLEM", 259, 288], ["preterm infants", "PROBLEM", 320, 335], ["RSV", "PROBLEM", 350, 353], ["lengths", "OBSERVATION_MODIFIER", 26, 33], ["RSV", "OBSERVATION", 37, 40], ["heart", "ANATOMY", 201, 206], ["disease", "OBSERVATION", 207, 214], ["chronic", "OBSERVATION_MODIFIER", 216, 223], ["lung", "ANATOMY", 224, 228], ["disease", "OBSERVATION", 229, 236], ["immunodeficiency", "OBSERVATION", 238, 254], ["multiple", "OBSERVATION_MODIFIER", 259, 267], ["congenital", "OBSERVATION_MODIFIER", 268, 278], ["anomalies", "OBSERVATION", 279, 288]]], ["These data are in accordance with our observations in British Columbia.DiscussionDue to the high rate of pediatric hospitalization and extended lengths of stay, there are significant medical costs related to LRTI.", [["LRTI", "DISEASE", 208, 212], ["significant medical costs", "PROBLEM", 171, 196], ["LRTI", "PROBLEM", 208, 212], ["significant", "OBSERVATION_MODIFIER", 171, 182], ["LRTI", "OBSERVATION", 208, 212]]], ["Previous economic analyses indicate that infants with LRTI have healthcare costs over $9000 higher in the first year of life than infants without infection [21].", [["LRTI", "DISEASE", 54, 58], ["infection", "DISEASE", 146, 155], ["infants", "ORGANISM", 41, 48], ["infants", "ORGANISM", 130, 137], ["infants", "SPECIES", 41, 48], ["infants", "SPECIES", 130, 137], ["Previous economic analyses", "TEST", 0, 26], ["infection", "PROBLEM", 146, 155]]], ["The LRTI burden on the healthcare system in British Columbia is expected to increase in the next 20 years as estimates of population growth suggest that the number of acute care beds needed to care for pediatric LRTI hospitalizations will rise.", [["LRTI", "DISEASE", 4, 8], ["LRTI", "DISEASE", 212, 216], ["The LRTI burden", "PROBLEM", 0, 15], ["population growth", "PROBLEM", 122, 139], ["acute care beds", "TREATMENT", 167, 182], ["pediatric LRTI hospitalizations", "TREATMENT", 202, 233], ["LRTI", "OBSERVATION_MODIFIER", 4, 8], ["burden", "OBSERVATION", 9, 15], ["increase", "OBSERVATION_MODIFIER", 76, 84]]], ["The study estimated an increase in the pediatric population of approximately 17% by 2030 which may be a conservative estimate compared to other published reports which calculate 31% growth in the population of children 0\u201319 years of age in British Columbia from 2010 to 2031 [22].", [["children", "ORGANISM", 210, 218], ["children", "SPECIES", 210, 218], ["The study", "TEST", 0, 9], ["increase", "OBSERVATION_MODIFIER", 23, 31]]], ["However, predictions describing the implementation and evaluation of effective public health prevention strategies indicate that such measures can potentially reduce the incidence of the severe viral infections that are predominant contributors to LRTI hospitalizations and can significantly contribute to pediatric acute care sustainability.", [["viral infections", "DISEASE", 194, 210], ["LRTI", "DISEASE", 248, 252], ["evaluation", "TEST", 55, 65], ["effective public health prevention strategies", "TREATMENT", 69, 114], ["the severe viral infections", "PROBLEM", 183, 210], ["LRTI hospitalizations", "PROBLEM", 248, 269], ["pediatric acute care sustainability", "TREATMENT", 306, 341], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["viral", "OBSERVATION_MODIFIER", 194, 199], ["infections", "OBSERVATION", 200, 210]]], ["Non-pharmacological intervention strategies can occur in the home, and health care practitioners need to educate parents and caregivers about methods that can be used to prevent children from infections.", [["infections", "DISEASE", 192, 202], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 178, 186], ["Non-pharmacological intervention strategies", "TREATMENT", 0, 43], ["infections", "PROBLEM", 192, 202], ["infections", "OBSERVATION", 192, 202]]], ["These include frequent hand washing which can significantly reduce the rate of spread of infection from 4.2 to 0.6\u20131.1% [23] and separating infected people from non-infected people, especially at-risk children [24].", [["hand", "ANATOMY", 23, 27], ["infection", "DISEASE", 89, 98], ["people", "ORGANISM", 149, 155], ["people", "ORGANISM", 174, 180], ["children", "ORGANISM", 201, 209], ["people", "SPECIES", 149, 155], ["people", "SPECIES", 174, 180], ["children", "SPECIES", 201, 209], ["frequent hand washing", "TREATMENT", 14, 35], ["infection", "PROBLEM", 89, 98], ["infection", "OBSERVATION", 89, 98]]], ["The effectiveness of other public health initiatives warrants evaluation.DiscussionThe significance of developing public health response strategies to infectious diseases was illustrated during the 2009 H1N1 influenza pandemic.", [["infectious diseases", "DISEASE", 151, 170], ["influenza pandemic", "DISEASE", 208, 226], ["H1N1 influenza pandemic", "SPECIES", 203, 226], ["evaluation", "TEST", 62, 72], ["infectious diseases", "PROBLEM", 151, 170], ["H1N1 influenza pandemic", "PROBLEM", 203, 226]]], ["Public opinion polls demonstrated that 59\u201367% Americans adopted hand washing and 35\u201338% avoided exposure to others with influenza-like symptoms [10].", [["hand", "ANATOMY", 64, 68], ["influenza-like symptoms", "DISEASE", 120, 143], ["Americans", "ORGANISM", 46, 55], ["Public opinion polls", "TEST", 0, 20], ["hand washing", "TREATMENT", 64, 76], ["influenza", "PROBLEM", 120, 129], ["symptoms", "PROBLEM", 135, 143]]], ["While the effectiveness of such awareness campaigns are difficult to ascertain, strategies that can decrease the prevalence of LRTIs may have considerable impact on acute care settings especially during seasonal LRTI and RSV outbreaks.", [["LRTIs", "DISEASE", 127, 132], ["LRTI", "DISEASE", 212, 216], ["RSV", "ORGANISM", 221, 224], ["RSV", "SPECIES", 221, 224], ["LRTIs", "PROBLEM", 127, 132], ["acute care settings", "TREATMENT", 165, 184], ["seasonal LRTI", "TREATMENT", 203, 216], ["RSV outbreaks", "PROBLEM", 221, 234], ["LRTIs", "OBSERVATION", 127, 132], ["acute", "OBSERVATION_MODIFIER", 165, 170]]], ["Compliance with vaccines that are efficacious at reducing the incidence of severe viral respiratory infections [25] or the use of monoclonal antibodies to reduce the risk of RSV hospitalization in high-risk infants [26] may also have a significant contribution to reducing the demand of LRTIs on pediatric inpatient settings.", [["respiratory", "ANATOMY", 88, 99], ["viral respiratory infections", "DISEASE", 82, 110], ["RSV", "DISEASE", 174, 177], ["LRTIs", "DISEASE", 287, 292], ["RSV", "ORGANISM", 174, 177], ["infants", "ORGANISM", 207, 214], ["monoclonal antibodies", "PROTEIN", 130, 151], ["infants", "SPECIES", 207, 214], ["RSV", "SPECIES", 174, 177], ["vaccines", "TREATMENT", 16, 24], ["severe viral respiratory infections", "PROBLEM", 75, 110], ["monoclonal antibodies", "TREATMENT", 130, 151], ["RSV hospitalization", "PROBLEM", 174, 193], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["respiratory infections", "OBSERVATION", 88, 110], ["RSV", "OBSERVATION", 174, 177], ["significant", "OBSERVATION_MODIFIER", 236, 247], ["LRTIs", "OBSERVATION", 287, 292]]], ["In some areas, a modified combination of prevention may be useful.", [["some", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13]]], ["This may be applicable in British Columbia in the Interior, Northern BC, and Vancouver Island where LRTI hospitalization rates among all children <19 years of age and infants <1 year of age were higher than the average provincial rate.", [["LRTI", "DISEASE", 100, 104], ["children", "ORGANISM", 137, 145], ["infants", "ORGANISM", 167, 174], ["children", "SPECIES", 137, 145], ["infants", "SPECIES", 167, 174], ["may be", "UNCERTAINTY", 5, 11], ["Interior", "ANATOMY_MODIFIER", 50, 58]]], ["Furthermore, this study revealed that the primary diagnosis for LRTIs were predominantly for an unspecified cause.", [["LRTIs", "DISEASE", 64, 69], ["LRTIs", "CANCER", 64, 69], ["this study", "TEST", 13, 23], ["LRTIs", "PROBLEM", 64, 69]]], ["Improved surveillance on the cause of pediatric LRTI hospitalizations may provide valuable insight for assessing current and future demand as well as for developing targeted prevention strategies.DiscussionOur study reflects the impact of LRTIs in a closed population [14].", [["LRTI", "DISEASE", 48, 52], ["pediatric LRTI hospitalizations", "TREATMENT", 38, 69], ["targeted prevention strategies", "TREATMENT", 165, 195], ["DiscussionOur study", "TEST", 196, 215], ["LRTIs", "TREATMENT", 239, 244], ["LRTIs", "OBSERVATION", 239, 244]]], ["This may be an advantage over other nationwide administrative analyses that only evaluate a sample of a population.", [["administrative analyses", "TEST", 47, 70]]], ["There are however limitations associated with this study.", [["this study", "TEST", 46, 56]]], ["First, the use of ICD-10 codes with hospital discharge diagnoses to estimate LRTI hospitalizations may be unsatisfactory as discharge diagnoses can be miscoded.", [["LRTI", "DISEASE", 77, 81], ["ICD", "TREATMENT", 18, 21]]], ["Second, as previously noted the sensitivity of the use of LRTI ICD-10 codes is uncertain as most of the LRTI hospitalizations were for an unspecified viral cause.", [["LRTI", "DISEASE", 58, 62], ["LRTI", "DISEASE", 104, 108], ["LRTI ICD", "TREATMENT", 58, 66], ["the LRTI hospitalizations", "PROBLEM", 100, 125], ["an unspecified viral cause", "PROBLEM", 135, 161]]], ["The study was unable to determine if each hospitalization had a laboratory investigation to determine the underlying cause.", [["The study", "TEST", 0, 9], ["a laboratory investigation", "TEST", 62, 88]]], ["Third, it is difficult to evaluate the impact of health prevention strategies in decreasing severe respiratory disease as the effectiveness of such measures may only be quantified using the best estimates available in the literature.", [["respiratory", "ANATOMY", 99, 110], ["respiratory disease", "DISEASE", 99, 118], ["health prevention strategies", "TREATMENT", 49, 77], ["decreasing severe respiratory disease", "PROBLEM", 81, 118], ["such measures", "TREATMENT", 143, 156], ["decreasing", "OBSERVATION_MODIFIER", 81, 91], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["respiratory disease", "OBSERVATION", 99, 118]]], ["Fifth, the study only assessed the inpatient utilization of pediatrics with a primary LRTI diagnosis, whereby those with secondary diagnoses, for example those acquiring nosocomial LRTI, were not included.", [["LRTI", "DISEASE", 86, 90], ["LRTI", "DISEASE", 181, 185], ["the study", "TEST", 7, 16]]], ["Finally, while our findings suggest that LRTIs are a significant burden on the healthcare system in British Columbia and public health prevention strategies can severely impact this, the generalizability of this data to other provinces in Canada and other countries is unknown.ConclusionIn summary, we present data for all pediatric LRTI and RSV/LRTI hospitalization occurrences in British Columbia during 2008\u20132010.", [["LRTIs", "DISEASE", 41, 46], ["LRTI", "DISEASE", 333, 337], ["LRTI", "DISEASE", 346, 350], ["LRTIs", "SIMPLE_CHEMICAL", 41, 46], ["RSV", "ORGANISM", 342, 345], ["RSV", "SPECIES", 342, 345], ["LRTIs", "PROBLEM", 41, 46], ["public health prevention strategies", "TREATMENT", 121, 156], ["LRTIs", "OBSERVATION", 41, 46], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["burden", "OBSERVATION_MODIFIER", 65, 71]]], ["We identified pediatric LRTIs, and specifically in infants <1 year of age and at-risk infants, as a significant burden on the acute care setting in British Columbia, having pronounced seasonal variability.", [["LRTIs", "DISEASE", 24, 29], ["infants", "ORGANISM", 51, 58], ["infants", "ORGANISM", 86, 93], ["infants", "SPECIES", 51, 58], ["infants", "SPECIES", 86, 93], ["pediatric LRTIs", "PROBLEM", 14, 29], ["pronounced seasonal variability", "PROBLEM", 173, 204], ["pediatric", "OBSERVATION_MODIFIER", 14, 23], ["LRTIs", "OBSERVATION", 24, 29], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["burden", "OBSERVATION", 112, 118], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["pronounced", "OBSERVATION_MODIFIER", 173, 183], ["seasonal variability", "OBSERVATION", 184, 204]]], ["Population projections suggest that this burden will increase in the next 20 years whereby the implementation of effective public health prevention strategies may be an important strategy for pediatric healthcare sustainability, particularly as it relates to acute care access with fixed infrastructure.", [["this burden", "PROBLEM", 36, 47], ["effective public health prevention strategies", "TREATMENT", 113, 158], ["pediatric healthcare sustainability", "TREATMENT", 192, 227], ["acute care access", "TREATMENT", 259, 276], ["fixed infrastructure", "PROBLEM", 282, 302], ["increase", "OBSERVATION_MODIFIER", 53, 61]]], ["Information about the risk of hospitalization in the pediatric population along with a greater understanding of the factors involved in the seasonality patterns of LRTI hospitalizations and the etiology for the LRTI hospitalizations may contribute to the development of algorithms that can identify risk and allow the development of prevention strategies to be implemented at specific times of the year.", [["LRTI", "DISEASE", 164, 168], ["LRTI", "DISEASE", 211, 215], ["LRTI hospitalizations", "TREATMENT", 164, 185], ["the LRTI hospitalizations", "PROBLEM", 207, 232], ["prevention strategies", "TREATMENT", 333, 354]]], ["Comprehensive knowledge of the province-specific impact and cause of pediatric LRTIs can lead to the development of prevention strategies that if effectively implemented can ease the burden of disease on patients, health care infrastructure, and budgets, all of which are important for healthcare sustainability.", [["LRTIs", "DISEASE", 79, 84], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["pediatric LRTIs", "PROBLEM", 69, 84], ["prevention strategies", "TREATMENT", 116, 137], ["disease", "PROBLEM", 193, 200]]], ["The methodology and analyses used to evaluate the burden of pediatric LRTIs in British Columbia may serve as a model that can be extrapolated for use in other Canadian provinces and countries.AbbreviationsLRTI: Lower Respiratory Tract Infection; RSV: Respiratory Syncytial Virus.Competing interestsYS has no competing interests or conflicts of interest to disclose.Authors\u2019 contributionsPS participated in the study design, identified the data requirements, carried out the analysis and helped to draft the manuscript.", [["LRTIs", "DISEASE", 70, 75], ["Respiratory Tract Infection", "DISEASE", 217, 244], ["Respiratory Syncytial Virus", "DISEASE", 251, 278], ["Lower Respiratory Tract", "ORGANISM", 211, 234], ["RSV", "ORGANISM", 246, 249], ["Respiratory Syncytial Virus", "ORGANISM", 251, 278], ["RSV", "SPECIES", 246, 249], ["The methodology and analyses", "TEST", 0, 28], ["Lower Respiratory Tract Infection", "PROBLEM", 211, 244], ["Respiratory Syncytial Virus", "PROBLEM", 251, 278], ["the study", "TEST", 406, 415], ["the analysis", "TEST", 470, 482], ["LRTIs", "OBSERVATION", 70, 75], ["Lower", "ANATOMY_MODIFIER", 211, 216], ["Respiratory Tract", "ANATOMY", 217, 234], ["Infection", "OBSERVATION", 235, 244], ["Respiratory Syncytial Virus", "OBSERVATION", 251, 278]]], ["KG conceived of the study, participated in its design and coordination, provided interpretation to the results and drafted the manuscript.", [["the study", "TEST", 16, 25]]], ["PV participated in the interpretation of results.", [["PV", "SPECIES", 0, 2]]], ["ML participated in the design and coordination of the study and drafting of manuscript.", [["the study", "TEST", 50, 59]]], ["YS arranged the provision of data and contributed in the interpretation of the analysis.", [["the analysis", "TEST", 75, 87]]], ["All authors read and approved the final manuscript.Ethics statementNon-identifiable administrative data was utilized for the purposes of this analysis and therefore ethics approval was not required.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication historyhttp://www.biomedcentral.com/1472-6963/12/451/prepub", [["Pre-publication", "DISEASE", 198, 213], ["pre-publication", "DISEASE", 225, 240], ["Pre-publication", "DISEASE", 285, 300], ["this analysis", "TEST", 137, 150], ["ethics approval", "TREATMENT", 165, 180]]]]}